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Coronary artery bypass grafting (CABG) is a surgical technique utilised to bypass 
one or more stenosed coronary arteries to re-establish blood supply to cardiac 
tissue. The great saphenous vein of the leg remains the most used conduit for all 
non-left anterior descending (LAD) territories. Despite advances in surgical 
technique and optimised pharmacological treatment, approximately 50% of all 
saphenous vein grafts (SVGs) fail at 10 years following coronary implantation 
often requiring potentially life-threatening and costly re-interventions. 
Pathogenic drivers of SVG disease include early thrombosis, neointima formation 
(NF) and accelerated atherosclerosis. Together, these pathologies culminate in 
SVG obstruction, thromboembolism, aneurysm formation and haemorrhaging. 
The key driver of SVG disease is occluding NF which is defined as a continuous 
thickening of the inner most layer of the venous conduit which culminates in 
lumenal obstruction. Pre-clinical and clinical studies have demonstrated that de-
differentiated smooth muscle cells (SMCs) are the main contributor to NF. This 
process is termed SMC phenotype switching which entails a loss in contractile 
properties and instead a gain in migratory and proliferative capacity. Targeting 
SMC phenotype switch-driven NF with specific pharmacological compounds and 
gene therapy remain important therapeutic strategies to prolong SVG patency 
following CABG surgery. 
Transforming growth factor (TGF)-b1 and bone morphogenetic protein (BMP)-9 
are both pleiotropic growth factors which are members of TGF-b superfamily. 
Whereas TGF-b1 may signal via the activin receptor-like kinase (ALK)5 or ALK1 
receptors, BMP-9 mainly signals via the ALK1 receptor. Studies in small and large 
animal models have shown that TGF-b1 is up-regulated following vein grafting. In 
contrast, BMP-9 has not yet been investigated in the context of vascular injury-
driven NF. To date, the role of TGF-b1 signalling in NF remains controversial. Our 
group has shown that TGF-b1/ALK1 signalling drives SMC migration and that NF in 
ligation-injured carotid arteries is blunted in heterozygous Smad1 knockout 
mice. Since BMP-9 signals via the ALK1 receptor, it may be speculated that this 
ligand acts as a pathogenic mediator of NF. Hence, the main aims of this PhD 
were to (i) determine the presence of BMP-9 and SMC phenotype switching in 




and ALK5-driven regulation of primary human saphenous vein (HSV) SMC 
phenotypes, (iii) to characterise single HSVSMC transcriptomes following BMP-9 
and/or TGF-b1 treatment and to (iv) develop a replication-deficient human 
adenovirus serotype 5 vector (HAdV-5) expressing the activin/BMP receptor 
activin A receptor type IIa (ACVR2A). 
Immunohistochemistry (IHC) demonstrated that BMP-9 was present in human 
pre-implantation SVGs and murine carotid arteries. Moreover, intimal SVG SMCs 
displayed a decrease in myosin heavy chain (MYH)11 and a trend towards a 
decrease in calponin expression compared to medial SMCs, suggesting in vivo 
SMC phenotype switching. In addition, carotid artery wire injury in mice 
triggered a trend towards an increase in total vascular BMP-9 levels, which was 
paralleled by SMC phenotype switching, indicating a potential role for BMP-9 in 
NF. Together, these results prompted an observational multiple timepoint 
carotid artery ligation study in mice which aimed to link BMP-9 presence with 
vascular injury responses. Carotid ligation triggered intimal and medial SMC 
proliferation which was paralleled by a loss of SMC a-smooth muscle actin (SMA) 
indicating SMC phenotype switching. Due to the COVID-19 pandemic and 
subsequent lab closure, BMP-9 staining could not be completed. A crosslinking 
study revealed that recombinant human (rh) BMP-9 bound to ALK1, ALK2, bone 
morphogenetic protein receptor (BMPR)2, ACVR2A/B and endoglin on primary 
HSVSMCs. Functionally, BMP-9-treated HSVSMCs displayed a time-dependent 
increase in s-mothers against decapentaplegic (SMAD)1 phosphorylation 
paralleled by an increase in ID1 (encodes inhibitor of differentiation-1) mRNA 
expression levels indicating that BMP-9 activates the SMAD1 pathway in this cell 
type. 
The observation of in vivo SMC phenotype switching in pre-implantation SVGs 
prompted development and generation of a ligand-independent contractile 
differentiation protocol for primary HSVSMCs and primary human coronary artery 
(HCA) SMCs. This enabled investigation of functional ALK1 and ALK5 signalling 
during contractile SMC differentiation. In parallel, the direct, ligand-mediated 
effect of TGF-b1 and BMP-9 on primary HSVSMCs was studied. Immunoblot, 
quantitative real-time polymerase chain reaction (qRT-PCR) and BrdU 




supplement (SMDS)-treated HSVSMCs displayed an accumulation of contractile 
SMC markers which was paralleled by a decrease in proliferation. These 
observations indicated the presence of a contractile HSVSMC phenotype. ALK1 
target gene ID1 mRNA expression levels were suppressed in SMDS-treated 
HSVSMCs indicating dampened ALK1 pathway activity during contractile 
differentiation. Moreover, SMDS treatment induced the expression of mRNA for 
the activin/BMP receptor ACVR2A in HSVSMCs suggesting a potential role for 
ACVR2A during contractile differentiation. Similar observations were made in 
HCASMCs. This prompted development and generation of a replication-deficient 
HAdV-5 expressing the ACVR2A transgene. HAdV-5-mediated delivery of ACVR2A 
to primary HSVSMCs was successful. However, increased ACVR2A expression had 
no effect on aSMA mRNA levels in 15% fetal calf serum (FCS)- or SMDS-treated 
HSVSMCs. Pharmacological ALK5 inhibition prevented contractile differentiation 
in SMDS-treated HSVSMCs. In contrast, pharmacological ALK1 inhibition had no 
effect on the induction of contractile gene expression. In line with these 
findings, TGF-b1 drove contractile gene expression in an ALK5-dependent manner 
and suppressed serum-induced HSVSMC proliferation and migration. BMP-9 had 
no effect on TGF-b1/ALK5-driven contractile gene expression. 
These findings led to an investigation into the impact of BMP-9 and/or TGF-b1 
stimulation on angiotensin (Ang)II-dependent intracellular Ca2+ mobilisation, 
which served as an upstream surrogate marker of SMC contraction. Following 
development of a robust fluorescence-based Ca2+ handling protocol, it was 
observed that TGF-b1-treated HSVSMCs displayed an increase in AngII-driven 
intracellular Ca2+ mobilisation in an ALK5-dependent manner, indicating an 
increase in contractile potential. In contrast, BMP-9 blunted this effect 
indicating ALK5 antagonism and/or differential utilisation of intracellular Ca2+. 
Opposed to findings in primary HSVSMCs, TGF-b1 had no effect on AngII-
dependent Ca2+ release in primary HCASMCs indicating differential regulation of 
Ca2+ handling in this cell type. Single cell (sc) region of interest (ROI) analysis 
revealed heterogeneous Ca2+ transient responses in HSVSMC populations 
independent of ligand treatment. However, TGF-b1-treated HSVSMC populations 
demonstrated a trend towards a reduction in non-responding cells and instead an 
increase in cells responding with higher fluorescence intensities indicating a 




homogeneity was reversed in the presence of BMP-9 paralleling whole ROI 
findings. 
Since primary HSVSMCs displayed heterogeneous Ca2+ transient responses, 
influenced by TGF-b1 and BMP-9, the next aim was to evaluate potential 
transcriptome heterogeneity in BMP-9 and/or TGF-b1-treated HSVSMCs using the 
10x Chromium microfluidics-based scRNA sequencing (seq) platform. Combined 
uniform manifold approximation and projection (UMAP)/Louvain clustering 
uncovered transcriptional heterogeneity in untreated and ligand treated 
HSVSMCs potentially reflecting a heterogeneous composition of SMC sub-lineages 
within pre-implantation SVG media. Both BMP-9 and TGF-b1 drove target gene 
expression demonstrating functional ALK5 and ALK1/ALK2 pathway activation. 
Principal component analysis (PCA) showed greater spatial distances between 
TGF-b1 and BMP-9-treated HSVSMCs suggesting that TGF-b1 triggered greater 
transcriptional activation compared to BMP-9. Within BMP-9 treated HSVSMCs, 
combined RNA velocity and gene ontology (GO) analysis revealed a potential 
osteogenic HSVSMC sub-lineage. Finally, GO identified potentially contractile 
and pro-fibrotic sub-lineages within TGF-b1-treated HSVSMCs. 
In conclusion, the TGF-b1/ALK5 pathway positively regulates the contractile 
HSVSMC phenotype. In contrast, BMP-9 drives ID1 expression and blunts TGF-
b1/ALK5-driven AngII-dependent Ca2+ responses via ALK1 and/or ALK2 indicating 
partial ALK5 antagonism. Together, these data suggest that ALK5 agonism/ALK1 
antagonism may protect HSVSMCs from phenotype switching and dampen NF in 








1.1 Coronary artery disease 
Coronary artery disease (CAD) is caused by thickening of the innermost vessel 
layer (intima) or neointima formation (NF), intimal lipid deposition/plaque 
formation and stiffening of the middle vessel layer (media) which culminates in 
lumenal narrowing and/or thrombosis (Kumar et al., 2007) (Figure 1-1). This 
results in reduced blood flow and insufficient oxygen/nutrient supply of cardiac 
tissue. Clinical complications include angina pectoralis, myocardial infarction 
(MI), cardiac arrhythmias and chronic heart failure (CHF) (Cassar et al., 2009). 
Classic risk factors for developing CAD include age, obesity, type 2 diabetes 
(T2DM), systemic hypertension, dyslipidaemias and chronic kidney disease (CKD) 
(Kumar et al., 2007). To date, CAD is the leading cause of death worldwide, 
entails substantial personal/socioeconomic burden and affects approximately 
3.5% of the UK population (Bhatnagar et al., 2015; Collaborators, 2015). CAD 
management includes life-style modification, drug treatment and 
revascularisation therapies including non-invasive percutaneous coronary 
intervention (PCI) and invasive coronary artery bypass graft (CABG) surgery 
(Neumann et al., 2019). 
 
Figure 1-1 Schematic cross-sectional representation of a narrowed coronary artery. The coronary artery 
wall is made up of three distinct layers (starting from the inner most layer: intima, media and adventitia). 
Continuous intimal thickening drives lipid deposition and plaque formation in CAD (Nakashima et al., 2007). 
This results in lumenal obstruction and impedes coronary blood flow to cardiac tissue. Image taken and 




1.2 Coronary artery bypass graft surgery 
CABG is a surgical technique which utilises the internal mammary artery (IMA), 
the radial artery (RA) or the great saphenous vein (SV) of the leg to bypass one 
or more critically occluded coronary arteries (Harris et al., 2013) (Figure 1-2). 
Following European and US guidelines CABG surgery is the gold standard for the 
treatment of patients with multivessel CAD and left anterior descending (LAD) 
CAD (Fihn et al., 2014; Neumann et al., 2019). Overall, 14,527 CABG surgeries 
were performed in the UK between 2017 and 2018 highlighting the medical and 
socioeconomic importance of this operation (NICOR, 2019). 
 
Figure 1-2 Schematic representation of coronary artery bypass graft surgery using the great 
saphenous vein. In brief, CABG involves performing sternotomy to gain access to the heart (Harris et al., 
2013). The great SV, IMA or RA are harvested and placed into a sterile preservation solution. These conduits 
are engrafted to bypass critically stenosed coronary arteries thereby restoring cardiac blood supply. 
Abbreviations: RCA, right coronary artery; LCX, left circumflex artery; LAD, left anterior descending artery. 




1.2.1 Saphenous vein graft versus internal mammary artery graft 
The IMA and great SV are both composed of three distinct layers: the intima, 
media and adventitia (Canham et al., 1997). Cross-sectional schematic 
representations are presented in Figure 1-3. Despite the same basic structure, 
the two vessels display substantial histological differences due to distinct 
functions within the cardiovascular system (Canham et al., 1997) (Table 1-1). 
 
Figure 1-3 Cross-sectional schematic representation of Internal mammary artery versus great 
saphenous vein histology. (Left image) IMA: the intima consists of a single ellipsoidal EC layer and thin sub-
endothelium. The intima separates the vessel lumen from the vessel wall. Continuous and well-defined 
internal elastic lamina (IEL) separates intima from media. Depending on anatomic location, IMA media is 
composed of several distinguishable elastic laminae and interspersed SMCs (proximal and distal segments) or 
mainly elastic laminae (middle segment). A well-defined continuous external elastic lamina (EEL) separates 
media from adventitia. IMA adventitia contains few vasa vasorum. (Right image) Great SV. The intima 
consists of a single layer of short and wide ECs and sub-endothelium. Valves project into the SV lumen 
guiding blood flow towards the upper torso. A poorly developed IEL separates the intima from the media. The 
media is thinner compared to IMA media and contains an inner layer of longitudinally orientated SMCs and an 
outer layer of circumferentially orientated SMCs. The EEL is absent. The adventitia contains longitudinally 
orientated collagen fibres, fibroblasts, few longitudinally orientated SMCs and vasa vasorum. Compared to the 
IMA, SV adventitia constitutes most of the wall thickness. Images taken and adapted from Servier Medical Art 




Table 1-1 List of histological differences between the internal mammary artery and great saphenous vein. 
Parameter Internal mammary artery Great saphenous vein 
Anatomy • Chest 
• Originates from subclavian artery 
• Guides blood towards musculophrenic and 
superior epigastric arteries 
• Lower limb 
• Guides blood flow towards torso 
Intravascular flow and pressure • High • Low 
Intima • Single lumenal endothelial layer and sub-
endothelium 
• Ellipsoidal ECs, alignment in direction of blood 
flow 
• Continuous and well-defined IEL and EEL 
• Distinguishable elastic lamellae 
• Single lumenal endothelial layer and sub-
endothelium 
• Valves projecting into lumen, guide blood flow 
towards torso 
• Short and wide ECs 
• Poorly developed IEL 
• Undistinguishable elastic lamellae 
Media • Thin, thicker compared to SV 
• Proximal: elasto-muscular (elastic laminae and 
SMCs) 
• Transitions to predominantly elastic in nature 
with few SMCs 
• Distal: elasto-muscular 
• Thinner compared to IMA 
• Inner media: longitudinally orientated SMCs 
• Outer media: circumferentially orientated SMCs 
Adventitia • Longitudinally orientated collagen fibres 
• Few vasa vasorum 
• Constitutes approximately half of wall thickness 
• Longitudinally orientated collagen fibres with 
interspersed longitudinally orientated SMCs 
• Fibroblasts and vasa vasorum 
• Constitutes majority of wall thickness 




Due to its elasto-muscular nature, long-standing adaptation to the arterial high 
pressure/high flow environment and relative protection from developing 
atherosclerosis the IMA graft (IMAG) displays a higher patency rate compared to 
the SVG (Gaudino et al., 2019). 
However, the SVG remains the most utilised graft for all non-LAD territories (80-
90% of all patients) (Caliskan et al., 2020). SVGs display several advantages when 
compared to arterial grafts. They are easily harvested, readily available in most 
patients, easier to handle when performing anastomoses, display absence of 
vasospasm following coronary implantation and reduce the risk of sternal 
infection following the CABG procedure (De Vries et al., 2016). SVGs are 
preferable for patients with poor distal targets, for patients who may benefit 
from higher initial blood flow in SVGs and for patients who require redo surgery 
following failure of an arterial conduit (Anyanwu and Adams, 2018). 
Furthermore, SVGs harvested with “no-touch technique” demonstrated improved 
patency rates compared to SVGs harvested with the conventional technique 
(Samano et al., 2015). The same study revealed that patency rates achieved in 
SVGs harvested with the “no-touch technique” were comparable to IMAG 
patency rates at 16 years follow up. Taken together, SVGs are and will remain a 
crucial repertoire for CABG surgery. 
1.3 Saphenous vein graft disease 
Early thrombosis (Grondin et al., 1974), occlusive intimal thickening or NF 
(Kockx et al., 1996) and accelerated atherosclerosis (Bulkley and Hutchins, 1977) 
drive SVG disease and contribute to SVG failure. To date, 10-15% of SVGs fail 
within the first year rising to approximately 50% at 10 years following CABG 
surgery (Harskamp et al., 2013). A schematic representation of SVG disease 
pathology is shown in Figure 1-4 and a chronological order of key 





Figure 1-4 Saphenous vein graft disease pathology following CABG surgery. Following implantation into the coronary arterial system, SVG endothelium is subjected to increased blood 
flow and pressure culminating in endothelial denudation, local thrombus formation and leukocyte infiltration into the SVG wall (Sasaki et al., 2000). In addition to triggering re-
endothelialisation (Shiokawa et al., 1989), SVG injury drives early medial SMC apoptosis (Rodriguez et al., 2000), medial SMC phenotype switching (Kockx et al., 1992) and fibroblast-to-
myofibroblast differentiation (Kalra and Miller, 2000; Shi et al., 1997) orchestrating occlusive NF and medial thickening. Together, these biological changes drive accelerated neointimal 
atherosclerosis (Bulkley and Hutchins, 1977), neointimal fibrosis (Unni et al., 1974; Vlodaver and Edwards, 1971) and medial calcification (Pedigo et al., 2017). Late complications of SVG 
disease include NF-driven lumenal narrowing (Kockx et al., 1996), plaque rupture/thrombosis (Walts et al., 1982) and aneurysm formation/haemorrhaging (Neitzel et al., 1986). Abbreviations: 




Table 1-2 Summary of key pathophysiological features of SVG disease following CABG surgery. 
Stages Key pathophysiological features Key molecular and cellular responses Clinical therapies 
Saphenous vein 
harvest 
• Surgical handling during harvest 
• Dilatation during leakage check 
• Ischaemia 
• EC apoptosis/necrosis • No-touch harvesting technique 
Saphenous vein 
engraftment 
• Reperfusion à longitudinal and 
circumferential shear stress 
• EC apoptosis/necrosis 
• Local thrombosis 
• Inflammatory cell infiltration and 
initiation of inflammatory signalling 
• Single and dual anti-platelet drug 
therapy 
Early stage (<1 month) • Thrombus formation 
• Initiation of NF 
• Platelet aggregation 
• SMC phenotype switching 
• Single (Aspirin) and dual anti-
platelet (Aspirin + Clopidogrel) drug 
therapy 
Intermediate stage (1 
month to 1 year) 
• Continuous neointimal expansion 




• Fibrotic remodelling of neointima 
• Neointimal lipid retention and foam 
cell formation 
• LDL lowering drug therapy 
Late stage (>1 year) • Calcification 
• Accelerated atherosclerosis and lumenal 
occlusion 
• Necrotic core formation, intraplaque 
haemorrhage, plaque rupture and 
thromboembolism 
• Aneurysm formation 
• Osteoblastic SMC de-differentiation 
• Neointimal foam cell and SMC 
apoptosis 
• Thrombectomy 
• Repeat CABG surgery 





Surgical and pharmacological strategies for tackling SVG disease focus on 
preserving endothelial function, early/late thrombosis and accelerated 
atherosclerosis. The surgical “no-touch technique” preserves SVG endothelium 
during harvesting (Souza et al., 1999), improves SVG tension development and 
contractility (Vestergaard et al., 2017) and improves overall SVG patency at 16-
years follow up (Samano et al., 2015). Single anti-platelet therapy (aspirin) 
(Goldman et al., 1989), dual anti-platelet therapy (aspirin and clopidogrel) 
following off-pump CABG surgery (Deo et al., 2013) and lipid-lowering (Kulik et 
al., 2011) drug therapies reduce SVG thrombosis and atherosclerosis rates, 
respectively. 
Leading complications of late SVG disease culminating in graft failure include 
NF-driven lumenal obstruction (Kockx et al., 1996), atherosclerotic plaque 
rupture resulting in thromboembolism (Walts et al., 1982) and aneurysm 
formation pre-disposing to haemorrhaging (Neitzel et al., 1986). Treatment 
strategies for late SVG complications are potentially life-threatening and include 
thrombectomy (Kuntz et al., 2002), repeat CABG surgery (Locker et al., 2019) 
and percutaneous stent implantation with or without balloon angioplasty (Latif 
et al., 2020). 
1.3.1 Neointima formation 
Occlusive intimal thickening or NF is a key pathological feature of SVG disease 
(Kockx et al., 1996) (Figure 1-4). Evidence obtained from human SVGs (Kockx et 
al., 1992) and experimental murine vein graft injury studies (Wu et al., 2020; 
Zou et al., 1998) demonstrated that SMCs were the main contributors of SVG NF. 
In large vessels, quiescent SMCs within the media provide structural support and 
regulate vascular tone, pressure and blood flow via contraction and relaxation 
(Rensen et al., 2007). Quiescent or contractile vascular (v)SMCs express high 
levels of contractile proteins such as a-smooth muscle actin (SMA), calponin, 
smooth muscle protein (SM)22-a and myosin heavy chain (MYH)11 (Chen et al., 
2016b; Han et al., 2009). Following vascular injury, vSMCs de-differentiate 
triggering vascular repair and NF. This process is known as ‘phenotype switching’ 
and entails loss of contractile protein expression, a universally accepted 
indicator of SMC de-differentiation (Frismantiene et al., 2018) and instead a gain 




(Chen et al., 2016b; Kumar and Lindner, 1997; Liao et al., 2016; Yu et al., 2011) 
(Figure 1-4). 
1.3.1.1 Local thrombosis and Inflammation 
Surgical handling as well as an increase in blood pressure and blood flow within 
the coronary arterial system damage the inner lining of SVGs following 
implantation and culminate in EC denudation. SVG endothelium breakdown 
triggers local platelet aggregation/thrombus formation and allows leukocytes 
and erythrocytes to infiltrate SVG intima (Hoch et al., 1994; Sasaki et al., 2000) 
(Figure 1-4). Pre-clinical in vivo vein graft models have shown that these two 
pathophysiological processes result in the local production and release of growth 
factors and pro-inflammatory cytokines (Francis et al., 1994; Li et al., 2014; 
Sterpetti et al., 1998). These factors include but are not limited to transforming 
growth factor (TGF)-b1, platelet-derived growth factor (PDGF), fibroblast growth 
factor (FGF), interleukin (IL)-1 and tumor necrosis factor (TNF)-α. These 
powerful factors orchestrate complex downstream cellular signalling events 
which trigger initiation of SVG wall remodelling following coronary implantation. 
Although these events are important for adaptive SVG remodelling, pre-clinical 
studies have demonstrated that TGF-b1 (Wolff et al., 2006), PDGF (Hu et al., 
1999), FGF (Dol-Gleizes et al., 2013), IL-1b (Li et al., 2014) and TNF-α (Zhang et 
al., 2004) drive ‘SMC phenotype switching’ and vein graft NF. 
1.3.1.2 Regulation of vSMC quiescence 
Experimental in vivo studies and histological evidence from occluded human 
SVGs demonstrates that vascular injury triggers SMC phenotype switching which 
in turn drives NF (Chappell et al., 2016; Chen et al., 2016b; Kockx et al., 1992) 
(Figure 1-4). In uninjured vessels, vSMCs maintain a quiescent state which 
enables regulation of vascular tone and blood flow. Transitioning of vSMCs from 
a quiescent/differentiated state to a de-differentiated state is a tightly 
regulated molecular process and forms the basis for ‘SMC phenotype switching’. 
The transcription factors serum response factor (SRF) and myocardin (MYOCD) 
jointly regulate contractile gene expression in vSMCs (Du et al., 2003; Rensen et 




box sequence (CC[A/T]6CC) which is predominantly found in muscle and 
cytoskeletal genes (McDonald et al., 2006; Minty and Kedes, 1986; Strobeck et 
al., 2001). In contractile vSMCs the transcription factor MYOCD forms a complex 
with SRF and the CArG sequence thereby selectively driving aSMA, SM22-a, 
CNN1 and MYH11 gene expression subsequently maintaining the contractile 
phenotype (Du et al., 2003; Rensen et al., 2006; Yoshida et al., 2003) (Figure 1-5 
left panel). In experimental vascular injury in mice, adenoviral (AdV)-mediated 
delivery of myocd reduced NF by dampening SMC migration and proliferation 
(Talasila et al., 2013). The same study demonstrated that heterozygous Myocd-
deficient mice displayed enhanced NF and SMC de-differentiation following 
vascular injury, highlighting the ability of Myocd to prevent SMC de-
differentiation and NF. 
Several transcription factors may act as downstream regulators of vSMC de-
differentiation (Frismantiene et al., 2018) (Figure 1-5 right panel). Upon 
activation, Krüppel-like factor (KLF)4 translocates to the nucleus where it 
disrupts the CArG-SRF-MYOCD complex and binds to G/C repressor elements 
which results in loss of contractile gene expression in vSMCs (McDonald et al., 
2006; Salmon et al., 2012). Importantly, PDGF-BB, a strong regulator of SMC de-
differentiation and proliferation, drives KLF4 expression in SMCs thereby 
preventing CArG-SRF-MYOCD complex formation and repressing contractile gene 
expression (Liu et al., 2005a). Furthermore, experimental vascular injury 
triggers up-regulation and nuclear translocation of forkhead box protein (FOX)O4 
in SMCs enabling binding to MYOCD thereby disrupting the CArG-SRF-MYOCD 
complex and promoting SMC proliferation (Liu et al., 2005b). In line with these 
findings, genetic ablation of Foxo4 in mice prevented NF following vascular 
injury (Li et al., 2007). The same study demonstrated that siRNA-mediated 
inhibition of foxo4 prevented SMC migration highlighting this transcription factor 
as a driver of SMC de-differentiation. Moreover, ETS-like protein (ELK)-1 is a 





Figure 1-5 Schematic representation of contractile gene expression regulation in vSMCs. (1) Myocardin 
(MYOCD) and/or myocardin-related transcription factors (MRTFs) together with serum response factor (SRF) 
form a complex with the CArG box sequence positively regulating the contractile SMC phenotype. (2) The 
forkhead box protein (FOX)O4 translocates to the nucleus and binds MYOCD disrupting the MYOCD-SRF-
CArG complex. (3) Krüppel-like factor (KLF)4 translocates to the nucleus and binds to the CArG box sequence 
and G/C repressor elements thereby negatively regulating contractile gene expression. (4) ETS-like protein 
(ELK)-1 competes with MYOCD for complex formation with SRF-CArG negatively regulating contractile gene 




1.3.1.3 Regulation of vSMC proliferation 
Upon vascular injury, pro-proliferative pathways suppress CArG-SRF-MYOCD 
complex formation in vSMCs which culminates in a reduction of contractile gene 
expression and enables SMCs to enter the cell cycle and proliferate (Liu et al., 
2005b) (Figure 1-6). Experimental murine vascular injury models which 
recapitulate vSMC de-differentiation and NF are presented and discussed in more 
detail in section 3.1.1. 
Cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent inhibitors (CKIs) 
regulate the different phases of the cell cycle (Lim and Kaldis, 2013) (Figure 
1-6). Whereas cyclins activate a partner CDK (Andrews and Measday, 1998), CKIs 
deactivate CDKs (Dai and Grant, 2003). Cyclin/CDK complexes drive vSMC 
proliferation (Qin et al., 2014) and CKIs inhibit vSMC proliferation (Lee and Kang, 
2019). Moreover, upstream growth factor signalling pathways regulate 
downstream cyclin, CDK and CKI activity and subsequent vSMC proliferation 
(Weber et al., 1997). Cyclin A, cyclin B, cyclin C, cyclin D and cyclin E form the 
cyclin family (reviewed in) (Ding et al., 2020). Levels of cyclins D, E, A and B 
differ substantially during the different cell cycle stages and are associated with 
specific sets of CDKs (Figure 1-6). 
PDGF is a potent inducer of vSMC proliferation (Mii et al., 1993) which is locally 
released following vascular injury (Caplice et al., 1997) and promotes NF (Ferns 
et al., 1991). As well as disrupting the CArG-SRF-MYOCD complex by triggering p-
ELK1-SRF-CArG complex formation (Wang et al., 2004) (Figure 1-5 right panel), 
PDGF-BB drives vSMC proliferation via mitogen activated protein kinase kinase 
(MEK)/extracellular regulatory kinase (ERK)1 and MAPK14 activation (Wu et al., 
2019; Zhao et al., 2011). Weber and colleagues demonstrated that sustained 
PDGF-induced ERK1 activation in fibroblasts drove continued cyclin D1 (CCND1) 
expression thereby supporting G1 progression and cell proliferation (Weber et 
al., 1997). Similar observations were made in rat aortic SMCs (Izzard et al., 
2002) revealing a clear PDGF-driven proliferative signalling axis. This has led to 
the development of treatment strategies to inhibit vSMC proliferation in SVGs, 




The transcription factor (TF) E2F activates pro-proliferative factors including but 
not limited to CDK2 (Furukawa et al., 1994) and PCNA (proliferating cell nuclear 
antigen) (Yamaguchi et al., 1995). Edifoligide is an oligodeoxynucleotide decoy 
which binds the E2F-binding protein and, hence, blocks E2F-mediated activation 
of pro-proliferative factors (Morishita et al., 1995). Moreover, edifoligide 
prevented vSMC proliferation and NF following experimental vein graft inter-
positioning in rabbits (Ehsan et al., 2001). However, despite promising pre-
clinical results the Project of Ex-Vivo Vein Graft Engineering via Transfection 
(PREVENT)IV trial which included 3014 CABG patients did not show a beneficial 
effect of ex vivo SVG edifoligide treatment on restenosis rates at early time 
points (12 to 18 months) (Alexander et al., 2005) and at 5 years (Lopes et al., 
2012). 
 
Figure 1-6 Schematic representation of the cell cycle. The cyclin C/CDK3 complex regulates the quiescent 
state or gap (G)0 phase. Pro-mitogenic pathways drive cyclin D/CDK4/6 complex formation which promotes 
entry into the G1 phase (Chung et al., 2004; Ding et al., 2020). During the G1 phase the cell commits to cell 
division (reviewed in) (Tan et al., 2017). The cyclin E/CDK2 complex progresses the cell into the synthesis (S) 
phase which is characterised by DNA replication. The cyclin A/CDK2 complex terminates the S phase. Cyclin 
A then forms a complex with CDK1 which allows the cell to enter the G2 phase which enables the cell to 
check for any DNA damage prior to cell division. During the mitosis (M) phase, CDK1 activity is maintained by 
forming a complex with cyclin B allowing the cell to divide into two daughter cells. Together, the G1, S and G2 




1.3.1.4 Regulation of SMC migration 
Extensive SMC migration from the media to the intima is observed in SVGs within 
the first 24-h following CABG surgery (Kockx et al., 1992). The same study 
demonstrated a reduction in aSMA expression by medial SMCs within SVGs 
revealing the presence of non-quiescent SMC phenotypes. This indicates that 
vSMCs must enter the cell cycle (Figure 1-6) to migrate. Indeed, Fukui et al. 
showed that vSMCs achieved maximum migration capacity during the late G1 
phase following PDGF-BB stimulation (Fukui et al., 2000). In line with these in 
vitro findings, Chappell and colleagues demonstrated that medial SMC 
proliferation precedes medial SMC migration towards the intima following 
arterial injury in mice (Chappell et al., 2016) (Figure 1-4). A vein graft study in 
rats demonstrated that vein graft IEL degrades rapidly as a consequence of 
haemodynamic changes (Chang et al., 2009) potentially enabling an increase of 
SMC migration from the media to the intima. 
Mitogen-dependent stimulation of cell surface receptors and intracellular signal 
transduction initiate vSMC migration (Fukui et al., 2000; Grosskreutz et al., 
1999). Activation of upstream pro-migratory signalling pathways orchestrates 
remodelling events which alter the structure of the cytoskeleton (reviewed in) 
(Gerthoffer, 2007) (Figure 1-7). Together, these remodelling events enable 
protrusion of the leading edge of the cell followed by detachment of focal 





Figure 1-7 Schematic representation of vSMC migration. Mitogen-dependent activation of pro-migratory 
signalling pathways trigger vSMC migration (Fukui et al., 2000; Grosskreutz et al., 1999; Pickering et al., 
1997). Activation of pro-migratory pathways initiates filopodial formation at the leading edge of the migrating 
cell (Wang et al., 2009). Actin polymerisation at the leading edge of the cell enables lamellipodial formation 
(protrusion) (Cleary et al., 2014) followed by generation of focal adhesion contacts between the vSMC and 
ECM (Kohno et al., 2013). This is followed by disassembly of focal adhesion contacts at the trailing edge of 
the cell (Palecek et al., 1998). Actomyosin-driven contraction exceeds adhesiveness at the trailing edge 
pulling the cell forward (reviewed in) (Afewerki et al., 2019). Microtubules radiate from the microtubule-
organising centre (MTOC) towards the leading and trailing edge of the cell. Image taken and modified from 




1.3.1.5 Neointimal fibrosis 
Histopathological analysis of occluded human SVGs demonstrated marked intimal 
thickening and fibrosis (Vlodaver and Edwards, 1971). Importantly, electron 
microscopic examination by Unni and colleagues revealed the presence of SMCs, 
collagen fibres and ground substance within the thickened neointima (Unni et 
al., 1974). In line with histopathological findings in human SVGs, a vein graft 
study in rabbits demonstrated that late neointimal thickening was characterised 
by a conversion from a pro-proliferative to a pro-fibrotic morphology (Jiang et 
al., 2009). Taken together, it is speculated that de-differentiated SMCs may be 
the source of fibrotic neointimal remodelling in SVGs. 
In general, vascular fibrosis is characterised by a reduction in lumenal diameter 
accompanied by wall thickening/stiffening which culminates in vessel 
dysfunction (reviewed in) (Lan et al., 2013). Vascular SMC proliferation, ECM 
accumulation and inhibition of ECM degradation are key underlying pathological 
drivers of vascular fibrosis. Neointimal ECM accumulation in vein grafts is 
characterised by an increase in pro-fibrotic protein deposition including but not 
limited to proteoglycans (Jiang et al., 2009), connective tissue growth factor 
(CTGF) (Jiang et al., 2009), plasminogen activator inhibitor (PAI)-1 (Kauhanen et 
al., 1997) and collagens (Wolff et al., 2006). The TGF-b signalling pathway is a 
positive regulator of pro-fibrotic gene expression in pre-implantation SVG SMCs 
(unpublished data) (Low et al., 2019). In depth characterisation of TGF-b 
signalling is presented in section 1.4.4. 
1.3.1.6 Endothelial-to-mesenchymal transition 
The term endothelial-to-mesenchymal transition (EndMT) describes the 
phenotypic conversion of endothelial to mesenchymal cells (reviewed in) (Choi 
et al., 2020). EndMT entails a loss of EC-specific cluster of differentiation 
(CD)31, vascular endothelial (VE) cadherin, angiopoietin-1 receptor and von 
Willebrand factor expression and instead a gain in fibroblast-specific protein 
(FSP)-1, aSMA and type I/III collagen expression. In arterial and venous vessels, a 
single EC layer lines the lumenal side of the intima which forms an anatomic 
barrier between the lumen and the vascular wall (Figure 1-3 and Figure 1-4). In 




and relaxation), suppresses vSMC de-differentiation and exerts anti-
inflammatory and anti-thrombotic properties (reviewed in) (Davignon and Ganz, 
2004). Endothelial cell dysfunction underlies NF and subsequent vascular 
obstruction in pulmonary arterial hypertension (PAH) (Long et al., 2015). 
Reduced endothelial bone morphogenetic protein receptor (BMPR)2 (Evans et 
al., 2016)/activin receptor-like kinase (ALK)1 (Trembath et al., 2001) signalling 
is a key pathological process in PAH development and progression. The 
pleiotropic growth factor bone morphogenetic protein (BMP)-9 (section 1.4.3) 
activates ALK1/BMPR2 signalling (Figure 1-8) (Salmon et al., 2020; 
Scharpfenecker et al., 2007), restores defective ALK1/BMPR2 signalling and, 
hence, reverses experimental PAH in mice (Long et al., 2015). In contrast, Tu et 
al. implicated BMP-9 as a pathogenic driver of PAH development and progression 
(Tu et al., 2019). Taken together, these two studies found conflicting results 
warranting further research into physiological/pathophysiological actions of 
BMP-9 in the context of PAH and vascular disease. 
In the context of SVG disease, altered haemodynamic forces within the coronary 
arterial system trigger endothelial denudation within the venous conduit which 
culminates in local thrombus formation and infiltration of inflammatory cells 
(Sasaki et al., 2000). A pre-clinical vein graft study found that endothelial 
coverage ranged between 81.3% and 95.5% at 4 weeks post-implantation 
(Ishikawa et al., 1996). Whether or not, or to what extent, EndMT contributes to 
NF in SVGs following CABG surgery is a matter of ongoing scientific debate. 
Whereas Cooley et al. demonstrated that pharmacological EndMT inhibition 
prevented NF (Cooley et al., 2014), Wu and colleagues revealed that EndMT only 
marginally contributed to NF in a murine vein graft model (Wu et al., 2020). In 
addition, Cooley’s study revealed that TGF-b signalling was a driver of EndMT 
(Cooley et al., 2014). 
1.3.1.7 Fibroblast-to-myofibroblast differentiation 
In fibroblast-to-myofibroblast differentiation, fibroblasts acquire a SMC-like 
phenotype, termed myofibroblast (reviewed in) (Zent and Guo, 2018). In the 
context of vascular injury, this entails a loss of adventitial fibroblast-specific 
vimentin expression and instead a gain in SMC-specific aSMA expression (Shi et 




media, underwent fibroblast-to-myofibroblast transition and contributed to NF 
in a porcine vein graft model (Shi et al., 1997) (Figure 1-4). Next to driving pro-
fibrotic gene expression and EndMT, the TGF-b signalling pathway also positively 
regulates fibroblast-to-myofibroblast transition (Schwartze et al., 2014). 
1.3.1.8 Accelerated atherosclerosis 
Atherosclerosis is a progressive and inflammation-driven disease which primarily 
affects large arteries of the vascular system and is characterised by progressive 
intimal lipid deposition followed by fibroatheroma formation (reviewed in) 
(Lusis, 2000). Diffuse intimal thickening (Nakashima et al., 2007), subendothelial 
low-density lipoprotein (LDL) retention (Saxena et al., 1993; Saxena et al., 1992; 
Skålén et al., 2002), blood flow disturbance-driven endothelial dysfunction 
(Chang et al., 2017; Dai et al., 2004; Ku et al., 1985), inflammatory cell 
recruitment (Babaev et al., 1993), LDL modification (Heinecke et al., 1984; 
Steinbrecher et al., 1984) and macrophage foam cell formation (Kruth et al., 
2002) drive arterial atherosclerosis development and progression. Arterial fatty 
streak lesion/intimal xanthoma development occurs early in the life course, with 
studies showing that fatty streaks are already present in teenagers (Strong et 
al., 1999). Some neointimal fatty streak lesions gradually remodel into early 
fibroatheroma which are characterised by an accumulation of lipids, macrophage 
foam cells, inflammatory cells and vessel resident cells (reviewed in) (Insull, 
2009). In time, SMC and macrophage foam cell necrosis occur within the 
fibroatheroma triggering necrotic core formation. Together, these changes 
disrupt the normal architecture of the intima. A fibrous cap which mainly 
consists of SMCs, connective tissue and macrophages develops to cover the lipid-
rich necrotic core (reviewed in) (Virmani et al., 2000). A thin-cap fibroatheroma 
(TCFA) is characterised by a thin overlying fibrous cap (<65 µm) which contains a 
high degree of macrophage infiltration (Virmani et al., 2002). TCFAs are 
precursor lesions of plaque rupture (Virmani et al., 2002). Following TCFA 
rupture the highly thrombogenic core is exposed to the circulation which triggers 
thrombosis, a potentially life-threatening event (Moreno et al., 1996). 
Furthermore, advanced atherosclerosis pre-disposes to arterial aneurysm 





Histopathological analysis of SVGs demonstrated that atherosclerosis also 
presented within SVG neointima following CABG surgery and contributed to late 
SVG occlusion (Bulkley and Hutchins, 1977; Neitzel et al., 1986) (Figure 1-4). 
Moreover, SVG neointimal atherosclerotic remodelling may similarly culminate in 
fibroatheroma rupture/thrombosis (Walts et al., 1982) and aneurysm formation 
(Neitzel et al., 1986) contributing to late SVG failure. Kockx and colleagues 
found that neointimal thickening correlated with lumenal accumulation of foam 
cells and mural thrombi in sub-occluded SVGs (mean SVG age 9.9 ± 2.4 years) 
(Kockx et al., 1994). These findings demonstrated that atherosclerotic 
remodelling of SVGs progressed more rapidly compared to arteries, highlighting 
atherosclerotic susceptibility of SVGs. Next to monocyte-derived macrophage 
foam cell formation, pre-clinical data suggests that cholesterol uptake into 
intimal vSMCs induces a macrophage-like SMC phenotype (Allahverdian et al., 
2014; Vengrenyuk et al., 2015). Hence, cholesterol-driven SMC de-differentiation 
may contribute to atherosclerotic lesion formation in SVGs. 
1.3.2 vSMC heterogeneity 
Vascular SMCs derive from at least 8 distinct origins during embryonic 
development giving rise to inter-regional SMC phenotypic diversity (reviewed in) 
(Majesky, 2007). Inter-regional SMC phenotypic diversity may partially explain 
why arterial and venous SMCs respond differently to the same external stimuli, 
which in turn may explain why SVGs display enhanced susceptibility to NF and 
atherosclerosis (Shi et al., 2001; Turner et al., 2007). 
In addition to inter-regional SMC phenotypic diversity, in vitro studies identified 
two major SMC phenotypes which resided in arterial media within the same area 
(Hao et al., 2002; Li et al., 2001a). Li et al. reported cloning of 12 distinct 
primary human SMC lines from a single fragment of distal internal thoracic artery 
(Li et al., 2001a). Of these 12 SMC lines, 3 lines were spindle-shaped, and 9 lines 
were epithelioid-shaped. Spindle-shaped SMCs were larger in size, grew slower 
and showed more robust Ca2+ transients in response to AngII stimulation. In 
contrast, epithelioid-shaped SMCs displayed greater proliferation and migration 
in response to PDGF-BB treatment. In line with these findings, a study by Hao et 
al. revealed spindle- and rhomboid-shaped SMC phenotypes in porcine coronary 




lesions from stented porcine coronary arteries revealed a large proportion of 
rhomboid-shaped SMCs which demonstrated higher proliferative and migratory 
activities compared to spindle-shaped SMCs. Furthermore, Frid et al. showed 
that based on immunobiochemical characteristics, cell morphology and elastic 
lamellae arrangement pattern at least four distinct vSMC phenotypes resided in 
mature bovine pulmonary arterial media (Frid et al., 1994). More recently, single 
cell (sc) RNA transcriptomic analysis has investigated vSMC heterogeneity in the 
context of vascular disease and injury (Dobnikar et al., 2018). Key findings are 
presented in section 6.1.1. 
Taken together, these studies strongly suggest that distinct SMC sub-populations 
reside within healthy vascular media in different vascular beds. It may be 
speculated that these distinct phenotypes exert different functions regarding 




1.4 Vascular TGF-β superfamily signalling 
1.4.1 The TGF-β superfamily 
TGF-b1 and BMP-9 are pleiotropic growth factors which belong to the TGF-b 
superfamily (reviewed in) (David and Massagué, 2018). The TGF-b superfamily 
comprises 32 growth factors widely conserved across species and is mainly 
subdivided into TGF-b, BMP and Activin/Inhibin subfamilies except for some 
outliers (for example, Mullerian Inhibiting Substance). The TGF-b subfamily 
includes three TGF-b isoforms (TGF-b1, TGF-b2 and TGF-b3), two activin isoforms 
(activin A and activin B), Nodal, myostatin and several related growth 
differentiation factors (GDF). In contrast, the BMP subfamily includes twelve 
BMP isoforms, the anti-Muellerian hormone and several related GDFs. Together, 
TGF-b superfamily members orchestrate normal embryonic development and 
maintenance of whole-body homeostasis. 
1.4.2 TGF-β1 production, storage and activation 
TGF-b1 is synthesised as a 390 amino acid pre-pro-TGF-b1 monomer which is 
formed of the N-terminal signal peptide (29 amino acids), the latency associated 
protein (LAP) (249 amino acids) and C-terminal mature TGF-b1 (112 amino acids) 
(Gentry and Nash, 1990). The pre-pro-TGF-b1 monomer enters the rough 
endoplasmic reticulum (ER) where the N-terminal signal peptide is enzymatically 
removed yielding pro-TGF-b1 (Gentry et al., 1988). In addition, two pro-TGF-b1 
monomers dimerise via three disulphide bonds (two within the LAP and one 
within mature TGF-b1) within the rough ER (Gentry et al., 1988) forming the pro-
TGF-b1 homodimer. Furin convertase cleaves the pro-TGF-b1 homodimer which 
culminates in LAP homodimer and mature TGF-b1 homodimer separation (Dubois 
et al., 1995). Despite cleavage, both monomers remain non-covalently bound 
forming the small latent complex (SLC) (Wakefield et al., 1988). The SLC binds 
covalently binds to the larger latent TGF-b1-binding protein (LTPB) forming the 
large latent complex (LLC) (Saharinen et al., 1996). This step is critical for 
efficient LLC secretion from the cell (Miyazono et al., 1991). Following 
secretion, the inactive LLC complex is anchored to the ECM (Unsöld et al., 
2001). Microenvironmental changes such as acidification (Jullien et al., 1989) 




well as matrix metalloproteinases (MMPs) (Yu and Stamenkovic, 2000) and 
integrins (Munger et al., 1999) enable the release of mature TGF-b1 from the 
ECM-anchored LLC. 
The spleen, placenta, bone marrow, lymph nodes and the lung demonstrate the 
highest TGFB1 mRNA expression levels within the human body (The Human 
Protein Atlas). In relation to the spleen, relative smooth muscle TGFB1 mRNA 
expression levels are approximately 4-fold times lower. Next to ECM storage, 
latent TGF-b1 circulates in blood plasma (Areström et al., 2012; Hering et al., 
2002) or is stored in circulating platelet cells (Blakytny et al., 2004) in humans. 
Immunohistochemical analysis revealed that TGF-b1 and LTBP were present in 
human SVG intima and media (Friedl et al., 2004). The same study showed that 
SVGs with NF demonstrated an increase in TGF-b1 and LTBP staining compared to 
SVGs without NF. Dr Emma Low (previous PhD student) demonstrated that SMCs 
isolated from pre-implantation SVGs expressed TGFB1 suggesting SMCs as a TGF-
b1 source within the SVG wall. 
1.4.3 BMP-9 production and secretion 
In contrast to TGFB1, GDF2 (gene encoding BMP-9) is almost exclusively 
expressed in the liver in humans (The Human Protein Atlas) (Bidart et al., 2012). 
BMP-9 is synthesised as a 429 amino acid precursor peptide monomer which 
comprises an N-terminal signal peptide (22 amino acids), a pro-domain (297 
amino acids) and C-terminal mature BMP-9 (109 amino acids) (Tillet and Bailly, 
2014). Following N-terminal signal peptide cleavage, two precursor BMP-9 
monomers form a precursor BMP-9 homodimer via a disulfide bridge within the 
mature domain. A furin convertase cleaves both BMP-9 monomers between the 
pro- and mature domain (Bidart et al., 2012). Despite cleavage, both pro-
domains remain non-covalently bound to the mature BMP-9 homodimer. Bidart 
and colleagues demonstrated that human BMP-9 circulates in its inactive (40%, 
unprocessed precursor BMP-9 homodimer) and its active form (60%, mature BMP-
9 homodimer). Next to BMP-9 homodimers, Tillet et al. went on to show that a 
BMP-9 monomer could also associate with a BMP-10 monomer to form a 
biologically active heterodimer (Tillet et al., 2018). The same study 




1.4.4 Canonical and non-canonical signalling pathways in the 
vasculature 
TGF-b superfamily members signal via transmembrane serine/threonine kinase 
TGF-b type I (TbRI) and TGF-b type II receptors (TbRII) (reviewed in) (David and 
Massagué, 2018). There are seven TbRI (ALKs) and five TbRIIs. TGF-b superfamily 
ligands bind to the extracellular domain of TbRI and/or TbRIIs which culminates 
in complex formation with a second TbRI or TbRII. Next to TbRI and TbRIIs, the 
transmembrane TGF-b type III co-receptors (TbRIII) endoglin and betaglycan also 
bind TGF-b superfamily ligands (Barbara et al., 1999; López-Casillas et al., 1994) 
and may complex with TbRI and/or TbRIIs (Blanco et al., 2005; López-Casillas et 
al., 1993). Both endoglin and betaglycan may modulate TbRI/TbRII-dependent 
downstream pathway activation (Lebrin et al., 2004; Schwartze et al., 2014). 
Ligand-dependent complex formation between a TbRI and TbRII results in 
activation of kinase sites within the TbRI or TbRII’s cytoplasmic domain (Figure 
1-8 and Figure 1-9). Activated cytoplasmic domains drive phosphorylation of 
receptor-regulated (R)-s-mothers against decapentaplegic (SMAD)s which 
function as intracellular signalling messengers. TbRIs are internalised via 
endocytosis following activation, another important component of R-SMAD 
phosphorylation (Di Guglielmo et al., 2003; Tao et al., 2020). Following 
internalisation, receptors may be recycled to the cell surface where they may 
signal again (Di Guglielmo et al., 2003). In addition, the TbRII bone 
morphogenetic protein receptor (BMPR)2 may be degraded via the lysosomal 
pathway, a mechanism which enables a stable equilibrium of cell surface BMPR2 
presence (Gomez-Puerto et al., 2019). 
R-SMAD phosphorylation triggers canonical TGF-b signalling pathway activation. 
Upon phosphorylation, R-SMADs complex with the common (co)-SMAD4 which 
enables the heteromeric complex to enter the nucleus where it acts as a TF for 
target genes. Depending on complex composition, R-SMAD/co-SMAD4 complexes 
interact with distinct DNA elements. These elements include but are not limited 
to the 8-base pair (bp) palindromic 5’-GTCTAGAC-3’ sequence (SMAD-binding 




motif) (Dennler et al., 1998), 5’-AGACAAGGTTGT-3’ (Song et al., 1998) and GC 
rich BMP responsive elements (BREs) (Katagiri et al., 2002). 
The inhibitory (I)-SMADs, SMAD6 and SMAD7, disrupt R-SMAD activation thereby 
forming a negative feedback loop mechanism (Hata et al., 1998; Yan et al., 
2016). Furthermore, the SMAD specific E3 ubiquitin protein ligase (SMURF)1 and 
SMURF2 mediate ubiquitination-proteasome-dependent degradation of R-SMADs, 
thereby contributing to negative regulation of TGF-b signalling (Lin et al., 2000; 
Zhu et al., 1999). In addition, SMURF2 may also associate with SMAD7 which 
induces direct degradation of the TbRI ALK5 and the TbRII transforming growth 
factor-b receptor (TGFBR)2 via proteasome and lysosomal pathways (Kavsak et 
al., 2000). Moreover, protein phosphatases including but not limited to protein 
phosphatase (PP)1 and the Bδ subunit of PP2A dephosphorylate activated ALK5, 
thereby forming an additional negative feedback mechanism (Batut et al., 2008; 
Shi et al., 2004). 
Next to activation of canonical SMAD signalling, active ALK5 may also drive 
major non-canonical cell signalling pathways including but not limited to 
phosphatidylinositol 3-kinase (Yi et al., 2005), extracellular regulatory kinase 
(ERK) (Lee et al., 2007), p38 MAPK (Yu et al., 2002) and c-Jun N-terminal kinase 





Figure 1-8 Basic schematic representation of canonical TGF-b superfamily signalling. (1) The TGF-
β1/TGFBR2/ALK5 signalling axis: activated TGF-β1 binds to the extracellular domain of the type II TGF-β 
receptor (TGFBR)2 (Wrana et al., 1992). Following activation, TGF-β1/TGFBR2 complexes with the TβRI 
ALK5. Complex formation activates kinase sites within the ALK5 cytoplasmic domain which drive 
phosphorylation (p) of the R-SMADs SMAD2 (Macías-Silva et al., 1996) and SMAD3 (Liu et al., 1997). 
Phosphorylated SMAD2 and SMAD3 form a heteromeric complex with co-SMAD4 which enables the complex 
to translocate to the nucleus (Zhang et al., 1997) and function as a TF (Dennler et al., 1998). This complex 
interacts with CAGA boxes on the DNA within promoter or repressor regions of target genes (Dennler et al., 
1998). The SERPINE1 gene (encodes the protein PAI-1) is a target gene of the TGF-β1/TGFBR2/ALK5 
signalling axis (Dennler et al., 1998). (2) The TGF-β1/TGFBR1/ALK5 signalling axis: TGF-β1/TGFBR2 
interaction may also trigger ALK5-dependent complex formation with the TβRI ALK1 (Goumans et al., 2003; 
ten Dijke et al., 1994). Activated ALK1 phosphorylates the R-SMADs SMAD1 and SMAD5 (Goumans et al., 
2003). (3) The BMP-9/ALK1/BMPR2 signalling axis: BMP-9 binds to the extracellular domain of the ALK1 
receptor (Salmon et al., 2020; Scharpfenecker et al., 2007). Following activation, BMP-9/ALK1 complexes with 
either the TβRII bone morphogenetic protein receptor (BMPR)2 or the TβRIIs activin a receptor type IIa/IIb 
(ACVR2A/B) (Upton et al., 2009). Complex formation activates cytoplasmic kinase domains of BMPR2 and/or 
ACVR2A/B which drives SMAD1 and SMAD5 phosphorylation. Phosphorylated SMAD1 and SMAD5 recruit 
the co-SMAD4 to form a heteromeric complex which enables nuclear translocation (Ramachandran et al., 
2018; Zhang et al., 1997). This complex acts as a TF by interacting with GC rich BREs on the DNA within 
promoter and repressor regions of target genes (Chai et al., 2015; Katagiri et al., 2002). The ID1 gene 
(encodes the protein inhibitor of differentiation-1) is a target gene of the TGF-β1/TGFBR2/ALK1 (Lebrin et al., 
2004) and the BMP-9/ALK1/BMPR2 signalling axes (Upton et al., 2009). I-SMADs SMAD6/SMAD7 and TβRIII 
co-receptors modulate ALK5 and ALK1-dependent downstream pathway activation. SMAD7 pre-dominantly 
disrupts ALK5-driven SMAD2/3 phosphorylation (Yan et al., 2016), SMAD6 inhibits ALK1/BMPR2-driven 
SMAD1/5 phosphorylation (Hata et al., 1998). Betaglycan binds all three TGF-β isoforms (Cheifetz et al., 
1990). Upon ligand binding, betaglycan forms a complex with TGFBR2 (López-Casillas et al., 1993). Endoglin 
(ENG) binds TGF-β1, TGF-β3 (Cheifetz et al., 1992) and BMP-9 (Scharpfenecker et al., 2007) and may 
complex with ALK1 (Blanco et al., 2005). Although ALK5 signalling outweighs ALK1 signalling in vSMCs and 






Figure 1-9 Schematic representation of ACVR2A/B signalling. ACVR2A and ACVR2B are transmembrane 
serine/threonine TbRIIs (Attisano et al., 1992; Mathews and Vale, 1991). (1) Activins bind to the extracellular 
domain of ACVR2A (Mathews and Vale, 1991) and/or ACVR2B (Attisano et al., 1992). Upon activation 
ACVR2A/B complex with the TbRIs ALK4 (ten Dijke et al., 1994) or ALK7 (Tsuchida et al., 2008) and induce 
SMAD2/3 phosphorylation (Bernard, 2004). (2) Myostatin binds to the extracellular domains of ACVR2A or B 
(Lee et al., 2005; Rebbapragada et al., 2003). This triggers complex formation with either ALK5 or ALK7 and 
subsequent SMAD2/3 phosphorylation. (3) In contrast, BMP/ALK1,2,3 and 6 complexes may recruit 
ACVR2A/B or BMPR2 which culminates in SMAD1/5 phosphorylation (Ebisawa et al., 1999; Salmon et al., 
2020; Yamashita et al., 1995). Phosphorylated SMAD2/3 and SMAD1/5 complexes recruit the common 




1.4.5 Vascular development and hereditary vascular disorders 
Vascular TGF-b superfamily signalling mediators are in continuous physiological 
balance and maintain vascular homeostasis. 
Defective global ALK1 signalling culminates in embryonic lethality as a result of 
major vascular defects including arteriovenous malformation (AVMs) in Acvrl1 
(encodes ALK1) knockout mice (Urness et al., 2000). In humans, genetic defects 
within the ACVRL1 gene are linked to hereditary haemorrhagic telangiectasia 
(HHT) type 2 (Bossler et al., 2006), a hereditary vascular disorder (HVD) 
characterised by organ telangiectasias and AVMs prone to potentially life-
threatening haemorrhaging. Similarly, defective ALK5 signalling in Tgfbr1 
(encodes ALK5) knockout mice also culminates in embryonic lethality because of 
defective vasculogenesis (Larsson et al., 2001). In humans, defects within the 
TGFBR1 gene are linked to the Loeys-Dietz Syndrome (LDS) type I (Loeys et al., 
2005), a complex syndrome characterised by defects in cardiovascular, 
craniofacial, neurodegenerative and skeletal development. LDS type I patients 
typically display arterial tortuosity and aneurysms prone to potentially life-
threatening haemorrhaging. 
Many more murine knock out studies have revealed that intact TGF-b 
superfamily signalling is crucial for normal cardiovascular development and 
homeostasis (reviewed in) (Pardali et al., 2010) (Table 1-3). Furthermore, many 
more genetic defects within genes encoding for TGF-b superfamily proteins have 
been linked to HVDs in humans highlighting the importance of intact vascular 




Table 1-4). Involvement of vascular BMP-9, TGF-b1 and ACVR2A signalling in the 
pathophysiological context of vascular injury/SVG disease is presented in 




Table 1-3 List of murine homozygous knockout models and their cardiovascular phenotypes. 
Gene name Protein name Cardiovascular phenotype Reference 
Tgfb1 Tgf-b1 Defective vascular development (Dickson et al., 1995) 
Tgfb2 Tgf-b2 Aortic arch malformation (Molin et al., 2002) 
Tgfb3 Tgf-b3 Cardiac outflow tract and atrioventricular canal defects (Chakrabarti et al., 2020) 
Gdf2 Bmp-9 No overt defects in vascular development (Ricard et al., 2012) 
Tgfbr1 Alk5 Embryonic lethality, severe angiogenesis defects (Larsson et al., 2001) 
Acvrl1 Alk1 Embryonic lethality, vascular defects, AVM (Urness et al., 2000) 
Tgfbr2 Tgfr2 Embryonic lethality, defective vascular development (Oshima et al., 1996) 
Bmpr2 Bmpr2 Embryonic lethality, impaired mesoderm development (Beppu et al., 2000) 
Acvr2a Acvr2A No overt defects in vascular development (Matzuk et al., 1995) 
Acvr2b Acvr2B Randomised heart position, malposition of the great arteries, and ventricular and atrial septal defects (Oh and Li, 1997) 
Tgfbr3 Betaglycan Embryonic lethality, impaired coronary vessel development (Compton et al., 2007) 
Eng Endoglin Embryonic lethality, defective vascular development, cardiac defects (Arthur et al., 2000) 
Madh1 Smad1 Embryonic lethality, impaired allantois formation (Tremblay et al., 2001) 
Madh2 Smad2 Embryonic lethality, impaired visceral endoderm function and deficiency of mesoderm formation (Hamamoto et al., 2002) 
Madh3 Smad3 Premature death due to aortic aneurysm (van der Pluijm et al., 2016) 
Madh4 Smad4 Embryonic lethality (Takaku et al., 1998) 
Madh5 Smad5 Embryonic lethality, lack of well-organised vasculature (Chang et al., 1999) 
Madh6 Smad6 Embryonic and post-natal lethality, hyperplastic cardiac valve thickening, outflow tract septation defects, 
hypertension, embryonic vessel haemorrhaging 
(Wylie et al., 2018) 
Madh7 Smad7 Embryonic and post-natal lethality, ventricular septal defect, outflow tract malformation, impaired cardiac 
function, cardiac arrhythmias 





Table 1-4 List of known genetic defects culminating in HVDs in humans. 
Gene name Protein name Syndrome;loss or gain of gene/protein function; disease and vascular phenotype Reference 
FBN1 Fibrillin 1 Marfan’s syndrome; loss of function; aortic root dilatation, dysfunctional fibrillin 1 fails to sequester 
LLC to ECM culminating in excessive vascular wall TGF-b1 signalling 
(Matt et al., 2009) 
TGFB2 TGF-b2 LDS type 4; loss of function; familial thoracic aneurysms and dissections (Boileau et al., 2012; Lindsay 
et al., 2012) 
TGFB3 TGF-b3 LDS type 5; loss of function; aortic aneurysms and dissections (Bertoli-Avella et al., 2015) 
GDF2 BMP-9 HHT5; loss of function; AVMs, dermal telangiectasia (Wooderchak-Donahue et al., 
2013) 
BMP10 BMP-10 PAH; predicted loss of function (Eyries et al., 2019) 
ENG Endoglin HHT1 and HHT-associated PAH; loss of function; AVMs, telangiectasia, PAH (Bossler et al., 2006; Mache et 
al., 2008) 
TGFBR1 ALK5 LDS type; loss of function; arterial aneurysms/tortuosity (Loeys et al., 2005) 
ACVRL1 ALK1 HHT2 and HHT-associated PAH, loss of function; AVMs, telangiectasia, PAH (Trembath et al., 2001) 
TGFBR2 TGFBR2 LDS type 2; gain of function; aortic aneurysm/dissection (Loeys et al., 2005) 
BMPR2 BMPR2 HPAH; loss of function (Evans et al., 2016) 
BMPR1B ALK6 HPAH; gain of function (Chida et al., 2012) 
MADH1 SMAD1 HPAH; loss of function (Nasim et al., 2011) 
MADH3 SMAD3 LDS type 3; gain of function; arterial aneurysms/tortuosity (van de Laar et al., 2012) 
MADH4 SMAD4 JP-HHT Syndrome; loss of function; AVMs, telangiectasia, aortic root dilatation (Jelsig et al., 2016) 
MADH5 SMAD5 HPAH; loss of function (Nasim et al., 2011) 
MADH9 SMAD9 HPAH; loss of function (Nasim et al., 2011) 
SKI v-ski avian sarcoma viral 
oncogene homologue 
SGS; loss of function; aortic aneurysm (Doyle et al., 2012) 





1.5 Adenoviral vector-based gene therapy in saphenous 
vein graft disease 
Identification of causative defects in genes encoding for TGF-b superfamily 
members culminating in HVDs in humans opens the door for therapeutic genetic 
targeting. Gene therapy is defined as the treatment of a disease by transfer of 
engineered genetic material into human cells, often achieved by viral 
transduction (Scheller and Krebsbach, 2009). SVG occlusion rates following CABG 
surgery remain high despite optimal pharmacological treatment (Harskamp et 
al., 2013) and, hence, there remains an unmet clinical need to improve long-
term SVG outcomes. Gene therapy has been proposed as one novel approach to 
tackle SVG occlusion, particularly via the use of adenoviral-mediated gene 
transfer. 
1.5.1 Adenovirus structure and genome organisation 
Adenoviruses are classified under the family of adenoviridae which is subdivided 
into 5 distinct generations: mastadenovirus, aviadenovirus, siadenovirus, 
atadenovirus, and ichtadenovirus (reviewed in) (Harrach et al., 2011). HAdVs 
belong to the generation of mastadenoviridae which are subdivided into 7 
subgroups (A-G) with a total number of 67 known serotypes (reviewed in) (Singh 
et al., 2018). A schematic representation of AdV structure and genome 
organisation is presented in Figure 1-10. 
In humans, wild-type HAdVs typically cause conjunctivitis, keratoconjunctivitis, 
upper and lower respiratory infections, pneumonia, gastroenteritis, hepatitis and 
cystitis (Borkenhagen et al., 2019). AdVs infect a broad range of species and 
include, simian, bovine, porcine, ovine, canine, murine, fowl, bat, snake, reptile 





Figure 1-10 Schematic representation of AdV structure and genome organisation. (A) AdV virions are 
non-enveloped and are made up of icosahedral-shaped capsids ranging from 70 to 90 nm in diameter 
(Robinson et al., 2011). Each capsid encompasses a total of 252 proteins classified into 240 trimeric hexons, 
12 penton bases and 12 trimeric proteins (reviewed in) (Lee et al., 2017). The capsid contains linear double-
stranded (ds) DNA ranging from 26-46 kb. (B) The AdV genome is divided into 4 early (E) and 5 late (L) 
transcriptional units. Early transcriptional units encode non-structural proteins which regulate AdV DNA 
replication and host cell metabolism (Russell, 2000). Late transcriptional units encode structural proteins 
which form the AdV virion. *Indicates regions which are often manipulated/deleted to generate HAdV-5 gene 
therapy vectors. Abbreviations: IX, gene encoding capsid protein IX; pIIIa, gene encoding capsid protein 
precursor pIIIa; III, gene encoding penton base; pVII, gene encoding core protein precursor VII; V, gene 
encoding core protein V; pVI, gene encoding capsid protein precursor VI; pVIII, gene encoding capsid protein 
precursor VIII; CR1-α, gene encoding membrane glycoprotein E3 CR1-α; GP19K, gene encoding membrane 
glycoprotein E3 gp19K; RID-β, membrane protein E3 RID-β; ITR, inverted terminal repeat; pTP, gene 




1.5.2 Distinct AdV vector generations 
Distinct genetic modifications of the AdV genome enabled the development of a 
variety of replication-deficient Ads capable of delivering transgenes to target 
cells/tissues. Based on specific viral gene deletion, replication deficient AdVs 
are classified into first, second and third generation vectors. In addition, 
conditionally replicating or oncolytic AdVs were designed to target and destroy 
tumour cells. 
In first generation AdV vectors the E1 and often E3 regions are substituted for an 
expression cassette with an insert capacity of 8.2 kb (reviewed in) (Capasso et 
al., 2014; Danthinne and Imperiale, 2000) (Figure 1-10 B). Genes within the E1 
region encode proteins which orchestrate viral replication and promote host cell 
proliferation (reviewed in) (Danthinne and Imperiale, 2000; Steegenga et al., 
1999; Zamanian and La Thangue, 1992). The development of the HEK293 cell 
line which is integrated with adenoviral DNA encoding the E1 region provided a 
crucial helper cell line able to provide the key replicative functions of the virus 
in trans to enable laboratory amplification and production of replication 
deficient vectors (Graham et al., 1977). In contrast, the E3 region contains genes 
encoding proteins which modulate the immune response (Fu et al., 2011) 
functions which are only activated when E1 is functional, and E3 is therefore 
dispensable for the function of adenovirus as a gene therapy vector. Owing to 
the nature of triggering strong immunogenic responses AdV-based vectors are 
widely employed for vaccine development (reviewed in) (Tatsis and Ertl, 2004). 
Recent non-replicating human and non-human AdV-based vectors for vaccine 
development include but are not limited to Ad26.COV2.S and simian ChAdOx1 
nCoV-19 for SARS-CoV-2 (Folegatti et al., 2020; Mercado et al., 2020), 
Ad26.ZEBOV/MVA-BN®-Filo for Ebola (Anywaine et al., 2019) and Ad26.Mos4.HIV 
for HIV (Baden et al., 2020). A list of current AdV-based vaccine development 
programmes is presented in Table 1-5. 
Conditionally replicating or oncolytic AdVs have the ability to directly target and 
terminate cancer cells due to the lytic nature of replicating AVs (reviewed in) 
(Fernandes et al., 2016). Intact E1A and E1B regions are crucial for AdV 
replication in healthy host cells to enable the virus to block host cell defence 




contrast, these regions are dispensable in tumour cells with defective Rb or p53 
tumour suppressor signalling. Hence, manipulation/deletion of specific E1A or 
E1B genes enables targeted AdV replication in cancerous cells and subsequent 
termination (Bischoff et al., 1996; Lamfers et al., 2002). Targeted tumour cell 
lysis may also be achieved by tissue-specific promoter-driven transcriptional 
control of the E1 region (Cheng et al., 2006; Li et al., 2001b). Oncolytic HAdV-5-
based products approved by the China Food and Drug Administration include 
Oncorine (rAd5-H101) and Gendicine (rAd-p53) (Liang, 2018; Pearson et al., 
2004). 
Second generation AdV vectors feature a combination of E1/E3 with E2 and/or 
E4 deletions and are less immunogenic compared to first generation vectors 
(reviewed in) (Fernandes et al., 2016) (Figure 1-10 B). However, their use has 
largely been surpassed using third generation adenoviral vectors. 
Third generation or helper-dependent (HD) AdV vectors lack all viral genes 
except two ITRs and the packaging signal, thereby allowing a maximal insert size 
of 36 kb (Alemany et al., 1997; Fisher et al., 1996). HD-AdV propagation requires 
an additional E1-deleted helper virus (HV) which provides all viral proteins 
crucial for the rescue of the HD-AdV. To reduce HV contamination in the final 
product, HD-AdVs are upscaled in a 293-derived cell line which stably expresses 
Cre recombinase (Parks et al., 1996). The packaging site of the HV is flanked by 
two loxP sites and, hence, Cre recombinase excises the HV’s packaging site 
rendering the HV genome unpackageable. In order to eliminate HV contaminants 
from the final product, Lee et al. successfully upscaled a HD-AdV with a helper 




Table 1-5 List of current AdV vector-based vaccine development programmes. 
Start and 
finish date 


















 ChAdOx1 10260 II and 
III 






 Ad5 vectored 
COVID-19 vaccine 






Gam-COVID-Vac Lyo 1st dose: rAd26.S 
2nd dose: rAd5.S 




Gamaleya Research Institute of Epidemiology and 





MERS-CoV  ChAdOx1 MERS 24 Ib NCT04170829 King Abdulaziz Medical City, National Guard Health 










HIV Ad26.Mos4.HIV Ad26 3800 III NCT03964415 Janssen 
Abbreviations: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; MERS-CoV, Middle Eastern respiratory syndrome-related coronavirus; HIV, human 




1.5.3 HAdV-5-dependent transgene delivery 
The HAdV serotype 5 (HAdV-5) belongs to the HAdV subgroup C (Sharma et al., 
2009) and many viral vectors employed in current cardiovascular gene therapy 
trials are based on HAdV-5 (Table 1-6). HAdV-5 utilises a range of cell surface 
receptors for cell attachment and internalisation. These include the coxsackie 
and adenovirus receptor (CAR) (Tomko et al., 1997), heparan sulphate 
proteoglycans (HSPG) (Shayakhmetov et al., 2005), major histocompatibility 
complex (MHC)-I (Hong et al., 1997), vascular cell adhesion molecule (VCAM)-1 
(Chu et al., 2001) and integrins (Wickham et al., 1993) (Figure 1-11). Following 
receptor-mediated endocytosis (Wickham et al., 1993), the viral capsid gradually 
disassembles allowing binding to the nuclear pore complex, and viral DNA import 
into the nucleus (Greber et al., 1993). Nuclear uptake of viral DNA initiates 
transcription of early units followed by transcription of late units (reviewed in) 
(Russell, 2000). In wild-type AdVs replicated viral genomes are packaged into 
fully functional viral capsids culminating in virus-induced cell lysis which is 
followed by viral release (Fernandes et al., 2016). E1 and/or E3 deletions in 
HAdV-5 render the viral genome unpackageable and, hence, the genetically 
modified HAdV-5 cannot replicate in healthy wild-type host cells. The E1 and/or 
E3 regions are often substituted for an expression cassette which contains a 
transgene of interest. Following delivery to a target cardiovascular cell the 
transgene is expressed in the nucleus, remains extrachromosomal and produces 





Figure 1-11 Schematic representation of HAdV-5-dependent transgene delivery and its clinical 
challenges. Replication-deficient HAdV-5 enters a target cardiovascular cell via an entry ± accessory entry 
receptor. Following receptor-mediated endocytosis, HAdV-5 is broken down and the viral DNA is imported into 
the nucleus via nuclear core complexes. The transgene remains extrachromosomal and produces a 
therapeutic protein. Clinical limitations following HAdV-5 delivery include viral elimination by the immune 
system, off target effects and hepatotoxicity, reduced transduction efficiency based on tissue-dependent 





1.5.4 HAdV-5-based gene therapy advantages and clinical 
challenges 
The continued use of HAdV-5-based gene therapy vectors for in vitro and in vivo 
applications is based on several advantages. The HAdV-5 genome has been 
extensively researched which has thus facilitated genetic engineering enabling 
reproducible HAdV-5 genome manipulation and/or therapeutic transgene 
insertion (reviewed in) (Alonso-Padilla et al., 2016). Furthermore, HAdV-5 
demonstrates wide tropism for quiescent and non-quiescent cells and its genome 
does not integrate into the host cell genome which reduces the risk of 
mutagenesis (Benihoud et al., 1999; Dormond et al., 2009). From an industry 
perspective, replication-deficient HAdV-5 gene therapy vectors can be upscaled 
achieving high titers of up to 1013 viral particles (VPs)/ml following good 
manufacturing practices. In contrast, HAdV-5-based gene therapy products also 
carry a range of clinical challenges. 
Elimination of replication-deficient HAdV-5 by the immune system poses a major 
challenge for clinical gene therapy trials. Based on the geographical setting, the 
seroprevalence of neutralising antibodies (nAbs) for HAdV-5 in humans ranges 
between 72-85.2% (Mast et al., 2010; Yu et al., 2012). Clinical trials have 
demonstrated that these nAbs suppress immunogenicity of HAdV-5-based vaccine 
vectors, thereby hampering vaccine efficiency (Priddy et al., 2008; Zhu et al., 
2020). Murine in vivo studies showed that systemic recombinant AdV delivery 
activated innate immune mechanisms which resulted in rapid AdV clearance and, 
hence, inefficient transgene delivery/expression (Worgall et al., 1997; Zhang et 
al., 2001). Yang et al. demonstrated that retrograde biliary E1-deleted HAdV-5 
delivery in mice not only resulted in desired hepatocyte transgene expression 
but also in low-grade viral gene expression (Yang et al., 1994). This triggered a 
virus-specific cellular immune response culminating in the destruction of 
genetically modified hepatocytes highlighting the role of the adaptive immune 
system in eliminating recombinant HAdV-5. 
Targeted cardiovascular transgene delivery via the vascular route is further 
complicated by sequestration of replication-deficient HAdV-5 to the liver 
combined with reduced viral transduction efficiency in the vasculature and aged 




2001; Work et al., 2004). More importantly, intra-portal vein delivery of E1-
deleted HAdV-5 to non-human primates led to hepatotoxicity and features of 
potentially life-threatening systemic inflammatory response syndrome (SIRS) 
(Schnell et al., 2001). In the human context, intra-hepatic artery delivery of E1-
/E4-deleted HAdV-5 harbouring the human OTC gene (encoding ornithine 
transcarbamylase) to an OTC-deficient patient triggered a fatal SIRS resulting in 
the termination of one of the first gene therapy trials in humans (Raper et al., 
2003). Finally, pre-clinical in vivo studies have demonstrated transient loss of 
transgene expression due to episomal degradation following first generation 
HAdV-5-dependent delivery (Ehrhardt and Kay, 2002; Vassalli et al., 1999). 
1.5.5 Recent and current HAdV-5-based cardiovascular gene 
therapy trials in humans 
Despite significant clinical obstacles, substantial progress has been made around 
improving HAdV-5 vector safety and efficacy enabling cardiovascular gene 
therapy trials in humans. Current strategies to circumvent potential deleterious 
side effects of recombinant HAdV-5 administration in the context of 
cardiovascular disease include optimised local delivery strategies and dose 
adjustments. Current cardiovascular gene therapy trials focus on improving 
cardiac angiogenesis and function. A list of recent and current trials is provided 




Table 1-6 List of current cardiovascular gene therapy trials employing recombinant HAdV-5 vectors. 
Trial name Start and 
finish date 




Phase Clinical trial 
number 
Company/university 





ex vivo perinodal 
injection 
39 II NCT03658967 Herantis Pharma Plc. 





ex vivo perinodal 
injection 
15 I NCT02994771 Herantis Pharma Plc. 
EXACT 01/2020 until 
09/2021 




29 I and 
II 
NCT04125732 XyloCor Therapeutics Inc. 
n/a 12/2020 until 
10/2030 




41 I and 
II 
NCT01757223 Weill Medical College of 
Cornell University 
FLOURISH 06/2019 until 
06/2023 





0 III NCT03360448 Renova Therapeutics 






56 I and 
II 
NCT00787059 Renova Therapeutics 
AFFIRM 06/2021 until 
12/2022 










160 III NCT02928094 Angionetics Inc., Huapont Life 
Sciences 





30 IIa n/a The First Affiliated Hospital 
with Nanjing Medical University 
n/a 07/2017 (3-
year study) 
Severe CAD  Ad-HGF 
Intracoronary infusion 
22 I n/a The First Affiliated Hospital 
with Nanjing Medical University 
n/a 07/2008 (35-
day and 11-14 
month follow 
ups) 
3-vessel CAD  Ad-HGF 
Intracoronary infusion 
18 I n/a The First Affiliated Hospital 
with Nanjing Medical University 




1.5.6 Pre-clinical evidence for efficacy of HAdV-5-based gene 
therapy in preventing vein graft NF 
Although HAdV-5 vectors have been used in the clinical context of CAD and/or 
CHF, they have only been employed in pre-clinical studies of vein graft occlusion 
trials to date. These studies have shown that gene therapy is an attractive 
strategy to prevent experimental NF in rodent vascular injury models (Deguchi et 
al., 1999; Engelse et al., 2002; Kloppenburg et al., 2009; Wolff et al., 2006). 
From a translational point of view, lumenal AdV-mediated transgene delivery to 
human SVGs may be achieved (Dakin et al., 2015) while the graft remains 
outside of the patient’s body thereby eliminating off target effects. George et 
al. showed that RAdTIMP-3 (E1-deleted HAdV-5 expressing tissue inhibitor of 
metalloproteinase-3 from a CMV promoter) inhibited NF in ex vivo human pre-
implantation SVG organ cultures and in porcine SVGs 28 days following carotid 
artery inter-position grafting, a translationally relevant large animal model of 
vein graft occlusion (George et al., 2000). A subsequent study by George et al. 
confirmed that ex vivo RAdTIMP-3 delivery to porcine SVGs reduced NF 3 months 
after carotid artery inter-positioning (George et al., 2011). This is a significant 
observation with the knowledge that transgene expression following first 
generation HAdV-5 delivery is typically lost by 21 days due to the host immune 
response (Yang et al., 1994) and suggests that early and acute intervention to 





1.6 Aims of the study 
Systemic pharmacological and genetic ablation of ALK1-mediated SMAD1/5 
signalling retards NF following experimental carotid artery injury in mice, 
indicating that ALK1 is pathogenic driver of NF. BMP-9 circulates in the blood 
and binds strongly to ALK1 thereby activating SMAD1/5 signalling in vascular ECs. 
Furthermore, de-regulation of BMP-9/ALK1 signalling is implicated in 
endothelial-driven vascular diseases such as HPAH or HHT. To date, the role of 
BMP-9 in SVG disease has not been investigated. TGF-b1 induces ALK5/SMAD2/3 
and lateral ALK1/SMAD1/5 signalling in vascular cells. To date, the role of TGF-
b1 in vascular injury-driven NF has been controversial with many studies 
demonstrating opposing results. Vascular SMC de-differentiation predominantly 
drives NF following vascular injury and, hence, this study aimed to explore BMP-
9 and/or TGF-b1-driven ALK1/ALK5 crosstalk and dependent downstream 
regulation of HSVSMC phenotypes in the context of SVG disease. 
1.6.1 Aims 
• To determine the presence of BMP-9 and SMC phenotype switching in 
human pre-implantation saphenous vein grafts and murine vascular injury 
models. 
• To evaluate ALK1 and ALK5 driven regulation of HSVSMC phenotypes. 
• To characterise single HSVSMC transcriptomes following BMP-9 and/or 
TGF-b1 stimulation. 









2.1 Preparation of saphenous vein samples from CABG 
patients 
Surplus pre-implantation saphenous veins from patients undergoing CABG surgery 
at the Golden Jubilee National Hospital in Glasgow (UK) were collected after 
ethical approval in collaboration with the NHS Greater Glasgow & Clyde 
Biorepository (REC reference 16/WS/0207; Bio-repository project reference 
107). The study was authorised by the West of Scotland Research Ethics 
Committee 4 (reference number: 10/S0704/60) and conformed to the 
Declaration of Helsinki. Informed consent was obtained from each donor prior to 
surgery. Anthropometric donor characteristics of samples utilised for ex vivo/in 
vitro experiments are presented in Table 2-1. 
Table 2-1 Summary of anthropometric donor characteristics 
2.1.1 Human saphenous vein sample fixation 
A section of surplus human saphenous vein (HSV) sample was placed in a 15 mL 
Universal tube (cat. no.: PF-SL-155254, Starlab, Germany) and fixed in 4% (w/v) 
PFA (cat. no.: 76240, Fluka, NJ, USA) at 4°C overnight (Table 2-2). The following 
day, samples were washed twice in sterile 1´ PBS, placed in a 15 mL Universal 
tube with 70% (v/v) ethanol (cat. no.: E/0600DF/17, UN1170 Fisher Scientific, 
PA, USA) and stored at 4°C. 
Table 2-2 Recipe for 1 L of 4% (w/v) PFA solution. 
Anthropometric parameters mean ± S.E.M (N=34)1 range 
Male/female 17/8  
Age [years] 56.96 ± 2.75 31-82 
1 unable to establish authorisation for sharing characteristics for N=4 CABG patients, 
N=5 CABG patients withdrew consent for sharing donor characteristics. 
Reagent Amount 
PFA powder 40 g 
sterile 1´ PBS 1 L 




2.2 Cell culture 
2.2.1 Primary HSVSMC isolation and outgrowth 
The remaining surplus HSV sample was placed in a sterile plastic petri dish in a 
cell culture hood. Superfluous tissue and surgical sutures were carefully removed 
using a pair of sterile scissors. Sample veins were cut open longitudinally and the 
EC layer was removed by gently rubbing down the vessel with a plunger from a 5 
mL syringe (Injekt®-F Solo, B. Braun, Germany). The media was carefully pulled 
off the vessel by using a pair of sterile forceps and placed in a new sterile plastic 
petri dish containing wash medium Table 2-3. 
Table 2-3 Wash medium composition. 
Saphenous vein media was homogenised using a McIlwain tissue chopper (Ted 
Pella Inc., CA, USA) and transferred to a sterile 50 mL centrifuge tube (cat. no.: 
430828, Corning Life Sciences, NY, USA) containing 40 mL wash medium. 
Floating tissue debris was removed by gently discarding the supernatant. 
Homogenised tissue was washed twice with wash medium and then covered in 
15% (v/v) fetal calf serum (FCS) SMC growth medium (15% FCS media) (Table 2-4) 
for 5 min. Homogenised tissue was smeared onto the bottom of a T25 flask (cat. 
no.: CLS430639, Merck, Germany) using a 1 mL syringe. Excess 15% (v/v) FCS 
media was carefully removed and the T25 flask was placed in an incubator (37°C 
and 5% CO2) overnight. The next day, 5 mL 15% (v/v) FCS media were added to 
the T25 flask. Upon achieving 90-100% confluence, primary HSVSMCs were 
transferred to a fresh T75 flask (cat. no.: CLS430641U, Merck, Germany).  
Reagent Volume 
Minimal Essential Medium (cat. no.: 11090081, Thermo 
Fisher Scientific, MA, USA) 500 mL 
HEPES (cat. no.: 75277-39-3, VWR International, PA, USA) 25 mM 
L-glutamine (cat. no.: 25030081, Thermo Fisher Scientific, 
MA, USA) 2 mM 
Sodium pyruvate (cat. no.: 11360070, Thermo Fisher, MA, 
USA) 100 nM 
Penicillin/streptomycin (cat. no.: 15070063, Thermo Fisher 
Scientific, MA, USA) 
5 mL (100 I.U/mL 




Table 2-4 15% (v/v) FCS media smooth muscle cell growth medium composition. 
2.2.2 Primary HSVSMC expansion and cryopreservation 
Upon achieving 90-100% confluence, cells were expanded 1:3 until passage (P)4. 
15% (v/v) FCS media was removed from the T75 flask and primary HSVSMCs were 
gently washed in 1× sterile Ca2+-free phosphate buffered saline (PBS; NaCl 0.137 
M, KCl 0.0027 M, Na2HPO4 0.01 M, KH2PO4 0.0018 M; cat. no.: 10010023, Thermo 
Fisher Scientific, MA, USA). 1× PBS was removed, 5 mL 1× sterile trypsin (cat. 
no.: 59427C, MilliporeSigma, MO, USA) were added and the T75 flask was placed 
in an incubator (37°C and 5% CO2) for 5 min. 7 mL 15% (v/v) FCS media were 
added to the flask. The cell suspension was transferred to a sterile 50 mL 
centrifugation tube and subjected to centrifugation at 500 g and room 
temperature for 5 min. Supernatant was discarded and cells were re-suspended 
in 9 mL 15% (v/v) FCS media. 12 mL 15% (v/v) FCS media were added to each of 
3 fresh T75 flasks. 3 mL cell suspension were added to each T75 flask (15 mL 15% 
(v/v) FCS media/flask). Flasks were gently swirled and placed in an incubator 
(37°C and 5% CO2). All primary HSVSMC experiments were initiated at P5. 
Whenever possible, early passaged primary HSVSMCs were subjected to 
cryopreservation (1 confluent T75 flask/2 mL cryopreservation vial). Early 
passaged primary HSVSMCs were detached from 1 T75 flask and pelleted as 
described above. Cells were re-suspended in 1 mL 15% (v/v) FCS media 
containing 10% (v/v) dimethyl sulfoxide (DMSO; cat. no.: D/4120/PB08, Thermo 
Fisher Scientific, MA, USA). The cell suspension was transferred to a sterile 2 mL 
cryopreservation tube (cat. no.: BCS-2502, Brooks Life Sciences, UK). Cells were 
gradually frozen down by submerging the cell suspension-containing 
cryopreservation vial in 100% (v/v) isopropanol (cat. no.: 24137, Honeywell 
Reagent Volume 
Smooth Muscle Cell Growth Medium 2 (cat. no. C-22262, 
PromoCell GmbH, Germany) 500 mL 
Smooth Muscle Cell Growth Medium 2 SupplementMix (cat. 
no.: C-39267, PromoCell GmbH, Germany) 25 mL 
L-glutamine 2 mM 
FCS (cat. no.: 10500064, Thermo Fisher Scientific, MA, 
USA) 50 mL 




International Inc., NC, USA) and placing the submerged vial in a -80°C freezer 
for 24-h. The following day, the cryopreservation vial was transferred to a liquid 
nitrogen tank. Cryopreserved HSVSMCs were revived by rapid thawing in a 37°C 
water bath. 12 mL 15% (v/v) FCS media were added to a T75 flask. Upon 
thawing, 1 mL cell suspension from 3 cryopreservation vials (same passage, same 
donor) were added to the T75 flask. The following day, media was replaced with 
fresh 15% (v/v) FCS media and cells were cultured as described above. 
2.2.3 Primary HCASMC expansion 
Primary HCASMCs were obtained from Thermo Fisher Scientific (cat. no.: 
C0175C, MA, USA). One vial of cryopreserved primary HCASMCs was revived as 
described in section 2.2.2 and was added into 15 mL smooth muscle growth 
supplement (SMGS) medium (Table 2-5) in a T75 flask. Upon achieving 90-100% 
confluency, primary HCASMCs were expanded 1:3 as described in section 2.2.2. 
All experiments were performed between P5 and P8. 
Table 2-5 SMGS medium composition. 
2.2.4 SMDS-induced contractile differentiation protocol for 
primary human SMCs 
This protocol was partially based on a study by Chen et al. (Chen et al., 2016b). 
Confluent primary HSVSMCs and HCASMCs intended for mRNA expression analysis 
were seeded into 12-well plates (cat. no.: 3513, Corning Life Sciences, NY, USA) 
(1×105/well, technical n=3/condition) and cells intended for protein expression 
analysis were seeded into 6-well plates (cat. no.: 3516, Corning Life Sciences, 
NY, USA) (1.5×105/well, technical n=3/condition). 
Reagent Volume 
Medium 231 (cat. no.: M231500, Thermo Fisher Scientific, 
MA, USA) 500 mL 
Smooth muscle growth supplement (cat. no.: S00725, 
Thermo Fisher Scientific, MA, USA), final concentration of 
components: 4.9% (v/v) FCS, human basic fibroblast growth 
factor (FGF) 2 ng/mL, human epidermal growth factor 0.5 
ng/mL, heparin 5 ng/mL, recombinant human insulin-like 
growth factor-I 0.01 µg/mL, bovine serum albumin (BSA) 
0.2 µg/mL 
25 mL 




Primary HSVSMCs were cultured in 15% (v/v) FCS media and upon achieving 80% 
confluence, cells were divided into 3 groups (Figure 2-1). To maintain 
proliferation, the first group was cultured in 15% (v/v) FCS media (Table 2-4). To 
induce contractile differentiation, the second group was cultured in smooth 
muscle differentiation supplement (SMDS) 231 medium (Table 2-6). The third 
group was cultured in SMGS 231 medium (Table 2-5). Primary HSVSMCs were 
lysed for RNA and/or protein extraction at indicated time points. 
Table 2-6 SMDS medium composition. 
 
Figure 2-1 Workflow for SMDS-induced contractile differentiation of primary HSVSMCs. Primary SMCs 
were isolated from pre-implantation SVs from CABG patients and subjected to outgrowth. Upon achieving 
confluency, cells were seeded into 12-(mRNA expression) or 6-well plates (protein expression) and split into 3 
treatment groups (group 1 à 15% (v/v) FCS media, group 2 à SMDS, group 3 à SMGS). Cells were lysed 
for RNA and/or protein extraction at indicated time points.  
Reagent Volume 
Medium 231 500 mL 
Smooth muscle differentiation supplement (cat. no. S0085, 
Thermo Fisher Scientific, MA, USA), final concentration of 
components: 1% (v/v) FCS, heparin 30 µg/mL. 
5 mL 
Penicillin/streptomycin 5 mL (100 I.U/mL 




Primary HCASMCs were cultured in SMGS medium and upon achieving 80% 
confluency, cells were divided into 2 groups (Figure 2-2). To induce contractile 
SMC differentiation, the first group was cultured in SMDS medium (Table 2-6) 
and the second group was cultured in SMGS medium (Table 2-5). Primary 
HCASMCs were lysed for RNA and/or protein extraction at indicated time points. 
 
Figure 2-2 Workflow for SMDS-induced contractile differentiation of primary HCASMCs. Confluent 
primary HCASMCs were seeded into 12-(mRNA expression) or 6-well plates (protein expression) and split into 
2 treatment groups (group 1 à SMDS, group 2 à SMGS). Cells were lysed for RNA and/or protein extraction 




2.2.5 Ligand stimulation in primary HSVSMCs 
Confluent primary HSVSMCs intended for mRNA expression analysis were seeded 
into 12-well plates (1×105/well, technical n=3/condition) and cells intended for 
protein expression analysis were seeded into 6-well plates (1.5×105/well, 
technical n=3/condition). Upon achieving 80% confluence, 15% (v/v) FCS media 
was removed, and cells were starved in L-glutamine-free 0.2% (v/v) FCS 
starvation medium (SVM) (MEDIA1) for 72-h (Table 2-7) to achieve quiescence. 
Cells intended for experiments including the pharmacological ALK5 inhibitor 
SB525334 (cat. no.: S8822, MilliporeSigma, MO, USA) were split into two groups 
of four (Figure 2-3). To achieve pharmacological ALK5 inhibition prior to ligand 
stimulation, the first 4 groups were incubated in MEDIA1 containing 10 µM 
SB525334 (dissolved in DMSO) vehicle) for 30 min. In parallel, the second 4 
groups were incubated in MEDIA1 containing DMSO vehicle (1:1000) for 30 mins. 
Following this incubation step, medium was replaced with fresh MEDIA1 
containing recombinant human (rh) BMP-9 (10 ng/mL) (dissolved in 4 mM HCl 
containing 1% (w/v) BSA, cat. no.: 3209-BP-010, R&D Systems, MN, USA), rh TGF-
b1 (10 ng/mL) (dissolved in 4 mM HCl containing 1% (w/v) BSA, cat. no.: 240-B-
010, R&D Systems, MN, USA), both ligands and vehicle control (4 mM HCl/1% 
(w/v) BSA) ± DMSO (1:1000) or SB525334 (10 µM). After 24-h stimulation, primary 
HSVSMCs were either lysed and subjected to RNA and/or protein extraction or 
utilised for Ca2+ handling studies. 
Table 2-7 SMC starvation medium composition (without L-glutamine) (MEDIA1). 
Reagent Volume 
DMEM (cat. no.: 21969035, Thermo Fisher Scientific, MA, 
USA) 500 mL 
FCS 1 mL 
Penicillin/streptomycin 5 mL (100 I.U/mL 





Figure 2-3 Workflow for ligand stimulation experiments in primary HSVSMCs. Confluent primary 
HSVSMCs were seeded into 12-(mRNA expression) or 6-well plates (protein expression). Upon achieving 
80% confluence, cells were quiesced for 72-h. Cells were subsequently incubated in medium containing BMP-
9, TGF-b1, both ligands or vehicle control (4 mM HCl/1% (w/v) BSA) ± 30-min pre-incubation in SB525334 or 




2.2.6 HAdV-5-mediated ACVR2A delivery to primary HSVSMCs 
Confluent primary HSVSMCs (P4) were seeded into 12-well plates (1×105/well, 
technical n=3/condition) and cultured in 15% (v/v) FCS media. Upon achieving 
80% confluence, cells were divided into 2 main groups (Figure 2-4). Cells 
intended for virus-mediated transgene delivery were transduced with an 
increasing amount of HAdV-5 GFP and HAdV-5 ACVR2A (2.9) (1,000 viral particles 
(VP), 5,000 VP and 10,000 VP/cell) in 15% (v/v) FCS media overnight. Cells 
intended for mock control treatment were also cultured in 15% (v/v) FCS media 
overnight. The next day, one set of mock 15% (v/v) FCS media-treated cells were 
lysed and subjected to RNA extraction. Non-virus and virus-containing 15% (v/v) 
FCS media was replaced with fresh non-virus containing 15% (v/v) FCS media and 
SMDS media. Following 24-h incubation, HAdV-5 GFP-transduced HSVSMCs were 
imaged on a fluorescence/brightfield microscope at 10´ magnification to 
determine the efficiency of virus-mediated transgene delivery. Following 48-h 
incubation, cells were lysed and subjected to RNA extraction. 
 
Figure 2-4 Workflow for HAdV-5-mediated ACVR2A transgene delivery. Confluent primary HSVSMCs 
were seeded into 12-well plates. Upon achieving 80% confluence, cells were divided into 2 main groups 
(mock/no virus vs virus transduction). The virus group was transduced with indicated HAdV-5 GFP or HAdV-5 
ACVR2A VPs in 15% (v/v) FCS media overnight. The mock group remained in fresh 15% (v/v) FCS media 
overnight. The next day, virus- and non-virus containing medium was replaced with fresh non-virus containing 
15% (v/v) FCS media or SMDS medium. GFP fluorescence was determined at 24-h. 48-h post transduction, 




2.2.7 HEK293 cell expansion 
HEK293 cells were already available and cultured in T150 flasks (cat. no.: 
CLS430825, Merck, Germany) containing 25 mL of HEK293 medium (Table 2-8) in 
an incubator (37°C and 5% CO2). 1 vial of cryopreserved HEK293 cells was 
revived as described in section 2.2.2 and added to a T150 flask containing 25 mL 
HEK293 medium. Upon achieving 90% confluence, 1 T150 flask was expanded 
1:5. Growth medium was removed, and cells were washed in 1× sterile Ca2+-free 
PBS. PBS was removed, and 5 mL 1× sterile citric saline was added to the T150 
flask to induce cell detachment. The flask was placed in an incubator (37°C and 
5% CO2) for 5 minutes. 7 mL HEK293 medium were added to the T150 flask. The 
cell suspension was transferred to a sterile 50 mL centrifugation tube and 
subjected to centrifugation at 500 g for 5 min. The supernatant was discarded, 
and cells were re-suspended in fresh 15 mL HEK293 medium. 22 mL HEK293 
medium was added to each of 5 fresh T150 flasks and 3 mL cell suspension was 
added to each T150 flask. Flasks were placed in an incubator (37°C and 5% CO2). 
Table 2-8 HEK293 medium composition. 
2.3 Gene expression analysis 
2.3.1 RNA extraction, purification and quantification 
RNA extraction was performed using the miRNeasy Mini Kit (cat. no.: 217004, 
Qiagen, Netherlands) following the manufacturer’s instructions. 
In brief, culture medium was removed, and cells were washed once in ice cold 
sterile 1´ PBS. PBS was discarded and 700 µL Qiazol Lysis reagent were added to 
Reagent Volume 
Minimal Essential Medium 500 mL 
FCS 50 mL 
Sodium pyruvate 100 nM 
L-Glutamine 2 mM 
Penicillin/streptomycin 5 mL (100 I.U/mL 




each well underneath a hood. Each well was scratched with the top of a sterile 
1,000 µL pipette tip to ensure efficient cell lysis. Lysis reagent containing lysed 
cells was transferred to a sterile RNase-free 1.5 mL microcentrifuge tube and 
140 µL chloroform (cat. no.: C/4960/17, Thermo Fisher Scientific, MA, USA) 
were added to each sample. Microcentrifuge tubes were shaken for 15 s and left 
to incubate at room temperature for 3 min. Centrifugation was performed at 
12,000 g and 4°C for 15 min. The RNA-containing upper aqueous phase was 
transferred to a fresh 1.5 mL sterile RNase-free microcentrifuge tube and 525 µL 
100% (v/v) ethanol were added to each sample. The solution was gently mixed 
by pipetting up and down several times and transferred onto a fresh RNeasy 
Mini-spin column. Centrifugation was performed at 8,000 g and room 
temperature for 15 s. The flow-through was discarded and 350 µL RWT buffer 
were added onto the column. Centrifugation was performed at 8,000 g and room 
temperature for 15 s. The flow-through was discarded and 80 µL DNase/buffer 
solution (10 µL DNase + 70 µL Buffer RDD per sample) were added onto the 
column and left to incubate at room temperature for 15 min. 350 µL RWT buffer 
were added onto the column. Centrifugation of the column was performed at 
8,000 g and room temperature for 15 s and the flow-through was discarded. 500 
µL RPE buffer were added onto the column, centrifugation of the column was 
performed at 8,000 g and room temperature for 15 s and the flow-through was 
discarded. 500 µL RPE buffer were added onto the column and centrifugation 
was performed at 8,000 g and room temperature for 2 min and the flow-through 
was discarded. The RNeasy column was placed on a fresh sterile RNase-free 2 mL 
collection tube. Centrifugation was performed at full speed and room 
temperature for 1 min. The RNeasy column was placed on a fresh sterile RNase-
free 1.5 mL microcentrifuge tube and 30 µL RNase-free H2O were added onto the 
column to elute the RNA. Centrifugation of the column was performed at 8,000 g 




RNA concentrations for each sample were determined using the NanoDropTM 1000 
spectrophotometer (Thermo Fisher Scientific, MA, USA). The RNA concentration 
for each sample was calculated utilising Beer’s Law. 
c = A/(E*b) 
A = absorbance (represented in absorbance units), E = wavelength-dependent 
molar absorptivity (extinction co-efficient in L/(mol-cm)), b = path length in cm, 
c = sample concentration in moles/L. The 260/280 nm and the 260/230 nm ratios 
were calculated to determine RNA purity. A 260/280 ratio of ³ 2.0 and a 
260/230 ratio between 1.8-2.2 generally reflect pure RNA. RNA samples were 
either directly subjected to complementary c(DNA) synthesis or stored at -80°C. 
2.3.2 Reverse transcription reaction 
The reverse transcription reaction was performed for each RNA sample to 
generate cDNA. RNA samples were diluted in RNase-free H2O to a final 
concentration of 100 ng/10 µL in a sterile RNase-free 96-well plate (cat. no.: 
E1403-5200, Starlab, Germany) on ice as outlined in Table 2-9. 
Table 2-9 RNA sample preparation for reverse transcription reaction. 
  
Reagent Volume 
RNA sample (diluted in RNase-free H2O) x µL (equals 100 ng) 
RNase-free H2O x µL 
Note: total volume 10 µL/sample, add 2 negative controls for each 96-well 
plate à 1 RNase-free H2O control with reverse transcriptase and 1 RNA sample 




The reverse transcription master mix was prepared as outlined in Table 2-10. 
Table 2-10 Reverse transcription master mix. 
The 96-well plate was sealed (cat. no.: ZLAB0558, Thermo Fisher Scientific, MA, 
USA), placed on the MJ Research Tetrad PTC-225 Thermal Cycler (Global Medical 
Instrumentation Inc, MN, USA) and the outlined thermal cycling programme was 
initiated (denaturation: 10 min at 70°C; add reverse transcription master mix: 
10 min at 4°C; primer binding: 10 min at 25°C; elongation: 60 min at 42°C; 
enzyme inactivation: 15 min at 72°C). Following the denaturation step, the 96-
well plate was briefly removed and 10 µL reverse transcription master mix were 
added to each sample bringing the total volume up to 20 µL per sample. Each 
sample was mixed by gently pipetting up and down several times. The 96-well 
plate was sealed and placed back into the thermal cycler. 
Following completion of the reverse transcription programme, the 96-well plate 
was removed, and each cDNA sample was diluted by adding 80 µL RNase-free 
H2O. Samples were either directly subjected to quantitative real-time 
polymerase chain reaction (qRT-PCR) analysis or stored at -20°C. 
2.3.3 TaqMan™ quantitative real-time polymerase chain reaction 
Relative mRNA expression levels of target genes were determined by 
TaqMan™qRT-PCR analysis utilising custom-made TaqMan™ gene expression assays 
Reagent Volume 
SuperScript™ II Reverse Transcriptase 10 U/µL (cat. no.: 18064022, 
Thermo Fisher Scientific, MA, USA) 1 µL 
5´ SuperScript™ II buffer (supplied with SuperScript™ II Reverse 
Transcriptase, Thermo Fisher Scientific, MA, USA) 4 µL 
Deoxynucleotides (dNTPs; cat. no.: N0447S, New England BioLabs® 
Inc. (NEB), MA, USA) 1 µL 
Random hexamers (cat. no.: SO142, Thermo Fisher Scientific, MA, 
USA) 1 µL 
Dithiothreitol 5 mM (DTT; (supplied with SuperScript™ II Reverse 
Transcriptase, Thermo Fisher Scientific, MA, USA) 1 µL 
RNase inhibitor (cat. no.: N8080119, Thermo Fisher Scientific, MA, 
USA) 0.5 µL 
RNase-free H2O 1.5 µL 




(Table 2-12 and Table 2-13). Each TaqMan™ gene expression assay consists of a 
forward primer, a reverse primer and a complementary probe which contains a 
fluorophore (FAM® or VIC®) attached to the 5'-end and a quencher attached to 
the 3'-end. Each qRT-PCR reaction was prepared in duplicate in a sterile RNase-
free 384-well plate (cat. no.: 4309849, Thermo Fisher Scientific, MA, USA) on ice 
as outlined in Table 2-11. The RNase-free H2O control (+ reverse transcriptase) 
and the RNA control (- reverse transcriptase) served as negative controls for 
each TaqMan™ qRT-PCR experiment. 
Table 2-11 TaqMan™ qRT-PCR reaction mix. 
The 384-well plate was sealed and placed in the QuantStudio™ 12K Flex Real-
Time PCR System (Thermo Fisher Scientific, MA, USA). Each Taqman™ qRT-PCR 
experiment was performed utilising the following thermal cycling programme: 
hold: 2 min at 50°C; hold: 10 min at 95°C, 40 cycles: 15 s at 95°C followed by 1 
min at 60°C. 
The threshold cycle (Ct) was utilised to determine relative mRNA expression 
levels of target genes in each sample. The Ct is the number of cycles necessary 
for probe-mediated fluorescent signals to cross the background level. Whereas 
low Ct values are indicative of high relative mRNA expression levels, high Ct 
values reflect low relative mRNA expression levels. Normalisation was performed 
by subtracting housekeeping gene polyubiquitin-c (UBC) Ct values from 
respective target gene Ct values thereby generating delta Ct (ΔCt) values. ΔCt 
values were subjected to fold change/relative quantification (RQ) 
transformation (RQ = 2-ΔΔCt, ΔΔCt = target ΔCt – control ΔCt).  
Reagent Volume 
TaqMan™ Universal MasterMix II (cat. no.: 4440040, Thermo Fisher 
Scientific, MA, USA) 5 µL 
Respective Thermo Fisher Scientific TaqMan™ probe (MA, USA) 0.5 µL 
cDNA sample 2.5 µL 
RNase-free H2O 2 µL 




Table 2-12 List of Thermo Fisher Scientific TaqMan™ gene expression assays (part 1). 
  
Gene abbreviation Gene name cat. no. 
UBC Polyubiquitin-C Hs01871556_s1 
αSMA α-smooth muscle actin Hs00426835_g1 
CNN1 Calponin Hs200959434_m1 
MYH11 Myosin heavy chain 11 Hs00975796_m1 
SM22-α Smooth muscle protein 22-α Hs1038777_g1 
SERPINE1 Plasminogen activator inhibitor-1 Hs00167155_m1 
ID1 Inhibitor of differentiation-1 Hs03676575_s1 
AGTR1 Angiotensin II type 1 receptor Hs00258938_m1 
AGTR2 Angiotensin II type 2 receptor Hs03987590_g1 
MAS1 Mas proto-oncogene Hs00267157_s1 
SP7 Osterix Hs01866874_s1 
ALPL Alkaline phosphatase Hs01029144_m1 
LGALS3 Galectin-3 Hs00173587_m1 
CD68 Cluster of differentiation 68 Hs02836816_g1 
PCNA Proliferating cell nuclear antigen Hs00427214_g1 
CCND1 Cyclin D1 Hs00765553_m1 




Table 2-13 List of Thermo Fisher Scientific TaqMan™ gene expression assays (part 2). 
2.4 Protein expression analysis 
2.4.1 Cell lysis 
Cell lysis was performed on ice. Culture medium was removed, and cells were 
washed once in ice cold sterile 1× PBS. PBS was discarded and 70 µL of ice cold 
radioimmunoprecipitation assay (RIPA) buffer (Table 2-14) supplemented with 
protease and phosphatase inhibitors were added to each well. Each well was 
scratched with the base of a 1,000 µL pipette tip to ensure cell lysis. Protein 
lysates from 3 wells (technical n=3) were pooled, transferred to a sterile 1.5 mL 
microcentrifuge tube and centrifuged at maximum speed and 4°C for 1 min. The 
supernatant was transferred to a fresh sterile 1.5 mL microcentrifuge tube and 
placed on ice. Protein samples were either directly subjected to BCA reactions 
or stored at -20°C.  
Gene abbreviation Gene name cat. no. 
ALK5 Activin receptor-like kinase 5 Hs00610320_m1 
ALK1 Activin receptor-like kinase 1 Hs00953798_m1 
ALK2 Activin receptor-like kinase 2 Hs00153836_m1 
TGFBR2 TGF-b receptor 2 Hs00234253_m1 
BMPR2 BMP receptor type 2 Hs00176148_m1 
ACVR2A Activin A receptor type 2A Hs00155658_m1 




Table 2-14 Recipe for 100 mL RIPA buffer (pH 8.8). 
2.4.2 Determining protein sample concentration 
Sample protein concentration was determined utilising the Pierce™ BCA Protein 
Assay kit (cat. no.: 23227, Thermo Fisher Scientific, MA, USA) following the 
manufacturer’s instructions. 
In brief, BSA standards were prepared via serial dilution in sterile 1× PBS (range: 
25 – 2000 µg/mL). Sterile 1× PBS was used as a blank control (0 µg/mL). Next, 10 
µL of each respective standard were pipetted into duplicate wells of a clear, 
flat-bottomed 96-well plate. Next, 10 µL of each respective protein sample were 
pipetted into remaining wells (one well per sample). The working BCA solution 
was made up by mixing 1 part of Reagent B with 50 parts of Reagent A in a 15 
mL centrifuge tube (cat. no.: 430790, Corning Life Sciences, NY, USA). 150 µL 
working BCA solution were gently added to each well. The 96-well plate was 
gently tapped to ensure mixing and left to incubate in the dark at 37°C for 30 
min. Following 30-min incubation, the 96-well plate was placed into the Wallac 
1420 Victor2 Microplate Reader (LabMakelaar Benelux B.V., Netherlands) and 
absorbance was determined at 562 nm. Blank control absorbance was subtracted 
from each sample to adjust for background and duplicate readings for each 
standard were averaged to generate a standard curve. Unknown protein sample 
Reagent Amount 
Tris-HCl (cat. no.: 15506017, Thermo Fisher Scientific, MA, USA) 50 mM 
NaCl (cat. no.: X190, VWR International, PA, USA) 150 mM 
Ethylenediaminetetraacetic acid (EDTA; cat. no.: 15576-028, 
Thermo Fisher Scientific, MA, USA) 1 mM 
Triton™ X-100 (cat. no.: 9002-93-1, MilliporeSigma, MO, USA) 1 mL 
Sodium dodecyl sulfate (cat. no.:  BP166-500, Thermo Fisher 
Scientific, MA, USA) 0.1 g 
Sodium deoxycholate (cat. no.: D6750, MilliporeSigma, MO, USA) 0.5 g 
ddH2O 100 mL 
Note: pH to 8.8. For each use, add ½ tablet cOMPLETE protease inhibitor (cat. 
no.: 11873580001, Roche, Switzerland) and 50 µL phosphatase inhibitor (cat. 




concentrations were calculated using the linear equations based on this standard 
curve. 
2.4.3 Protein sample preparation for SDS-PAGE and 
immunoblotting 
Protein samples (total volume: 45 µL) were prepared in a sterile 96-well plate 
(protein sample: x (equals 20 µg); sterile 1× PBS: x µL; 4× NuPAGE™ LDS Sample 
Buffer (cat. no.: NP0007, Thermo Fisher Scientific, MA, USA): 9 µL). Following 
preparation, the 96-well plate was sealed and placed on the MJ Research Tetrad 
PTC-225 Thermal Cycler to enable denaturation at 95°C for 5 min. 
2.4.4 Immunoblot analysis 
First, 45 µL denatured protein sample were gently loaded into one well of a 12-
well NuPAGE™ 4-12% Bis-Tris resolving gel (cat. no.: WG1401BOX, Thermo Fisher 
Scientific, MA, USA) and separated in 1× NuPAGE™ MES SDS running buffer (cat. 
no.: NP002, Thermo Fisher Scientific, MA, USA) at room temperature and 120 V 
for approximately 2 h. 2.5 µL Chameleon Duo protein ladder (cat. no.: 928-
60000, LI-COR Biosciences, NE, USA) were added to each gel as a protein size 
reference. Following separation, protein transfer from the pre-cast gel onto 
Amersham™ Protran™ 0.2 µm nitrocellulose membrane (cat. no.: GE10600001, 
Merck, Germany) was achieved via electroelution in 1× transfer buffer (Table 
2-15) at 4°C and 100 V for 90 min. 
Table 2-15 Recipe for 1× transfer buffer. 
Following protein transfer, each nitrocellulose membrane was subjected to 
Ponceau staining (Table 2-16) to ascertain successful transfer.  
Reagent Amount 
Tris-base (cat. no.: BP152-1, Thermo Fisher Scientific, MA, USA) 6.06 g 
Glycine (cat. no.: BP381-1, Thermo Fisher Scientific, MA, USA) 28.8 g 
ddH2O 1,600 mL 
Methanol (cat. no.:  M/4056/17, Thermo Fisher Scientific, MA, 




Table 2-16 Recipe for Ponceau stain. 
Following Ponceau staining, each nitrocellulose membrane was placed into a 
plastic trough and washed in sterile 1× PBS on a shaker at room temperature for 
5 min. PBS was discarded and depending on the primary antibodies (Table 2-17), 
membranes were either blocked in 1× TBS 0.05% (v/v) Tween (Table 2-47)/SEA 
BLOCK (cat. no.: 37527, Thermo Fisher Scientific, MA, USA) 1:1 or 1× TBS 0.05% 
(v/v) Tween/3% (w/v) BSA on a shaker at room temperature for 1 h. Membranes 
were incubated with respective primary antibodies diluted in respective blocking 
buffer in sealed plastic bags on a shaker at 4°C overnight. The next day, 
membranes were subjected to 3 5-min washes in 1× TBS 0.05% (v/v) Tween on a 
shaker at room temperature. Membranes intended for αSMA, calponin and SM22-
α protein expression analysis were incubated with a secondary fluorescently 
conjugated goat anti-rabbit IgG antibodies (IgG Alexa Fluor® 680, 2 mg/mL, 
1:15,000, cat. no.: A-21109, Thermo Fisher Scientific, MA, USA) in 1× TBS 0.05% 
(v/v) Tween/SEA BLOCK 1:1 on a shaker protected from light at room 
temperature for 1 h. Membranes intended for pMLC9 and tMLC9 protein 
expression analysis were incubated with the same secondary antibodies (1:5,000) 
in 1× TBS 0.05% (v/v) Tween on a shaker protected from light at room 
temperature for 1 h. Membranes were subjected to 3 5-min washes in 1× TBS 
0.05% (v/v) Tween on a shaker protected from light at room temperature. 
Membranes were visualised utilising the LI-COR system (model: ODYSSEY CLx, LI-
COR Biosciences, NE, USA).  
Reagent Amount 
Ponceau S tetrasodium salt (cat. no.: 14330, Cayman Chemical, MI, 
USA) 0.5 g 
Acetic acid (cat. no.: 20104.323, VWR International, PA, USA) 25 mL 
ddH2O 475 mL 
Note: add 25 mL acetic acid to 400 mL ddH2O, add 0.5 g ponceau S 




Table 2-17 List of primary antibodies for immunoblot analysis. 
Following visualisation, membranes were placed in plastic troughs on a shaker 
and stripped in 200 mM sodium hydroxide solution (Table 2-18) at room 
temperature for 20 min. Membranes were re-blocked in 1× TBS 0.05% (v/v) 
Tween/SEA BLOCK 1:1 at room temperature for 1 h and subsequently incubated 
with an anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies in 
1× TBS 0.05% (v/v) Tween/SEA BLOCK 1:1 in sealed plastic bags on a shaker at 
4°C overnight. The next day, membranes were subjected to 3 5-min washes in 
1× TBS 0.05% (v/v) Tween on a shaker at room temperature and subsequently 
incubated with the secondary fluorescently conjugated goat anti-rabbit IgG 
antibodies (1:15,000) in 1× TBS 0.05% (v/v) Tween/SEA BLOCK 1:1 on a shaker 
protected from light at room temperature for 1 h. Membranes were subjected to 
3 5-min washes in 1× TBS 0.05% (v/v) Tween on a shaker at room temperature 
protected from light and subsequently visualised. Band intensities were 
quantified by densitometry using the Image Studio Lite Ver 5.2 software (LI-COR 
Biosciences, NE, USA). Target protein expression was normalised to housekeeper 
Protein Source Clonality Conc [mg/mL] 
Working dilution, 
blocking buffer 
cat. no. / 
company 
αSMA Rabbit Polyclonal 0.2 
1:500, 





Calponin Rabbit Monoclonal 0.063 
1:2,000, 





SM22-α Rabbit Polyclonal 1 
1:1,000, 





pMLC9 Rabbit Polyclonal 1 
1:1,000, 




abcam®, UK  
tMLC9 Rabbit Polyclonal unknown 
1:1,000, 








GAPDH Rabbit Polyclonal unknown 
1:3,000, 










GAPDH expression ([target protein]/[GAPDH]). The constant 1 was added to each 
value prior to log10 transformation. Log10-transformed values were subjected to 
statistical analyses. 
Table 2-18 Recipe for stripping buffer. 
  
Reagent Amount 
Sodium hydroxide (cat. no.: 1310-73-2, Thermo Fisher Scientific, 
MA, USA) 2 pellets 




2.5 Scratch assay 
Prior to seeding primary HSVSMCs into 12-well plates (1×105 cells/well, technical 
n=3/condition) in 15% FCS media, 3 equally distanced lines were drawn with a 
marker pen on the back of each plate (Figure 2-5). 
Upon achieving 80% confluence, cells were quiesced in L-glutamine-free SVM for 
72-h. Following quiescence, a scratch was performed down the middle of each 
well using the tip of a sterile 200 µL pipette tip (cat. no.: Z365688, 
MilliporeSigma, MO, USA). Next, L-glutamine-free SVM was gently replaced with 
stimulation medium. Scratches were imaged at 3 locations on the EVOS 
microscope (Thermo Fisher Scientific, MA, USA) at 10× magnification (0-h time 
point). Following a 20-h stimulation period, the same 3 locations were imaged 
again. For each image, distances between 10 points along both edges were 
measured using the ImageJ software. Values were expressed as % closure of the 
scratch compared to the 0-h baseline distance. 
 
Figure 2-5 Scratch closure quantification. Scratches were imaged at 10× magnification at the same 3 
locations at 0 and 20 h (left image à pre-drawn equally distanced lines on back of 12-well plate). Distances 
between scratches were measured between 10 pre-defined points at each of the 3 locations using the ImageJ 
software (right image). Values were averaged (30 points/scratch) for each treatment group and time point. 




2.6 BrdU proliferation assay 
5-bromo-2'-deoxyuridine (BrdU) proliferation assays (cat.no.: 2750, Merck, 
Germany) were performed following the manufacturer’s instructions. Primary 
HSVSMCs were seeded into 96-well plates (1×104 cells/well, technical 
n=5/condition) and cultured in 100 µL 15% (v/v) FCS media. Upon achieving 80% 
confluence, respective experiments were initiated. For ligand stimulation 
experiments, cells were cultured in SMC starvation medium containing L-
glutamine (Table 2-19). 
Table 2-19 SMC starvation medium composition (with L-glutamine) (MEDIA2). 
2.6.1 BrdU incorporation and cell fixation/denaturation 
Depending on the experimental set-up, BrdU was incorporated (1:2,000, final 
volume 100 µL/well) either 24 or 48-h prior to termination of the experiment. 
At least one set of cells was not loaded with BrdU, and 5 wells remained without 
cells filled with medium only for background correction. Following each 
respective period, stimulation medium was removed, and cells were fixed in 70 
µL ready-made fixing/denaturing solution at room temperature for 30 min. The 
fixing/denaturing solution was aspirated, and 96-well plates were patted dry. 
Plates were either directly subjected to BrdU ELISA analysis or stored in a heat-
sealed plastic bag protected from light at 4°C for up to a week. 
2.6.2 BrdU ELISA analysis 
The required amount of 1× washing buffer (1:50 dilution in ddH2O) was made up 
prior to performing BrdU ELISA analyses. 96-well plates were subjected to 3 
washes with 1× washing buffer (200 µL/well). 50 µL ready-made BrdU detection 
antibodies were added to each well and plates were left to incubate on a shaker 
Reagent Volume 
DMEM (cat. no. 21969035, Thermo Fisher Scientific, MA, 
USA) 500 mL 
FCS 1 mL 
L-glutamine 2 mM 




at room temperature protected from light for 1-h. Plates were again subjected 
to 3 washes with 1× washing buffer (200 µL/well). The secondary antibodies 
were made up in ready-made conjugate diluent (1:2,000 solution) and sterile 
filtered. 50 µL secondary antibody solution were added to each well and plates 
were left to incubate on a shaker at room temperature protected from light for 
30 min. Plates were again subjected to 3 washes with 1× washing buffer (200 
µL/well) and 1 final wash with ddH2O (flood the plate). Plates were patted dry 
prior to incubation with ready-made substrate solution (50 µL/well) at room 
temperature protected from light for 30 min and 50 µL ready-made stop solution 
were added to each well. The 96-well plate was placed into a Wallac 1420 
Victor2 Microplate Reader and absorbance was determined at 450 nm. All 
absorbance values were corrected for background intensity by subtracting the 
mean background values derived from unloaded cells from target values. 
2.7 Calcium handling studies 
Primary human SMCs were seeded into 12-well plates (1×105 cells/well, technical 
n=3/condition). Primary HSVSMCs were cultured in 15% (v/v) FCS media medium 
and primary HCASMCs were cultured in SMGS medium. Upon achieving 80% 
confluence, HSVSMCs were quiesced in MEDIA1 (Table 2-7) and HCASMCs were 
quiesced in MEDIA2 (Table 2-19). Quiescence media was removed, and SMCs 
were stimulated with respective ligands/pharmacological inhibitors (see section 
2.2.5) in respective quiescence media. 
Following 24-h, stimulation medium was replaced with 400 µL 0.5% (v/v) FCS 
HEPES medium (Table 2-20) containing 2 µM single wave Ca2+ indicator Cal-520 
(dissolved in DMSO, cat. no.: ab171868, abcam®, UK). Cells were left to incubate 
at 37°C and 5% CO2 protected from light for 75 min. Cal-520-containing medium 
was removed and cells were gently washed once with Ca2+-free 0.1 mM ethylene 
glycol-bis(b-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) HEPES solution 
(Table 2-21). Cells were incubated in 800 µL Ca2+-free 0.1 mM EGTA HEPES 
solution and left to equilibrate at room temperature protected from light for 25 
min. For pharmacological inhibitor studies, cells were incubated with 800 µL 
Ca2+-free 0.1 mM EGTA HEPES solution containing 10 µM losartan (dissolved in 
sterile ddH2O, cat. no.: 61188, MilliporeSigma, MO, USA), 10 µM fasudil 




vehicle control (sterile ddH2O) at room temperature protected from light for 25 
min. 
Following equilibration, 12-well plates were imaged (Excitation/Emission 
(Ex/Em) 490/525 nm) on a live-cell microscope (Zeiss, Germany) at 10× 
magnification. Each well was imaged for 6 min. Cells were left to equilibrate for 
2 min. At 2 min, 100 µL Ca2+-free 0.1 mM EGTA HEPES solution containing AngII 
(cat. no.: A9525, MilliporeSigma, MO, USA) were added into respective wells 
(final concentration à 1 µM AngII) to induce intracellular Ca2+ release and a 
subsequent increase in fluorescence intensity mediated by Cal-520/Ca2+ ion 
interaction. At 4 min, 100 µL Ca2+-free 0.1 mM EGTA HEPES solution containing 
ionomycin (IM, cat. no.: I0634, MilliporeSigma, MO, USA) were added into 
respective wells (final concentration à 1 µM IM) to induce maximum 
intracellular Ca2+ release by puncturing all cellular membranes (Beeler et al., 
1979). At 6 min, the trace was terminated. 
Table 2-20 HEPES medium composition for Ca2+ handling studies. 
  
Reagent Volume 
DMEM, low glucose, pyruvate, HEPES medium (cat. no.: 
22320-022, Thermo Fisher Scientific, MA, USA) 500 mL 
FCS 2.5 mL 




Table 2-21 Recipe for 1´ Ca2+-free 0.1 mM EGTA-containing HEPES solution. 
2.7.1 Whole region of interest analysis 
Following live-cell recordings, all whole frame fluorescent traces were 
background corrected using the Zeiss Zen software (Zeiss; Germany) and plotted 
using the GraphPad Prism 4.0 software (GraphPad Software, Inc., CA, USA). 
Trace normalisation to background fluorescence enabled calculation of AngII- 
(AngIImax fluorescence – baseline fluorescenceaverage) and IM-induced fluorescence 
amplitudes (IMmax - baseline fluorescenceaverage). 
2.7.2 Single cell region of interest analysis 
Live-cell video recordings were imported into the ImageJ software. Each 
recording was duplicated, set to the correct scale and brightened using the same 
settings for each recording. The recording was played and paused shortly after 
IM-induced fluorescence intensity facilitating identification of single cells. Single 
regions of interest were drawn around each cell within one frame and 5 
individual background regions were defined. A screenshot was taken for each 
frame prior to using the multi measure tool to assess time-dependent 
fluorescence intensity changes within each cell. The generated data matrix was 
then exported into an excel file. Background fluorescence changes were 
calculated for each timepoint averaging values from the 5 pre-defined 
background regions. Cell fluorescence values for each timepoint were then 
normalised to respective background fluorescence values. This enabled 
Reagent Amount [g] 
NaCl 7.6 (130 mM) 
KCl (cat. no.: 26752.366, VWR International, PA, USA) 0.373 (5 mM) 
MgCl2 hexahydrate (cat. no.: 0288, VWR International, PA, 
USA) 0.203 (1 mM) 
HEPES 4.77 (20 mM) 
D-glucose (cat. no.: 15023021, Thermo Fisher Scientific, MA, 
USA) 1.8 (10 mM) 
EGTA (cat.no.: 324626, MilliporeSigma, MO, USA) 0.38 (0.1 mM) 





calculation of AngII-induced amplitudes (AngIImax – baselineaverage) for each cell. 
AngII-induced amplitudes for each treatment group were plotted as a histogram 
using the GraphPad Prism 4.0 software enabling visualisation of distribution. 
2.8 Crosslinking of 125I-BMP-9 to HSVSMC cell surface 
receptors 
This experiment was based on a protocol developed by Professor P. ten Dijk’s 
group (University Medical Center, Leiden, Netherlands) and performed by Dr 
Emma Low (University of Glasgow, Glasgow, UK) and Midory Thorikay (University 
Medical Center, Leiden, Netherlands). In brief, primary HSVSMCs were cultured 
in 15% (v/v) FCS media in T75 flasks and upon achieving confluence, cells were 
washed twice in ice cold 1× PBS containing 1% (w/v) BSA. Cells were incubated 
with 125I-BMP-9 (100 µg/mL) and gently rocked at 4°C for 3-h. Following 3-h 
incubation, radiolabelled BMP-9 was removed, and cells were washed twice in 
ice cold 1× PBS containing 1% (w/v) BSA to remove unbound 125I-BMP-9. 
Crosslinking was performed by subjecting cells to 54 nM disuccinimidyl suberate 
and 3 mM bis(sulfosuccinimidyl)suberate at 4°C for 15 min. Cells were washed 
twice with 4 mL detachment buffer (10 mM Tris-HCl, 1 mM EDTA, 10% (v/v) 
glycerol, 1 mM phenylmethylsulfonylfluoride (PMSF), pH 7.4) and detached using 
a cell scraper. Cell suspensions were transferred to 1.5 mL microcentrifuge 
tubes and subjected to centrifugation at 10,000 g for 2 min. Supernatants were 
removed, and cell pellets were re-suspended in 500 µL solubilisation buffer (125 
mM NaCl, 10 mM Tris-HCl pH 7.4, 1 mM EDTA pH 7.4, 1% (v/v) Triton X-100, PMSF 
(10 µL/mL), aprotinin (1 µL/mL) and leupeptin (1 µL/mL)) and left to incubate 
on ice for 30 min. Lysates were subjected to centrifugation at maximum speed 
for 10 min and transferred to fresh 15 mL centrifugation tubes. Lysates were 
incubated with primary antibodies against ALK1, ALK2, BMPR2, ENG and 
ACVR2A/B at 4°C overnight. The next day, immune complexes were precipitated 
by incubation with protein A beads on a rotating wheel at 4°C for 45 min. 
Following incubation, beads were washed 4 times with solubilisation buffer 
containing 1´ Complete Protease Inhibitor Cocktail to remove any non-specific 
binding. Samples were boiled in SDS sample buffer (50 mM Tris-HCl, 2% (w/v) 
SDS, 10% (v/v) glycerol, 1% (v/v) b-mercaptoethanol, 12 mM EDTA and 0.02% 




buffer (25% (v/v) methanol and 7.5% (v/v) acetic acid) for 30 min. Next, gels 
were washed in drying buffer (25% (v/v) methanol and 10% (v/v) glycerol) and 
analysed on an autoradiograph. 
2.9 Cloning methods using the pAdEasy-1 system for 
generation of a recombinant HAdV-5 
The pAdEasy-1/pSHUTTLE-CMV system (Agilent Technologies, CA, USA)  was used 
to generate HAdV-5 ACVR2A (Alba et al., 2012). In brief, the pAdEASY-1 plasmid 
contains DNA for an E1/E3-deficient HAdV-5. The pSHUTTLE-CMV system 
contains a CMV promoter which drives expression of an inserted transgene of 
interest. The CMV/transgene section is inserted into the pAdEasy-1 plasmid via 
homologous recombination. 
2.9.1 Construct design and plasmid preparation 
The full human ACVR2A exon protein-coding sequence (name: ACVR2A-201, 
transcript ID: ENST00000241416.12) excluding the untranslated region was 
downloaded from the Ensembl genome browser 
(https://www.ensembl.org/index.htmL). Using the translated region as a 
template a SalI endonuclease restriction site (ERS) was designed at the 5' and a 
XhoI ERS was designed at the 3' end (total construct length: 1,605 base pairs 
(bp)). This sequence was artificially synthesised into the commercially available 
pEX-A2 carrier plasmid (Eurofins Scientific, Luxembourg). The lyophilised pEX-
A2::ACVR2A plasmid was diluted in sterile ddH2O to approximately 100 ng/mL 
prior to transformation. 
2.9.2 Transformation and propagation of XL10-Gold 
Ultracompetent Cells® 
XL10-Gold Ultracompetent Cells® (cat. no.: #200317, Agilent Technologies, CA, 
USA) were transformed with respective plasmids (pEX::ACVR2A, pSHUTTLE-
CMV::ACVR2A, pAdEasy-1::pSHUTTLE-CMV::ACVR2A). Depending on the plasmid’s 
antibiotic resistance open reading frame, transformed XL10-Gold cells were 
incubated/plated on either ampicillin (AMP)- or kanamycin (KAN)-containing 
AGAR (Formedium™). One 50 µL aliquot of XL10-Gold cells was thawed on ice for 




brought to room temperature. One round-bottom polypropylene 14 mL BD 
centrifuge tube (cat. no.: 352059, Becton Dickinson, NJ, USA) was pre-chilled on 
ice and SOC outgrowth medium (cat. no.: B9020S, NEB, MA, USA) was pre-
warmed to 42°C. The XL10-Gold aliquot was transferred to pre-chilled centrifuge 
tube and 4 µL b-mercaptoethanol (part of cat. no.: 200317, Agilent 
Technologies, CA, USA) were added to competent cells to increase 
transformation efficiency. The centrifuge tube was gently swirled and incubated 
on ice for 10 min swirling the centrifuge tube every 2 min. Respective plasmid 
(pEX-A2::ACVR2A à 1 µL; pSHUTTLE-CMV::ACVR2A à 2 µL; pAdEasy::pSHUTTLE-
CMV::ACVR2A à 2 µL) was added to XL10-Gold cell suspension and the 
Centrifuge tube was gently swirled and placed on ice for 30 min. For 
transformation with pSHUTTLE-CMV::ACVR2A an additional set of competent 
cells was transformed with de-phosphorylated double cut pSHUTTLE-CMV to 
control for background bacterial growth. 
Heat shock was performed at 42°C for 30 s to facilitate plasmid uptake by 
permeabilising the bacterial membrane. Following heat shock, the centrifuge 
tube was placed on ice for 2 min. Following heat shock, centrifuge tubes were 
placed on ice for 2 min. 900 µL pre-warmed SOC medium were added to 
respective centrifuge tube which was placed on a shaker at 5.7 g and 37°C for 1-
h. 100 µL SOC medium/competent cell suspension (low density group) were 
pipetted and spread onto pre-warmed AMP- or KAN-containing AGAR plate. 
Remaining 900 µL cell suspension were subjected to centrifugation at 13,000 g 
and 37°C for 1 min. Pellets were re-suspended in 100 µL pre-warmed SOC 
medium (high density group). Suspensions were pipetted and spread onto pre-
warmed AMP- or KAN-containing AGAR plates. AGAR plates were placed in an 
incubator at 37°C overnight. 
The next day, 12 colonies were picked with sterile 200 µL pipette tips. Each tip 
was placed in 5 mL liquid AMP- or KAN-containing Luria broth (LB) medium 
(Table 2-23) in a 15 mL centrifuge tube which was placed in a shaker at 5.7 g 
and 37°C overnight (MINI culture). pSHUTTLE-CMV::ACVR2A and pAdEasy-
1::pSHUTTLE-CMV::ACVR2A MINI-cultures were subjected to MINI plasmid 
purification and subsequent diagnostic restriction digest. The next day, 5 mL of 




medium in a 2 L Erlenmeyer flask. The flask was placed in a shaker at 3.6 g and 
37°C overnight (MAXI culture). 1 mL of respective MINI culture was frozen at -
80°C in 500 µL glycerol (cat. no.: G5516, MilliporeSigma, MO, USA) (total volume 
1.5 mL) in a cryovial. The next day, the MAXI culture was transferred to a large 
bug pot which was subjected to centrifugation at 6,000 g and 4°C for 15 min. 
The MAXI culture was either frozen at -20°C or subjected to plasmid 
purification. 
Table 2-22 Recipe for AGAR. 
Table 2-23 Recipe for Luria Broth medium. 
2.9.3 MINI plasmid purification 
MINI plasmid purifications were performed using the PureYield™ Plasmid 
Miniprep System (cat. no.: A1223, Promega, Wis, USA). 
Ready-made Neutralisation Solution was pre-chilled at 4°C. 1 mL LB 
medium/competent cell suspension was retained in a 4°C fridge. 4 mL LB 
medium/competent cell suspension were transferred into 2 sterile 2 mL 
microcentrifuge tubes. Tubes were subjected to centrifugation at maximum 
speed and 4°C for 30 s. Supernatants were discarded. The bacterial pellet was 
re-suspended in 600 µL sterile ddH2O. 100 µL ready-made Cell Lysis Buffer were 
Reagent Amount 
AGAR (cat. no.: AGA03, Formedium, UK) 7.5 g 
Luria broth Miller’s (cat. no.: 12795027, Thermo Fisher 
Scientific, MA, USA) 7.75 g 
Ampicillin (cat. no.: A5354, MilliporeSigma, MO, USA) or 
kanamycin (cat. no.: K0254, MilliporeSigma, MO, USA) 100 mg/mL  
Note: add 500 mL of ddH2O, mix well and autoclave. 1Add respective antibiotic 
after autoclave step, leave to cool down and then poor into respective petri 
dishes. 
Reagent Amount 
Luria broth Miller’s 15 g 
Ampicillin or kanamycin1 100 mg/mL  
Note: add 1 L of ddH2O, mix well and autoclave. 1Add respective antibiotic 




added and each tube was gently inverted 6 times. 350 µL pre-chilled Neutralising 
Solution were added and each tube was inverted 6 times. Tubes were subjected 
to centrifugation at maximum speed and room temperature for 3 min. 
PureYield™ Minicolumns were placed into Collection Tubes. 900 µL plasmid-
containing supernatant were transferred onto a PureYield™ Minicolumn without 
disturbing the cell debris pellet. Columns were subjected to centrifugation at 
maximum speed and room temperature for 15 s. The flow-through was 
discarded. 200 µL ready-made Endotoxin Removal Wash (ERB) were added onto 
each column which were centrifuged at maximum speed at room temperature 
for 15 s. The flow-through was discarded. 400 µL ready-made Column Wash 
Solution (CWC) were added to each column which were subjected to 
centrifugation at maximum speed at room temperature for 30 s. Each column 
was transferred onto a fresh sterile 1.5 mL microcentrifuge tube and 30 µL 
sterile ddH2O were added to elute plasmid DNA. The columns were left to 
incubate at room temperature for 1 min and then subjected to centrifugation at 
maximum speed and room temperature for 15 s. The plasmid DNA concentration 
for each sample was determined using a NanoDrop™ 1000 spectrophotometer. 
2.9.4 MAXI plasmid purification 
MAXI plasmid preparations were performed using the Qiagen Plasmid Maxi Kit 
(cat. no.: 12162, Qiagen, Netherlands). 
The ready-made P3 buffer was pre-chilled at 4°C while the bacterial pellet 
thawed. The pellet was re-suspended in 10 mL ready-made P1 buffer. 10 mL 
ready-made P2 buffer was added, and the bug pot was inverted 6 times and left 
to incubate at room temperature for 5 min. 10 mL pre-chilled P3 buffer was 
added and inverted 6 times. The lysate was poured into a fresh bug pot and 
subjected to centrifugation at 12,000 g at 4°C for 10 min. The supernatant was 
gently poured into a Qiagen Cartridge barrel and left to incubate at room 
temperature for 10 min. The Qiagen tip was placed on a rack and equilibrated 
with 10 mL QBT buffer. The barrel was allowed to empty by gravity. A plunger 
was gently inserted into the Qiagen Cartridge and the plasmid-containing lysate 
was filtered onto the equilibrated Qiagen tip which was allowed to empty by 




50 mL collection centrifuge tube was placed underneath the Qiagen tip and 
plasmid DNA was eluted with 15 mL ready-made QF buffer. 
10.5 mL isopropanol was added to the centrifuge tube. The solution was 
transferred to a fresh small container. The container was inverted 6 times to 
ensure mixing and was subjected to centrifugation at 15,000 g and 4°C for 30 
min. The supernatant was decanted. The plasmid DNA pellet was re-suspended 
with 1.5 mL 70% (v/v) ethanol and transferred to a fresh sterile 1.5 mL 
microcentrifuge tube. The tube was subjected to centrifugation at 15,000 g and 
room temperature for 10 min. The supernatant was decanted, and the plasmid 
DNA pellet was re-suspended in 200 µL sterile ddH2O. The plasmid DNA 
concentration was determined using the NanoDropTM 1000 spectrophotometer. 
2.9.5 Restriction digests 
Large scale double restriction digest of pEX-A2::ACVR2A and pSHUTTLE-CMV 
(cat. no.: 16403, Addgene, MA, USA) was performed with the SalI (cat. no.: 
R0138T, NEB, MA, USA) and XhoI (cat. no.: R0146S, NEB, MA, USA) restriction 
enzymes as outlined in Table 2-24. 
Table 2-24 Large scale double restriction digest for pEX-A2::ACVR2A and pSHUTTLE-CMV. 
In addition, pSHUTTLE-CMV plasmid DNA was subjected to single restriction 
digests with SalI and XhoI as outlined in Table 2-25.  
Reagent Amount 
Plasmid DNA x µL (equals 10 
µg)   
SalI 2.5 µL 
XhoI 2.5 µL 
10× CutSmart® buffer (cat. no.: B7204S, NEB, MA, USA) 5.5 µL 
Sterile ddH2O x µL 
Note: total volume 55 µL/reaction, mix well in a sterile 1.5 mL 




Table 2-25 Single restriction digest for pSHUTTLE-CMV. 
Diagnostic restriction digests were performed as outlined in Table 2-26. 
Table 2-26 Set-up for double-cut diagnostic digest. 
  
Reagent Amount 
Plasmid DNA x µL (equals 1 
µg)   
SalI or XhoI 1 µL 
10× CutSmart® buffer 2 µL 
Sterile ddH2O x µL 
Note: total volume 20 µL/reaction, mix well in a sterile 1.5 mL 
microcentrifuge tube and incubate at 37°C for 2-h. 
Reagent Amount 
Plasmid DNA x µL (equals 1 
µg)   
SalI 0.5 µL 
XhoI 0.5 µL 
10× CutSmart® buffer 2 µL 
Sterile ddH2O x µL 
Note: total volume 20 µL/reaction, mix well in a sterile 1.5 mL 




PmeI linearisation was performed on pSHUTTLE-CMV::ACVR2A as outlined in 
Table 2-27. pSHUTTLE-CMV::ACVR2A linearisation is required for homologous 
recombination with pAdEasy-1. 
Table 2-27 Set-up for PmeI linearisation. 
PacI diagnostic digests were performed for pAdEasy-1::pSHUTTLE-CMV::ACVR2A 
as outlined in Table 2-28. 
Table 2-28 Set-up for PacI diagnostic digest. 
  
Reagent Amount 
pSHUTTLE-CMV::ACVR2A plasmid DNA x µL (equals 10 
µg)   
PmeI (cat. no.: R0560S, NEB, MA, USA) 2.5 µL 
10× CutSmart® buffer 5.5 µL 
ddH2O x µL 
Note: total volume 55 µL/reaction, mix well in a sterile 1.5 mL 
microcentrifuge tube and incubate at 37°C for 2-h. 
Reagent Amount 
Plasmid DNA x µL (equals 1 
µg)   
PacI (cat. no.: R0547S, NEB, MA, USA) 1 µL 
10× CutSmart® buffer 2 µL 
Sterile ddH2O x µL 
Note: total volume 20 µL/reaction, mix well in a sterile 1.5 mL 




A large scale PacI linearisation for pAdEasy-1::pSHUTTLE-CMV::ACVR2A was 
performed as outlined in Table 2-29. 
Table 2-29 Set-up for large scale PacI linearisation. 
Successful restriction digests were confirmed by agarose gel electrophoresis. 
2.9.6 Agarose gel electrophoresis 
11 µL 6× loading dye (cat. no.: B7024S, NEB, MA, USA) were added to 55 µL 
double cut pEX-A2::ACVR2A. This sample was loaded into two combined wells of 
a 0.7% (w/v) agarose gel (Table 2-30). 5 µL uncut, single and double cut 
pSHUTTLE-CMV were made up to 20 µL using ddH2O. 4 µL 6× loading dye were 
added to each sample prior to gel loading. 4 µL 6× loading dye were added to 
each single/double cut plasmid DNA sample. 10 µL 1 kbp DNA ladder (cat. no.: 
10787018, Thermo Fisher Scientific, MA, USA) were loaded into one pocket of 
each 0.7% (w/v) agarose gel for DNA size reference. Samples were run out at 130 
V for 45 min in 1´ TBE buffer and subsequently imaged (ChemiDocTM XRS+, Bio-
Rad, CA, USA). When required, respective DNA bands were cut out on a UV light 
table and gel DNA extraction was performed.  
Reagent Amount 
pAdEasy-1::pSHUTTLE-CMV::ACVR2A x µL (equals 20 
µg)   
PacI 2 µL 
10× CutSmart® buffer 5 µL 
Sterile ddH2O x µL 
Note: total volume 50 µL/reaction, mix well in a sterile 1.5 mL 




Table 2-30 Recipe for 0.7% (w/v) agarose gel. 
2.9.7 Gel DNA extraction 
DNA purification following gel extraction was performed using QIAquick Gel 
Extraction Kit (cat. no.: 28115, Qiagen, Netherlands). The gel slice containing 
the respective DNA band was weighed in a fresh sterile 1.5 mL microcentrifuge 
tube. 3 volumes ready-made QG buffer were added to 1 volume gel (100 µL QG 
buffer equals 100 mg gel). The tube was incubated at 50°C for 10 min and then 
vortexed for 3 min. 1 gel volume isopropanol was added to the tube. A QIAquick 
spin column was placed onto a provided 2 mL collection tube. The DNA sample 
was pipetted onto the QIAquick spin column which was subjected to 
centrifugation at 13,000 g for 1 min. The flow-through was discarded. 750 µL 
ready-made PE buffer were added to the column which was subjected to 
centrifugation at 13,000 g for 1 min. The flow through was discarded. The 
column was left to incubate at room temperature for 5 min and was subjected to 
centrifugation at 13,000 g for 1 min to remove residual wash buffer. The column 
was placed onto a fresh sterile 1.5 mL microcentrifuge tube. 30 µL sterile ddH2O 
were added to the column which was subjected to centrifugation at 13,000 g for 
1 min to elute the DNA. 
2.9.8 Phenol/chloroform purification (PCP) 
150 µL sterile ddH2O were added to each respective sample. An equal volume of 
phenol/chloroform/isoamyl alcohol (cat. no.: P3803, MilliporeSigma, MO, USA) 
was added to each sample. The tube was vortexed for 30 s and was subjected to 
centrifugation at 13,000 g and room temperature for 2 min. The upper aqueous 
Reagent Amount 
Agarose (cat. no.: 16500100, Thermo Fisher Scientific, MA, USA) 1.4 g   
1´ TBE buffer (cat. no.: 15581044, Thermo Fisher Scientific, MA, 
USA) 
200 mL 
Ethidium bromide (cat. no.: E1510, MilliporeSigma, MO, USA) 4 µL 
Note: add agarose powder to 1´ TBE buffer in an Erlenmeyer flask and swirl 
gently, place flask in microwave and bring solution to boiling, prepare gel 
mould under hood while agarose/TBE solution is heating in the microwave, 
remove flask from microwave and place under hood, add 4 µL ethidium 
bromide to flask and swirl gently, pour solution into gel mould and leave to 




phase containing the DNA was carefully removed and transferred to a fresh 
sterile 1.5 mL microcentrifuge tube. An equal volume of chloroform was added 
to remove phenol residue. The tube was vortexed for 30 s and was subjected to 
centrifugation at 13,000 g and room temperature for 2 min. The upper phase 
was carefully transferred to a fresh sterile 1.5 mL microcentrifuge tube. 1/10 
volume 3 M sodium acetate (pH 5.2) and 2 volumes 100% (v/v) ethanol were 
added to the DNA sample. The sample was placed in a -80°C freezer for 30 min. 
The tube was subjected to centrifugation at 13,000 g and 4°C for 10 min. The 
supernatant was gently discarded, and the DNA pellet was re-suspended in 100 
µL 70% (v/v) ethanol. The tube was subjected to centrifugation at 13,000 g and 
4°C for 2 min. The supernatant was carefully removed. The DNA pellet was left 
to air dry for 10 min and was re-suspended with the original ddH2O volume. The 
DNA concentration was determined using the NanoDrop™ 1000 
spectrophotometer. 
2.9.9 pSHUTTLE-CMV de-phosphorylation 
Following PCP, 1 µg double-cut pSHUTTLE-CMV was de-phosphorylated as 
outlined in Table 2-31 to reduce background bacterial growth following 
ligation/transformation. 
Table 2-31 De-phosphorylation of double-cut pSHUTTLE-CMV backbone. 
2.9.10 DNA ligation 
Ligation between de-phosphorylated double cut pSHUTTLE-CMV and the ACVR2A 
DNA fragment was performed as outlined in Table 2-32. 
Reagent Amount 
Double-cut pSHUTTLE-CMV plasmid DNA x µL (equals 1 
µg)   
Antarctic phosphatase (cat. no.: M0289S, NEB, MA, USA) 1 µL 
Antarctic phosphatase buffer (cat. no.: B0289S, NEB, MA, 
USA) 2 µL 
Sterile ddH2O x µL 
Note: total volume 20 µL/de-phosphorylation reaction, mix well in a sterile 
1.5 mL microcentrifuge tube and incubate at 37°C for 30 min, heat 




Table 2-32 Set-up for ligation reaction. 
2.9.11 Plasmid sequencing 
The ACVR2A insertion site was sequenced (Eurofins Scientific, Luxembourg) to 
confirm DNA identity and integrity using respective primers: forward (fw)1 
primer: 5'-CGCAAATGGGCGGTAGGC-3', fw2 primer: 5'-TGTTCCAACTCAAGACC-3'; 
fw3 primer: 5'-CTATGGGAACTGGCTTC-3'. 
2.9.12 Homologous recombination 
Homologous recombination between pAdEasy-1 and PmeI-linearised pSHUTTLE-
CMV::ACVR2A was performed in BJ5183-AD-1 Electroporation Competent Cells 
(cat. no.: #200157, Agilent, CA, USA). BJ5183-AD-1 cells already contain 
pAdEasy-1. 
BJ5183-AD-1 cells were thawed on ice. SOC medium and electroporation 
cuvettes (cat. no.: ECU105, Geneflow Ltd., UK) were pre-chilled on ice. 1 µg 
PmeI-linearised pSHUTTLE-CMV::ACVR2A was added to sterile ddH2O (total 
volume 6 µL) in a sterile 1.5 mL microcentrifuge tube which was placed on ice. 
Linearised plasmid/ddH2O suspension was added to 50 µL thawed BJ5183-AD-1 
cell suspension and mixed by gently pipetting up and down several times. The 
entire sample was transferred to a pre-chilled electroporation cuvette and left 
to incubate on ice for 3 min. The cuvette was placed into an electroporator 
(MicroPulser, Bio-Rad, CA, USA) and pulsed for 1 s (Ec2 mode, 200 Ω, 2.5 kV, 25 
Reagent Amount 
De-phosphorylated double-cut pSHUTTLE-
CMV plasmid DNA 2 µL (equals 100 ng, 7.5 kbp)   
ACVR2A DNA fragment 
x µL (1,605 bp equals 1         
(pSHUTTLE-CMV):5 (ACVR2A cDNA 
insert) molar equivalent 
DNA ligase T4 (cat. no.: M0202S, NEB, MA, 
USA) 1 µL 
DNA ligase buffer (cat. no.: B0202S, NEB, 
MA, USA) 2 µL 
Sterile ddH2O x µL 
Note: total volume 20 µL/ligation reaction, mix well in a sterile 1.5 mL 
microcentrifuge tube and incubate at 16°C overnight, heat inactivation at 




µF). The cuvette was immediately removed and 500 µL of pre-chilled SOC 
medium were added. The cell/plasmid/SOC medium suspension was mixed by 
gently pipetting up and down several times and then transferred to a fresh 
sterile 1.5 mL microcentrifuge tube. The tube was placed in a shaker at 5.7 g 
and 37°C for 1-h. The tube was subjected to centrifugation at 2,000 g for 1 min. 
The pellet was re-suspended in 100 µL SOC medium. The suspension was plated 
and spread onto a kanamycin-containing AGAR plate which was placed in an 
incubator at 37°C overnight. The next day, 12 smallest colonies were subjected 
to MINI-culture and MINI plasmid purification. 
2.9.13 HEK293 transfection with pAdEasy-1::pSHUTTLE-
CMV::ACVR2As 
Plasmid transfection into HEK293 cells was performed using the Xfect™ 
transfection Reagent (cat.no.: 631317, TaKaRa Bio, Japan). HEK293 cell DNA 
contains the HAdV-5 packaging signal and E1 region which are necessary for viral 
replication. 
HEK293 cells were seeded into one 6-well plate (6×105 cells/in 1 mL medium). 
Upon achieving 50-70% confluence, plasmid transfection was performed. 
Precipitated PacI-linearised AdEasy-1::pSHUTTLE-CMV::ACVR2A and the control 
GFP plasmid were thawed on ice. Just prior to use, Xfect™ Polymers and Xfect™ 
Reaction Buffer were brought to room temperature. Both reagents were 
vortexed prior to use. 5 µg plasmid DNA (equals 1 well) were diluted in Xfect™ 
Reaction Buffer to a final volume of 100 µL in a sterile 1.5 mL microcentrifuge 
tube. The tube was vortexed for 5 s. 1.5 µL Xfect™ Polymer was added to diluted 
plasmid solution. The tube was vortexed for 10 s (RATIO: 0.3 µL of Xfect™ 
Polymer equals 1 µg of plasmid DNA) and left to incubate at room temperature 
for 10 min to allow nanoparticle complex formation. The entire volume was 
added dropwise to respective well. The 6-well plate was rocked gently for 10 s 
and incubated at 37°C and 5% CO2 for 4-h. Nanoparticle-containing medium was 
replaced with 2 mL fresh HEK293 growth medium and the 6-well plate was 
placed back in an incubator at 37°C and 5% CO2. 
Following 48-h, GFP plasmid-transfected cells were imaged on a microscope at 




medium was replaced with fresh medium every 2-3 days. Medium replacement 
was stopped once plaque formation became evident. Plaque-containing wells 
were marked, and the 6-well plate was left to incubate until the cytopathic 
effect (CPE) was complete (approximately 2 additional days). 
2.9.14 Crude virus isolation 
Once CPE had spread throughout the entire well, HEK293 cells gradually started 
to lift off the bottom of the well. Each well was carefully washed with medium 
from the same well and HEK293 cell suspensions containing crude HAdV-5 
ACVR2A (HEK293 cells contain crude virus) were transferred to separate sterile 
1.5 mL microcentrifuge tubes (1 mL/tube, 2 tubes for 1 well). Tubes were 
subjected to centrifugation at 250 g and room temperature for 10 min. 
Supernatants were gently discarded. Cell pellets were gently re-suspended in 
250 µL sterile 1× PBS and 250 µL 1,1,2-Trichloro-1,2,2-trifluoro-ethane (cat. no.: 
34874, MilliporeSigma, MO, USA) were added to the suspension. Tubes were 
gently inverted 6 times, gently shaken and subjected to centrifugation at 750 g 
and room temperature for 10 min. The crude virus-containing top liquid layer 
was carefully transferred to fresh sterile 1.5 mL microcentrifuge tubes (50 
µL/tube). Crude virus aliquots were either directly subjected to the first round 




2.9.15 First plaque purification 
HEK293 cells were seeded into a 96-well plate (12 medium + 8 mL HEK293 
suspension from one T150 flask à 200 µL/well). The first and last column were 
filled with 1× sterile PBS. The next day, a serial virus dilution was performed in 
HEK293 growth medium (Table 2-33). 
Table 2-33 Virus dilution table 
HEK293 growth medium was very carefully replaced with 100 µL respective virus 
suspension or non-virus containing control medium. The next day, respective 
virus suspension was very carefully replaced with 200 µL fresh HEK293 growth 
medium. Growth medium was replaced with fresh medium every 2 days. Medium 
replacement was stopped once CPE became evident and wells containing plaque 
were marked. The aim was to isolate HAdV-5 ACVR2A from the lowest possible 
virus suspension treatment group to exclude crude virus contamination. Once 
CPE had spread throughout an entire well of a low virus suspension treatment 
group, mature virus isolation was performed. Respective well was gently washed 
with 200 µL growth medium from the same well to detach the plaque and the 
HEK293 cell suspension was gently transferred to a fresh sterile 1.5 mL 
microcentrifuge tube. The tube was subjected to centrifugation at 250 g and 
room temperature for 10 min. The supernatant was gently discarded. The cell 
pellet was carefully re-suspended in 200 µL sterile 1× PBS and 200 µL 1,1,2-
Dilution Virus [µL] Medium [µL] 
10-2 50 (crude virus) 4,950 
10-3 500 of 10-2 4,500 
10-4 500 of 10-3 4,500 
10-5 500 of 10-4 4,500 
10-6 500 of 10-5 4,500 
10-7 500 of 10-6 4,500 
10-8 500 of 10-7 4,500 




Trichloro-1,2,2-trifluoro-ethane were added. The tube was gently inverted 6 
times, shaken and subjected to centrifugation at 750 g and room temperature 
for 10 min. The virus-containing top liquid layer was carefully transferred to 
fresh sterile 1.5 mL microcentrifuge tubes (50 µL/tube). Virus aliquots were 
either directly subjected to a second round of plaque purification or stored in a -
80°C freezer. 
2.9.16 Second plaque purification 
The second plaque purification was performed as outlined in section 2.9.15. The 
aim was to isolate HAdV-5 ACVR2A from the lowest possible virus suspension 
treatment group to further exclude crude virus contamination during subsequent 
seed stock generation. Mature virus aliquots were either directly subjected to 
seed stock generation or stored at -80°C. 
2.9.17 Seed stock generation 
HEK293 cells were seeded into two T150 flasks (25 mL growth medium/T150 
flask). Upon achieving 80-90% confluency, one T150 flask was infected with one 
HAdV-5 ACVR2A 50 µL aliquot derived from the 2nd plaque purification. The 
second T150 flask remained as an uninfected control. The next day, virus- and 
non-virus-containing medium was replaced with 25 mL fresh growth medium. 
Once CPE was complete (approximately 3-4 days), the HEK293 cell layer was 
gently detached in 25 mL growth medium from the same flask. The cell 
suspension was transferred to a fresh sterile 50 mL centrifuge tube. The 
centrifuge tube was subjected to centrifugation at 250 g and room temperature 
for 10 min. The supernatant was gently discarded, and the pellet was gently re-
suspended in 1.2 mL sterile 1× PBS. The suspension was transferred to a fresh 
sterile 15mL centrifuge tube. 1.2 mL 1,1,2-Trichloro-1,2,2-trifluoro-ethane were 
added, and the centrifuge tube was gently inverted 6 times, shaken and 
subjected to centrifugation at 750 g and room temperature for 10 min. The top 
liquid layer containing HAdV-5 ACVR2A was transferred to fresh sterile 1.5 mL 




2.9.18 Scale up and virus isolation 
HEK293 cells were seeded into one T150 flask (25 mL growth medium/T150 
flask). Upon achieving 90% cell confluence, the flask was split 1:5. Upon 
achieving 90% cell confluence, the 5 flasks were again split 1:5 generating a 
total number of 25× T150 flasks. Upon achieving approximately 70% confluence, 
24× T150 flasks were infected with purified HAdV-5 ACVR2A (1× 50 µL HAdV-5 
ACVR2A aliquot was added to 1× bottle HEK293 growth medium, 25 mL infected 
growth medium/T150 flask). 1× T150 flask remained as an uninfected control. 
The next day, virus- and non-virus-containing medium was replaced with 25 mL 
fresh growth medium. Once CPE was complete (approximately 2-3 days), the 
HEK293 cell layer was gently detached in 25 mL growth medium from the same 
flask. Cell suspensions were transferred to fresh sterile 50 mL centrifuge tubes. 
Centrifuge tube were subjected to centrifugation at 2,000 g and room 
temperature for 10 min. Supernatant was discarded and cell pellets were gently 
re-suspended in 6 mL sterile 1× PBS. 6 mL 1,1,2-Trichloro-1,2,2-trifluoro-ethane 
were added to each Centrifuge tube. Centrifuge tubes were inverted 5 times and 
subjected to centrifugation at 3,000 g and room temperature for 15 min. Upper 
aqueous layers containing HAdV-5 ACVR2A were transferred to a fresh sterile 50 
mL centrifuge tube. The virus suspension was either directly subjected CsCl 
gradient purification or stored at -80°C. 
2.9.19 CsCl gradient preparation and centrifugation 
HAdV-5 ACVR2A suspension was subjected to two sequential CsCl gradients to 
separate all viral particles from debris. Gradient preparation was performed 
underneath a cell culture hood. 
The required number of SW40 ultracentrifuge tubes (cat. no.: 344060, Beckman 
Coulter Life Sciences, IN, USA) were rinsed in 70% (v/v) ethanol and sterile 1× 




Table 2-38)/1× TD buffer (Table 2-34) were carefully added to the bottom of an 
ultracentrifuge tube. 2.5 mL 1.25 g/mL CsCl (Table 2-36)/1× TD buffer were 
gently dripped on top. The virus suspension was carefully dripped on top. Sterile 
1× PBS was carefully dripped on top to completely fill the ultracentrifuge tube. 
The ultracentrifuge tube was carefully placed in a SW40 rotor and subjected to 
centrifugation in an ultracentrifuge (cat. no.: OptimaTM L-80 XP Ultracentrifuge, 
Beckman Coulter Life Sciences, IN, USA) at 218,000 g and 18°C for 90 min 
(acceleration à maximum, no brake). The ultracentrifuge tube was carefully 
removed from the spin column and placed in a tube holder underneath a cell 
culture hood. A plastic waste beaker was placed underneath the tube holder. 
The virus band was identified between both CsCl layers. 
The side of the ultracentrifuge tube was pierced with a 5 mL syringe (Injekt®-F 
Solo, B. Braun, Germany) + 21 G sterile green needle (Becton Dickinson, NJ, 
USA) (needle opening facing downwards) on the level of the 1.25 g/mL CsCl 
gradient above the virus band. Debris was carefully aspirated. The syringe + 
needle remained inside the ultracentrifuge tube, and the ultracentrifuge tube 
was rotated so the syringe faced the back of the hood. The side of the 
ultracentrifuge tube was pierced again with a fresh 5 mL syringe + 21 G green 
needle (needle opening facing downwards) just below the virus band. The 
needle opening was gently rotated upwards and with a sweeping motion the 
virus band was aspirated. The syringe was pulled out of the ultracentrifuge tube 
and the virus suspension was transferred to a fresh sterile 5 mL bijoux vial (cat. 
no.: E1412-0710, Starlab, Germany). 
HAdV-5 ACVR2A suspension was subjected to a second CsCl gradient purification 
to separate mature from immature viruses. Gradient preparation was performed 
in a SW40 ultracentrifuge tube. 5 mL 1.34 g/mL CsCl/1× TD buffer (Table 2-37) 
were carefully added to the bottom of an ultracentrifuge tube. The virus 
suspension was carefully dripped on top. Sterile 1× PBS was carefully dripped on 
top to completely fill the ultracentrifuge tube. The ultracentrifuge tube was 
then subjected to the same steps as described above. The virus suspension was 




Table 2-34 Recipe for 10´ TD buffer. 
Table 2-35 Recipe for 10´ Tris-EDTA (TE) buffer. 
Table 2-36 1.25 g/mL CsCl solution. 
Table 2-37 1.34 g/mL CsCl solution. 
  
Reagent Amount 
NaCl 80 g   
KCl 3.8 g 
Na2HPO4 12 H2O (cat. no.: 71649, MilliporeSigma, MO, USA) 2.5 g 
Tris-base 30 g 
Note: add 900 mL ddH2O, adjust pH to 7.4 with HCl, top up with ddH2O to 1 L. 
Autoclave and store at 4°C. 
Reagent Amount 
Tris-HCl 12.1 g   
EDTA 3.72 g 
Note: add 900 mL ddH2O, adjust pH to 8 with NaOH, top up with ddH2O to 1 L. 
Autoclave and store at room temperature. 
Reagent Amount 
CsCl (cat. no.: 289329, MilliporeSigma, MO, USA) 36.16 g   
1´ TD buffer 100 mL 
Note: check by weighing, filter sterilise underneath hood before use (0.22 µm 
filter) and store at room temperature for up 1 year. 
Reagent Amount 
CsCl 51.2 g   
1´ TD buffer 100 mL 
Note: check by weighing, filter sterilise underneath hood before use (0.22 µm 




Table 2-38 1.40 g/mL CsCl solution. 
2.9.20 Dialysis 
CsCl is removed from the virus suspension during this step. A 2 L plastic beaker 
was sprayed down with 70% (v/v) ethanol underneath a cell culture hood. The 
beaker was carefully washed with 200 mL autoclaved ddH2O. 2 L 1× TE buffer 
(200 mL 10× TE buffer (Table 2-35) + 1,800 mL autoclaved ddH2O) was added to 
the beaker. The beaker was placed on a magnetic stirrer plate underneath the 
cell culture hood. One injection port of a dialysis cassette (10,000 MWCO, cat. 
no.: 66380, Thermo Fisher Scientific, MA, USA) was circled to label the virus 
injection site. 
The virus suspension was aspirated with a 5 mL syringe + 21 G needle. 
Approximately 0.5 mL air were additionally aspirated into the syringe. The 
syringe needle was gently advanced into the pre-labelled injection port of the 
dialysis cassette until the opening just became visible inside the cassette. Air 
followed by virus sample were gently injected into the cassette without piercing 
the membrane. Once the sample was injected, as much air as possible was 
aspirated allowing the liquid sample level to rise to the top of the membrane. 
The dialysis cassette was placed in a floater and was floated upside down 
(cassette submerged in 1× TE buffer) in the pre-filled plastic beaker. The stirrer 
was switched on and the dialysis cassette was stirred for 2-h. 1× TE buffer was 
replaced with 2 L of fresh 1× TE buffer and the dialysis cassette was stirred for 
another 2-h. 1× TE buffer was replaced with glycerol-containing 1× TE buffer 
(200 mL 10× TE buffer + 200 mL autoclaved glycerol + 1600 mL autoclaved 
ddH2O) and the dialysis cassette was stirred overnight.  
Reagent Amount 
CsCl 62.2 g   
1´ TD buffer 100 mL 
Note: check by weighing, filter sterilise underneath hood before use (0.22 µm 




2.9.21 Virus aliquot preparation 
The next day, virus aliquot preparation was performed. 1.5 mL air were 
aspirated into a 5 mL syringe + 21 G needle and the needle was gently advanced 
along a different injection port of the dialysis cassette until the needle opening 
became fully visible. Air was then gently injected, and the virus solution was 
gently aspirated and transferred to a fresh sterile 5 mL bijoux. 50 µL aliquots 
were prepared in fresh sterile 1.5 mL microcentrifuge tubes and stored at -80°C. 
In addition, 1× 30 µL aliquot was also stored at -80°C and was later used for 
setting up the plaque-forming unit (PFU) titre plate. 
2.9.22 Viral particle quantification 
The Micro BCA™ Protein Assay Kit (cat. no.: 23235, Thermo Fisher Scientific, MA, 
USA) was utilised to determine the number of VPs/mL. 
BSA standards were prepared via serial dilution in sterile 1× PBS (range: 0.5 - 200 
µg/mL). Sterile 1× PBS was used as a blank control (0 µg/mL). 150 µL of each 
respective standard were pipetted into duplicate wells of a clear, flat-bottomed 
96-well plate. Next, 1, 3 and 5 µL purified HAdV-5 ACVR2A stock were added in 
duplicate to empty wells on the same 96-well plate. Volumes were adjusted to 
150 µL with sterile 1× PBS. The working Micro BCA solution was made up by 
mixing 25 parts of Reagent MA and 24 parts Reagent MB with 1 part of Reagent 
MC in a sterile 15 mL centrifuge tube. 150 µL working Micro BCA solution were 
gently added to each well. The 96-well plate was gently tapped to ensure mixing 
and left to incubate in the dark at 37°C for 2-h. Following 2-h incubation, the 
96-well plate was placed into the Wallac 1420 Victor2 Microplate Reader and 
absorbance was determined at 562 nm. Blank control absorbance was subtracted 
from each sample to adjust for background and duplicate readings for each 
standard were averaged to generate a standard curve. Unknown protein sample 
concentrations were calculated using the linear equation based on this standard 
curve. Protein sample concentrations were converted to respective VP titer 
(VP/mL) according to the following formula (1 µg viral protein equals 1×109 VP) 




2.9.23 Generation of recombinant E1/E3-deficient HAdV-5 
ACVR2A 
XL10-Gold Ultracompetent cells were transformed with pEX-A2::ACVR2A and 
subjected to propagation (2.9.2) (Figure 2-6). Transformed/propagated XL10 
Gold cells were subjected to MAXI plasmid isolation/purification (2.9.4). 
Propagated pEX-A2::ACVR2A and already available pSHUTTLE-CMV were 
subjected to SalI/XhoI restriction digests (2.9.5). Successful restrictions were 
confirmed by agarose gel electrophoresis (2.9.6). The ACVR2A DNA band was cut 
out on a UV table and subjected to gel extraction (2.9.7) and PCP (2.9.8). In 
addition, double cut pSHUTTLE-CMV was also subjected to PCP. 
S2.9.10uccessful ligation between purified ACVR2A and double cut pSHUTTLE-
CMV was achieved (2.9.10) (colony 10, Figure 2-6). Following overnight ligation, 
XL10-Gold cells were transformed with ligated pSHUTTLE-CMV::ACVR2A and 
subjected to propagation, MINI plasmid purification (2.9.3), SalI/XhoI diagnostic 
digests (2.9.5) and subsequent gel electrophoresis (2.9.6). pSHUTTLE-
CMV::ACVR2A deriving from colony was subjected to sequencing using respective 
primers (2.9.11). Following confirmation of DNA integrity, XL10-Gold cells were 
transformed with pSHUTTLE-CMV::ACVR2A and subjected to MAXI propagation 
(2.9.2). MAXI-prepped (2.9.4) pSHUTTLE-CMV::ACVR2A was subjected to a 
diagnostic SalI/XhoI restriction digest (2.9.5) and subsequent gel electrophoresis 





Figure 2-6 Workflow diagram for generation of pSHUTTLE-CMV::ACVR2A. The ACVR2A protein-coding 
exon sequence was inserted into pSHUTTLE-CMV downstream of the CMV promoter which drives gene 
expression. Sequencing confirmed that plasmids isolated from colony 10 contained the ACVR2A insert. 




MAXI prepped pSHUTTLE-CMV::ACVR2A was subjected to PmeI linearisation 
(2.9.5) which is necessary for homologous recombination with pAdEasy-1 (Figure 
2-7). PmeI-linearised pSHUTTLE-CMV::ACVR2A was subjected to gel 
electrophoresis. The linearised DNA band was cut out on a UV table and 
subjected to gel extraction (2.9.7). 
Homologous recombination between gel extracted/PmeI-linearised pSHUTTLE-
CMV::ACVR2A and pAdEasy-1 was performed in BJ5183-AD-1 cells (2.9.12). 
Transformed BJ5183-AD-1 cells were subjected to MINI culture propagation 
(2.9.2). MINI cultures were subjected to MINI plasmid purification (2.9.3) and 
PacI diagnostic digests (2.9.5). Subsequent gel electrophoresis (2.9.6) confirmed 
successful recombination between PmeI-linearised pSHUTTLE-CMV::ACVR2A and 
pAdEasy-1 (Figure 2-7). XL10-Gold cells were transformed with pAdEasy-
1::pSHUTTLE-CMV::ACVR2A deriving from colonies 1 and 2 and subjected to MAXI 
culture propagation (2.9.2). Cultures were subjected to MAXI plasmid 





Figure 2-7 PmeI linearisation and PacI linearisation following homologous recombination. (Top panel) 
Image on the right shows respective DNA bands of uncut and PmeI-linearised pSHUTTLE-CMV::ACVR2A 
following separation in a 0.7% (w/v) agarose gel. (Bottom panel) Image on the left shows respective DNA 
bands of uncut and PacI-linearised pSHUTTLE-CMV::ACVR2A and PacI-linearised pAdEasy-1::pSHUTTLE-




MAXI-prepped pAdEasy-1::pSHUTTLE-CMV::ACVR2A deriving from colonies 1 and 
2 were subjected to diagnostic PacI linearisation (2.9.5) (Figure 2-8 A). Gel 
electrophoresis (2.9.6) confirmed successful cleavage of respective 3.0 kbp and 
4.5 kbp fragments which contain the KAN resistance frame. Following 
confirmation of DNA integrity, pAdEasy-1::pSHUTTLE-CMV::ACVR2A was 
subjected to a large scale restriction digest with PacI (2.9.5) prior to HEK293 
transformation. This step is necessary to hinder transcription of the DNA 
sequence which contains the KAN resistance frame which counters transcription 
of the viral genome. Successful PacI linearisation was confirmed by gel 
electrophoresis (2.9.6) (Figure 2-8 B). 
HEK293 cells were transfected with PacI-linearised pAdEasy-1::pSHUTTLE-
CMV::ACVR2A to generate HAdV-5 ACVR2A (2.9.13). Control HEK293 cells which 
were transfected with a GFP plasmid displayed GFP-mediated fluorescence at 
48-h confirming successful transfection (Figure 2-8 C). Once CPE was complete, 
crude HAdV-5 ACVR2A isolation was performed (2.9.14). Crude HAdV-5 ACVR2A 
was subjected to two rounds of plaque purification (2.9.15,2.9.16) prior to seed 
stock generation (2.9.17) and scale up (2.9.18). Propagated HAdV-5 ACVR2A was 
isolated and subjected to CsCl gradient purification, ultracentrifugation (2.9.19) 
(Figure 2-8 D and E) and dialysis (2.9.20). Purified HAdV-5 ACVR2A was subjected 





Figure 2-8 Generation of recombinant HAdV-5 ACVR2A. (A) pAdEasy-1::pSHUTTLE-CMV::ACVR2A 
plasmids deriving from colonies 1 and 2 were propagated and subjected to diagnostic PacI restriction digest. 
Image shows respective DNA bands following separation of uncut and PacI-linearised pAdEasy-
1::pSHUTTLE-CMV::ACVR2A in a 0.7% (w/v) agarose gel. (B) pAdEasy-1::pSHUTTLE-CMV::ACVR2A 
deriving from colony 1 was subjected to a large scale PacI restriction digest. Image shows respective DNA 
bands following separation of uncut and PacI-linearised pAdEasy-1::pSHUTTLE-CMV::ACVR2A in a 0.7% 
(w/v) agarose gel. (C) Control GFP plasmid was transfected into HEK293 cells. 48-h following transfection, 
HEK293 cells were imaged at 10× magnification to determine GFP expression. Left image shows cells under 
bright field. Right image shows cells under GFP fluorescence. (D) First ultracentrifugation: image shows 
purified HAdV-5 ACVR2A band between both CsCl layers (layer above virus band à CsCl 1.25 g/mL, layer 
below virus band à CsCl 1.25 g/mL) following ultracentrifugation. Top CsCl layer contains debris. (E) Second 
ultracentrifugation: image shows purified HAdV-5 ACVR2A band between CsCl 1.34 g/mL and PBS layers 




2.10 Single cell RNA sequencing 
All experiments leading up to generation of single cell suspensions for each 
treatment group were performed by Julian Schwartze. 
2.10.1 Sample preparation 
Confluent primary HSVSMCs were seeded into 2× 6-well plates (1.5×105 
cells/well, 3× technical repeats for each treatment group) in 15% FCS media. 
Upon achieving 80% confluence, 15% (v/v) FCS media was replaced with MEDIA1 
for 72-h (Table 2-7). Medium was replaced with fresh MEDIA1 containing BMP-9 
(10 ng/mL), TGF-b1 (10 ng/mL), both ligands and vehicle control (4 mM HCl/1% 
(w/v) BSA). Following 24-h, stimulation medium was removed, and cells were 
washed once with sterile 1× PBS (2 mL/well). PBS was discarded and 1 mL 1× 
sterile trypsin was added to each well to detach cells from well bottoms. 6-well 
plates were placed in an incubator at 37°C and 5% CO2 for 5 min. Successful cell 
detachment was determined by imaging cells under a microscope. 1 mL L-
glutamine-free 0.2% (v/v) SVM was added to each well and suspensions were 
gently mixed to stop the trypsin reaction. Technical repeats (2 mL/well) were 
pooled in fresh sterile 15 mL universal tubes (total volume: 6 mL per treatment 
group). Tubes were subjected to centrifugation at 500 g and room temperature 
for 5 min. Supernatants were gently removed and cell pellets were re-suspended 
in 500 µL scRNAseq medium (Table 2-39). 
Table 2-39 scRNAseq medium composition. 
Cell strainers (pore size 70 µm, cat. no.: 542070, Greiner, Germany) were placed 
on respective fresh sterile 50 mL centrifuge tubes underneath a cell culture 
hood. 500 µL cell suspensions were pipetted onto respective cell strainers/50 mL 
centrifuge tubes. Cell count and viability were assessed by performing trypan 
blue (cat. no.: T18154, MilliporeSigma, MO, USA) staining (in a sterile 1.5 mL 
microcentrifuge tube à mix 50 µL cell suspension + 50 µL trypan blue). 50 µL 
Reagent Volume 
DMEM (cat. no. 21969035, Thermo Fisher Scientific, MA, 
USA) 500 mL 




cell/trypan blue suspensions were pipetted onto a prepared haemocytometer 
(cat. no.: BS 748, Hawksley, UK). The haemocytometer was imaged on a 
microscope and viable cells (unstained) were counted (4 squares; top right, top 
left, bottom right and bottom left à each square measuring 4×4 squares). The 
total number of cells per volume was calculated using the following formula: 
(total number of counted cells/4) × 10,000 × 0.5 mL. Cell suspensions were then 
delivered on ice to the Glasgow Polyomics Institute. 
2.10.2 The principle of 3′-end 10x Chromium microfluidics-
based single cell RNA sequencing 
The 3′-end 10x Chromium microfluidics-based scRNAseq platform allows high 
throughput single cell transcriptome analysis. Our group successfully utilised this 
technology to analyse transcriptomes from TGF-b1-treated and untreated control 
primary HSVSMCs (unpublished data) (Low et al., 2019). Gel Bead-in-Emulsion 
(GEM)s are generated by combining barcoded Single Cell 3′ v3 Gel Beads, a 
master mix containing HSVSMCs and partitioning oil on an 8-channel microfluidic 
chip (Figure 2-9 A) (Zheng et al., 2017). Each Gel Bead is made up of oligo(dT)VN 
primers which contain a unique 16 bp 10x barcode which allows mapping of each 
amplified RNA molecule to the original cell following next-generation sequencing 
(Figure 2-9 B). In addition, each primer contains an Illumina Read 1 sequence 
and a unique molecular identifier (UMI) sequence. Cells are delivered at a 
limiting dilution to minimise the chance of co-occurrence of more than one cell 
in the same GEM thereby achieving single cell resolution. Within each generated 
GEM, oligo(dT)VN primers prime mature mRNAs at the 3′ poly-A tail for reverse 
transcription. GEMs are then collected in the GEM outlet and subjected to cDNA 
library generation which forms the basis for next-generation sequencing. In 
summary, this technology enables individual transcriptome profiling of a defined 





Figure 2-9 Schematic representation of 3′-end 10x Chromium single cell RNA sequencing. (A) GEM 
generation by mixing of single cell/master mix suspension, Gel Beads and partitioning oil on an 8-channel 
microfluidic chip. (B) Single Cell 3′ v3 Gel Bead is a bead loaded with primers which contain an oligo(dT)VN, a 
12 bp UMI, a unique 16 bp 10x barcode and a 22 bp Illumina Read 1 sequence (TrueSeq1 Read1). Each 
GEM is subjected to reverse transcription, cDNA amplification/library preparation and NextGeneration 




2.10.3 cDNA library preparation and next-generation 
sequencing 
Single cell cDNA library preparation and next-generation sequencing were 
performed at the Glasgow Polyomics Institute. The 10x v3 chemistry kit (cat. 
no.: PN-1000092, 10x Genomics, CA, USA) was used to generate Illumina 
compatible cDNA libraries following the manufacturer’s instructions. Libraries 
were then sequenced on an Illumina NextSeq500 sequencer. 
2.10.4 Raw data processing 
Biomage Ltd (Adam Kurkiewicz and Marcell Pék) adapted an existing 
computational Python pipeline for single cell (sc) RNA sequencing (seq) analysis 
and performed biostatistical analyses. Julian Schwartze participated in 
biostatistical analyses. 
In brief, the CellRanger v3.1.0 software (10x Genomics, CA, USA) was used to 
process FASTQ files obtained from the NextSeq500 sequencer, to perform 
nucleotide sequence alignment against the GRCh38 reference genome and to 
generate BAM files (Zheng et al., 2017). The aligner utilised by the CellRanger 
software is the spliced transcripts alignment to a reference (STAR) aligner (Dobin 
et al., 2013). BAM files entailed position-sorted/aligned reads and error-
corrected cellular/molecular barcodes. The dropEst pipeline was utilised to 
process BAM files (Petukhov et al., 2018). This included estimating molecular 
counts per cell and creating a primary count matrix. To perform RNA velocity 
analysis, dropEst was utilised to separate count matrices which only accounted 
for UMIs classified as intronic, exonic or exon/intron spanning. Resulting R 
matrices were exported in the MatrixMarket format. Generated matrices 
containing cellular barcodes identified by CellRanger were loaded into the 
existing computational Python pipeline for scRNAseq. An aggregated AnnData 
matrix was generated for further data processing. Detailed notebooks are freely 
available on GitHub 
(https://nbviewer.jupyter.org/github/picrin/vascular_TGFB1/tree/master/analy




2.11 Carotid artery ligation study in mice 
All animal procedures were approved by the Home Office under the Animals 
Scientific Procedures Act 1986. This study was performed as authorised by the 
Home Office under the project license number 70/8572, procedure 3 (PPL 
holder: Prof. Simon Kennedy, ICAMs). 
2.11.1 Experimental mice and housing conditions 
Male C57BL/6 mice (8-10 weeks old) were ordered from Charles River 
Laboratories (MA, USA). Mice were housed in 12-h light/dark conditions at a 
constant temperature of 21°C with free access to water and standard mouse 
chow. Following arrival, mice were allowed to adjust to their new housing 
conditions for 2 weeks prior to being subjected to the carotid artery ligation 
procedure. Following the surgical procedure, mice were separated and housed in 
individual cages until termination (Schedule 1 procedure) at indicated time 
points. 
2.11.2 Study design 
Following the carotid artery ligation procedure (section 2.11.3), mice were 
divided into 6 groups (n=6-8 per group) and terminated at indicated time points 
(Figure 2-10). 5-ethynyl-2′-deoxyuridine (EdU) (cat. no.: C10337, Thermo Fisher 
Scientific, MA, USA) was made up in sterile 1´ phosphate-buffered saline (PBS; 
cat. no.: 14190144, Thermo Fisher Scientific, MA, USA) to achieve a 
concentration of 25 mg/mL. 100 µL of 25 mg/mL EdU/1´ PBS solution (effective 
dose 2.5 mg/animal) was injected intraperitoneally (i.p.) to each animal with a 
30G insulin syringe (cat. no.: 324826, Becton Dickinson, NJ, USA) 3-5 h prior to 
termination to label proliferating vascular cells. Following termination (section 





Figure 2-10 Carotid artery ligation study design. Following carotid artery ligation surgery, mice (aim à n=8 
per group) were terminated at indicated time points. EdU/1´ PBS solution (effective dose 2.5 mg/animal) was 
injected i.p. 3-5 h prior to termination and subsequent organ/blood harvest. EdU labels proliferating cells 




2.11.3 The carotid artery ligation procedure 
The carotid artery ligation procedure induces NF, and was performed as 
described by Kumar and colleagues (Kumar and Lindner, 1997) (Figure 2-11A). All 
operating instruments and equipment were sterilised prior to surgery. 
Prior to surgery, each animal received a subcutaneous (s.c.) 0.5 mL 
saline/glucose solution injection (0.9% (w/v) sodium chloride/5% (w/v) glucose, 
cat. no.: FKE1064, Baxter, IL, USA) to prevent dehydration during surgery. Each 
animal received a s.c. 0.03 mL buprenorphine injection for peri- and post-
operative pain relief (Vetergesic®, Ceva Animal Health Ltd., UK). Sedation was 
initiated with isoflurane (IsoFlo®, Zoetis, NJ, USA) at a flow rate of 2 L/min. 
Each animal’s neck incision site was shaved and pre-warmed chlorhexidine 
(Hydrex™, Ecolab, MI, USA) was applied to sterilise the skin. A lubricant creme 
was applied to the eyes to prevent drying out during surgery. The sedated mouse 
was gently positioned on its back below the operating microscope and above a 
pre-warmed heat pad, located below a sterile surgical field. The mouse’s back 
neck was placed on a small cushion to achieve neck extension thereby 
facilitating ventral neck incision. Both front paws were gently extended and 
loosely fixated with sterile autoclave tape. The mouse’s nose was placed inside 
an anaesthetic cone used to deliver isoflurane (flow rate 2 L/min) and 100% O2 
(flow rate 2 L/min) to achieve peri-operative sedation. The absence of paw 
reflexes indicated sedation prior to incision. A sterile surgical drape was placed 
over the anaesthetic cone prior to making the first incision. The operative 
assistant continuously monitored the mouse’s breathing throughout the surgical 
procedure. 
The initial incision was made below the chin towards the top of the sternum by 
using a sterile pair of scissors. Saline solution was injected onto the incision site 
with a 1 mL syringe (Injekt®-F Solo, B. Braun, Germany) to keep tissues 
hydrated. The left and right salivary glands were separated by blunt dissection 
using two pairs of fine sterile forceps. Following gland separation, the left 
salivary gland was liberated by creating a pocket between the gland and the 
skin. Some saline solution was added to the skin left of the incision site and a 
small swab was placed on top. The left salivary gland was everted onto the 




Saline solution was added to protect the gland from dehydration. The left 
common carotid artery (LCAR) was exposed by blunt dissection and carefully 
liberated from the left vagal nerve and surrounding tissues. A sterile non-
absorbable suture was cut to a length of approximately 7 cm, carefully passed 
underneath the left carotid artery and a single knot was made just caudal of the 
carotid bifurcation to achieve complete common carotid artery ligation. Surplus 
suture ends were cut off and the left salivary gland was placed back into its 
original position. The incision was closed with non-absorbable 6-0 Vicryl suture 
(Ethicon Inc., NJ, USA) using the uninterrupted suturing technique. Instrument 
sterilisation was performed prior to operating on the next mouse using an 
autoclave. 
Following surgery, each mouse was placed in a separate pre-labelled recovery 
cage with access to water, water-soaked chow and baby food (Cow & Gate, UK). 
Cages were placed in the recovery room and mice were monitored daily. EdU 





Figure 2-11 Schematic representation of carotid artery ligation procedure and target tissue 
processing. (A) The LCAR is exposed and ligated just caudal of the carotid bifurcation. The RCAR serves as 
an uninjured control. (B) Image shows surgical setup for cadaver practice. (C) Following termination, the 
LCAR (reaching from aortic arch to suture knot) is dissected. (D) Following tissue processing, the LCAR is 
wax embeded and sections are cut at 4 µm on a microtome (5-6 sections/slide, 5-6 slides/level, at least 5 
levels/LCAR with each level being 150 µm apart). LCAR sections are then subjected to haematoxylin and 




2.11.4 Schedule 1 procedure (termination) 
Mice were separately terminated at indicated time points following the schedule 
1 procedure. The mouse was placed into a CO2 chamber using the non-aversive 
tunnelling technique. The chamber was sealed, and CO2 flow rate was turned to 
2 L/min until the mouse was unconscious (approximately 2 min). The flow rate 
was turned up to 80% of the maximum flow rate for another 2 min. The CO2 
supply was turned off and the mouse remained in the sealed chamber for 
another 2 min. The terminated mouse was taken out of the chamber and 
checked for signs of life which included assessing breathing, paw reflexes and 
palpating for a heartbeat. The chamber was tipped over to allow CO2 to flow 
out. Death was confirmed by cervical dislocation prior to proceeding to 
organ/blood harvest. 
2.11.5 Organ/Blood harvest 
Following termination, the LCAR, the RCAR, the heart and the thoracic aorta 
were carefully removed, and a blood sample was taken. All dissected tissues 
were carefully placed in 4% (w/v) PFA (Table 2-2) in individual 1.5 mL 
microcentrifuge tubes and kept in a +4-°C fridge overnight. The next day, each 
tissue sample was washed twice in sterile 1´ PBS, placed in 70% (v/v) ethanol in 
a fresh sterile 1.5 mL microcentrifuge tube and stored in a 4°C fridge prior to 
tissue processing. Serum containers (cat. no.: 367959, Becton Dickinson, NJ, 
USA) were subjected to centrifugation at 8,000 g and room temperature for 1 
min enabling blood phase separation. The upper phase/blood serum was 
carefully transferred to a sterile 1.5 mL microcentrifuge tube which was stored 
in a -80°C freezer. 
2.12 EdU staining 
EdU staining was performed following the manufacturer’s instructions (cat. no.: 
C10337, Thermo Fisher Scientific, MA, USA). One slide per mouse was stained. 
This slide contained the level demonstrating the most pronounced lesion 
following ligation surgery (Figure 2-11 D). Respective slides were put in a slide 





Table 2-40 Processing sequence for dewaxing and rehydrating sections for EdU Click-iT staining. 
During the last step, 1´ citric saline antigen retrieval buffer (pH 6) was prepared 
(Table 2-41). 
Table 2-41 Recipe for 500 mL of 1´ citric saline antigen retrieval buffer (pH 6). 
The buffer was poured into a plastic trough, covered with saran wrap containing 
punched holes and was pre-heated on high power in a microwave for 4 min. The 
slide rack containing respective slides was placed in the plastic trough 
containing pre-heated antigen retrieval buffer. The plastic trough was covered 
with saran wrap containing punched holes and was microwaved on low power for 
15 min. The slide rack was placed under running tap water for 10 min to cool 
down the slides. Slides were gently patted dry on absorbent paper and wax 
circles were drawn around each individual section on each slide using a wax pen 
(cat. no.: NC9545623, CA, USA). Sections were then permeabilised with 70 µL 
0.1% (v/v) triton-X-100 (cat. no.: X100, MilliporeSigma, MO, USA)/1´ PBS 
solution in a humidifying chamber at room temperature for 10 min. During this 
Stage Reagent Time [min] 
Dewaxing 
Histoclear (cat. no.: HS 200, national 
diagnostics, GA, USA) 5 
Histoclear 5 
Rehydration 
100% (v/v) ethanol 5 
95% (v/v) ethanol 5 
70% (v/v) ethanol 5 
50% (v/v) ethanol 5 
Running tap water 5 
Reagent Amount 
Tri-sodium citrate (cat. no.: 71402, MilliporeSigma, MO, USA) 1.47 g 
ddH2O 500 mL 




step, the Click-iT reaction cocktail was made up allowing a final volume of 60 µL 
per section (Table 2-42). 
Table 2-42 Composition of Click-iT reaction cocktail for approximately 50 slides. 
The permeabilisation buffer was removed and sections were washed twice in 60 
µL 3% (w/v) BSA (cat. no.: A3311, MilliporeSigma, MO, USA)/1´ PBS solution. 
Following these washing steps, 60 µL Click-iT reaction cocktail was added to 
each section and slides were left to incubate in a humidifying chamber 
(protected from light) at room temperature for 30 min. The reaction cocktail 
was discarded, and sections were washed twice in 60 µL 3% (w/v) BSA/1´ PBS 
solution. Slides were washed once in 1´ PBS in a plastic trough covered with tin 
foil. During this step, a 1:1,000 Hoechst solution (part of the Click-iT kit) was 
prepared in 1´ PBS. Slides were gently tapped on absorbent paper to remove 
excess PBS. 1:1,000 Hoechst/1´ PBS solution was added to each section and 
slides were incubated in in a humidifying chamber (protected from light) at 
room temperature for 10 min. Slides were washed twice in 1´ PBS in a plastic 
trough covered with tin foil. Following these washing steps, slides were gently 
tapped on absorbent paper to remove excess 1´ PBS. Next, 4′,6-diamidino-2-
phenylindole (DAPI) Pro-long GOLD mounting medium (cat. no.: ab104139, 
abcam®, UK) was added to each section and a cover slip was carefully placed on 
each slide and left to set overnight. The next day, slides were sealed with nail 
varnish prior to imaging on the LSM880 confocal microscope (Zeiss, Germany). 
All visualisation and quantification steps are outlined in Figure 2-12.  
Component Volume 
1´ Click-iT reaction buffer 10.7 mL 
CuSO4 (component E) 500 µL 
Alexa Fluor azide 31 µL 
Reaction buffer additive 1.25 mL 
Note: total volume 12.5 mL, add ingredients in the order listed in the table 





Figure 2-12 Workflow for quantifying EdU-stained murine carotid artery sections. (A) Corresponding 
DAPI/EdU- (left) and H&E-stained (right) demo images of a ligation injured murine carotid artery. Left image à 
green dots indicate EdU+-positive nuclei, blue dots indicate DAPI-stained nuclei. Right image à EEL, external 
elastic lamina; IEL, internal elastic lamina; NI, neointima. (B) Workflow for imaging of DAPI/EdU co-stained 




2.13 Haematoxylin and Eosin staining 
Sections from ligation injured murine carotid arteries were subjected to H&E 
staining to determine changes in intimal area, medial area and intima/media 
ratio. Morphometric analysis for one ligation injured murine carotid artery 
entailed one slide (3-4 sections) for each level (Figure 2-11 D). Respective slides 
were put in a slide rack which was placed in a glass trough for dewaxing and 
rehydrating described in Table 2-43. 
Table 2-43 Processing sequence for dewaxing and rehydrating sections prior to H&E staining. 
Following dewaxing and rehydrating, slides were subjected to H&E staining 
outlined in Table 2-44.  





100% (v/v) ethanol 7 
95% (v/v) ethanol 7 





Table 2-44 Processing sequence for staining sections with H&E. 
Following the last step, slides were gently tapped on absorbent paper to remove 
excess Histoclear solution. 1 drop of DPX (mixture of distyrene, a plasticiser, and 
xylene; (cat. no.: 05622, MilliporeSigma, MO, USA) was carefully added to each 
section with a Pasteur pipette to preserve the H&E stain and a cover slip was 
placed on each slide. Slides were left to dry in the histology hood overnight and 
were sealed with nail varnish the next day. All visualisation and quantification 
steps are outlined in Figure 2-13.  
Stage Reagent Time 
H&E staining 
Harris modified Haematoxylin (cat. 
no.: HHS16, MilliporeSigma, MO, USA) 2 min 
Running tap water 5 min 
70% (v/v) ethanol 30 s (10 dips 
à 5 min) 
Eosin Y solution (cat. no.: 318906, 
MilliporeSigma, MO, USA) 2 min 
Dehydration 
95% (v/v) ethanol 30 s 
95% (v/v) ethanol 30 s 
100% (v/v) ethanol 1 min 
100% (v/v) ethanol 7 min 
100% (v/v) ethanol 5 min 
Histoclear 5 min 





Figure 2-13 Workflow for quantifying intimal and medial areas of H&E-stained ligation injured murine 
carotid arteries. (A) Demo image (20´ magnification) showing H&E-stained section of murine carotid artery 
10 days following ligation injury (haematoxylin staining à dark purple, indicates nuclei; eosin staining à light 
purple à indicates cytoplasm/ECM; dotted red lines indicate respective borders between vascular 
compartments. (B) Workflow for imaging H&E-stained murine carotid artery sections and quantifying intimal 




2.14 Tissue processing for histology 
Murine and human tissue samples were placed in labelled tissue cassettes and 
soaked in 70% (v/v) ethanol. Tissue cassettes were placed in a tissue cassette 
holder which was placed in a tissue processor for dehydration and paraffin wax 
embedding (cat. no.: 12505356, Shandon ExcelsiorTM, Fisher Scientific, PA, USA). 
The next day, tissues were paraffin wax embedded using the Shandon 
Histocentre 3 embedder (Thermo Fisher Scientific, MA, USA). Human and murine 
vessels (Figure 2-11 D) were embedded in the upright position. The wax mould 
containing target tissue/tissue cassette were left to cool for 30 min prior to 
removing the mould. Embedded tissues were stored at room temperature and 
placed at -20°C for 1-h prior to sectioning. Embedded HSV samples were 
sectioned at 5 µm and murine vessels were sectioned at 4 µm on a microtome. 
Wax ribbons were carefully transferred to a 40°C water bath and left to float. 
Wax ribbons were mounted on pre-labelled silane-treated glass slides (cat.no.: 
N/C360G, Dixon Science, UK), placed in a 60°C oven to melt the paraffin wax 
overnight and stored in a slide box at room temperature the next day. 
2.15 Immunohistochemistry 
HSV and murine carotid artery sections were subjected to IHC staining to 
determine target protein presence. Respective slides were put in a slide rack 
which was placed in a glass trough for dewaxing and rehydrating described in 




Table 2-45 Processing sequence for dewaxing and rehydrating sections prior to IHC staining. 
During the last step, 1´ citric saline antigen retrieval buffer (Table 2-41) was 
prepared and pre-heated in a plastic trough in a microwave. The slide rack was 
placed in the plastic trough containing pre-heated antigen retrieval buffer. The 
plastic trough was covered with saran wrap containing punched holes and was 
microwaved on low power for 15 min. The slide rack was placed under running 
tap water for 10 min to cool down the slides. Slides were gently patted dry on 
absorbent paper and wax circles were drawn around each individual section on 
each slide using a wax pen. Slides were washed 3 times for 3 min in 1´ tris-
buffered saline (TBS) buffer (Table 2-46). 
Table 2-46 Recipe for 1 L of 10´ TBS buffer (pH 7.5). 
Following these washing steps, each section was incubated in 1´ TBS + 0.05% 
(v/v) Tween 20 (TBST, (Table 2-47)/15% (v/v) goat serum (cat.no.: S-1000-20, 





100% (v/v) ethanol 5 
100% (v/v) ethanol 5 
90% (v/v) ethanol 5 
70% (v/v) ethanol 5 
50% (v/v) ethanol 5 
Running tap water 5 
Reagent Amount 
Tris-base 24.2 g 
NaCl (cat. no.: X190, VWR International, PA, USA) 87.7 g 
Note: add 900 mL of ddH2O, pH to 7.5 using HCl (cat. no.: 320331, 
MilliporeSigma, MO, USA), top up with ddH2O to 1 L. For 1 L of 1´ TBS buffer, 




Vector Laboratories, UK) in a humidified chamber at room temperature for 30 
min. 
Table 2-47 Recipe for 1 L of 10´ TBS 0.5% (v/v) Tween buffer (pH 7.5). 
Following the blocking and permeabilisation steps, sections were incubated with 
respective primary antibodies (Table 2-48) diluted to required concentrations in 
1× TBST/10% (v/v) goat serum at 4°C overnight. Appropriate IgG controls 
(normal rabbit IgG, 3 mg/mL, cat.no.: 10500C, Thermo Fisher Scientific, MA, 
USA; normal mouse IgG, 3 mg/mL, cat.no.: 10400C, Thermo Fisher Scientific, 
MA, USA) were diluted to corresponding concentrations in 1× TBST/10% (v/v) 
goat serum to control for non-specific staining.  
Reagent Amount 
Tris-base 24.2 g 
NaCl 87.7 g 
Tween 20 5 mL 
Note: add 900 mL of ddH2O, add 5 mL Tween 20, pH to 7.5 using HCl, top up 
with ddH2O to 1 L. For 1 L of 1´ TBST buffer, dilute 100 mL 10´ TBST buffer in 




Table 2-48 List of primary antibodies used for IHC. 
The next day, slides were gently tapped on absorbent paper to remove the 
primary antibody solution and washed 3 times for 5 min in 1´ TBS buffer. 
Following these washing steps, sections were incubated with the respective 
fluorescent secondary antibodies (goat anti-rabbit IgG Alexa Fluor® 546, 2 
mg/mL, 1:500, cat. no.: A-11035, Thermo Fisher Scientific, MA, USA; goat anti-
mouse IgG Alexa Fluor® 488, 2 mg/mL, 1:500, cat. no.: A-11001, Thermo Fisher 
Scientific, MA, USA) diluted in 1× TBST at room temperature for 2-h protected 
from light. Following this incubation step, slides were gently tapped on 
absorbent paper to remove the secondary antibody solution and washed 3 times 
for 5 min in 1´ TBS buffer protected from light. Each section was incubated with 
Sudan Black B (cat. no.: 199664, MilliporeSigma, MO, USA) in 70% (v/v) ethanol 
at room temperature for 10 min (protected from light) to quench lipofuscin-
mediated fluorescence. Following this step, slides were gently tapped on 
absorbent paper to remove Sudan Black B solution and washed 3 times for 5 min 
in 1´ TBS buffer protected from light. Sections were stained with 10 µg/mL DAPI 
diluted in 1´ TBS buffer at room temperature for 10 min (protected from light). 
DAPI Pro-long GOLD mounting medium was added to each section and a cover 
slip was carefully placed on each slide. Mounting medium was allowed to set 
overnight. The next day, slides were sealed with nail varnish prior to imaging on 
the LSM510 confocal microscope (Zeiss, Germany). 
For each related set of slides confocal microscope settings were guided by 
imaging IgG controls first to control for non-specific background fluorescence. 
Microscope settings were kept constant to allow unbiased comparisons between 










Calponin Rabbit Monoclonal 0.063 1:100 ab46794, abcam®, UK 
SM22-α Rabbit Polyclonal 1 1:100 ab14106, abcam®, UK 
MYH11 Rabbit Polyclonal 2 1:100 ab53219, abcam®, UK 




slides. Fluorescence intensity analysis was performed using the ImageJ software. 
Each set of related images was corrected for IgG background fluorescence and 
the total fluorescence area % was calculated. 
2.16 Statistical analysis 
Group sizes for carotid artery ligation studies in mice were calculated following 
the 3Rs guidelines (http://www.3rs-
reduction.co.uk/html/6__power_and_sample_size.html). The significance level 
was set at 5% and the power was set at 80%. Mean sham, mean injury and 
standard deviation (S.D.) injury were based on a previous carotid ligation study 
(Daria Boyd) in mice which investigated the effect of a pharmacological inhibitor 
on vascular proliferation and NF (I/M ratio uninjured carotid artery day 3 mean: 
0.04; I/M ratio injured carotid artery day 7 mean ± S.D.: 0.15 ± 0.11). The 
standard effect size (signal/noise ratio) was calculated following the formula 
(0.15-0.04)/0.11=1.0. Based on a power of 80% the sample size per group was 
calculated to be n=17. However, this was refined to group sizes of n=6-8 
assuming an approximate standard effect size of 1.6. 
Statistical analyses were performed using the GraphPad Prism 4.0 software 
package. Unless otherwise stated, data are presented as mean ± standard error 
of the mean (S.E.M.). Comparisons between multiple groups were made using a 
repeated measures one-way ANOVA test with Tukey’s post-hoc correction. Each 
in vitro experiment was carried out in triplicate and was repeated at least three 
independent times unless otherwise stated. Where indicated, a paired Student’s 
t-test was performed to determine significance. P-values <0.05 were considered 





Chapter 3 Investigating BMP-9 in human 







Coronary artery disease frequently entails partial or complete stenosis of one or 
more major coronary arteries limiting blood flow to cardiac tissue and causing 
common complications such as angina pectoralis, MI, CHF and cardiac 
arrhythmias (Cassar et al., 2009). Percutaneous coronary intervention or CABG 
revascularisation therapies may be indicated to re-establish blood flow to 
cardiac tissue by widening or bypassing stenosed coronary arteries (Neumann et 
al., 2019). However, re-stenosis is a common complication following these 
procedures (Campeau et al., 1983; Komatsu et al., 1998). Smooth muscle cell 
(SMC) phenotype switch-driven NF is a key pathological feature in in-stent re-
stenosis (ISR) and coronary SVG disease which results in lumenal obstruction and 
leads to a decrease in blood flow and subsequent cardiac ischaemia (Farb et al., 
1999; Grewe et al., 2000; Kockx et al., 1992; Kockx et al., 1996). 
3.1.1 SMC phenotype switching during NF in murine vascular 
injury models 
Several murine vascular injury models display SMC phenotype switch-driven NF, 
a key pathogenic feature of occlusive SVG disease and ISR (Table 3-1). 
Kumar et al. first described the murine carotid artery ligation model in which 
the common LCAR is exposed and ligated just proximal of the carotid bifurcation 
while the common RCAR serves as an uninjured control.(Kumar and Lindner, 
1997). Following total LCAR ligation and abrupt cessation of blood flow, the 
authors observed an early increase in medial and intimal SMC proliferation which 
was paralleled by a decrease in medial aSMA expression demonstrating SMC 
phenotype switching. In addition, leukocytes were detected within the 
adventitia and forming neointima indicating an inflammatory component during 
the injury response. Alongside medial hypertrophy 28-day old ligation-injured 
LCARs displayed an 80% reduction in lumenal area caused by external elastic 
lamina (EEL) shrinkage and NF. Transgenic mouse studies have since utilised this 
injury model to identify the origin of the neointimal cells. Yu et al. showed that 
diphteria toxin (DT)-mediated SMC depletion in transgenic SM22-a human DT 
receptor mice prior to carotid artery ligation blunted NF revealing vSMCs as the 




study in SMC lineage-tracing mice demonstrated that approximately 80% of cells 
within neointimal lesions derived from differentiated mature SMCs indicating 
SMC phenotype switching as a key pathogenic driver of NF (Herring et al., 2014). 
Although both studies identified vSMCs as the main source of neointimal cells 
following carotid artery ligation injury, it was unclear whether medial SMC 
proliferation preceded proliferation-independent SMC migration to the intima or 
not. More recently, the transgenic lineage tracing Myh11-CreERt2/Rosa26-
Confetti mouse has been utilised to address this question (Chappell et al., 2016). 
In these mice, vSMCs randomly express 1 of 4 fluorescent proteins (green, 
yellow, red and cyan) which enables more accurate tracing of neointimal cells 
following carotid artery ligation injury. Chappell et al. found that 28-day old 
vSMC-derived neointimal patches were connected to medial patches that 
expressed the identical fluorescent colour. This means that medial SMC 
proliferation precedes SMC migration to the intima and subsequent intimal SMC 
proliferation. The authors estimated that <0.1% of medial vSMCs contributed to 
NF highlighting extensive SMC plasticity. In addition to SMC phenotype switching, 
the murine carotid artery ligation model triggers endothelial dysfunction and 
inflammation thereby recapitulating additional pathogenic drivers of coronary 
SVG disease and ISR (Costa and Simon, 2005; de Vries et al., 2016; Squadrito et 
al., 2003; Yahagi et al., 2016; Yamashita et al., 2001). However, the presence of 
intact endothelium and absence of platelet aggregation limit this model’s ability 
to accurately mimic human pathology, since endothelial denudation along with 
platelet aggregation occur upon coronary SVG and/or stent implantation (Grewe 
et al., 2000; Sasaki et al., 2000). 
Lindner et al. introduced the murine carotid wire injury model in which a 
flexible wire (0.35 mm diameter) is inserted into the LCAR under rotation 
causing endothelial denudation (Lindner et al., 1993). The uninjured RCAR 
serves as a control. In contrast to ligation injury, wire injury enables the study 
of vascular injury responses in the absence of endothelium while blood flow is 
maintained. Hence, it more accurately mimics mechanical endothelial damage 
and platelet aggregation which occur upon coronary SVG and/or stent 
implantation. Like ligation injury, carotid artery wire injury induces early medial 
and intimal SMC proliferation accompanied by a loss of SMC aSMA expression 




proliferation only occurs in endothelium-denuded segments. 14-day old injured 
LCARs display mild NF alongside leukocyte infiltration and re-endothelialisation 
is fully achieved by day 21. Transgenic mouse studies have also been successful 
in identifying novel regulators of NF. Yoshida et al. showed that SMC-specific 
inhibition of pro-inflammatory nuclear factor (NF)κB signalling in transgenic 
SM22-a-Cre/IκBDeltaN mice attenuated repression of SMC contractile proteins 
and NF following carotid artery wire injury indicating SMCs as a major source of 
NF in this injury model (Yoshida et al., 2013). 
Although wild-type mice do not spontaneously develop atherosclerotic lesions 
following vascular injury, carotid artery ligation and wire injury in transgenic 
hyperlipidaemic ApoE-deficient mice fed an atherogenic diet triggers 
accelerated neointimal atherosclerotic plaque development compared to wild-
type controls (Chang et al., 2017; Schober et al., 2004). Hence, these injury 
models also enable the study of accelerated atherosclerosis, an important 
pathogenic feature in late stages of SVG disease and ISR (Hasegawa et al., 2006; 
Kern et al., 1981). From a technical point of view the carotid artery ligation 
surgery is less challenging compared to the carotid artery wire injury surgery and 
more reproducibly triggers NF. In terms of pathophysiological relevance for SVG 
disease and ISR, carotid artery wire injury more closely mimics human disease. 
In addition to ligation injury and carotid artery wire injury, the femoral artery 
wire injury and venous bypass graft atherosclerosis models were developed in 
mice to recapitulate human disease (Sata et al., 2000; Zou et al., 1998). In 
femoral artery wire injury, a guide wire is inserted into the right or left femoral 
artery causing endothelial denudation and vessel dilatation. Like carotid artery 
wire injury, femoral artery wire injury causes SMC phenotype switching. 
However, NF is greater, probably because of utilisation of a larger guide wire in 
a smaller vessel causing greater damage. Hence, this model more accurately 
mimics mechanical dilatation and endothelial denudation as seen in SVGs during 
checking for graft leakage and following implantation as well as in coronary 
balloon angioplasty and/or stent inflation (de Vries et al., 2016; Grewe et al., 
2000; Morinaga et al., 1985; Steele et al., 1985). In the murine venous bypass 
graft atherosclerosis model, either the autologous right external jugular vein 




common carotid artery via end-to-end anastomosis triggering vein graft SMC 
phenotype switching and NF (Zou et al., 1998). In addition, it is valuable tool for 
studying ex vivo gene transfer or drug treatment. Furthermore, this model may 
be used to inter-position vein grafts from genetically modified mice into carotid 
arteries from wild-type litter mates. Although this model most closely resembles 
human SVG disease compared to arterial injury models, high technical skills are 




Table 3-1 Murine vascular injury models 
Model Procedure Key pathogenic features of SVG disease 
and/or ISR 
Advantages/disadvantages 
Carotid ligation (Kumar and Lindner, 
1997) 
Complete CA ligation 
proximal to carotid 
bifurcation 
• Endothelial activation 
• Inflammation 
• SMC phenotype switching 
• Medial hypertrophy and NF 
• Non-thrombogenic surface, endothelium 
remains mechanically intact 
• Reproducible neointimal lesions 
• Simple procedure 
Carotid wire injury (Lindner et al., 
1993) 
Wire insertion via external 
CA into communal CA 
• ED 
• Inflammation 
• SMC phenotype switching 
• NF 
• ED in the presence of blood flow mimic 
early SVG disease 
• SMC proliferation stops once re-
endothelialisation has occurred 
• Neointima does not exceed 2-3 layers 
Femoral artery wire injury (Sata et 
al., 2000) 
Wire insertion via muscular 
FA branch into main FA 
• ED and early SMC apoptosis 
• Vessel dilatation 
• Inflammation 
• SMC phenotype switching 
• NF 
• ED in the presence of blood flow mimic 
early SVG disease 
• Reproducible neointimal lesions 
Perivascular collar (Moroi et al., 
1998) 
Cuff loosely tied in place 
around FA 
• Compromised vasa vasorum in 
adventitia 
• Inflammation 
• SMC phenotype switching 
• NF (male > female) 
• Non-thrombogenic surface, endothelium 
remains intact 
• Compromised vasa vasorum mimic initial 
loss of vasa vasorum in vein graft 
• Reproducible neointimal lesions 
Perivascular electric stimulation 
(Carmeliet et al., 1997) 
Single perivascular FA 
electric shock 
• ED and non-occlusive TF 
• Inflammation 
• SMC phenotype switching 
• NF 
• Non-occlusive TF mimics early SVG disease 
• Reproducible neointimal lesions 
• Great level of trauma to vessel 
Venous bypass graft atherosclerosis 
(Zou et al., 1998) 
Inter-positioning of 
autologous external JV or 
isogenic JV/VC 
• Ischaemia, ED and dilatation 
• Vessel wall degeneration 
• Inflammation 
• SMC phenotype switching 
• NF 
• Closely mimics early and intermediate 
SVG disease 
• Vein graft can derive from genetically 
modified mouse 
• Ex vivo gene transfer or drug treatment 
Abbreviations. CA, carotid artery; FA, femoral artery; JV, jugular vein; VC, vena cava; SVG DISEASE, vein graft disease; ISR, in-stent restenosis; CD45, cluster of 





3.1.2 BMP-9 in vascular health and disease 
BMP-9 is a member of the TGF-b superfamily and regulates osteogenesis and 
glucose and lipid metabolism (Liao et al., 2017; Song et al., 1995; Yang et al., 
2019). Two murine studies found that the liver and lung predominantly 
expressed BMP-9, which is encoded by the Gdf2 (growth differentiation factor 2) 
gene (Liu et al., 2020b; Miller et al., 2000). In healthy adult humans, circulating 
BMP-9 serum/plasma concentrations were found to range between 2 and 12 
ng/mL (David et al., 2008). For this study, the authors utilised an activity assay 
to determine BMP-9 serum and plasma levels. In contrast, Olsen et al. utilised an 
ELISA assay to determine circulating BMP-9 serum levels in healthy humans 
(Olsen et al., 2014). The study revealed a median of 110 pg/mL for circulating 
BMP-9 serum levels in healthy humans and, hence, much lower circulating BMP-9 
levels than previously reported. Importantly, Wang et al. found that circulating 
BMP-9 plasma levels, determined by ELISA assay, ranged between 20.8 and 60.7 
pg/mL in healthy humans (Wang et al., 2019). This indicates that circulating 
BMP-9 plasma levels were lower than serum levels as previously shown by Olsen 
et al. and, hence, BMP-9 plasma and serum levels are not equivocal. 
Functionally, BMP-9 binds to ALK1 triggering complex formation with BMPR2 
and/or ACVR2A/B and subsequent SMAD1/5 phosphorylation (David et al., 2007; 
Mitrofan et al., 2017). Pre-clinical and clinical studies have implicated de-
regulation of BMP-9/ALK1 signalling in endothelial-driven pathologies including 
cancer neo-angiogenesis, HHT and PAH (Brand et al., 2016; David et al., 2008; 
Hodgson et al., 2020; Levet et al., 2013; Long et al., 2015; Wang et al., 2019; 
Wooderchak-Donahue et al., 2013; Zhu et al., 2015). The involvement of BMP-
9/ALK1 signalling in angiogenesis has shown opposing results in different disease 
settings. Suzuki et al. found that BMP-9 treatment promoted in vivo angiogenesis 
in a Matrigel-plug assay and in a murine xenograft model of human pancreatic 
cancer indicating BMP-9/ALK1 signalling as a driver a cancer angiogenesis (Suzuki 
et al., 2010). In contrast, David et al. demonstrated that BMP-9 inhibited FGF-
driven angiogenesis suggesting that BMP-9 mediates vascular quiescence in 
healthy vessels (David et al., 2008). In line with these findings, a 2013 study 
showed that 4 distinct GDF2 mutations were linked with vascular activation and 




More recently, causal GDF2 mutations have also been identified in idiopathic 
(I)PAH patients (Wang et al., 2019). In addition, PAH patients carrying GDF2 
mutations also demonstrated reduced BMP-9 serum levels. Systemic 
administration of recombinant BMP-9 to mice carrying a heterozygous human 
BMPR2 mutation, known to cause PAH, reversed PAH suggesting a protective 
effect in the pulmonary vasculature (Long et al., 2015). Contrasting these 
findings, Tu et al. showed that loss of BMP-9 by genetic deletion or 
pharmacological inhibition partially protected mice and rats from experimental 
pulmonary hypertension indicating BMP-9 as a pathogenic driver of PAH (Tu et 
al., 2019). 
More recent studies investigating the role of BMP-9 in metabolic disease 
reported reduced circulating BMP-9 levels in newly diagnosed T2DM patients (Luo 
et al., 2017). In parallel to these findings, a further study demonstrated a 
negative association of circulating BMP-9 levels with BMI, hepatic insulin 
resistance (IR) and fasting glucose levels (Liu et al., 2019). The same study 
revealed reduced BMP-9 levels in CAD and systemic hypertension patients 
suggesting that lower BMP-9 levels may be linked to increased cardiovascular 
risk. Opposing these results, Zhu et al. found that paediatric CKD patients 
demonstrated increased circulating BMP-9 serum levels (Zhu et al., 2015). This 
study also showed that BMP-9/ALK1 signalling mediated osteoblastic 
differentiation of isolated primary murine aortic SMCs suggesting a role for BMP-
9 in arterial calcification. Furthermore, BMP-9/ALK1 signalling potentiated 
lipopolysaccharide (LPS)-induced monocyte recruitment to bovine ECs via up-
regulation of toll-like receptor (TLR)4, vascular adhesion molecule (VCAM)-1 and 
E-selectin expression (Appleby et al., 2016). The same study revealed that i.p. 
injection of BMP-9 increased leukocyte recruitment to pulmonary endothelium in 
LPS-challenged mice compared to LPS-challenged mice only, suggesting a role 
for BMP-9 in mediating vascular inflammatory responses. 
The pleiotropic cytokine TGF-b1 may also activate ALK1 signalling (Schwartze et 
al., 2014). TGF-b1 binds to TGFBR2 which either forms a complex with ALK5 or 
ALK1 (Bobik, 2006). Whereas ALK5 activation triggers SMAD2/3 phosphorylation, 
ALK1 activation induces SMAD1/5 phosphorylation (Schwartze et al., 2014). The 




challenge when investigating this pleiotropic cytokine in NF. SMC-specific 
depletion of ALK5 in transgenic mice attenuated NF following femoral artery 
wire injury indicating that ALK5 signalling drives phenotype switching (Liao et 
al., 2016). Less research has focussed on lateral opposing ALK1/SMAD1/5 
signalling in SMC phenotype-switch driven NF. Traditionally, vascular ALK1 
signalling predominates in ECs (Goumans et al., 2002; Lebrin et al., 2004). More 
recently, Low et al. demonstrated that ALK1 was also expressed on intimal 
aSMA+ SMCs and co-localised with TGFBR2 in pre-implantation SVGs from CABG 
patients (unpublished data) (Low et al., 2019). Furthermore, small interfering 
(si) RNA-mediated knockdown and pharmacological inhibition of ALK1 prevented 
TGF-b1-driven SMAD1/5 phosphorylation in primary HSVSMCs demonstrating TGF-
b1-dependent ALK1/SMAD1/5 pathway activity in HSVSMCs. The same study 
demonstrated that carotid artery wire injury-induced NF was reduced in 
heterozygous Smad1 knockout mice and in mice treated with the 
pharmacological inhibitor LDN-193189 potentially implicating ALK1/SMAD1/5 
signalling as a contributor to NF. Whereas Sanvitale et al. demonstrated ALK1 
inhibition with LDN-193189 in vitro (Sanvitale et al., 2013), Upton and 
colleagues showed that LDN-193189 did not prevent BMP-9-dependent ALK1 
signalling in ECs (Upton et al., 2020). Furthermore, LDN-193189 has also been 
shown to inhibit ALK2, ALK3, ALK6 and ActRIIa as well as other kinases including 
receptor-interacting serine/threonine-protein kinase (RIPK)2, fibroblast growth 
factor receptor (FGFR)2, calcium/calmodulin-dependent protein kinase kinase 
(CAMKK)-beta and vascular endothelial growth factor receptor (VEGF-R) (Horbelt 
et al., 2015; Vogt et al., 2011; Yu et al., 2008). Given the fact that LDN-193189 
inhibits a multitude of kinases, it is important to point out that observed 
inhibition of NF following systemic administration of LDN-193189 is likely not a 
result of sole ALK1 inhibition. 
In the context of atherosclerosis, human aortic atherosclerotic lesions display 
ALK1 presence (Yao et al., 2007). Kraehling et al. demonstrated that ALK1 
mediated low density lipoprotein (LDL)-cholesterol uptake into endothelial cells 
and promoted LDL transcytosis (Kraehling et al., 2016). The same study 
demonstrated that endothelium-specific ablation of ALK1 in hyperlipidaemic LDL 
receptor-deficient mice resulted in reduced endothelial LDL uptake, indicating a 




formation. Opposing the potentially pathogenic role of ALK1 in atherosclerosis, 
Kim et al. reported decreased BMPR2 presence in advanced human coronary 
atherosclerotic lesions (Kim et al., 2013). The authors demonstrated that BMPR2 
knockdown in ECs induced inflammatory signalling. Paralleling these findings 
hyperlipidaemic heterozygous BMPR2-deficient/apolipoprotein (Apo)E-deficient 
mice developed accelerated atherosclerosis indicating that BMPR2 exerts anti-
inflammatory and athero-protective actions. 
Taken together, the BMP-9/ALK1/BMPR2 pathway can either drive or attenuate 
vascular disease depending on disease setting, distinct vascular compartments 
and cell types as well as other signalling pathways. ALK1 signalling predominates 
in vascular ECs, however, vSMC ALK1 signalling may also partially contribute to 
vascular injury-driven NF. Since BMP-9 acts as an ALK1 ligand, it may be 
speculated that BMP-9 may regulate vSMC-driven NF in vascular injury via the 
ALK1 pathway to some extent. To date, no study has directly investigated BMP-9 





The aims of this chapter were: 
• To determine the presence of BMP-9 and mature SMC markers in pre-
implantation SVGs from CABG patients. 
• To evaluate BMP-9 expression during in vivo SMC phenotype switch-driven 
NF in murine carotid artery injury models. 
• To assess changes in vascular structure and vascular cell proliferation at 





3.3.1 BMP-9 is present in all layers of pre-implantation SVs from 
CABG patients 
Previous findings from our laboratory localised the BMP-9 receptor ALK1 to SMCs 
in pre-implantation SVGs from CABG patients (unpublished data) (Low et al., 
2019). This prompted evaluation of BMP-9 presence/expression in pre-
implantation SVG conduits. Surplus SVG samples were obtained from patients 
undergoing the CABG procedure at a hospital in Glasgow. BMP-9 IHC analysis was 
performed on SVG sections from 3 CABG patients. 
IHC analysis localised aSMA+ cells (green) and BMP-9 (red) to all pre-implantation 
SVG layers from CABG patients (Figure 3-1 A-C). BMP-9 directly co-localised 
(yellow) with aSMA+ cells within the intima and media indicating BMP-9 
expression in SVG SMCs (Figure 3-1 A and B). In addition, BMP-9 co-localised with 
nuclei (purple) in all SVG compartments (Figure 3-1 A-C). Furthermore, 
extracellular space within all SVG layers also stained positive for BMP-9. Taken 
together, these data demonstrate that BMP-9 is present in all pre-implantation 





Figure 3-1 BMP-9 is present in all layers of pre-implantation SVGs from CABG patients. Surplus SVG 
samples from CABG patients were fixed in paraformaldehyde, embedded in paraffin and sectioned on a 
microtome. IHC staining was performed to determine the presence of aSMA (green) and BMP-9 (red). 4′,6-
diamidino-2-phenylindole (DAPI) staining (blue) was used to detect nuclei. Respective IgG controls were 
added to adjust for unspecific binding (D). Images of the intima (A), media (B) and adventitia (C) were taken 
on a confocal microscope at 40× magnification. One representative image is shown for each vascular layer 
(n=3 CABG patients).  
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3.3.2 Pre-implantation SVs from CABG patients display SMC 
phenotype switching 
SMC phenotype switching is an early event following coronary SVG implantation 
forming the basis for neointimal lesion development (Kockx et al., 1992). 
Previous work from our group showed that intimal calponin and MYH11 mRNA 
expression levels in SVGs were lower compared to the media hinting at pre-
implantation in vivo SMC de-differentiation (Daniel Kelly, personal 
communication). To substantiate these observations IHC analysis was performed 
on pre-implantation SVGs from CABG patients to determine intimal and medial 
calponin, SM22-a and MYH11 expression. 
IHC localised calponin (red) to aSMA+ cells (green) within the intima and media 
of pre-implantation SVG conduits (Figure 3-1 A and B). Although not reaching 
statistical significance (p=0.08), intimal calponin immunoreactivity appeared 
visually decreased compared to the media (mean calponin area % ± S.E.M., 
intima: 1.12 ± 0.34, media: 5.8 ± 2.34) (Figure 3-2 E). Calponin+ cells were 
absent in the adventitia (Figure 3-2 C). SM22-a+ cells (red) co-localised with 
aSMA+ cells (green) within all layers of pre-implantation SVGs (Figure 3-3 A-C). 
Intimal SM22-a immunoreactivity appeared visually reduced compared to the 
media (mean SM22-a area % ± S.E.M., intima: 4.14 ± 1.1, media: 7.45 ± 1.01). 
However, this difference was not statistically significant (p=0.27) and was not as 
pronounced as changes observed for calponin and MYH11 (Figure 3-3 E). 
Paralleling SM22-a findings, MYH11+ cells (red) localised to aSMA+ cells (green) 
within all SVG layers (Figure 3-4 A-C). Furthermore, intimal MYH11 
immunoreactivity was significantly decreased compared to the media (mean 
MYH11 area % ± S.E.M., intima: 0.4 ± 0.09, media: 3.0 ± 0.38, p=0.01) (Figure 
3-4 D). Taken together, these findings suggest an overall trend towards a 
decrease of mature SMC marker expression within intimal SMCs compared to 
medial SMCs. This points towards an in vivo shift of quiescent SMCs to a de-





Figure 3-2 Decreased intimal calponin presence hints at in vivo SMC phenotype switching. Surplus 
SVG samples from CABG patients were fixed in paraformaldehyde, embedded in paraffin and sectioned on a 
microtome. IHC staining was performed to determine the presence of aSMA (green) and calponin (red). DAPI 
staining (blue) was used to detect nuclei. Respective IgG controls were added to adjust for unspecific binding 
(D). Images of the intima (A), media (B) and adventitia (C) were taken on a confocal microscope at 40× 
magnification. (E) The ImageJ software was used to quantify calponin pixel intensity (area %). Data are 
presented as mean ± S.E.M. (n=6 CABG patients). A paired Student’s t-test was used to compare groups (p-
value<0.05 was considered significant). One representative image is shown for each vascular layer. Daniel 
Kelly generously gifted calponin/aSMA-stained sections from 3 CABG patients.  
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Figure 3-3 SM22-a co-localises with aSMA+ cells in all layers of pre-implantation SVs from CABG 
patients. Surplus SVG samples from CABG patients were fixed in paraformaldehyde, embedded in paraffin 
and sectioned on a microtome. IHC staining was performed to determine the presence of aSMA (green) and 
SM22-a (red). DAPI staining (blue) was used to detect nuclei. Respective IgG controls were added to adjust 
for unspecific binding (D). Images of the intima (A), media (B) and adventitia (C) were taken on a confocal 
microscope at 40× magnification. (E) The ImageJ software was used to quantify SM22-a pixel intensity (area 
%). Data are presented as mean ± S.E.M. (n=6 CABG patients). A paired Student’s t-test was used to 
compare groups (p-value<0.05 was considered significant). One representative image is shown for each 
vascular layer (Daniel Kelly). Daniel Kelly generously gifted SM22-a/aSMA-stained sections from 3 CABG 
patients.  
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Figure 3-4 Decreased intimal MYH11 presence indicates SMC phenotype switching. Surplus SVG 
samples from CABG patients were fixed in paraformaldehyde, embedded in paraffin and sectioned on a 
microtome. IHC staining was performed to determine the presence of aSMA (green) and MYH11 (red). DAPI 
staining (blue) was used to detect nuclei. Images of the intima (A), media (B) and adventitia (C) were taken on 
a confocal microscope at 40× magnification. (E) The ImageJ software was used to quantify MYH11 pixel 
intensity (area %). Data are presented as mean ± S.E.M. (n=3 CABG patients). A paired Student’s t-test was 
used to compare groups (p-value<0.05 was considered significant). One representative image is shown for 
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Figure 3-5 Decreased intima/media ratios of mature SMC markers suggest SMC phenotype switching 
in pre-implantation SVGs from CABG patients. Surplus SVG samples from CABG patients were fixed in 
paraformaldehyde, embedded in paraffin and sectioned on a microtome. IHC staining was performed to 
determine the presence of calponin, SM22a and MYH11. Images of the intima and media were taken on a 
confocal microscope at 40× magnification. (A) The ImageJ software was used to quantify intimal and medial 
calponin, SM22a and MYH11 intensity (area %). One field per vascular compartment and section was 
assessed. Respective intima area % was divided by respective media area % (intima/media ratio). Data are 

























3.3.3 BMP-9 antibody optimisation in mouse lung tissue 
IHC analysis revealed BMP-9 presence in all layers of pre-implantation SVGs. In 
addition, SVG conduits displayed reduced mature SMC marker expression within 
the intima compared to the media hinting at pre-implantation in vivo SMC 
phenotype switching. The next aim was to study vascular BMP-9 expression 
during SMC phenotype switch-driven NF following carotid artery wire and ligation 
injury in mice. This required BMP-9 antibody optimisation in murine tissue. Since 
the lung expresses BMP-9, murine lung tissue served as a positive control to 
determine optimal BMP-9 antibody concentrations (Liu et al., 2020b; Miller et 
al., 2000). 
Lung parenchyma displayed an increase in BMP-9 immunoreactivity (red) with 
higher concentrations of antibodies (Figure 3-6 A-C). At the highest 
concentration (1:50 dilution), BMP-9 localised to nuclei potentially indicating 
unspecific nuclear staining (Figure 3-6 A). Since BMP-9/DAPI co-localisation was 
less pronounced at the 1:100 dilution (compare Figure 3-6 B and C with A), this 





Figure 3-6 Mouse lung tissue displays BMP-9 immunoreactivity. Control adult mice were terminated. 
Harvested lungs were fixed in paraformaldehyde, embedded in paraffin and sectioned on a microtome. IHC 
staining was performed to determine the presence of aSMA (green, 1:100 dilution) and BMP-9 (red). BMP-9 
antibodies (1 mg/ml) were used at three different concentrations (A à 1:50 dilution, B à 1:100 dilution, C à 
1:200 dilution, D à respective IgG controls). DAPI staining (blue) was used to detect nuclei. Images were 
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3.3.4 Carotid artery wire injury triggers an increase in vascular 
BMP-9 immunoreactivity and SMC phenotype switching 
Pre-implantation SVGs from CABG patients display BMP-9 presence and SMC 
phenotype switching. This prompted analysis of BMP-9 presence in uninjured 
(day 0, n=2) and wire injured (day 14, n=3; day 21, n=3) murine carotid arteries. 
Unstained sections from a previous carotid artery wire injury study by Dr Sammy 
El-Mansi were utilised for this IHC analysis. 
In uninjured day 0 controls BMP-9 (red) mainly localised to the adventitia (Figure 
3-7 A). Light punctate BMP-9 staining was also visible in the media. aSMA+ cells 
(green) localised to the media. 14-day old wire injured lesions displayed a 
reduction in total SMC aSMA expression suggesting SMC phenotype switching 
(mean total vessel staining % ± S.E.M., day 0 uninjured control: 6.8 ± 0.58, day 
14 injured: 1.51 ± 0.49, [p<0.05]) (Figure 3-7, compare B with A; Figure 3-9 B). 
Paralleling loss of vSMC aSMA expression, punctate BMP-9 staining was visible 
along the IEL and neointima (Figure 3-7 B). Furthermore, total vessel BMP-9 
immunoreactivity demonstrated a trend towards an increase compared to 
uninjured day 0 controls (day 0 uninjured control: 2.71 ± 0.43, day 14 injured: 
5.43 ± 0.92) (Figure 3-7, compare B with A; Figure 3-9 A). Although total vessel 
vSMC aSMA expression remained significantly suppressed in injured day 21 
vessels (day 0 uninjured control: 6.8 ± 0.58, day 21 injured: 3.2 ± 0.93, 
[p<0.05]), there was a visible trend towards restoration of aSMA expression 
within the intima and media suggesting the presence of a more quiescent SMC 
phenotype (compare Figure 3-8 A with Figure 3-7 A and B, Figure 3-9 B). Total 
vessel BMP-9 immunoreactivity demonstrated a trend towards a decrease 
compared to injured day 14 vessels reaching similar levels compared to 
uninjured day 0 controls (day 21 injured: 3.12 ± 0.52, day 14 injured: 5.43 ± 
0.92, p>0.05) (compare Figure 3-8 A with Figure 3-7 A and B, Figure 3-9 A). 
Taken together, these data suggest a dynamic increase in total BMP-9 vessel 
immunoreactivity following carotid artery wire injury which is paralleled by SMC 
de-differentiation. This prompted the initiation of a murine carotid artery 
ligation study aimed at evaluating BMP-9 presence at multiple time points and 
correlating IHC findings with vascular morphological changes, SMC phenotype 





Figure 3-7 Carotid artery wire injury triggers an increase in vascular BMP-9 immunoreactivity in mice. 
The carotid artery wire injury procedure was performed as described by (Lindner et al., 1993). C57BL/6J mice 
were terminated at indicated time points. Injured left carotid arteries and uninjured right carotid arteries were 
fixed in paraformaldehyde, embedded in paraffin and sectioned on a microtome. Unstained day 0 uninjured 
and day 14 injured sections were a generous gift from Dr Sammy El-Mansi (A and B). IHC staining was 
performed to determine the presence of aSMA (green) and BMP-9 (red). DAPI staining (blue) was used to 
detect nuclei. Images were taken on a confocal microscope at 40× magnification. One representative image is 
shown for each group (day 0 uninjured, n=2; day 14 injured, n=3). Adv, adventitia; M, media; NI, neointima.  
day 0 uninjured  
murine carotid artery wire injury study 

























































Figure 3-8 Wire injured murine carotid arteries display BMP-9 immunoreactivity at 21 days following 
injury. Unstained day 21 injured sections were a generous gift from Dr Sammy El-Mansi (A). IHC staining was 
performed to determine the presence of aSMA (green) and BMP-9 (red). DAPI staining (blue) was used to 
detect nuclei. (B) Respective IgG controls were added to adjust for unspecific binding. Images were taken on 
a confocal microscope at 40× magnification. One representative image is shown for each group (day 21 
injured, n=3). Adv, adventitia; M, media; NI, neointima.  
day 21 injured  
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Figure 3-9 Carotid wire injury triggers an increase in vascular BMP-9 immunoreactivity and SMC 
phenotype switching in mice. Uninjured and ligation-injured murine carotid arteries were fixed in 
paraformaldehyde, embedded in paraffin and sectioned on a microtome. IHC staining was performed to 
determine the presence of BMP-9 and aSMA. Images were taken on a confocal microscope at 40× 
magnification. The ImageJ software was used to determine total vessel BMP-9 (A) and aSMA (B) pixel 
intensity (area %). Data are presented as mean ± S.E.M. (uninjured day 0, n=2; injured day 14, n=3; injured 
day 21, n=3). A One-way ANOVA with a Tukey’s correction was performed to compare groups. * p-value<0.05 

































































3.3.5 Carotid artery ligation triggers neointima formation and 
media hypertrophy in mice 
These findings together with previous results demonstrating a dynamic increase 
in total vessel BMP-9 immunoreactivity following carotid artery wire injury 
prompted a multiple timepoint murine carotid artery ligation study to link BMP-9 
with early and late vascular changes following ligation injury. The first aim was 
to analyse morphometric changes in injured carotid arteries at day 3 (Daria 
Boyd), day 5, day 7 (Daria Boyd), day 10, day 14 and day 28 following carotid 
artery ligation injury. Injured and uninjured control carotid artery sections were 
stained with H&E to determine intimal area, medial area and the intima to 
media (I/M) ratio which served as an indicator of NF (Figure 3-10, Figure 3-11 
and Figure 3-12). 
It is important to point out that morphometric data obtained from these 2 in 
vivo studies requires careful interpretation due to the amount of intra-group 
variability which may explain the absence of significant changes between 
different time points. The potential underlying reasons for this are discussed in 
3.4. Despite increased variability, presented findings demonstrate that 
structural changes occur in ligation injured carotid arteries. Elastic laminae 
stretching in 3- and 5-day old, injured vessels was evident suggesting onset of 
lesion formation (Figure 3-10 B and C). Reduced medial haematoxylin staining in 
day 3, 5 and 7 injured carotid arteries indicated SMC loss (Figure 3-10 B and C). 
At day 7, 3 injured vessels displayed NF indicated by an increase in intimal 
nuclear haematoxylin staining and an increase in I/M ratio (Figure 3-10 D and 
Figure 3-11 D). At day 10, intimal lesions were detected in 5 out of 6 injured 
carotid arteries (Figure 3-11 A and D). This was paralleled by a trend towards an 
increase in I/M ratio indicating neointimal expansion (mean log10-transformed 
I/M ratio ± S.E.M., day 10 injured: 0.09 ± 0.03, day 3 uninjured control: 0.02 ± 
0.003, p>0.05) (Figure 3-11 D). Furthermore, the media surface area significantly 
increased compared to that of the day 5 injury group indicating medial 
hypertrophy (mean media surface area [µm2] ± S.E.M., day 10 injured: 37,448.1 
± 3,567.4, day 5 injured: 22,942 ± 1394,4, [p<0.05]) (Figure 3-11 A and Figure 
3-12 B). Only 4 out of 7 injured vessels displayed neointimal lesions at day 14 
(Figure 3-11 B and D). Visually, these lesions demonstrated less intimal nuclear 




compared to day 7 and 10 timepoints indicating neointimal remodelling. All 3 
day 28-old, injured vessels showed neointimal lesions (Figure 3-11 C and D). 
Taken together, the I/M ratio in injured vessels increases between the day 5 and 
10 timepoint and peaks at day 10 suggesting that maximal intimal thickening is 
achieved between these 2 timepoints. Furthermore, intimal remodelling occurs 
in two phases. Enhanced intimal nuclear haematoxylin staining at day 7 and 10 
indicates cell hyperplasia within the developing neointima. Between the day 10 
and 28 timepoint, intimal nuclear haematoxylin staining visually decreases and 
eosin staining increases pointing towards neointimal remodelling. Finally, the 





Figure 3-10 Carotid artery ligation triggers NF in mice (part 1). The carotid artery ligation procedure was 
performed as described by Kumar et al. (Kumar and Lindner, 1997). C57BL/6J mice were terminated at 
indicated time points. Injured left carotid arteries and uninjured right carotid arteries were fixed in 
paraformaldehyde, embedded in paraffin and sectioned on a microtome. H&E staining was performed to 
determine morphometric changes. H&E-stained day 3 and 7 sections were a generous gift from Daria Boyd. 
This figure displays representative images of H&E-stained uninjured day 3 (A, n=3), injured day 3 (B, n=8), 
injured day 5 (C, n=6) and injured day 7 (D, n=8) carotid arteries. H&E-stained sections were imaged on a 
microscope at 20× magnification. EEL, external elastic lamina; IEL, internal elastic lamina; NI, neointima. 
Haematoxylin à purple = nuclei, eosin à pink = cytoplasm.  
uninjured day 3 injured day 3 
injured day 5 























Figure 3-11 Carotid artery ligation triggers NF in mice (part 2). The carotid artery ligation procedure was 
performed as described by Kumar et al. (Kumar and Lindner, 1997). C57BL/6J mice were terminated at 
indicated time points. Injured left carotid arteries were fixed in paraformaldehyde, embedded in paraffin and 
sectioned on a microtome. H&E staining was performed to determine morphometric changes. H&E-stained 
sections were imaged on a microscope at 20× magnification. This figure displays representative images of 
H&E-stained injured day 10 (A, n=6), injured day 14 (B, n=7) and injured day 28 (C, n=3) carotid arteries. (D) 
The ImageJ software was used to determine intimal and medial areas (µm2). Log10-transformed intima/media 
ratios (log10(intima/media + 1)) are displayed as mean ± S.E.M. (one data point represents one animal). A 
One-way ANOVA with Tukey’s correction was performed to compare groups. One representative image is 
shown for each group. Haematoxylin à purple = nuclei, eosin à pink = cytoplasm NI, neointima.  
intima to media ratio 
A B 
C D 
injured day 10 injured day 14 





























































Figure 3-12 Carotid artery ligation triggers NF and medial hypertrophy. The carotid artery ligation 
procedure was performed as described by Kumar et al. (Kumar and Lindner, 1997). C57BL/6J mice were 
terminated at indicated time points. Injured left carotid arteries were fixed in paraformaldehyde, embedded in 
paraffin and sectioned on a microtome. H&E staining was performed to determine morphometric changes. 
H&E-stained sections were imaged on a microscope at 20× magnification. Intima (A) and media (B) surface 
areas of H&E-stained injured day 5 (n=6), day 10 (n=6), day 14 (n=7) and day 28 (n=3) left carotid artery 
sections were quantified using the ImageJ software and are displayed in µm2 as mean ± S.E.M. (one data 
point represents one animal). A One-way ANOVA with a Dunnett’s correction was performed to compare 
respective groups versus the injured day 5 group (* p-value<0.05, p<0.05 was considered statistically 
significant). Data from Daria Boyd’s in vivo trial was excluded in this analysis since images of uninjured and 
injured carotid artery sections were taken on a different microscope with different settings.  



















































3.3.6 Carotid artery ligation triggers early peripheral vascular cell 
proliferation in mice 
The second aim was to investigate time- and area-dependent vascular cell 
proliferation in injured versus uninjured carotid arteries following ligation injury 
and to link these findings to onset and progression of NF. As outlined in section 
3.3.5, two studies were merged to interrogate this aim. The EdU to DAPI ratio 
served as a surrogate marker for proliferating vascular cells. 
In similarity to previously presented findings, this EdU analysis requires careful 
interpretation due to increased intra-group variability which may explain the 
absence of statistical significance between groups. The potential underlying 
reasons for this are discussed in section 3.4. In uninjured day 3 controls, some 
nuclei in peripheral vascular cells stained positive for EdU (Figure 3-13 A). 3-day 
old, injured vessels displayed increased EdU+ nuclei within cells in the adventitia 
and perivascular tissue indicating increased cell proliferation (Figure 3-13, 
compare A with B; Figure 3-15 B). Although EdU staining was less pronounced in 
injured day 5 vessels, EdU+ nuclei were still detected in the adventitia and 
peripheral vascular tissue indicating ongoing proliferation in these vascular 
compartments (Figure 3-13, compare C with A and B). At day 7, EdU+ nuclei were 
detected in 6 out of 8 injured carotid arteries (Figure 3-14 A, Figure 3-15 B). The 
EdU/DAPI ratio peaked at this timepoint with proliferating cells localising to 
perivascular tissue, the adventitia, the media and the intima (mean log10-
transformed EdU+/DAPI+ ± S.E.M., day 7 injured: 0.015 ± 0.003, day 3 uninjured 
control: 0.004 ± 0.002, p>0.05). 10-, 14- and 28-day old neointimal lesions did 
not display any EdU+ nuclei potentially indicating absence of vascular cell 
proliferation (Figure 3-14 B and C, Figure 3-15 A and B). 
Overall, these findings show that carotid artery ligation triggers peripheral, 
medial and intimal vascular cell proliferation at early time points following 
vascular injury (day 3-7). SMC proliferation within the media and intima reflects 
SMC phenotype switching. Later time points (day 10-28) did not show any 





Figure 3-13 Carotid artery ligation triggers early peripheral vascular cell proliferation. The carotid artery 
ligation surgery was performed as described by Kumar et al. (Kumar and Lindner, 1997). EdU in 1× sterile 
PBS (dose: 100 mg/kg body weight) was injected intraperitoneally 3-h prior to termination at indicated time 
points. Injured left carotid arteries and uninjured right carotid arteries were fixed in paraformaldehyde, 
embedded in paraffin and sectioned on a microtome. EdU (green)/DAPI (blue) co-staining was performed to 
assess the number of proliferating vascular cells. Unstained day 3 sections were a generous gift from Daria 
Boyd. This figure displays representative images of DAPI/EdU-stained uninjured day 3 (A, n=3), injured day 3 
(B, n=7) and injured day 5 (C, n=6) carotid arteries. EdU-stained sections were imaged on a confocal 































































Figure 3-14 Carotid artery ligation triggers intimal and medial cell proliferation at day 7. The carotid 
artery ligation surgery was performed as described by Kumar et al. (Kumar and Lindner, 1997). EdU in 1× 
sterile PBS (dose: 100 mg/kg body weight) was injected intraperitoneally 3-h prior to termination at indicated 
time points. Injured left carotid arteries and uninjured right carotid arteries were fixed in paraformaldehyde, 
embedded in paraffin and sectioned on a microtome. EdU (green)/DAPI (blue) co-staining was performed to 
assess the number of proliferating vascular cells. Unstained day 7 sections were a generous gift from Daria 
Boyd. This figure displays representative images of DAPI/EdU-stained injured day 7 (A, n=8), injured day 10 
(B, n=6) and injured day 14 (C, n=7) carotid arteries. EdU-stained sections were imaged on a confocal 































































Figure 3-15 28-day old neointimal lesions do not display proliferating cells in mice. The carotid artery 
ligation surgery was performed as described by Kumar et al. (Kumar and Lindner, 1997). EdU in 1× sterile 
PBS (dose: 100 mg/kg body weight) was injected intraperitoneally 3-h prior to termination at indicated time 
points. Injured left carotid arteries and uninjured right carotid arteries were fixed in paraformaldehyde, 
embedded in paraffin and sectioned on a microtome. EdU (green)/DAPI (blue) co-staining was performed to 
assess the number of proliferating vascular cells. This figure displays representative images of a DAPI/EdU-
stained injured day 28 carotid artery (A, n=3). (B) The ImageJ software was used to determine EdU- and 
DAPI-positive area percentages following threshold normalisation. Log10-transformed EdU/DAPI ratios 
((log10(EdU %/DAPI % + 1)) are displayed as mean ± S.E.M. (one data point represents one animal). A One-

































































3.3.7 Preliminary IHC aSMA staining indicates in vivo SMC 
phenotype switching following carotid ligation injury 
Previously presented findings demonstrate that carotid artery ligation triggers 
early vascular cell proliferation which precedes NF and media hypertrophy. 
Intimal and medial SMC proliferation indicated SMC phenotype switching. To 
characterise the SMC phenotype in more detail following carotid artery ligation 
injury, IHC analysis was performed to evaluate SMC aSMA expression in uninjured 
and injured carotid arteries. Due to the 2020 COVID-19 pandemic and 
subsequent lab closure aSMA IHC analyses could only be performed on few n 
numbers. Moreover, BMP-9 and phospho-SMAD1 staining could not be performed. 
Hence, presented data requires careful interpretation due to small n numbers. 
IHC localised aSMA+ cells to the media of uninjured day 3 carotid arteries (Figure 
3-16 A Figure 3-18 C). 3- and 5-day old, lesioned vessels displayed reduced 
medial aSMA immunoreactivity compared to uninjured controls (Figure 3-16, 
compare B and C with A; Figure 3-18 C). At day 7, injured vessels showed close 
to 0 aSMA+ cells indicating loss of SMC aSMA expression (Figure 3-17 A). aSMA 
immunoreactivity in injured vessels remained suppressed at day 10 and 14 
(Figure 3-17 B and C). At day 28, IHC localised aSMA+ cells to the neointima and 
media suggesting a recovery of aSMA expression in vSMCs (Figure 3-18 A and C). 
Overall, this data set points towards a loss of SMC aSMA expression following 
carotid artery ligation injury. Taken together with previous proliferation data, 
suppression of SMC aSMA expression at day 7 is paralleled by an increase in 





Figure 3-16 Carotid artery ligation triggers a decrease in medial aSMA immunoreactivity in mice. The 
carotid artery ligation procedure was performed as described by Kumar et al. (Kumar and Lindner, 1997). 
C57BL/6J mice were terminated at indicated time points. Injured left carotid arteries and uninjured right carotid 
arteries were fixed in paraformaldehyde, embedded in paraffin and sectioned on a microtome. Unstained day 
3 sections were s generous gift from Daria Boyd. IHC staining was performed to determine the presence of 
aSMA (green). DAPI staining (blue) was used to detect nuclei. This figure displays representative images of 




































































Figure 3-17 Carotid artery ligation triggers a decrease in medial aSMA immunoreactivity in mice. The 
carotid artery ligation procedure was performed as described by Kumar et al. (Kumar and Lindner, 1997). 
C57BL/6J mice were terminated at indicated time points. Injured left carotid arteries were fixed in 
paraformaldehyde, embedded in paraffin and sectioned on a microtome. IHC staining was performed to 
determine the presence of aSMA (green). DAPI staining (blue) was used to detect nuclei. Unstained day 7 
sections were a generous gift from Daria Boyd. This figure displays representative images of aSMA /DAPI-




































































Figure 3-18 28-day old neointimal lesions display aSMA immunoreactivity in mice. The carotid artery 
ligation procedure was performed as described by Kumar et al. (Kumar and Lindner, 1997). C57BL/6J mice 
were terminated at indicated time points. Injured left carotid arteries were fixed in paraformaldehyde, 
embedded in paraffin and sectioned on a microtome. IHC staining was performed to determine the presence 
of aSMA (green). DAPI staining (blue) was used to detect nuclei. (A) One representative image is displayed 
for injured day 28 timepoint (n=2). (B) Respective IgG control was added to adjust for unspecific binding. (C) 
The ImageJ software was used to determine total vessel aSMA pixel intensity (area %) following threshold 












































































The aims of this chapter were to evaluate BMP-9 and SMC phenotype switching in 
pre-implantation SVGs from CABG patients and injured murine carotid arteries, 
and to characterise vascular remodelling and cell proliferation at multiple time 
points following carotid artery ligation injury in mice. 
Abundant BMP-9 immunoreactivity was detected in all SVG layers and co-
localised with aSMA+ cells suggesting SMC GDF2 expression. Some BMP-9 staining 
was also detected within the extracellular space. These data confirm the 
presence of BMP-9 in pre-implantation SVGs from patients undergoing CABG 
surgery. However, it is not clear whether SVG SMCs are also the source of BMP-9. 
Since BMP-9 circulates in the bloodstream in humans, it maybe speculated that 
BMP-9 penetrates the saphenous vein wall via the lumen or vasa vasorum and is 
then stored extracellularly or taken up into vSMCs (David et al., 2008). In line 
with this speculation, Miller et al. demonstrated that radioactively labelled 
[125]BMP-9 was taken up into liver ECs and Kupffer cells via an unknown receptor 
(Miller et al., 2000). Surprisingly, qRT-PCR analysis did not detect any BMP-9 
(GDF2) mRNA expression levels in isolated primary HSVSMCs (data not shown). 
Outgrowth in 15% FCS SMC growth media may suppress BMP-9 mRNA expression 
levels which may then become undetectable, or primer insufficiency may have 
generated false negative results. Moreover, BMP-9 may be produced by other 
vascular cell types such as ECs, fibroblasts or inflammatory cells. In addition, 
BMP-9 antibody specificity may not be accurate. It should be noted that liver 
tissue, rather than lung tissue (as shown in Figure 3-6) would have been more 
appropriate for confirming BMP-9 antibody specificity. For example, Owen et al. 
confirmed BMP-9 antibody specificity in livers of wild-type and homozygous Bmp-
9 knockout mice (Owen et al., 2020). Moreover, co-incubation of BMP-9 
antibodies with rising concentrations of rh BMP-9 should be undertaken to 
confirm antibody specificity for IHC in the future. Furthermore, in situ 
hybridisation should be used in future experiments aimed at localising potential 
BMP-9 mRNA expression in pre-implantation SVG sections. 
IHC analysis demonstrated that SVGs displayed SMC phenotype switching 
indicated by reduced intimal SMC calponin and MYH11 expression compared to 




pre-implantation SVG CNN1 (encodes calponin) and MYH11 mRNA expression 
levels compared to the media (unpublished data) (Low et al., 2019). 
Furthermore, a study by Panettea et al. demonstrated that pre-implantation 
SVGs from CABG patients displayed marked pre-existing neointimal thickening, a 
known risk factor for early and late vein graft failure (VGF) (Panetta et al., 
1992). In addition, decreased medial calponin expression is an independent risk 
factor for VGF following CABG surgery (Perek et al., 2013). A post-mortem study 
investigating SMC phenotype switching in SVGs following CABG surgery 
demonstrated early SMC de-differentiation towards a synthetic phenotype with 
reduced aSMA expression (Kockx et al., 1992). Taken together, pre-existing SMC 
phenotype switching may contribute to neointimal thickening in pre-
implantation SVGs which then may exacerbate acute SMC phenotype switching 
following coronary implantation. 
Pre-implantation SVGs from CABG patients displayed BMP-9 and SMC phenotype 
switching. To determine the potential pathophysiological relevance of BMP-9 in 
SMC de-differentiation-driven NF, wire-injured and uninjured murine carotid 
arteries were stained for BMP-9 and aSMA. Uninjured control carotid arteries 
demonstrated punctate medial and adventitial BMP-9 immunoreactivity. 14-day 
old wire-injured carotids displayed a trend towards an increase in total BMP-9 
presence compared to uninjured controls, indicating a potential dynamic 
increase in vascular BMP-9 levels. In line with previous findings by Lindner et al., 
14-day old injured carotid arteries displayed reduced SMC aSMA expression 
indicating SMC phenotype switching following wire injury (Lindner et al., 1993). 
Alongside adventitial immunoreactivity, punctate BMP-9 staining was visible 
along the IEL and neointima at this time point. 21-day old, injured carotids 
displayed punctate BMP-9 staining within the neointima, media and adventitia. 
Total vascular BMP-9 levels had dropped to levels observed in uninjured control 
carotid arteries. This data set should be interpreted with caution. Firstly, BMP-9 
staining was only performed in a small number of experimental animals. 
Secondly, only wire-injured day 14 and 21 carotid arteries were included in this 
study. Thirdly, morphometric and proliferation data were not readily available. 
Hence, more n numbers including corresponding uninjured controls, 





Despite these limitations, this study, for the first time, suggests that the ALK1 
ligand BMP-9 is present in the murine arterial vasculature. Moreover, a dynamic 
increase in total vascular BMP-9 immunoreactivity is accompanied by SMC 
phenotype switching and NF following wire injury. Furthermore, Garrido-Martín 
et al. found that ECs and vSMCs displayed an increase in ALK1 expression 
following femoral artery wire injury in mice (Garrido-Martín et al., 2013). BMP-
9/ALK1 signalling drives endothelial TLR4, VCAM-1 and E-selectin expression 
thereby potentiating LPS-induced monocyte recruitment (Appleby et al., 2016). 
The same study showed that systemic BMP-9 delivery to LPS-challenged mice 
enhanced leukocyte recruitment to pulmonary endothelium indicating pro-
inflammatory functions of BMP-9. In line with these findings, Cai et al. 
demonstrated that the damage associated molecular pattern (DAMP) protein 
high mobility group box (HMGB)1 was upregulated and interacted with TLR4 in 
wire injured murine carotid arteries (Cai et al., 2015). The same study showed 
that HMGB1 activated TLR4 signalling in macrophages and SMCs triggering 
macrophage chemotactic protein (MCP)-1 production and pro-inflammatory NF-
κB signalling driving monocyte recruitment within the injured vessel. 
Furthermore, pharmacological inhibition of HMGB1/TLR4 interaction and genetic 
ablation of TLR4 prevented monocyte recruitment and NF in wire injured carotid 
arteries implicating the innate immune system as a pathogenic driver of intimal 
hyperplasia following vascular injury. In the context of SVG occlusion, Karper et 
al. showed that lesions in pre-implantation and failed SVGs displayed abundant 
TLR4 presence (Karper et al., 2011). The same study investigated the functional 
role of TLR4 in NF in a murine carotid artery venous inter-positioning model. The 
authors found that transgenic Tlr4-deficient and TLR4 gene silencing in 
hyperlipidaemic APOE* Leiden mice showed reduced NF following vein graft 
inter-positioning. This is in line with aforementioned study by Cai et al. 
demonstrating that TLR4 is a driver of NF following carotid artery wire injury in 
mice (Cai et al., 2015). Hence, it may be speculated that BMP-9 enhances TLR4 
expression via ALK1 pathway activation thereby driving monocyte recruitment 
and NF following vascular injury. This hypothesis could be addressed in a future 
murine carotid artery ligation, wire injury or vein graft study evaluating the 
impact of neutralising BMP-9 antibodies or recombinant BMP-9 on vascular 





BMP-9 findings from wire-injured carotid arteries prompted a multiple timepoint 
murine carotid artery ligation study aimed at correlating potential changes in 
vascular BMP-9 levels with SMC phenotype switching and NF. Although no 
statistically significant changes were found between groups due to increased 
intra-group variability, carotid artery ligation triggered early adventitial and 
peripheral vascular cell proliferation, SMC phenotype switching, NF and medial 
hypertrophy. The potential underlying reasons for the absence of statistical 
significances between groups will be explained in respective paragraphs. 
Furthermore, immunohistochemical BMP-9 staining could not be performed due 
to the COVID-19 pandemic and subsequent lab closure and should be performed 
in the future. 
Three- and 5-day old injured carotid arteries demonstrated reduced medial 
cellularity indicating SMC loss. These findings are in line with a previous study 
investigating NF in Enos (encodes endothelial nitric oxide synthase)-deficient 
C57BL/6J mice following carotid artery ligation injury (Zhang et al., 2020). This 
is interesting, since early medial SMC loss has mainly been reported in the 
murine femoral artery wire injury and venous bypass graft atherosclerosis 
models (Sata et al., 2000; Zou et al., 1998). Together, these findings stand in 
contrast to Kumar’s study, which reported medial cell proliferation in 5-day old 
injured carotid arteries following carotid artery ligation in FVB mice (Kumar and 
Lindner, 1997). This discrepancy may be explained by utilisation of C57BL/6J 
mice in the presented study. Indeed, Kelley et al. showed that mechanisms of 
lumen narrowing following carotid artery ligation differed substantially between 
several investigated inbred mouse strains (Harmon et al., 2000). Early medial 
SMC loss occurs upon coronary SVG and/or stent implantation and this is 
recapitulated in 3- and 5-day old ligation injured carotid arteries (Heldman et 
al., 2001; Kockx et al., 1992). Therefore, this model may prove useful for 
determining efficacy of novel experimental therapies aimed at preventing early 
SMC loss following ligation injury. 
In addition to early medial SMC loss, 3-, 5- and 7-day old injured carotid arteries 
displayed visually enhanced EdU+ nuclei compared to uninjured day 3 controls 
suggesting increased vascular cell proliferation. Whereas proliferating cells at 
day 3 and 5 were localised to the adventitia and perivascular tissue, replicating 




phenotype switching. Very few to no proliferating cells were detected at later 
time points within ligation-injured carotid arteries. The absence of proliferating 
intimal cells beyond day 7 stands in contrast to Kumar’s study, which 
demonstrated sustained intimal cell proliferation until 28 days following carotid 
artery ligation (Kumar and Lindner, 1997). Several reasons may explain this 
discrepancy. Firstly, as mentioned above, the authors utilised the FVB mouse 
strain in their study, which may affect vascular responses following injury. 
Secondly, mice received two BrdU injections at 12- and 1-h prior to termination, 
thereby potentially achieving enhanced incorporation into proliferating vascular 
cells. Thirdly, EdU staining in sections obtained from first ligation study (day 3 
and 7 time points) appeared much brighter compared to sections obtained from 
the second ligation study (day 5, 10, 14 and 28 time points). Surgical procedures, 
EdU dosage/injections and tissue analyses for both studies were performed 
following the same established protocols. The fact that 5-day old injured carotid 
arteries displayed weak EdU staining, which co-localised with DAPI staining, 
confirmed that EdU incorporation had been achieved. However, the EdU batch 
utilised in the second ligation study differed from that utilised in the first study 
and this may explain the discrepancy. As an alternative to EdU staining, 
proliferating cellular nuclear antigen (PCNA) staining may be utilised to 
determine vascular cell proliferation in presented carotid artery ligation studies 
(Sata et al., 2000). Although EdU+ nuclei were visually increased in day 3 and 7 
ligation injured carotid arteries, no statistically significant differences were 
found when comparing these findings to uninjured day 3 controls. Enhanced 
inter-group variability may be explained by the low n number of experimental 
animals, the differences in EdU staining between the first and the second carotid 
artery ligation study and the fact that not all sections display cell proliferation. 
Despite these limitations, interesting observations were made at day 3, 5 and 7 
time points where ligation injured carotid arteries displayed enhanced 
adventitial and perivascular proliferation. Similar observations were made in a 
study by Zhang et al. in which 1-week old ligation injured murine carotid 
arteries demonstrated increased adventitial proliferation and thickness (Zhang 
et al., 2020). In line with these findings, 2- and 3-day old balloon injured porcine 
coronary arteries showed enhanced adventitial fibroblast proliferation (Shi et 




differentiation and subsequent myofibroblast migration to the forming 
neointima. Adventitial fibroblast-to-myofibroblast differentiation and 
myofibroblast migration contribute to SVG NF in pigs (Shi et al., 1997). Taken 
together, it may be speculated that carotid artery ligation injury triggers 
adventitial fibroblast proliferation and subsequent fibroblast-to-myofibroblast 
differentiation. In addition, both Kumar and Zhang reported the presence of 
adventitial CD45+ leukocytes as well as F4/80+ and CD107b+ macrophages in 
ligation injured vessels indicating inflammatory cell infiltration (Kumar and 
Lindner, 1997; Zhang et al., 2020). In line with these findings, Okamoto et al. 
demonstrated up-regulation of perivascular adhesion molecule expression as well 
as adventitial neutrophil and macrophage infiltration in balloon injured coronary 
arteries in pigs (Okamoto et al., 2001). This indicates that inflammatory cells 
may enter the injured vessel wall via activated vasa vasorum. Hence, future 
experiments should be aimed at characterising proliferating adventitial and 
perivascular cells in more detail following carotid artery ligation in mice. 
In line with previous findings by Zhang et al., carotid arteries at the 7-day 
timepoint demonstrated intimal nuclear haematoxylin staining indicating onset 
of NF (Zhang et al., 2020). This was paralleled by a trend towards an increase in 
I/M ratio. Paralleling results from Kumar’s study, IHC detected few to no medial 
SMCs displaying aSMA immunoreactivity compared to uninjured day 3 controls 
suggesting loss of SMC aSMA expression (Kumar and Lindner, 1997). Together 
with an increase in medial SMC proliferation these findings indicate in vivo SMC 
phenotype switching. Although these findings corroborate with previous murine 
carotid artery ligation studies, they require careful interpretation since IHC 
aSMA analysis was only performed on 1-2 animals/group. To overcome this 
limitation, more n numbers should be added to this IHC analysis in the future. 
Alongside hyperplasia, 10-day old neointimal lesions demonstrated a visual 
increase in eosin staining, potentially indicating ECM expansion. The I/M ratio 
showed a trend towards an increase compared to 7-day old injured carotid 
arteries. Beyond day 10, the I/M ratio remained unchanged suggesting that 
maximal neointimal area expansion was achieved by this timepoint. In line with 
Kumar’s findings, carotid arteries at the day 10 timepoint displayed an increase 




(Kumar and Lindner, 1997). At the day 28 timepoint, neointimal lesions 
demonstrated reduced cellularity accompanied by ECM expansion compared to 
neointimal lesions at the 10-day timepoint. These findings corroborate with a 
study by Liao et al. which reported that SMC-specific Tgfbr1 deficiency in 
C57BL/6J mice attenuated NF following femoral artery wire injury compared to 
wild-type controls (Liao et al., 2016). Attenuation of NF was characterised by 
enhanced intimal cell proliferation, apoptosis and a reduction in intimal collagen 
content. Whereas functional ALK5 receptor signalling dampened SMC 
proliferation and apoptosis this pathway also drove neointimal ECM expansion. 
Interesting observations were made at day 10 and 14 time points. Although 
intimal lesions appeared to be covered by endothelium, they frequently 
appeared to detach from the IEL forming subendothelial spaces which were 
filled with erythrocytes. Kumar et al. reported similar findings in perfusion-
fixed, ligation-injured carotid arteries at the 5 day timepoint (Kumar and 
Lindner, 1997). The authors speculated that this may be explained by persistent 
and fixed vessel contraction indicated by the presence of wavy elastic laminae. 
Hence, it may be speculated that persistent vessel contraction in this injury 
model may cause endothelial discontinuities allowing erythrocytes to enter the 
sub-endothelial space which may impact neointimal remodelling (Kumar and 
Lindner, 1997). 
As previously outlined, morphometric findings from both presented carotid 
artery ligation studies should be interpreted with caution. Firstly, two 10- and 
three 14-old injured carotid arteries did not display neointimal lesions although 
injured carotid arteries had been evaluated at 5 points (150 µm apart) distal to 
the ligation. This may be explained by technical tissue handling errors during 
paraffin embedding. For example, it is possible that some carotid arteries were 
not embedded at a vertical angle which may hamper subsequent lesion detection 
when cutting sections on the microtome. Secondly, only injured carotid arteries 
were analysed for the second carotid artery ligation study. Uninjured controls 
were not added to this preliminary data set because that the main aims of the 
study were to primarily determine time-dependent NF and SMC phenotype 
switching in injured carotid arteries and to link these responses with the 




arteries should be added to complete morphometric and proliferation analysis of 





Presented findings reveal BMP-9 presence in pre-implantation human SVGs and 
murine arterial vasculature. Moreover, SVGs display in vivo SMC phenotype 
switching which may drive pre-existing SV NF, a known risk factor for early and 
late vein graft disease. Carotid artery wire injury in mice triggered a trend 
towards an increase in total vascular BMP-9 levels which was paralleled by SMC 
phenotype switching indicating a potential role for BMP-9 in NF. These findings 
prompted initiation of an observational multiple timepoint murine carotid artery 
ligation study aimed at linking BMP-9 presence with vascular responses following 
injury. Carotid artery ligation injury in C57BL/6J mice triggered early adventitial 
and perivascular tissue cell proliferation paralleled medial SMC loss. 1-week old 
injured carotid arteries displayed onset of NF, intimal and medial cell 
proliferation and loss of SMC aSMA expression indicating SMC phenotype 
switching. Unfortunately, BMP-9 staining could not be performed for this study 




Chapter 4 Exploring TGF-β superfamily 





Quiescent contractile vSMCs express high levels of contractile markers including 
aSMA, SM22-a, CNN1 and MYH11, important components of the SMC contraction 
machinery (Chen et al., 2016b; Han et al., 2009). SMC phenotype transition 
encompasses a decrease in contractile marker expression, a universally accepted 
indicator of SMC de-differentiation (Frismantiene et al., 2018). Depending on the 
vascular disease setting, this may be paralleled by a gain in proliferative, 
migratory or ECM production capacity or by transitioning to a macrophage-like, 
mesenchymal stem cell (MSC)-like or osteogenic phenotype (Chappell et al., 
2016; Liao et al., 2016; Vengrenyuk et al., 2015; Zhu et al., 2015). Together, the 
transcription factors SRF and MYOCD jointly regulate contractile gene expression 
in vSMCs (Du et al., 2003; Rensen et al., 2006; Yoshida et al., 2003). 
4.1.1 TGF-β-dependent regulation of contractile gene expression 
in vSMCs 
Intact TGF-b superfamily signalling is crucial for normal vascular development 
and adult vascular homeostasis (reviewed in) (Schwartze et al., 2019). TGF-b1 
plays an important role in the regulation of vSMC development (Shah et al., 
1996) and contractile gene expression (Hautmann et al., 1997). 
Shah et al. demonstrated that TGF-b1 induced vSMC differentiation in rodent 
neural crest stem cells (NCSCs) evidenced by an increase in aSMA and calponin 
expression along with an acquisition of SMC morphology (Shah et al., 1996). In 
line with these findings, TGF-b1 induced vSMC differentiation in multi-lineage 
progenitor cells which originated from human umbilical cord blood (Yang et al., 
2011). Furthermore, Grainger and colleagues showed that young heterozygous 
Tgfb1 knockout mice displayed a decrease in aortic contractile protein 
expression levels compared to wild-type controls (Grainger et al., 1998). Taken 
together, these 3 studies demonstrated that TGF-b1 can drive embryonic vSMC 
differentiation and positively regulate contractile gene/protein expression levels 
in vitro and in vivo. However, little was known about the underlying molecular 
mechanisms by which TGF-b1 drove vSMC differentiation. To address this 
question, Hautmann et al. delivered several SM22-a promoter deletion mutants 




(Hautmann et al., 1997). The authors showed that two CArG boxes and a TGF-b 
control element (TCE) conferred TGF-b1 responsiveness driving SM22-a 
expression levels. Further analysis revealed enhanced binding of SRF to CArG 
elements and an unidentified factor to the TCE. In addition, this study showed 
that TGF-b1 also drove MYH11 and CNN1 expression levels. Since this initial 
study, mechanistic studies have uncovered additional molecular mechanisms of 
TGF-b1-dependent regulation of contractile gene expression. 
In line with Hautmann et al.’s findings, Chen et al. demonstrated that the TGF-
b1-inducible SMAD3/SMAD4 complex directly bound to an SBE situated within the 
SM22-a promoter thereby also driving SM22-a expression (Chen et al., 2003). 
Nishimura and colleagues investigated the TF δEF1 in the context of TGF-b1-
dependent transcriptional control of SM22-a in rat aortic SMCs (Nishimura et al., 
2006). The study showed that δEF1 TGF-b1-dependently cooperated with SMAD3 
and SRF thereby enhancing SM22-a  promoter activity. Moreover, Qiu et al. 
found that the known CArG regulator MYOCD participated in TGF-b1-dependent 
induction of SM22-a, MYH11 and aSMA promoters (Qiu et al., 2005). The authors 
demonstrated direct interaction of activated SMAD3 and MYOCD in vitro and in 
vivo revealing functional synergy between these 2 TFs. In summary, these 
mechanistic studies showed that TGF-b1-dependent regulation of contractile 
gene expression in vSMCs may be achieved by several molecular mechanisms. 
Although these studies uncovered complex TGF-b1-dependent transcriptional 
networks, they did not investigate via which signalling axis TGF-b1 regulated the 
contractile vSMC phenotype. This is important since TGF-b1 may transduce 
signals via the ALK5/SMAD2/3 or ALK1/SMAD1/5 signalling axis (Schwartze et al., 
2014). Low et al. showed that pharmacological and siRNA-mediated inhibition of 
ALK5 and ALK1 in HSVSMCs attenuated TGF-b1-dependent SMAD2/3 and SMAD1/5 
phosphorylation respectively (unpublished data) (Low et al., 2019). Whereas 
TGF-b1 drove contractile gene expression levels via the ALK5 signalling axis, 
pharmacological ALK1 inhibition had no impact on TGF-b1-dependent induction 
of contractile gene expression. In line with these findings, combined 
pharmacological ALK4/5/7 with SB431542 inhibited TGF-b1-driven contractile 




b1/ALK5/SMAD2/3-driven contractile differentiation (Tang et al., 2010). Taken 
together, these studies showed that TGF-b1 positively regulated contractile gene 
expression in venous and arterial vSMCs via the ALK5/SMAD2/3 pathway. Overall, 
presented in vitro and in vivo studies coherently identified TGF-b1 as a driver of 
the contractile vSMC phenotype. 
4.1.2 Conflicting role of TGF-β signalling in vascular injury-driven 
NF 
Friedl et al. showed that SVGs with neointimal lesions displayed an increase in 
TGF-b1 and LTBP compared to SVGs without NF (Friedl et al., 2004). 
Furthermore, Nikol and colleagues uncovered an increase in TGFB1 mRNA 
expression levels within re-stenosed coronary arteries following balloon 
angioplasty (Nikol et al., 1992). Taken together, these two studies suggested the 
involvement of TGF-b1 in NF following coronary SVG implantation and PCI. 
Subsequently, studies investigating the role of TGF-b signalling in in vivo 
vascular injury models generated conflicting results. 
Tsai et al. revealed that balloon-injured rat carotid arteries displayed enhanced 
Smad3 expression compared to uninjured control (Tsai et al., 2009). Subsequent 
adenoviral-mediated Smad3 delivery to injured arteries triggered an increase in 
vSMC proliferation and worsened NF. Although TGF-b1 treatment alone 
suppressed rat aortic SMC proliferation, TGF-b1 potentiated adenoviral-mediated 
Smad3 overexpression-driven proliferation. A subsequent study by the same 
group found this effect was ERK/MAPK dependent (Suwanabol et al., 2012). This 
meant that TGF-b1-driven cell responses might depend on intracellular signalling 
messenger expression levels. Although a study by Kobayashi et al. reported that 
TGF-b1/SMAD3 signalling suppressed serum-induced SMC proliferation, Smad-3 
depleted cells did not prevent TGF-b1-driven chemotaxis indicating that this pro-
migratory effect may be driven by the lateral TGFBR2/ALK1/SMAD1 signalling 
axis (Kobayashi et al., 2005). In the context of SVG disease, Cooley and 
colleagues demonstrated that TGF-b signalling antagonism by neutralising 
antibodies, short hairpin RNA-mediated Smad2 or Smad3 knockdown, Smad3 
haploinsufficiency and EC-specific Smad2 knockdown prevented TGF-b1-driven 




adenoviral-mediated TGF-b1 antisense mRNA delivery to epigastric veins 
following inter-positional grafting into femoral arteries in rats significantly 
reduced NF (Wolff et al., 2006). These studies identified TGF-b1 as a 
pathological driver of NF in murine arterial and venous vascular injury models. It 
was speculated that pharmacological inhibition of induction of Tgfb1, Tgfb3 and 
Alk5 mRNA expression levels in balloon-injured rat carotid arteries with tranilast 
would dampen NF following balloon angioplasty in humans (Ward et al., 1998). 
The Tranilast Restenosis Following Angioplasty Trial (TREAT-2) reported a 
marked reduction in restenosis rates in tranilast-treated patients receiving 
percutaneous transluminal coronary angioplasty compared to placebo-treated 
control trial participants (Tamai et al., 2002). However, the much larger 
Prevention of REStenosis with tranilast and its outcomes (PRESTO) Trial did not 
find a significant improvement of restenosis in patients receiving PCI treatment 
(Holmes et al., 2002). The fact, that anti-TGF-b1 treatment did not yield a 
positive result means that human pathophysiology does not entirely reflect 
experimental in vivo findings. 
Since vSMC de-differentiation largely contributes to NF following vascular injury 
and TGF-b1-positively regulates the contractile vSMC phenotype, it appears 
conceivable that ALK5 agonism would protect vSMCs from phenotype switching 
and subsequent NF. Indeed, Nishimura’s study clearly demonstrated positive 
TGF-b1/δEF1-dependent regulation of SM22-a expression (Nishimura et al., 
2006). The same study showed that adenoviral-mediated δEF1-overexpression 
promoted vSMC differentiation and prevented NF following experimental arterial 
injury in mice. Two in vitro studies found that TGF-b1 attenuated PDGF- and/or 
serum-induced proliferation and migration of vSMCs (Martin-Garrido et al., 2013; 
Mii et al., 1993). In line with these findings Smad3-deficient mice displayed 
enhanced NF following femoral artery wire injury compared to wildtype controls 
(Kobayashi et al., 2005). The same study showed that TGF-b1 suppressed serum-
induced murine aortic SMC proliferation in a Smad3-depedendent manner. 
Moreover, Chen et al. found that enhanced ALK5/SMAD2 signalling by inhibition 
of antagonistic pro-proliferative FGF signalling, even in the presence of high 
serum levels, induced a contractile HASMC phenotype (Chen et al., 2016b). The 
same study demonstrated that SMC-specific FGF receptor adaptor substrate 2-α 




ALK5 receptor protects vSMCs from de-differentiation. In contrast to studies 
presented in the previous paragraph, these studies show that TGF-b1 protects 
the contractile vSMC phenotype and attenuates SMC de-differentiation/NF 
following experimental vascular injury. 
4.1.3 Activin A receptor type 2A/B signalling in vSMCs and 
vascular disease 
In the context of contractile SMC phenotype regulation, Groenendijk et al. 
demonstrated the ACVR2A ligand activin A drove aSMA, CNN1 and SM22-a mRNA 
expression levels in primary HSVSMCs (Groenendijk et al., 2011). In line with 
these findings, adenovirus-mediated activin A delivery inhibited NF in ex vivo 
human SVG organ cultures and following femoral artery cuff injury in mice 
(Engelse et al., 2002). Furthermore, Kloppenburg et al. demonstrated that 
adenovirus-mediated activin a delivery to epigastric vein dampened SMC 
proliferation and NF following inter-positioning into the femoral artery in rats 
(Kloppenburg et al., 2009). In contrast, Yndestad et al. found that PAH patients 
displayed elevated circulating activin A levels (Yndestad et al., 2009). The 
authors went on to demonstrate that hypoxia-induced experimental PAH in mice 
triggered an increase in pulmonary activin A mRNA expression levels and that 
activin a drove PASMC proliferation in vitro. In agreement with this study, Yung 
et al. showed that the myostatin/BMP11/activin ligand trap ActRIIa-FC 
attenuated PASMC and pulmonary microvascular EC proliferation. Moreover 
ActRIIa-FC administration improved pulmonary haemodynamics and attenuated 
right ventricular dysfunction and arteriolar remodelling in SUGEN5416/hypoxia-
induced PAH in rats (Yung et al., 2020). Taken together, these studies suggest 
that activin A/ACVR2A/B signalling may either be protective or deleterious 
depending on the underlying vascular disease and potentially on distinct vascular 
beds. 
4.1.4 Venous versus arterial SMCs 
Owing to differences in blood flow and blood pressure pre-implantation SVGs and 
IMAGs differ substantially in histological structure (section 1.2.1) (Canham et al., 
1997). Less well-defined histological structures such as the poorly developed IEL 




NF and atherosclerosis compared to IMAGs. In addition, it may be speculated 
that differences in differentiation status between SVG and IMAG SMCs 
differentially impact the injury response following CABG surgery. 
Wong et al. demonstrated phenotypical differences between jugular vein and 
carotid artery SMCs in rabbits (Wong et al., 2005). The authors showed that 
venous SMCs demonstrated an increase in proliferative, migratory and collagen 
synthesis capacity compared to arterial SMCs suggesting that venous SMCs were 
more prone to de-differentiation. Deng and colleagues compared gene 
expression profiles and functional cell behaviour in response to oxidised (ox)-LDL 
and PDGF stimulation between HCASMCs and HSVSMCs (Deng et al., 2006). While 
ox-LDL inhibited HCASMC proliferation and migration, it promoted HSVSMC 
proliferation and simultaneously drove pro-inflammatory signalling pathways. 
Moreover, HSVSMCs elicited an increase in proliferation in response to PDGF 
treatment compared to HCASMCs paralleling findings from Wong’s study. Shi et 
al. compared lipid retention and oxidative stress responses between SVGs and 
arterial grafts following graft inter-positioning in hyperlipidaemic pigs (Shi et al., 
2001). In line with above-presented findings, the study revealed that SVG SMCs 
exhibited an increase in oxidative stress and LDL accumulation compared to 
arterial graft SMCs. Turner and colleagues went on to show that HSVSMCs 
displayed an increase in proliferative and migratory capacity in response to 
mitogenic stimuli compared to paired IMAG SMCs highlighting that HSVSMCs are 
more proliferative and invasive. 
In conclusion, these studies comprehensively demonstrate that venous SMCs are 
more prone to de-differentiation compared to arterial SMCs which may in part 
explain why SVGs are more prone to NF and accelerated atherosclerosis 





• To develop and validate an undirected contractile differentiation protocol 
for primary human vSMCs. 
• To determine TGF-b type I, II and III receptor expression levels and 
ALK1/ALK5 pathway activation during contractile differentiation of 
primary human vSMCs. 
• To evaluate the impact of pharmacological ALK5 inhibition during 
contractile differentiation of primary HSVSMCs. 
• To assess HAdV-5 ACVR2A transgene delivery to primary HSVSMCs. 
• To determine BMP-9/TGF-b receptor complex formation on primary 
HSVSMCs. 
• To characterise BMP-9 and/or TGF-β1-driven phenotypical responses in 





4.3.1 Generation of a contractile differentiation protocol for 
primary HSVSMCs 
Previous data shown in Chapter 3 demonstrated in vivo SMC phenotype switching 
in pre-implantation SVGs from CABG patients and injured murine carotid 
arteries. Pre-clinical and clinical studies have shown that SMC phenotype 
switching is a key contributor to NF in SVG disease and ISR (Chappell et al., 
2016; Grewe et al., 2000; Kockx et al., 1992; Yu et al., 2011; Zou et al., 1998). 
Together, these findings prompted generation and validation of a low 
serum/heparin-induced contractile differentiation protocol (termed 
‘undirected’) for primary human vSMCs enabling detailed investigation of ALK1 
and ALK5 signalling during SMC phenotype switching in the context of SVG 
disease and ISR. This protocol was based on a study investigating cross-talk 
between FGF and TGF-b/ALK5 signalling during SMC phenotype-switch driven NF 
in vascular injury (Chen et al., 2016b). 
Quantitative RT-PCR analysis demonstrated that relative aSMA (RQmean + max 
day 4 SMDS vs day 0 15% FCS: 26.3+5.1, p<0.01), CNN1 (encodes calponin; day 4 
SMDS vs day 0 15% FCS: 43.5+6.8, p<0.001), MYH11 (day 4 SMDS vs day 0 15% 
FCS: 441.9+100.1, p<0.001) and SM22-a (day 4 SMDS vs day 0 15% FCS: 5.5+0.6, 
p<0.05) mRNA expression levels significantly increased in the SMDS and SMGS 
condition over a period of 6 days compared to 15% FCS-treated day 0 controls 
(Figure 4-1 A-D). 15% FCS-cultured HSVSMCs also demonstrated a significant 
increase in relative CNN1 (day 6 15% FCS vs day 0 15% FCS: 16.8+2.9, p<0.001) 
and MYH11 (day 6 15% FCS vs day 0 15% FCS: 158.2+34.2, p<0.01) mRNA 
expression levels compared to day 0 controls (Figure 4-1 B and C). Taken 
together, changes in contractile gene levels were most pronounced in the SMDS 
condition. The next aim was to establish whether increased relative contractile 
SMC marker mRNA expression levels were paralleled by increased protein 
expression levels. Whereas 15% FCS treatment suppressed mature SMC marker 
expression, SMDS-cultured HSVSMCs demonstrated a visual increase in aSMA 
(densitometrymean ± S.E.M. day 0 15% FCS: 0.03±0.02, day 6 SMDS: 0.3±0.17, 
p>0.05), calponin (day 0 15% FCS: 0.02±0.01, day 6 SMDS: 0.06±0.02, p>0.05) and 




compared to day 0 controls paralleling previous mRNA expression findings (Figure 
4-2 A-D). In addition, day 6 SMDS-cultured HSVSMCs demonstrated a significant 
increase in calponin protein expression levels compared to day 6 15% controls 
(day 6 15% FCS: 0.01±0.002, day 6 SMDS: 0.06±0.02, p<0.05) (Figure 4-2 A and 
C). The absence of statistical significances for changes in aSMA and SM22-a 
protein levels following densitometric analysis may be explained by intra- and 
inter-patient variability and a low number of biological repeats (n=4 CABG 
patients). Nevertheless, immunoblot analysis paralleled mRNA expression 
findings consistently revealing higher levels of contractile SMC markers in SMDS-





Figure 4-1 SMDS treatment drives accumulation of contractile gene expression levels in primary 
HSVSMCs. Cells were stimulated with 15% FCS (white bars), SMDS (blue bars) or SMGS (red bars). Cells 
were lysed for mRNA isolation and reverse transcription was performed to generate cDNA. Quantitative RT-
PCR was performed to determine relative aSMA (A), CNN1 (B), MYH11 (C) and SM22-a (D) mRNA 
expression levels at indicated time points. Relative target gene expression was normalised to UBC expression 
to determine dCT values, which were used to calculate relative quantification (RQ) values (target group versus 
day 0 control). Data are presented as RQmean + error (biological n=3). A One-way repeated ANOVA with a 
Tukey’s correction was performed to compare groups based on dCT values. P-value<0.05 was considered 
statistically significant (* p-value<0.05, ** p-value<0.01 and *** p-value <0.001, target group versus day 0 15% 




















































































































































































Figure 4-2 SMDS treatment drives accumulation of contractile protein expression levels in primary 
HSVSMCs. Cells were cultured in 15% FCS, SMDS or SMGS. Cells were lysed for protein isolation. (A) 
Immunoblot analysis (20 µg protein sample/lane) was performed to determine aSMA (A and B), calponin (A 
and C) and SM22-a (A and D) protein expression levels at indicated time points. GAPDH served as a 
housekeeper control. Densitometry (B-D) was performed to determine band intensities. Following 
normalisation to GAPDH (target protein/GAPDH) the constant 1 was added to each ratio value prior to log10-
transformation. Data are presented as mean ± S.E.M. (biological n=4). A One-way repeated ANOVA with a 
Tukey’s correction was performed to compare groups. P-value<0.05 was considered statistically significant (* 





























































































































































































4.3.2 Contractile HSVSMCs display a decrease in proliferation 
SMC phenotype switching entails loss of contractile protein expression and 
instead a gain in proliferative capacity following vascular injury (Chappell et al., 
2016; Chen et al., 2016b; Kumar and Lindner, 1997; Liao et al., 2016; Yu et al., 
2011). This prompted evaluation of changes in proliferation in 15% FCS- and 
SMDS-cultured HSVSMCs. Quantitative RT-PCR was performed to determine 
proliferation marker expression and 5-bromo-2'-deoxyuridine (BrdU) analysis was 
utilised as a surrogate marker of HSVSMC proliferation. 
Pro-proliferative CCND1 (encodes cyclin D1) (RQmean + error: day 6 SMDS vs day 0 
15% FCS: 0.14+0.03, p<0.001) and PCNA mRNA expression levels (day 6 SMDS vs 
day 0 15% FCS: 0.27+0.05, p<0.01) time-dependently decreased in SMDS- and 
SMGS-treated HSVSMCs compared to day 0 15% FCS-treated controls (Figure 4-3 B 
and C). In addition, SMDS-treated cells demonstrated significantly reduced 
CCND1 mRNA expression levels compared to 6-day 15% FCS-treated controls (day 
6 SMDS: 0.14+0.03, RQ day 6 15% FCS: 0.56+0.1, p<0.01) (Figure 4-3 B). PCNA 
expression levels were substantially reduced in day 6 15% FCS-treated HSVSMCs 
compared to the day 0 15% FCS-treated controls (day 6 15% FCS vs day 0 15% 
FCS: 0.34+0.01, p<0.05) (Figure 4-3 C). Although comparisons between 6-day 15% 
FCS/SMDS treatment and day 0 15% FCS did not achieve statistical significance, 
there was a trend in up-regulation of anti-proliferative CDKN1A (encodes cyclin-
dependent kinase inhibitor 1) expression levels (RQ day 6 SMDS: 2.4+0.4, RQ day 
6 15% FCS: 5.1+0.9, RQ day 0 15% FCS: 1±0.3, p>0.05). (Figure 4-3 C). Functional 
assessment of HSVSMC proliferation utilising BrdU incorporation assays revealed 
that SMDS-cultured HSVSMCs were significantly less proliferative compared to 
15% FCS-treated controls (absorbancemean ± S.E.M.; 15% FCS: 0.48±0.02, SMDS: 
0.11±0.006, p<0.01) (Figure 4-4 A). Moreover, treatment of SMDS-cultured 
HSVSMCs with PDGF, demonstrated a trend towards an increase in BrdU 
incorporation, suggesting that contractile HSVSMCs could respond to a pro-
proliferative stimulus (SMDS control: 0.11±0.006, SMDS + PDGF: 0.3±0.03, 
p>0.05) (Figure 4-4 A). 
Taken together with previous data, SMDS-treated HSVSMCs displayed an 










Figure 4-3 Contractile HSVSMCs demonstrate reduced levels of pro-proliferative gene expression 
levels. Cells were cultured in 15% FCS, SMDS or SMGS. Cells were lysed for mRNA isolation and reverse 
transcription was performed to generate cDNA. Quantitative RT-PCR was performed to determine relative 
CDKN1A (A), CCND1 (B) and PCNA (C) mRNA expression levels at indicated time points. Relative target 
gene expression was normalised to UBC expression to determine dCT values, which were used to calculate 
relative quantification (RQ) values (target group versus day 0 control). Data are presented as RQmean + error 
(biological n=3). A One-way repeated ANOVA with a Tukey’s correction was performed to compare groups 
based on dCT values. P-value<0.05 was considered statistically significant (* p-value<0.05, ** p-value<0.01 
and *** p-value <0.001, target group versus day 0 15% FCS control; # p-value<0.05, ## p-value <0.01, target 



































































































































Figure 4-4 SMDS-treated primary HSVSMCs display decreased proliferation. (A) Cells were seeded into 
96-well plates (1*104 cells/well) and cultured in 15% FCS (technical n=5/group). Upon achieving 80% 
confluence (day 0) media was removed and cells were either cultured in 15% FCS or SMDS. At day 5, one of 
the two groups within the 15% FCS or SMDS treatment group was stimulated with PDGF-BB (20 ng/ml) or 
vehicle control (ddH20, 10 mM acetic acid, 0.2% BSA). BrdU (1:2000) was incorporated simultaneously and 
incorporation was assessed 24-h later. Scatter plot indicates mean ± S.E.M. (biological n=3). A One-way 
repeated ANOVA with a Tukey’s correction was performed to compare groups. P-value<0.05 was considered 




































4.3.3 Activin A receptor type 2a mRNA expression levels increase 
during contractile differentiation of HSVSMCs 
Chen et al. demonstrated that TGFBR1 expression increased during SMDS 
induced contractile differentiation of primary HASMCs (Chen et al., 2016b). This 
was paralleled by an increase in SMAD2 phosphorylation indicating an increase in 
ALK5 pathway activity. Hence, the next aim was to determine TGF-b type I and 
type II receptor mRNA expression levels during contractile differentiation of 
primary HSVSMCs. 
15% FCS, SMDS and SMGS treatment did not significantly affect type I ALK5, ALK1 
or ALK2 receptor mRNA expression levels (Figure 4-5 A-C). In contrast, day 4 
SMDS and SMGS-treated HSVSMCs displayed increased type II ACVR2A receptor 
expression levels compared to 15% FCS-treated day 0 controls (RQmean + error, 
day 4 SMDS vs day 0 15% FCS: 7.56+1.25, p<0.05) (Figure 4-6 C). The type II 
receptors TGFBR2, BMPR2 (n=2 CABG patients) and ACVR2B were not 
significantly affected by 15% FCS, SMDS or SMGS treatment (Figure 4-6 A, B and 
D). 
In summary, ACVR2A mRNA expression levels were upregulated during 
contractile differentiation. It may be hypothesised that changes in ACVR2A 





Figure 4-5 TGF-b type I receptor gene expression levels remain unchanged during contractile 
differentiation of primary HSVSMCs. Cells were cultured in 15% FCS, SMDS or SMGS. Cells were lysed for 
mRNA isolation and reverse transcription was performed to generate cDNA. Quantitative RT-PCR was 
performed to determine relative ALK5 (A), ALK1 (B) and ALK2 (C) mRNA expression levels at indicated time 
points. Relative target gene expression was normalised to UBC expression to determine dCT values, which 
were used to calculate relative quantification (RQ) values (target group versus day 0 control). Data are 
presented as RQmean + error (biological n=3). A One-way repeated ANOVA with a Tukey’s correction was 
































































































































Figure 4-6 Contractile differentiation is paralleled by an increase in ACVR2A mRNA expression levels 
in primary HSVSMCs. Cells were cultured in 15% FCS, SMDS or SMGS. Cells were lysed for mRNA 
isolation and reverse transcription was performed to generate cDNA. Quantitative RT-PCR was performed to 
determine relative TGFBR2 (A), BMPR2 (B à biological n=2), ACVR2A (C) and ACVR2B (D) mRNA 
expression levels at indicated time points. Relative target gene expression was normalised to UBC expression 
to determine dCT values, which were used to calculate relative quantification (RQ) values (target group versus 
day 0 control). Data are presented as RQmean + error (biological n=3). A One-way repeated ANOVA with a 
Tukey’s correction was performed to compare groups based on dCT values. P-value<0.05 was considered 








































































































































































4.3.4 Contractile differentiation is paralleled by a reduction in ID1 
mRNA expression levels in HSVSMCs 
SMDS treatment robustly triggered contractile protein expression in HSVSMCs 
paralleling previous findings in primary human aortic (HA)SMCs by Chen et al. 
(Chen et al., 2016b). This enabled evaluation of the ALK5 target gene SERPINE1 
and the ALK1 target gene ID1 serving as surrogate markers of respective pathway 
activation (unpublished data) (Low et al., 2019). 
Whereas SERPINE1 mRNA expression remained unchanged during contractile 
differentiation, SMDS- and SMGS-treated cells displayed a time-dependent 
decrease in ID1 expression levels compared to 15% FCS-treated day 0 controls 
(RQmean + error, day 6 SMDS vs day 0 15% FCS: 0.04+0.02, p<0.01) (Figure 4-7 A 
and B). Although the 15% FCS-treated day 6 group demonstrated a trend towards 
reduced ID1 expression levels compared to day 0 controls, the difference 
between groups was not statistically significant (day 6 15% FCS vs day 0 15% FCS: 
0.23+0.07, p>0.05) (Figure 4-7 B). At this point, it must be noted that serum 
naturally contains active BMP-9 (David et al., 2008) and that serum drives 
relative ID1 mRNA expression levels (Lewis and Prywes, 2013). Hence, higher 
relative ID1 mRNA expression levels in HSVSMCs cultured in 15% FCS may solely 
reflect higher FCS and/or serum-derived BMP-9 concentrations rather than the 
cell differentiation state. 
Overall, contractile HSVSMCs displayed reduced relative ID1 mRNA expression 
levels, likely a reflection of reduced serum and/or serum-derived BMP-9 





Figure 4-7 Contractile primary HSVSMCs display a reduction in relative ID1 mRNA expression levels. 
Cells were cultured in 15% FCS, SMDS or SMGS. Cells were lysed for mRNA isolation and reverse 
transcription was performed to generate cDNA. Quantitative RT-PCR was performed to determine relative 
SERPINE1 (A) and ID1 (B) mRNA expression levels at indicated time points. Relative target gene expression 
was normalised to UBC expression to determine dCT values, which were used to calculate relative 
quantification (RQ) values (target group versus day 0 control). Data are presented as RQmean + error 
(biological n=3). A One-way repeated ANOVA with a Tukey’s correction was performed to compare groups 
based on dCT values. P-value<0.05 was considered statistically significant (* p-value<0.05, ** p-value<0.01 
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4.3.5 Generation of an undirected contractile differentiation 
protocol for primary HCASMCs 
Previous findings demonstrated that SMDS treatment robustly induced a 
contractile HSVSMC phenotype suggesting that this approach is a valuable in 
vitro tool for studying cellular mechanisms that drive SMC de-differentiation in 
SVG disease. The next aim was to establish whether SMDS treatment also 
triggered contractile differentiation in primary HCASMCs using a similar protocol. 
SMDS-treated HCASMCs demonstrated a time-dependent significant increase in 
relative aSMA (RQmean + error, day 4 SMDS vs day 0 SMGS: 17.9+2.51, p<0.01), 
CNN1 (RQmean + error, day 4 SMDS vs day 0 SMGS: 8.8+0.24, P<0.05), MYH11 
(RQmean + error, day 4 SMDS vs day 0 SMGS: 75.1+16.2, p<0.01) and SM22-a 
(RQmean + error, day 4 SMDS vs day 0 SMGS: 2.4+0.57, p<0.01) mRNA expression 
levels compared to day 0 SMGS-treated controls paralleling findings in primary 
HASMCs from a previous study (Figure 4-8 A-D) (Chen et al., 2016b). In contrast, 
culture in SMGS had no effect on contractile gene expression indicating a 
proliferative SMC phenotype (Figure 4-8 A-D). Paralleling mRNA expression 
findings immunoblot revealed a time-dependent increase in aSMA 
(densitometrymean ± S.E.M.: day 8 SMDS: 0.11±0.008, day 0 SMGS: 0.003±0.001, 
p<0.001) and calponin (day 8 SMDS: 0.03±0.008, day 0 SMGS: 0.005±0.002, 
p<0.001) protein expression levels compared to day 0 SMGS-treated controls 
(Figure 4-9 A-C). Moreover, SMGS treatment had no effect on aSMA and calponin 
protein levels corroborating mRNA expression findings (Figure 4-9 A-C). 
In conclusion, SMDS treatment robustly induced contractile differentiation in 





Figure 4-8 SMDS-cultured primary HCASMCs accumulate contractile gene expression levels. Cells 
were stimulated with SMDS (blue bars) or SMGS (red bars). Cells were lysed for mRNA isolation and reverse 
transcription was performed to generate cDNA. Quantitative RT-PCR was performed to determine relative 
aSMA (A), CNN1 (B), MYH11 (C) and SM22-a (D) mRNA expression levels at indicated time points. Relative 
target gene expression was normalised to UBC expression to determine dCT values, which were used to 
calculate relative quantification (RQ) values (target group versus day 0 control). Data are presented as RQmean 
± error (1 patient, biological n=3). A One-way repeated ANOVA with a Tukey’s correction was performed to 
compare groups based on dCT values. P-value<0.05 was considered statistically significant (* p-value<0.05, 








































































































































































































Figure 4-9 SMDS-cultured primary HCASMCs accumulate contractile protein expression levels. Cells 
were stimulated with SMDS (blue bars) or SMGS (red bars). Cells were lysed for protein isolation. (A) 
Immunoblot analysis (20 µg protein sample/lane) was performed to determine aSMA (A and B), calponin (A 
and C) and SM22-a (A and D) protein expression levels at indicated time points. GAPDH served as a 
housekeeper control. Densitometry (B-D) was performed to determine band intensities. Following 
normalisation to GAPDH (target protein/GAPDH) the constant 1 was added to each ratio value prior to log10-
transformation. Data are presented as mean ± S.E.M. (1 patient, biological n=3). A One-way repeated ANOVA 
with a Tukey’s correction was performed to compare groups. P-value<0.05 was considered statistically 




























































































































































































































4.3.6 Contractile differentiation is paralleled by an increase in 
TGF-β superfamily receptor mRNA expression levels in 
HCASMCs 
SMDS treatment robustly triggered accumulation of contractile markers in 
primary HCASMCs paralleling previous findings in HSVSMCs. The next aim was to 
evaluate TGF-b type I and II receptor mRNA expression levels in SMDS-cultured 
HCASMCs. 
SMDS treatment induced a time-dependent increase in ALK5 (RQmean + error, day 
6 SMDS vs day 0 SMGS: 5.03+0.87, p<0.001), ALK1 (day 6 SMDS vs day 0 SMGS: 
2.5+0.86, p<0.05) and ACVR2A (day 6 SMDS vs day 0 SMGS: 3.67+1.69, p<0.05) 
mRNA expression levels compared to day 0 SMGS-treated controls (Figure 4-10 A, 
C and D). Although SMGS-cultured HCASMCs displayed a slight significant 
increase in ALK5 expression compared to day 0 control cells, these changes were 
not as pronounced as observed in SMDS-treated cells (Figure 4-10 A). TGFBR2, 
ALK2 and ACVR2B expression levels remained unaffected by SMDS and SMGS 
treatment (Figure 4-10 B, E and F). SMDS-triggered accumulation of contractile 
proteins was paralleled by a reduction in ID1 mRNA expression levels compared 
day 0 controls (RQmean + error, day 6 SMDS vs day 0 SMGS: 0.14+0.05, p<0.05) 
(Figure 4-11 A). As described in section 4.3.4, a reduction in ID1 expression 
levels in primary HCASMCs cultured in SMDS media may solely reflect lower FCS 
and/or serum-derived BMP-9 concentrations rather than the cell differentiation 
state. 
In summary, ALK5, ACVR2A and surprisingly ALK1 mRNA expression levels 
dynamically increased during contractile differentiation of HCASMCs. In contrast, 
SMDS-cultured primary HCASMCs displayed a reduction in ID1 mRNA expression 






Figure 4-10 Increased contractile protein expression levels are paralleled by an increase in ALK5, 
ALK1 and ACVR2A mRNA expression levels in primary HCASMCs. Cells were stimulated with SMDS 
(blue bars) or SMGS (red bars). Cells were lysed for mRNA isolation and reverse transcription was performed 
to generate cDNA. Quantitative RT-PCR was performed to determine relative ALK5 (A), TGFBR2 (B), ALK1 
(C), ACVR2A (D), ALK2 (E) and ACVR2B (F) mRNA expression levels. Relative target gene expression was 
normalised to UBC expression to determine dCT values, which were used to calculate relative quantification 
(RQ) values (target group versus day 0 control). Data are presented as RQmean ± error (1 patient, biological 
n=3). A One-way repeated ANOVA with a Tukey’s correction was performed to compare groups based on 
dCT values. P-value<0.05 was considered statistically significant (* p-value<0.05, ** p-value<0.01, *** p-

























































































































































































































































































Figure 4-11 Contractile primary HCASMCs demonstrate a reduction in relative ID1 mRNA expression 
levels. Cells were stimulated with SMDS (blue bars) or SMGS (red bars). Cells were lysed for mRNA isolation 
and reverse transcription was performed to generate cDNA. Quantitative RT-PCR was performed to determine 
relative ID1 (A) mRNA expression levels. Relative target gene expression was normalised to UBC expression 
to determine dCT values, which were used to calculate relative quantification (RQ) values (target group versus 
day 0 control). Data are presented as RQmean ± error (1 patient, biological n=3). A One-way repeated ANOVA 
with a Tukey’s correction was performed to compare groups based on dCT values. P-value<0.05 was 





















































4.3.7 Pharmacological ALK5 inhibition prevents contractile 
differentiation of primary HSVSMCs 
Chen et al. demonstrated that pharmacological ALK4/5/7 inhibition (SB431542) 
blunted SMDS-induced accumulation of contractile proteins in primary HASMCs 
indicating the ALK5 pathway as a regulator of contractile differentiation (Chen 
et al., 2016b). 
Quantitative qRT-PCR analysis revealed a time-dependent increase in aSMA 
mRNA expression levels in SMDS/vehicle-treated primary HSVSMCs compared to 
day 0 15% FCS-treated controls (RQmean + error, day 6 SMDS vs day 0 15% FCS: 
34.5+13.2, p<0.001) (Figure 4-12 A). 15% FCS treatment achieved full 
suppression of aSMA mRNA expression levels during the entire time course. 
Whereas ALK5 (SB525334, blue bars, day 6 SMDS/vehicle: 34.5+13.2, day 6 
SMDS/SB525334: 11.3+4.1, p>0.05) and ALK4/5/7 inhibition (SB431542, red bars, 
day 6 SMDS/vehicle: 34.5+13.2, day SMDS/SB431542: 8.7+1.3, p<0.01) dampened 
accumulation of aSMA expression levels in SMDS-cultured HSVSMCs, ALK1 
inhibition (K02288, purple bars, day 6 SMDS/vehicle: 34.5+13.2, day 6 
SMDS/K02288: 42.6+11.8, p>0.05) had no effect on SMDS-induced increase in 
aSMA expression levels. Interestingly, SB525334 and SB431542 did not entirely 
prevent accumulation of aSMA expression levels in the presence of SMDS at day 
2 and 4 potentially suggesting early ALK4/5/7-independent mechanisms driving 
contractile differentiation. Additional biological repeats confirmed that both 
SB525334 and SB431542 significantly blunted contractile gene expression in the 
presence of SMDS compared to vehicle-treated day 6 and 15% FCS-treated day 0 
controls (unpublished data) (Low et al., 2019). 
Taken together with findings from Low et al.’s study, singular pharmacological 
ALK5 and combined pharmacological ALK4/5/7 inhibition equally prevented 
accumulation of contractile gene expression levels indicating the ALK5 receptor 
as a driver of contractile differentiation in primary HSVSMCs (unpublished data) 
(Low et al., 2019). In contrast, singular pharmacological ALK1 inhibition did not 
affect SMDS-driven contractile gene expression levels. These findings prompted 
validation of contractile protein expression changes in the presence of SMDS and 





15% FCS treatment suppressed contractile protein expression levels in primary 
HSVSMCs at day 6 (Figure 4-13 A-D and Figure 4-14 A-C). The presence of 
SB525334 had no significant impact on target protein expression levels in 15% 
FCS-treated cells (Figure 4-13 A-D and Figure 4-14 A-C). At day 6, SMDS 
treatment significantly drove contractile protein expression levels compared to 
day 6 15% FCS/vehicle and day 0 15% FCS controls (mean log10-transformed 
(αSMA/GAPDH)+1 ± S.E.M., day 6 SMDS/vehicle: 0.29±0.12, day 6 15%: 
0.07±0.03, p<0.05) (Figure 4-13 A-D and Figure 4-14 A-C). At day 6, the presence 
of SB525334 significantly prevented SMDS-induced accumulation of αSMA (day 6 
SMDS/SB525334: 0.15±0.07, day 0 15% control: 0.08±0.03, p>0.05), calponin (day 
6 SMDS/SB525334: 0.01±0.004, day 0 15% control: 0.003±0.001, p>0.05) and total 
(t) myosin light chain (MLC)9 protein levels (day 6 SMDS/SB525334: 0.007±0.002, 
day 0 15% control: 0.004±0.001, p>0.05) compared to day 0 15% FCS-treated 
control cells (Figure 4-13 A-C, Figure 4-14 A and C). Although day 6 
SMDS/SB525334-treated HSVSMCs did not demonstrate a significant reduction in 
αSMA, calponin, SM22-α and phospho (p)MLC9 protein levels compared to day 6 
SMDS/vehicle-treated controls, there was a visible trend towards a decrease in 
expression levels (Figure 4-13 A-D, Figure 4-14 A and B). In contrast, SMDS-driven 
increase in tMLC9 protein levels was significantly blunted by SB525334 at day 6 
(day 6 SMDS/vehicle: 0.02±0.009, day 6 SMDS/SB525334: 0.007±0.002, p<0.05) 
(Figure 4-14 A and C). 
In summary, these two data sets coherently demonstrate that functional ALK5 
signalling is necessary for SMDS-driven contractile differentiation. Hence, the 
ALK5 pathway plays an important role in the regulation of the contractile 





Figure 4-12 Pharmacological ALK5 inhibition prevents SMDS-triggered increase in aSMA gene 
expression levels in primary HSVSMCs. Upon achieving 80% confluence (day 0) one set of cells was lysed 
for RNA extraction and served as a reference control. Cells were stimulated with 15% FCS or SMDS in the 
presence of the ALK5 inhibitor SB525334 (10 µM, blue bars), the ALK4/5/7 inhibitor SB431542 (10 µM, red 
bars), the ALK1 inhibitor K02288 (0.1 µM, purple bars) and vehicle control (DMSO, white bars). Media was 
replaced with fresh respective media containing respective pharmacological inhibitors or vehicle control every 
2 days. Respective groups were lysed on day 2, 4 and 6 for RNA extraction (technical n=3/group). Reverse 
transcription was performed to generate cDNA. Quantitative RT-PCR was performed to determine relative 
aSMA (A) mRNA expression levels. Relative target gene expression was normalised to UBC expression to 
determine dCT values, which were used to calculate relative quantification (RQ) values (target group versus 
day 0 control). Data are presented as RQmean ± error (biological n=1). A One-way repeated ANOVA with a 
Tukey’s correction was performed to compare groups based on dCT values. P-value<0.05 was considered 
statistically significant (** p-value<0.01 and *** p-value <0.001, target group versus day 0 15% FCS control; ## 

















































Figure 4-13 Pharmacological ALK5 inhibition prevents SMDS-driven contractile protein expression 
levels in primary HSVSMCs. Upon achieving 80% confluence (day 0) one set of cells was lysed for protein 
extraction and served as a reference control. Cells were stimulated with 15% FCS or SMDS in the presence of 
the ALK5 inhibitor SB525334 (10 µM) or vehicle control (DMSO, white bars). Media was replaced with fresh 
respective media containing SB525334 or vehicle control every 2 days. Respective groups were lysed on day 
6 for protein extraction (technical n=3/group). Immunoblot analysis (20 µg protein sample/lane) was performed 
to determine aSMA (A and B), calponin (A and C) and SM22-a (A and D) protein expression levels. GAPDH 
served as a housekeeper control. Densitometry (B-D) was performed to determine band intensities. Following 
normalisation to GAPDH (target protein/GAPDH) the constant 1 was added to each ratio value prior to log10-
transformation. Data are presented as mean ± S.E.M. (biological n=5). A One-way repeated ANOVA with a 
Tukey’s correction was performed to compare groups. P-value<0.05 was considered statistically significant (* 






























































































































































































































Figure 4-14 Pharmacological ALK5 inhibition inhibits SMDS-induced phosphorylation of MLC9 and 
increase in total-MLC9 protein expression levels in primary HSVSMCs. Upon achieving 80% confluence 
(day 0) one set of cells was lysed for protein extraction and served as a reference control. Cells were 
stimulated with 15% FCS or SMDS in the presence of the ALK5 inhibitor SB525334 (10 µM) or vehicle control 
(DMSO, white bars). Media was replaced with fresh respective media containing SB525334 or vehicle control 
every 2 days. Respective groups were lysed on day 6 for protein extraction (technical n=3/group). (A) 
Immunoblot analysis (20 µg protein sample/lane) was performed to determine pMLC9 (A and B) and tMLC9 
(A and C) protein expression levels. GAPDH served as a housekeeper control. Densitometry (B-D) was 
performed to determine band intensities. Following normalisation to GAPDH (target protein/GAPDH) the 
constant 1 was added to each ratio value prior to log10-transformation. Data are presented as mean ± S.E.M. 
(biological n=5). A One-way repeated ANOVA with a Tukey’s correction was performed to compare groups. P-
value<0.05 was considered statistically significant (* p-value<0.05, ** p-value<0.01, *** p-value<0.001, target 






























































































































































4.3.8 HAdV-5-mediated ACVR2A delivery to HSVSMCs increases 
ACVR2A mRNA expression levels 
Previous findings demonstrated a dynamic increase in ACVR2A mRNA expression 
during SMDS-induced contractile differentiation of primary HSVSMCs and 
HCASMCs. This prompted development of a replication-deficient HAdV-5 
expressing the ACVR2A transgene (section 2.9.23). Following virus generation 
and propagation, the next aim was to test HAdV-5-mediated ACVR2A delivery to 
primary HSVSMCs and to assess the potential impact on SMDS-driven increase in 
and 15% FCS-driven suppression of aSMA mRNA expression levels. 
HAdV-5 GFP-transduced HSVSMCs dose-dependently displayed an increase in GFP 
expression indicating successful transduction (Figure 4-15 A and B). However, 
transduction efficiency appeared low with 2.58% (10,000 VPs/cell) of cells 
displaying GFP expression (Figure 4-15 B). In line with previous findings SMDS 
treatment triggered a significant increase in ACVR2A mRNA expression levels in 
un-transduced mock HSVSMCs (RQmean + error, day 2 SMDS/MOCK versus day 0 
15% FCS/MOCK: 8.47+0.56, p<0.001) (Figure 4-16 A, green bar). ACVR2A 
expression levels also significantly increased in 15% FCS media (Figure 4-16 A, 
purple bar). However, this increase was significantly less pronounced compared 
to SMDS-treated cells (Figure 4-16 A, compare green and purple bar) (day 2 
SMDS/MOCK: 8.47±0.56, day 2 15% FCS/MOCK: 2.46±0.31, p<0.001). At day 2, 
HAdV-5 ACVR2A-transduced cells in 15% FCS demonstrated a significant dose-
dependent increase in ACVR2A expression levels compared to 15% FCS-treated 
mock controls. At the lowest concentration (1,000 VP/cell), HAdV-5 ACVR2A 
transduction of 15% FCS-treated HSVSMCs did not result in increased ACVR2A 
expression levels compared to HAdV-5 GFP 15% FCS controls. However, at higher 
doses (5,000 and 10,000 VP/cell), HAdV-5 ACVR2A-transduced cells in 15% FCS 
displayed a significant increase in ACVR2A expression levels compared to HAdV-5 
GFP 15% FCS controls (day 2 15% FCS/5,000 VP HAdV-5 ACVR2A: 13.9±1.53, day 2 
15% FCS/5,000 VP HAdV-5 GFP 3.86±0.79, p<0.001; day 2 15% FCS/10,000 VP 
HAdV-5 ACVR2A: 22.5+0.56, day 2 15% FCS/10,000 VP HAdV-5 GFP: 3.61±1.07, 
p<0.001). In contrast, HAdV-5 ACVR2A-transduced cells in SMDS only 
demonstrated a significant increase in ACVR2A expression at the highest 
concentration (10,000 VP/cell) compared to un-transduced SMDS-treated mock 




8.47±0.56, p<0.001). Moreover, HAdV-5 ACVR2A-transduced cells in SMDS did not 
display increased ACVR2A expression compared to HAd-5 GFP/SMDS controls. 
Further analysis of the same data set showed that SMDS drove aSMA mRNA 
expression levels in un-transduced HSVSMCs compared to day 0 mock controls 
(Figure 4-17 A, green bar). In addition, 15% FCS-treated cells also demonstrated 
a significant increase in aSMA expression levels compared to day 0 controls 
(Figure 4-17 A, purple bar). However, this increase was significantly less 
pronounced compared to SMDS-treated cells (Figure 4-17 A, compare green and 
purple bar). Both HAdV-5 GFP- and HAdV-5 ACVR2A-transduced cells in SMDS 
demonstrated a dose-dependent increase in aSMA expression levels compared to 
day 2 SMDS mock controls. 
In conclusion, HAdV-5 ACVR2A successfully delivered the ACVR2A transgene to 
HSVSMCs in 15% FCS at a concentration of 5,000 or 10,000 VP/cell. However, 
HAdV-5 ACVR2A transduction of HSVSMCs cultured in SMDS did not result in 
higher ACVR2A expression levels compared to HAdV-5 GFP or un-transduced 
SMDS-treated controls. Furthermore, HAdV-5 GFP transduction of HSVSMCs dose-
dependently induced aSMA mRNA expression levels in the presence of SMDS 
indicating an unspecific potentiating effect of GFP expression and/or VP count 
per cell on aSMA gene expression. Hence, the dose-dependent increase in aSMA 
expression levels observed in SMDS-treated HAdV-5 ACVR2A-transduced cells 
most likely depends on the number of VPs per cell rather than an increase in 





Figure 4-15 HAdV-5 GFP transduction efficiency. Primary HSVSMCs were transduced with increasing 
doses of HAdV-5 GFP in 15% FCS media and incubated overnight. (A) At 24-h post transduction cells were 
imaged on a brightfield (BF)/fluorescence microscope at 10´ magnification. (B) The ImageJ software was 



































Figure 4-16 HAdV-5 ACVR2A successfully delivers the ACVR2A transgene to primary HSVSMCs. Upon 
achieving 80% confluence, cells were divided into 2 main groups. Cells intended for virus-mediated transgene 
delivery were transduced with an increasing amount of HAdV-5 GFP and HAdV-5 ACVR2A (1,000 viral 
particles (VP), 5,000 VP and 10,000 VP/cell) in 15% FCS media overnight. Cells intended for mock control 
treatment were also cultured in 15% FCS media overnight. The next day, one set of mock 15% FCS media-
treated cells were lysed and subjected to RNA extraction. Non-virus and virus-containing 15% FCS media was 
replaced with fresh non-virus containing 15% FCS media and SMDS media. Following 48-h incubation, cells 
were lysed and subjected to RNA extraction. Reverse transcription was performed to generate cDNA. 
Quantitative RT-PCR was performed to determine relative ACVR2A (A) mRNA expression levels at indicated 
time points. Relative target gene expression was normalised to UBC expression to determine dCT values, 
which were used to calculate relative quantification (RQ) values (target group versus day 0 mock control, 
black bar). Data are presented as RQmean ± error (biological n=1). A One-way repeated ANOVA with a Tukey’s 
correction was performed to compare groups based on dCT values. P-value<0.05 was considered statistically 
significant (## p-value<0.01, ### p-value<0.001, target group versus day 0 mock control; * p-value<0.05, *** 
p-value <0.001, target group versus day 2 15% FCS mock control; $ p-value<0.05, $$$ p-value<0.001, target 
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Figure 4-17 HAd-5 GFP dose-dependently potentiates SMDS-driven aSMA expression levels in primary 
HSVSMCs. Upon achieving 80% confluence, cells were divided into 2 main groups. Cells intended for virus-
mediated transgene delivery were transduced with an increasing amount of HAdV-5 GFP and HAdV-5 
ACVR2A (1,000 viral particles (VP), 5,000 VP and 10,000 VP/cell) in 15% FCS media overnight. Cells 
intended for mock control treatment were also cultured in 15% FCS media overnight. The next day, one set of 
mock 15% FCS media-treated cells were lysed and subjected to RNA extraction. Non-virus and virus-
containing 15% FCS media was replaced with fresh non-virus containing 15% FCS media and SMDS media. 
Following 48-h incubation, cells were lysed and subjected to RNA extraction. Reverse transcription was 
performed to generate cDNA. Quantitative RT-PCR was performed to determine relative aSMA (A) mRNA 
expression levels at indicated time points. Relative target gene expression was normalised to UBC expression 
to determine dCT values, which were used to calculate relative quantification (RQ) values (target group versus 
day 0 mock control, black bar). Data are presented as RQmean ± error (biological n=1). A One-way repeated 
ANOVA with a Tukey’s correction was performed to compare groups based on dCT values. P-value<0.05 was 
considered statistically significant (## p-value<0.01, ### p-value<0.001, target group versus day 0 mock 
control; * p-value<0.05, *** p-value <0.001, target group versus day 2 15% FCS mock control; $ p-value<0.05, 
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4.3.9 BMP-9 binds to type I and type II TGF-β superfamily 
receptors on HSVSMCs 
Immunohistochemistry localised BMP-9 to aSMA+ SMCs within all layers of pre-
implantation SVGs from CABG patients. Furthermore, qRT-PCR analysis 
demonstrated that primary HSVSMCs expressed the type I TGF-b receptors ALK1, 
ALK2 and ALK5 as well as the type II TGF-b receptors TGFBR2, BMPR2, ACVR2A 
and ACVR2B. Moreover, our group has previously shown that TGF-b1 binds to 
ALK1, ALK5, TGFBR2, ENG and betaglycan on primary HSVSMCs (unpublished 
data) (Low et al., 2019). This prompted evaluation of BMP-9/TGF-b receptor 
interactions on primary HSVSMCs utilising a radioactive crosslinking assay. 
Immunoprecipitation revealed that BMP-9 bound to the TGF-b type I receptors 
ALK1 and ALK2 (Figure 4-18 A and B, lane 2 and 3). The double band after ALK1 
immunoprecipitation may be caused by monomeric or dimeric BMP-9 crosslinked 
to the receptor (Scharpfenecker et al., 2007). Furthermore, BMP-9 directly 
bound to the TGF-b type II receptors BMPR2 and ACVR2A/B (Figure 4-18 A and B, 
lane 4 and 6) and the TGF-b type III receptor endoglin (Figure 4-18 A and B, lane 
5). 
In summary, crosslinking analysis demonstrated that BMP-9 bound to respective 






Figure 4-18 125I-BMP-9 crosslinking assay in primary HSVSMCs. Presented crosslinking analysis was 
performed by Dr Emma Low and Midori Thorikay in Prof. P. ten Dijk’s laboratory (Leiden University Medical 
Centre, Leiden, Netherlands). Confluent cells were incubated with radioactively labelled 125I-BMP-9 in T75 
flasks for 3-h. Following incubation, cells were harvested for immunoprecipitation with TGF-b superfamily 
receptor antibodies (ALK1, ALK2, BMPR2, endoglin and ACVR2A and B). Anti-FLAG antibodies was utilised 
as a negative control. Autoradiography was performed to detect immunoprecipitated type I and type II TGF-b 
superfamily receptors crosslinked to 125I-BMP-9. Autoradiography after 24-h exposure (A) and 48-h exposure 































































4.3.10 BMP-9 treatment drives SMAD1 phosphorylation in 
primary HSVSMCs 
The next aim was to evaluate whether BMP-9 activated SMAD1 phosphorylation 
in primary HSVSMCs and whether there was synergism in the presence of TGF-b1. 
BMP-9 significantly induced SMAD1 phosphorylation in a time-dependent manner 
indicating ALK1/ALK2 pathway activation (mean log10-transformed 
(pSMAD1/GAPDH)+1 ± S.E.M, 15-min BMP-9: 0.034±0.04, 15-min control: 
0.004±0.001, [p>0.05], 30-min BMP-9: 0.063±0.02, 30-min control: 0.01±0.002, 
[p<0.05] (Figure 4-19 A and B). In addition, TGF-b1 also triggered a visual 
increase in SMAD1 phosphorylation via ALK1. However, SMAD1 phosphorylation 
following TGF-b1 stimulation occurred later and was less pronounced compared 
to BMP-9 treatment. No significant additive effect on SMAD1 phosphorylation 
was observed in the presence of both ligands compared to BMP-9 treatment 
alone. 
These immunoblot analyses demonstrate that BMP-9 drives SMAD1 
phosphorylation in primary HSVSMCs in vitro and, hence, this pathway may be 
biologically active in pre-implantation SVGs prior to implantation. Furthermore, 






Figure 4-19 BMP-9 time-dependently drives SMAD1 phosphorylation in primary HSVSMCs. (A) Cells 
were seeded into 6-well plates (1.5*106 cells/well) and cultured in 15% FCS. Upon achieving 80% confluence 
cells were quiesced in 0.2% FCS media for 72-h. Quiesced cells were stimulated with BMP-9 (10 ng/ml, B9), 
TGF-b1 (10 ng/ml, Tb1), both ligands and vehicle control (4 mM HCl, BSA 1 mg/ml, CTRL) for 15, 30 and 60 
min respectively (technical n=3/group). Cells were lysed at respective timepoints and immunoblot analysis (20 
µg protein sample/lane) was performed to determine pSMAD1 protein levels (A). Densitometry (B) was 
performed to determine band intensities. Following normalisation to GAPDH (target protein/GAPDH) the 
constant 1 was added to each ratio value prior to log10-transformation. Data are presented as mean ± S.E.M. 
(biological n=3). A One-way repeated ANOVA with a Tukey’s correction was performed to compare groups. P-
value<0.05 was considered statistically significant (* p-value<0.05, ** p-value<0.01, target group versus 15-











































































































4.3.11 BMP-9 and TGF-β1 treatment induce target gene 
expression in primary HSVSMCs 
Both BMP-9 and TGF-β1 and their respective type I receptors ALK1 and ALK5 are 
present in pre-implantation SVGs from CABG patients and co-localise with aSMA+ 
SMCs (unpublished data) (Low et al., 2019). Furthermore, both ligands 
demonstrate biological activity in isolated primary HSVSMCs. Moreover, 
pharmacological ALK5 inhibition prevented undirected contractile differentiation 
in the same cell type indicating the ALK5 receptor as a regulator of the 
contractile phenotype. Hence, the next aim was to evaluate expression of the 
ALK1 target gene ID1, the ALK5 target gene SERPINE1 and contractile genes in 
response to direct BMP-9 and/or TGF-b1 treatment in the presence and absence 
of the ALK5 inhibitor SB525334. 
Pharmacological ALK5 inhibition blunted TGF-b1-induced SERPINE1 expression 
levels indicating ALK5 pathway dependency (RQmean + error, TGF-b1 + DMSO: 
15.3+0.83, DMSO CTRL: 1+0.2, p<0.001; TGF-b1 + DMSO: 15.3+0.83 vs TGF-b1 + 
SB525334: 0.53+0.16, p<0.001) (Figure 4-20 A). In contrast, the presence of BMP-
9 did not affect the ability of TGF-b1 to drive SERPINE1 expression. In line with 
previously presented pSMAD1 immunoblot findings, BMP-9 induced ID1 mRNA 
expression levels compared to vehicle-treated controls indicating ALK1 and/or 
ALK2 pathway activation (BMP-9 + DMSO: 40.9+8.28, DMSO CTRL: 1+0.25, p<0.05) 
(Figure 4-20  B). The presence of TGF-b1 blunted the ability of BMP-9 to induce 
ID1 expression levels (BMP-9 + TGF-b1: 8.4+1.64, DMSO CTRL: 1+0.25, p>0.05). 
Finally, pharmacological ALK5 inhibition did not prevent BMP-9-driven ID1 
expression (BMP-9 + SB525334: 24.16+8.58, SB525334 CTRL: 1.64+0.4, p<0.05) 
indicating that BMP-9-mediated ALK1/ALK2 pathway activation does not depend 
on functional ALK5 receptor signalling. 
In conclusion, both ligands induced respective target gene expression in primary 
HSVSMCs. Whereas the presence of BMP-9 did not prevent TGF-b1-driven 
SERPINE1 expression, the presence of TGF-b1-blunted the ability of BMP-9 to 
induce ID1 expression indicating that TGF-b1-driven ALK5/SMAD2/3 signalling 





Figure 4-20 BMP-9 and TGF-b1 induce target gene expression in primary HSVSMCs. 80% confluent 
primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. To achieve pharmacological ALK5 
inhibition prior to ligand stimulation, the first 4 groups were incubated in MEDIA1 containing 10 µM SB525334 
for 30 min. In parallel, the second 4 groups were incubated in MEDIA1 containing DMSO vehicle (1:1,000) for 
30 mins. Media was replaced with fresh MEDIA1 containing BMP-9 (10 ng/mL), TGF-b1 (10 ng/mL) ± DMSO 
(1:1,000) or SB525334 (10 µM). After 24-h stimulation, primary HSVSMCs were lysed and subjected to RNA 
extraction. Reverse transcription was performed to generate cDNA. Quantitative RT-PCR was performed to 
determine relative SERPINE1 (A) and ID1 (B) mRNA expression levels. Relative target gene expression was 
normalised to UBC expression to determine dCT values, which were used to calculate relative quantification 
(RQ) values (target group versus DMSO vehicle control). Data are presented as RQmean ± error (biological 
n=3). A One-way repeated ANOVA with a Tukey’s correction was performed to compare groups based on 
dCT values. P-value<0.05 was considered statistically significant (* p-value<0.05 and *** p-value <0.001, 








































































4.3.12 Pharmacological ALK5 inhibition prevents TGF-β1-
induced increase in contractile gene expression in 
HSVSMCs 
Both BMP-9 and TGF-β1 induced target pathway activity in primary HSVSMCs 
evidenced by up-regulation of target gene expression levels. TGF-b1 drives 
contractile gene expression in arterial SMCs and thereby promotes a contractile 
SMC phenotype (Björkerud, 1991; Hautmann et al., 1997). In line with these 
findings Groenendijk et al. found that TGF-b1 stimulated contractile gene 
expression in primary HSVSMCs paralleling findings in arterial SMCs (Groenendijk 
et al., 2011). However, this study did not investigate whether this effect was 
mediated via the ALK5 or ALK1 receptor. Furthermore, the potential effects of 
BMP-9 on contractile gene expression have not been investigated in this cell type 
so far. Together, this prompted investigation of contractile gene expression in 
primary HSVSMCs in response to BMP-9 and/or TGF-b1 stimulation in the 
presence of pharmacological ALK5 inhibition with SB525334. 
24-h TGF-β1 treatment induced aSMA (RQmean + error, TGF-β1: 19+3.39, DMSO 
CTRL: 1+0.3, p<0.001), CNN1 (TGF-β1: 27.84+9.16, DMSO CTRL: 1+0.2, p<0.001), 
MYH11 (TGF-β1: 38.63+20.4, DMSO CTRL: 1+0.41, p<0.05) and SM22-a (TGF-β1: 
4.21+1.05, DMSO CTRL: 1+0.12, p<0.01) mRNA expression levels in primary 
HSVSMCs compared to vehicle-treated controls (Figure 4-21 A-D). 
Pharmacological ALK5 inhibition with SB525334 blunted TGF-β1-driven 
contractile gene expression indicating ALK5-dependent up-regulation of 
contractile gene expression (Figure 4-21 A-D). BMP-9 did not affect the ability of 
TGF-β1 to induce aSMA, CNN1 and SM22-a expression levels (Figure 4-21 A, B and 
D). Finally, BMP-9 stimulation mildly induced aSMA expression compared to 
vehicle-treated controls which was blunted by pharmacological ALK5 inhibition 
(BMP-9: 4.67+0.88, DMSO CTRL: 1+0.3, p<0.05) (Figure 4-21 A). 
In line with previous findings, TGF-β1 drives contractile gene expression. These 
findings prompted evaluation of contractile protein expression level changes in 
response to ligand treatment. Contrasting gene expression findings, 24-h ligand 
treatment had no impact on aSMA, calponin or SM22-a expression levels in 
quiesced primary HSVSMCs (Figure 4-22 A-D). Vehicle-treated, control quiesced 




may explain the absence of an increase in protein expression following TGF-β1 
treatment. 
Taken together with previously presented data, these findings highlight 
functional TGF-β1/ALK5 signalling as a regulator of contractile gene expression in 
primary HSVSMCs. Moreover, BMP-9 induced aSMA expression levels in an ALK5-
dependent manner. Vehicle-treated controls demonstrated high contractile 
protein levels. Target protein to GAPDH ratios were higher compared to those of 
6-day SMDS/vehicle-treated cells indicating that 72-h quiescence in 0.2% FCS 





Figure 4-21 TGF-b1 drives contractile gene expression levels in primary HSVSMCs via the ALK5 
pathway. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. To 
achieve pharmacological ALK5 inhibition prior to ligand stimulation, the first 4 groups were incubated in 
MEDIA1 containing 10 µM SB525334 for 30 min. In parallel, the second 4 groups were incubated in MEDIA1 
containing DMSO vehicle (1:1,000) for 30 mins. Media was replaced with fresh MEDIA1 containing 
recombinant BMP-9 (10 ng/mL), TGF-b1 (10 ng/mL) ± DMSO (1:1,000) or SB525334 (10 µM). After 24-h 
stimulation, primary HSVSMCs were lysed and subjected to RNA extraction. Reverse transcription was 
performed to generate cDNA. Quantitative RT-PCR was performed to determine relative aSMA (A), CNN1 
(B), MYH11 (C) and SM22-a (D) mRNA expression levels. Relative target gene expression was normalised to 
UBC expression to determine dCT values, which were used to calculate relative quantification (RQ) values 
(target group versus DMSO vehicle control). Data are presented as RQmean ± error (biological n=3). A One-
way repeated ANOVA with a Tukey’s correction was performed to compare groups based on dCT values. P-
value<0.05 was considered statistically significant (* p-value<0.05, ** p-value<0.01 and *** p-value <0.001, 


















































































































































Figure 4-22 72-h starved HSVSMCs demonstrate an increase in contractile protein expression levels. 
80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. To achieve 
pharmacological ALK5 inhibition prior to ligand stimulation, the first 4 groups were incubated in MEDIA1 
containing 10 µM SB525334 for 30 min. In parallel, the second 4 groups were incubated in MEDIA1 containing 
DMSO vehicle (1:1,000) for 30 mins. Media was replaced with fresh MEDIA1 containing BMP-9 (10 ng/mL), 
TGF-b1 (10 ng/mL) ± DMSO (1:1,000) or SB525334 (10 µM). After 24-h stimulation, primary HSVSMCs were 
lysed and subjected to protein extraction. (A) Immunoblot analysis (20 µg protein sample/lane) was performed 
to determine aSMA (A and B), calponin (A and C) and SM22-a (A and D) protein expression levels (A). 
Densitometry (A-C) was performed to determine band intensities. Following normalisation to GAPDH (target 
protein/GAPDH) the constant 1 was added to each ratio value prior to log10-transformation. Data are 
presented as mean ± S.E.M. (biological n=3). A One-way repeated ANOVA with a Tukey’s correction was 









































































































































































4.3.13 TGF-β1 demonstrates anti-proliferative effects in 
primary HSVSMCs 
TGF-β1 ALK5-dependently drove contractile gene expression in primary HSVSMCs. 
SMC de-differentiation underlies NF following acute vascular injury (Chappell et 
al., 2016). Taken together, these findings prompted investigation of PDGF- and 
serum-induced primary HSVSMC proliferation in the presence of BMP-9 and/or 
TGF-b1. 
At 48-h, 15% FCS/vehicle- and 15% FCS/BMP-9-treated cells demonstrated a 
significant increase in BrdU incorporation compared to 0.2% FCS/vehicle-treated 
controls indicating enhanced cell proliferation (absorbancemean ± S.E.M.: 15% FCS 
CTRL: 0.48±0.13, 0.2% FCS CTRL: 0.07±0.02, p<0.01; 15% FCS + BMP-9: 
0.43±0.09, 0.2% FCS CTRL: 0.07±0.02, p<0.01) (Figure 4-23 A). TGF-β1 blunted 
the ability of 15% FCS to significantly induce cell proliferation (TGF-β1: 
0.28±0.07, 0.2% FCS CTRL:0.07±0.02, p>0.05). PDGF/vehicle-treated controls 
displayed a trend towards an increase in BrdU incorporation compared to 0.2% 
FCS vehicle-treated controls suggesting a trend towards an increase in cell 
proliferation (0.2% FCS + PDGF: 0.34±0.06, 0.2% FCS CTRL: 0.07±0.02, p>0.05). 
Although BMP-9 stimulation appeared to reduce PDGF-driven cell proliferation 
compared to the 0.2%/PDGF treatment group, the difference between these two 
groups was not statistically significant. Neither BMP-9 nor TGF-β1 had an impact 
on BrdU incorporation in the presence of 0.2% FCS media. As outlined in sections 
4.3.4 and 4.3.6, serum-derived BMP-9 may impact on the increase in 
proliferation observed in 15% FCS-cultured HSVSMCs. 
Overall, TGF-β1 stimulation prevented serum-induced HSVSMC proliferation 
thereby suggesting that early transient and selective ALK5 agonism may present 
a therapeutic strategy for preventing early medial SMC proliferation and 





Figure 4-23 TGF-β1 prevents serum-induced primary HSVSMC proliferation. Cells were seeded into 96-
well plates (1*104 cells/well) and cultured in 15% FCS. Upon achieving 80% confluence cells were quiesced in 
0.2% FCS media for 72-h. Quiesced cells were stimulated with BMP-9 (10 ng/ml, B9), TGF-b1 (10 ng/ml, Tb1), 
both ligands and vehicle control in the presence of 0.2% FCS, PDGF-BB (20 ng/ml) or 15% FCS (technical 
n=5/group). BrdU (1:2,000) was incorporated simultaneously and incorporation was assessed 48-h later. 
Scatter plot indicates mean ± S.E.M. (biological n=3). A One-way repeated ANOVA with a Tukey’s correction 
was performed to compare groups. P-value<0.05 was considered statistically significant (** p-value<0.01, 




















































4.3.14 TGF-β1 stimulation indicates inhibition of serum-
induced migration in primary HSVSMCs 
Medial SMC migration to the intima prompts the expansion of intimal monoclonal 
SMCs following vascular injury, driving NF (Chappell et al., 2016). The next aim 
was to establish whether BMP-9 and/or TGF-β1 had an impact on serum-induced 
HSVSMC migration in wound healing/scratch assays. 
Quiesced control HSVSMCs demonstrated 42.65% scratch closure in the absence 
of serum or extrinsic growth factors (Figure 4-24 A and Figure 4-25 A). In 
contrast,15% FCS controls demonstrated 64.82% scratch closure (p<0.05 versus 
0.2% FCS). Moreover, TGF-β1 significantly reduced serum-induced scratch closure 
to baseline levels (mean scratch closure % ± S.E.M., 15% FCS/vehicle: 
64.82±0.25, 15% FCS/ TGF-β1: 34.91±4.74, p<0.05). In contrast, BMP-9 had no 
effect on serum-induced scratch closure. As previously outlined in section 4.3.4, 
it is possible that serum-derived BMP-9 may impact on the increase in scratch 
closure observed in 15% FCS-cultured HSVSMCs. 
In summary, TGF-β1 prevented serum-induced scratch closure indicating an anti-
migratory effect. However, it is not clear whether this effect occurs because of 





Figure 4-24 TGF-β1 prevents serum-induced primary HSVSMC-driven scratch closure. Cells were 
seeded into 12-well plates (1*106 cells/well) and cultured in 15% FCS. Upon achieving 80% confluence cells 
were quiesced in 0.2% FCS media for 72-h. Wells were horizontally scratched with a sterile 200 µl pipette tip 
and imaged under a microscope at 10´ magnification (left panel). Media was removed and replaced with fresh 
0.2% FCS or 15% FCS containing vehicle control, BMP-9 (10 ng/ml), TGF-b1 (10 ng/ml) or both ligands 
(technical n=3/group). Scratches were imaged again at 20 h at 10´ magnification (right panel). White dotted 
lines indicate scratch edges.  


































Figure 4-25 TGF-β1 demonstrates anti-migratory effects on serum-induced primary HSVSMC-driven 
scratch closure. Cells were seeded into 12-well plates (1*106 cells/well) and cultured in 15% FCS. Upon 
achieving 80% confluence cells were quiesced in 0.2% FCS media for 72-h. Wells were horizontally scratched 
with a sterile 200 µl pipette tip and imaged under a microscope at 10´ magnification (left panel). Media was 
removed and replaced with fresh 0.2% FCS or 15% FCS containing vehicle control, BMP-9 (10 ng/ml), TGF-b1 
(10 ng/ml) or both ligands (technical n=3/group). Scratches were imaged again at 20 h at 10´ magnification 
(right panel). White dotted lines indicate scratch edges. (A) The ImageJ software was used to determine 
scratch closure percentage. Scatter plot indicates mean ± S.E.M. (biological n=2). A One-way repeated 
ANOVA with a Tukey’s correction was performed to compare groups. P-value<0.05 was considered 




































4.3.15 TGF-β1 suppresses osteoblast and macrophage-like 
gene expression via ALK5 in primary HSVSMCs 
Depending on the underlying vascular disease, vSMCs may also de-differentiate 
into an osteoblast- and/or macrophage-like phenotype (Allahverdian et al., 
2014; Zhu et al., 2015). Moreover, accelerated atherosclerotic lesion formation 
and calcification are key pathological features of SVG disease (Kern et al., 1981; 
Pedigo et al., 2017). These findings prompted evaluation of osteoblastic (SP7 à 
encodes osterix; ALPL à encodes alkaline phosphatase) and macrophage marker 
mRNA expression levels (LGALS3 à encodes galectin-3; CD68 à encodes cluster 
of differentiation 68) in primary HSVSMCs in response to ligand stimulation. 
24-h TGF-β1 treatment suppressed ALPL mRNA expression levels in an ALK5-
dependent manner (RQmean + error, TGF-β1 + DMSO: 0.43+0.1, CTRL DMSO: 
1+0.19, p<0.05; TGF-β1 + DMSO: 1+0.19, TGF-β1 + SB525334: 1.75+0.33, p>0.05) 
(Figure 4-26 C). Furthermore, BMP-9 blunted the ability of TGF-β1 to significantly 
down-regulate ALPL expression levels. In addition, double BMP-9/TGF-β1 
stimulation restored ALPL expression levels in the presence of ALK5 inhibition. A 
similar trend was observed for SP7 expression levels although TGF-β1-induced 
suppression compared to vehicle-treated controls did not reach statistical 
significance (Figure 4-26 A). ALK5 inhibition and BMP-9 both blunted the ability 
of TGF-β1 to significantly suppress CD68 expression (TGF-β1 + DMSO: 0.6+0.14 vs 
CTRL DMSO: 1+0.28, p<0.01; CTRL DMSO: 1+0.28 vs TGF-β1/BMP-9 + DMSO: 
0.78+0.22, p>0.05; TGF-β1 + DMSO: 0.6+0.14vs TGF-β1 + SB525334: 1.08+0.34, 
p<0.01 (Figure 4-26 D). In the presence of pharmacological ALK5 inhibition, BMP-
9 mildly induced CD68 expression compared to vehicle-treated DMSO controls. 
TGF-β1 stimulation demonstrated a trend towards a reduction in LGALS3 
expression levels (Figure 4-26 B). Pharmacological ALK5 inhibition in vehicle-
treated controls drove LGALS3 expression levels compared to vehicle-treated 
DMSO controls (CTRL + SB525334: 2.86+0.88 vs CTRL + DMSO: 1+0.36, p<0.05). 
Finally, combined BMP-9/TGF-β1 treatment restored LGALS3 expression levels in 
the presence of ALK5 inhibition (CTRL + SB525334: 2.86+0.88 vs BMP-9/TGF-β1 + 
SB525334: 1.19+0.15, p<0.05). Singular BMP-9 stimulation had no impact on 




In conclusion, TGF-β1 stimulation significantly suppressed ALPL and CD68 
expression levels in an ALK5-dependent manner potentially indicating the ALK5 
pathway as a negative regulator of osteoblastic and macrophage-like 
differentiation in primary HSVSMCs. Although BMP-9 treatment had no impact on 
osteoblastic or macrophage marker expression levels, it did prevent the ability 
of TGF-β1 to significantly suppress osteoblastic and macrophage marker 
expression levels. Moreover, BMP-9 and TGF-β1 synergised to restore suppression 
of osteoblastic and macrophage marker expression levels in the presence of ALK5 
inhibition suggesting that ALK1/SMAD1 signalling may favour osteoblastic and 
macrophage-like differentiation in primary HSVSMCs, in opposition to 





Figure 4-26 TGF-b1 ALK5-dependently suppresses osteoblastic and macrophage-like gene expression 
levels in primary HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media 
(MEDIA1) for 72-h. To achieve pharmacological ALK5 inhibition prior to ligand stimulation, the first 4 groups 
were incubated in MEDIA1 containing 10 µM SB525334 for 30 min. In parallel, the second 4 groups were 
incubated in MEDIA1 containing DMSO vehicle (1:1,000) for 30 mins. Media was replaced with fresh MEDIA1 
containing recombinant human BMP-9 (10 ng/mL), TGF-b1 (10 ng/mL) ± DMSO (1:1,000) or SB525334 (10 
µM). After 24-h stimulation, primary HSVSMCs were lysed and subjected to RNA extraction. Reverse 
transcription was performed to generate cDNA. Quantitative RT-PCR was performed to determine relative 
SP7 (A), LGALS3 (B), ALPL (C) and CD68 (D) mRNA expression levels. Relative target gene expression was 
normalised to UBC expression to determine dCT values, which were used to calculate relative quantification 
(RQ) values (target group versus DMSO vehicle control). Data are presented as RQmean ± error (biological 
n=3). A One-way repeated ANOVA with a Tukey’s correction was performed to compare groups based on 
dCT values. P-value<0.05 was considered statistically significant (* p-value<0.05 and ** p-value<0.01, target 















































































































































The discovery of in vivo SMC phenotype switching in pre-implantation SVGs from 
CABG patients prompted development and validation of an in vitro contractile 
differentiation protocol for primary HSVSMCs and HCASMCs. 
SMDS-cultured primary HSVSMCs time-dependently displayed an accumulation of 
aSMA, CNN1, SM22-a and MYH11 mRNA expression levels versus day 0 15% FCS-
treated controls indicating contractile differentiation. Although SMGS- and 15% 
FCS-cultured HSVSMCs also demonstrated a significant increase in contractile 
gene expression levels, fold changes were less pronounced compared to SMDS 
treatment. The increase in CNN1 mRNA levels in SMDS-cultured HSVSMCs was 
paralleled by a significant accumulation of calponin protein expression. 
Interestingly, calponin protein expression levels remained suppressed in 15% 
FCS-treated HSVSMCs although the same cells displayed a significant increase in 
CNN1 mRNA expression levels highlighting discrepancy between mRNA and 
protein expression levels. Although aSMA and SM22-a protein levels visually 
increased in the presence of SMDS, differences between groups did not reach 
statistical significance. This may be explained by increased inter-patient 
variability and low n-numbers (biological n=4 CABG patients). Indeed, isolated 
primary vSMCs are often pre-conditioned by their donors, which means that 
certain parameters such as age, gender and pharmacological treatment may 
affect SMC biology in vitro (Frismantiene et al., 2018). However, later studies 
investigating the effect of pharmacological ALK5 inhibition on SMDS-induced 
contractile HSVSMC differentiation revealed statistically significant differences 
between groups (biological n=5 CABG patients). Nevertheless, SMDS-induced 
accumulation of contractile gene and protein expression was paralleled by a 
significant decrease in pro-proliferative CCND1 and PCNA mRNA expression levels 
compared to 15% FCS-treated controls. Moreover, 15% FCS-treated HSVSMCs 
displayed enhanced BrdU incorporation compared to the SMDS treatment group 
indicating a proliferative SMC phenotype. 
SMDS-induced contractile differentiation of primary HSVSMCs prompted protocol 
validation for primary HCASMCs to assess potential differences between SMCs 
from distinct vascular beds. Indeed, SMDS-cultured HCASMCs demonstrated 




levels compared to SMGS-treated controls thereby displaying similar responses 
compared to primary HSVSMCs. Moreover, SMDS-cultured HCASMCs displayed a 
significant increase in aSMA and calponin protein expression levels matching 
mRNA level findings. Although SM22-a mRNA levels increased during SMDS 
treatment protein levels remained unchanged. 
Similar SMDS-driven responses in HSVSMCs and HCASMCs may indicate shared 
conserved contractile differentiation mechanisms between these two distinct 
cell types. However, these pro-contractile responses differed in force. Whereas 
SMDS-driven increase in aSMA fold change expression was similar, HSVSMCs 
displayed higher increases in CNN1 and MYH11 fold change expression compared 
to HCASMCs. In contrast, immunoblot data in primary HCASMCs was more 
consistent and showed more significant changes between SMDS- and SMGS-
treated groups. The reason for this may be explained by the fact that HCASMCs 
utilised for this experiment derived from one patient (biological n=3 repeats) 
whereas HSVSMCs derived from four individual CABG patients. This bias may be 
overcome by adding more experimental repeats utilising HCASMCs from different 
donor patients. Interestingly, SMGS media which contains the proliferative 
factors 4.9% FCS, hBFGF and hEGF more efficiently suppressed contractile gene 
expression in HCASMCs compared to SMGS-treated HSVSMCs potentially 
indicating less defined regulation of contractile differentiation in venous SMCs. 
Deng and colleagues demonstrated that primary HSVSMCs demonstrated an 
increase in proliferation in response to PDGF treatment compared to HCASMCs 
(Deng et al., 2006). Moreover, Turner and colleagues showed that primary 
HSVSMC were more proliferative and invasive than paired primary IMAG SMCs 
indicating functional differences between vSMCs from different vascular beds 
(Turner et al., 2007). Together, these two studies show that arterial SMCs 
possess more defined molecular mechanisms underlying regulation of cell 
behaviour which makes them less prone to de-differentiation compared to 
venous SMCs. Although SMDS-drives pro-contractile HSVSMC and HCASMC 
differentiation, HSVSMCs display higher contractile gene expression responses. 
Hence, it may be speculated that regulation of contractile differentiation is less 
defined in HSVSMCs compared to HCASMCs. Despite differences in pro-
contractile responses, these findings in primary HSVSMCs and HCASMCs match 




induced accumulation of contractile protein levels paralleled by a decrease in 
pro-proliferative gene expression and proliferation strongly suggest the presence 
of a contractile SMC phenotype. 
Protocol validation enabled investigation of TGF-b type I and II receptor and 
ALK1/ALK5 target gene mRNA expression levels during contractile differentiation 
of primary HSVSMCs and HCASMCs. SMDS-cultured HSVSMCs and HCASMCs 
displayed a dynamic increase in ACVR2A mRNA levels suggesting a potential role 
for this TGF-b type II receptor during contractile differentiation. Whereas 
SERPINE1 mRNA levels remained un-changed, SMDS treatment resulted in a 
significant decrease in ID1 mRNA levels in HSVSMCs. Moreover, SMDS-treated 
HCASMCs also displayed a dynamic decrease in ID1 mRNA levels. It is possible 
that this reduction in relative ID1 mRNA expression levels may indicate potential 
ALK1 pathway suppression during contractile differentiation in venous and 
arterial SMCs. However, it is more likely that this reduction reflects lower FCS 
and/or serum-derived BMP-9 concentrations rather than the cell differentiation 
state since serum naturally contains active BMP-9 (David et al., 2008) and serum 
drives relative ID1 mRNA expression levels (Lewis and Prywes, 2013). Compared 
to HSVSMCs and in addition to ACVR2A, SMDS-cultured HCASMCs displayed a 
dynamic increase in ALK5 and surprisingly ALK1 mRNA levels during contractile 
differentiation. Chen’s study also demonstrated that SMDS-cultured HASMCs 
displayed a dynamic increase in ALK5 protein expression levels along with 
increased SMAD2 phosphorylation (Chen et al., 2016b). The same study went on 
to show that combined pharmacological inhibition of ALK4/5/7 with SB431542 
prevented SMDS-induced contractile marker accumulation highlighting 
ALK5/SMAD2 signalling as a regulator of contractile differentiation. 
Unfortunately, this study did not assess ALK1/SMAD1 pathway activity during 
contractile differentiation. Despite best efforts to optimise antibodies and the 
immunoblot protocol, it was not possible to detect pSMAD1, tSMAD1, pSMAD2 or 
tSMAD2 in protein lysates from 15% FCS-, SMDS and SMGS-treated primary 
HSVSMCs and/or HCASMCs. In the future, this limitation may be overcome by 
transfecting pSMAD3-(pCAGA) and/or pSMAD1/5/8 (BMP-responsive element, 
BRE)-responsive luciferase plasmids into primary human SMCs and perform 
luciferase assays to assess ALK5 and ALK1 pathway activation during contractile 




inhibition, adenoviral-mediated receptor overexpression or siRNA-mediated 
receptor knockdown studies may be employed to determine the functional 
contribution of ALK1 and ALK5 signalling during contractile differentiation. 
The fact that pharmacological ALK4/5/7 inhibition with SB435142 prevented 
contractile differentiation of primary HASMCs evoked to test this approach in 
primary HSVSMCs. Indeed, combined pharmacological ALK4/5/7 and singular 
ALK5 inhibition prevented an increase in SMDS-induced aSMA mRNA expression 
levels compared to vehicle-treated controls. In contrast, pharmacological ALK1 
inhibition had no effect on SMDS-mediated increase in aSMA mRNA levels. 
Although this experiment was only performed in one set of patient cells 
(biological n=1) subsequent repeats confirmed these findings (unpublished data) 
(Low et al., 2019). Interestingly, pharmacological ALK4/5/7 and/or ALK5 
inhibition could not entirely prevent SMDS-induced accumulation of aSMA mRNA 
levels at day 4. Nonetheless, this initial experiment highlighted an important 
role for functional ALK5 signalling in driving contractile differentiation in 
primary HSVSMCs. This hypothesis was supported by subsequent immunoblot 
analyses demonstrating that pharmacological ALK5 inhibition with SB525334 
blocked SMDS-mediated accumulation of aSMA, calponin and tMLC9 protein 
expression levels compared to 15% FCS-treated controls (biological n=5 CABG 
patients). Furthermore, SMDS-cultured HSVSMCs displayed a significant increase 
in aSMA, calponin, SM22-a, tMLC9 and pMLC9 protein levels compared to 15% 
FCS-treated controls underlying the importance of functional ALK5 receptor 
signalling during SMC maturation. Importantly, as observed for aSMA mRNA 
levels, ALK5 inhibition did not entirely attenuate the ability of SMDS to enhance 
MLC9 phosphorylation which implies that more pathways may be involved during 
contractile differentiation of HSVSMCs. Importantly, functional ALK5 receptor 
signalling is essential for maintaining vascular stability. Nonsense mutations in 
TGFBR1 (encodes ALK5) causes type I LDS in humans, which, alongside 
widespread impaired organogenesis, is characterised by arterial aneurysms and 
tortuosity pre-disposing patients to potentially life-threatening bleeding events 
(Loeys et al., 2005). In the context of SVG disease, vein graft aneurysm 
formation on the basis of accelerated atherosclerosis pre-disposing to 
haemorrhaging events is observed in CABG patients (Neitzel et al., 1986). Hence, 




aneurysm formation. In the context of acute vascular injury SMC-specific Tgfbr1 
deletion in mice prevented NF following femoral artery wire injury (Liao et al., 
2016). However, ALK5-depleted injured femoral arteries displayed persistent 
neointimal cell proliferation and apoptosis, fewer SMCs, enhanced neointimal 
inflammatory infiltrates, reduced collagen content and a thickened adventitial 
layer. This means, that on the one hand ALK5 is involved in neointimal 
thickening, most likely by driving ECM production in intimal SMCs. On the other 
hand, ALK5 deficiency most likely impairs long-term vascular performance 
following injury highlighting the importance of this receptor in maintaining 
vascular stability. 
SMDS-cultured primary HSVSMCs and HCASMCs both displayed a dynamic increase 
in ACVR2A mRNA expression levels during contractile differentiation. This 
observation prompted development and validation of a HAdV-5 expressing 
ACVR2A and determining the effect of adenoviral-mediated ACVR2A delivery on 
proliferating and differentiating primary HSVSMCs (biological n=1 CABG patient). 
It was hypothesised that enhanced ACVR2A expression would potentiate SMDS-
induced aSMA mRNA expression levels at day 2. In 15% FCS, HAdV-5 ACVR2A-
transduced HSVSMCs demonstrated a dose-dependent increase in ACVR2A mRNA 
levels compared to HAdV-5 GFP-transduced controls indicating successful 
transgene delivery. In the presence of SMDS, only cells that were transduced 
with the highest dose (104 VP/cell) of HAdV-5 ACVR2A demonstrated a significant 
increase in ACVR2A mRNA levels versus mock controls. However, similar 
observations were made for SMDS-treated and HAdV-5 GFP-transduced cells (104 
VP/cell) indicating that the increase in ACVR2A mRNA levels most likely occurred 
because of virus-related cytotoxicity. This effect was even more pronounced for 
aSMA mRNA levels which dose-dependently increased in HAdV-5 GFP-transduced 
cells in the presence of 15% FCS and SMDS compared to mock controls. In 
conclusion, HAdV-5-mediated ACVR2A transgene delivery was successful in the 
presence of 15% FCS. In contrast, adenoviral-mediated ACVR2A delivery did not 
induce or potentiate aSMA mRNA expression levels in the presence of 15% FCS or 
SMDS respectively since increasing concentrations of control HAdV-5 GFP 




In general, it must be noted that these findings require careful interpretation 
since this experiment was only performed in one set of patient cells. More n 
numbers should be added to verify these observations in the future. Although 
qRT-PCR confirmed a dose-dependent increase in ACVR2A mRNA expression 
levels in primary HSVSMCs and HeLa cells, immunoblot analysis using two 
different antibodies from two different companies failed to detect ACVR2A 
protein levels in HeLa cell lysates (data not shown). In contrast, sequencing of 
the pAdEasy-1::pSHUTTLE-CMV::ACVR2A plasmid confirmed transgene integrity 
and identity suggesting that the utilised antibodies failed to detect ACVR2A. 
Hence, ACVR2A antibody optimisation for immunoblot and/or 
immunocytochemistry should be addressed in future experiments. Furthermore, 
viral transduction of HSVSMCs appeared inefficient since only 2.58% of HSVSMCs 
were GFP+ following infection with HAdV-5 GFP at 10,000 VP/cell. This 
inefficiency may be explained by the fact that vSMCs display low CAR availability 
(Parker et al., 2013), the main entry mechanism for non-modified HAdV-5 
(Nicklin et al., 2001). Work et al. demonstrated that genetic modification of 
HAdV-5 fibres by inserting the RGD-4C integrin targeting peptide into the HI loop 
significantly improved transduction of HSVSMC (Work et al., 2004). Hence, this 
limitation may be overcome by inserting the ACVR2A transgene into this 
genetically modified HAdV-5 vector in the future. 
Since SMDS-treated, un-transduced cells already displayed high levels of ACVR2A 
mRNA levels it may be speculated that adenoviral-mediated ACVR2A delivery to 
SMDS-treated HSVSMCs was unable to induce an additional increase in receptor 
expression levels. Although 15% FCS-treated HAdV-5 ACVR2A-transduced cells 
failed to demonstrate an increase in aSMA mRNA levels it may be hypothesised 
that higher ACVR2A levels may impact on other cellular functions such as 
proliferation or migration. Hence, future experiments should address serum-
induced BrdU incorporation and scratch closure in HAdV-5 ACVR2A-transduced 
HSVSMCs versus HAdV-5 GFP controls. Since SMDS-treated vSMCs demonstrated a 
dynamic increase in ACVR2A mRNA levels during contractile differentiation a 
future experiment should also determine the effect of siRNA-mediated ACVR2A 
knockdown in vSMCs in the presence of SMDS. In the context of acute vascular 
injury, a future in vivo study should assess NF following carotid artery ligation 




controls. A previous murine study investigating the impact of homozygous Acvr2a 
depletion on embryonic and post-natal development found that homozygous 
knockout mice were viable and only few demonstrated skeletal and facial 
abnormalities indicating that this transgenic mouse may be utilised for vascular 
injury studies. On the one hand, one may speculate that Acvr2a ablation may 
exacerbate NF following vascular injury since adenoviral-mediated activin A 
delivery to experimentally injured vessels prevented SMC proliferation and NF in 
rats and mice (Engelse et al., 2002; Kloppenburg et al., 2009). On the other 
hand, it is conceivable that Acvr2a depletion may ameliorate NF following 
vascular injury since administration of the ACVR2A-Fc ligand trap reversed 
experimental PAH in rats indicating a protective role for this signalling axis in 
the context of vascular injury (Yung et al., 2020). However, this discrepancy 
may also be explained by the fact that ACVR2A may exert different functions in 
distinct vascular beds. 
Pre-implantation SVGs and wire-injured murine carotid arteries displayed BMP-9+ 
staining in addition to in vivo SMC phenotype switching. Hence, the next step 
was to investigate functional BMP-9 properties in more detail. A crosslinking 
study demonstrated that BMP-9 bound to ALK1, ALK2, BMPR2, ACVR2A/B and 
endoglin on primary HSVSMCs (biological n=1 CABG patient). These findings 
suggested that BMP-9 transduced signals into HSVSMCs. Indeed, immunoblot 
analyses revealed a time-dependent increase in SMAD1 phosphorylation in 0.2% 
FCS quiesced HSVSMCs demonstrating that BMP-9 activated downstream SMAD1 
signalling. In addition, TGF-b1 also induced SMAD1 phosphorylation paralleling 
previous findings from our group (unpublished data) (Low et al., 2019). Low et 
al.’s study demonstrated that TGF-b1-induced SMAD1 activation was ALK1-
dependent. No additive effect on SMAD1 phosphorylation was detected in the 
presence of both ligands compared to BMP-9 treatment alone suggesting absence 
of ligand interaction. Given that BMP-9 may also simultaneously drive SMAD5 
phosphorylation (Upton et al., 2009), it must be noted that BMP-9/ALK1/ALK2-
driven effects may also induce SMAD5 phosphorylation in primary HSVSMCs and, 
therefore, SMAD5 may also potentially contribute to downstream pathway 
effects. Hence, a future experiment should aim to investigate SMAD5 
phosphorylation in response to BMP-9 stimulation in primary HSVSMCs. Despite 




to ligand treatment no reliable immunoblot nor in-cell western blot results could 
be achieved (data not shown). Hence, the potential impact of BMP-9 on lateral 
ALK5/SMAD2 signalling could not be assessed. Since Zhu et al. demonstrated that 
BMP-9 induced SMAD2 phosphorylation in addition to SMAD1 in primary mouse 
aortic SMCs, a continued effort should be undertaken to determine the potential 
impact on vSMC ALK5/SMAD2 signalling in the future (Zhu et al., 2015). 
Furthermore, at this stage it is unclear which receptors mediate BMP-9-
dependent SMAD1 phosphorylation in HSVSMCs. The question remains by which 
means BMP-9 mediates SMAD phosphorylation. Based on previous findings many 
combinations are possible (Andersson et al., 2006; Appleby et al., 2016; David et 
al., 2007; Lee et al., 2005; Mitrofan et al., 2017; Olsen et al., 2015; 
Rebbapragada et al., 2003; Scharpfenecker et al., 2007). Firstly, BMP-9/ALK1 
may recruit BMPR2 or ACVR2A/B triggering SMAD1 phosphorylation. Secondly, 
BMP-9/ALK2 may recruit the same TGF-b type II receptors. Thirdly, BMP-9 may 
bind to endoglin thereby potentiating ALK1 activation. Fourthly, BMP-
9/ACVR2A/B may recruit ALK4 or ALK5 triggering SMAD2/3 phosphorylation. More 
siRNA-mediated receptor knockdown studies should be performed to elucidate 
the exact signalling mechanism in HSVSMCs in the future. 
Both ligands induced proximal pathway activation in primary HSVSMCs. The next 
aim was to determine target ALK1/ALK5 and contractile gene expression in 
response to BMP-9 and/or TGF-b1 treatment. Matching pSMAD1 findings, BMP-9 
robustly induced ID1 mRNA expression levels in an ALK5-independent manner. 
Although TGF-b1 did not prevent BMP-9 driven SMAD1 activation, the presence of 
TGF-b1 attenuated the ability of BMP-9 to drive ID1 gene expression, a known 
downstream SMAD1 pathway target gene (Yang et al., 2013). Furthermore, TGF-
b1 induced SMAD1 phosphorylation did not translate into an increase in ID1 mRNA 
levels. This discrepancy may be explained by ALK5-driven lateral downstream 
pathway inhibition (Goumans et al., 2002). TGF-b1 ALK5-dependently drove 
SERPINE1 mRNA levels, a known downstream ALK5/SMAD2/3 pathway target 
gene (Goumans et al., 2002). In contrast, BMP-9 had no direct effect on 
SERPINE1 mRNA levels and did not prevent TGF-b1-driven SERPINE1 gene 





In the context of contractile genes, TGF-b1-treated HSVSMCs displayed enhanced 
aSMA, CNN1, SM22-a and MYH11 mRNA expression levels compared to vehicle 
treated controls. Singular pharmacological ALK5 inhibition with SB525334 
attenuated TGF-b1-driven increase in contractile gene expression highlighting 
the importance of ALK5 receptor signalling in the context of contractile HSVSMC 
differentiation. Interestingly, BMP-9 treatment triggered a moderate ALK5-
dependent increase in aSMA mRNA levels. Taken together, these findings 
corroborate with previous findings demonstrating that singular pharmacological 
ALK5 inhibition attenuated ligand-independent accumulation of contractile vSMC 
markers. Furthermore, these findings are in line with a previous study which 
demonstrated increased contractile gene expression in primary HSVSMCs in 
response to TGF-b1 treatment (Groenendijk et al., 2011). However, this study 
did not investigate whether this TGF-b1-driven effect was mediated via ALK1 or 
ALK5. A further study showed that combined pharmacological ALK4/5/7 
inhibition prevented contractile protein expression in primary HASMCs 
implicating that functional ALK4/5/7 receptor signalling is necessary for 
contractile differentiation of arterial SMCs (Tang et al., 2010). In contrast, TGF-
b1 stimulation had no effect on aSMA, calponin or SM22-a protein expression 
levels in quiesced HSVSMCs. Since target protein/GAPDH ratios in vehicle-
treated cells were higher compared to day 6 SMDS/vehicle-treated cells 72-h 
quiescence in 0.2% FCS media prior to ligand stimulation may have already 
induced contractile differentiation. This speculation is supported by the fact 
that serum deprivation triggers contractile differentiation of primary human 
umbilical vein SMCs (Han et al., 2006). 
Accelerated atherosclerosis and calcification are key pathological hallmarks of 
chronic SVG disease (Kern et al., 1981; Pedigo et al., 2017). Depending on 
external factors vSMCs may transdifferentiate into macrophage-like and/or 
osteoblastic phenotypes thereby promoting atherosclerotic lesion formation and 
medial calcification respectively (Allahverdian et al., 2014; Vengrenyuk et al., 
2015; Zhu et al., 2015). These findings prompted evaluation of osteoblastic 
(ALPL and SP7) and macrophage (LGALS3 and CD68) gene expression in HSVSMCs 
in response to ligand treatment. The presence of BMP-9 and SB525334 prevented 
TGF-b1-driven ALPL suppression potentially indicating the ALK5 pathway as a 




towards down-regulation of SP7 in TGF-b1-treated cells versus vehicle-treated 
controls this difference failed to achieve statistical significance. Singular BMP-9 
treatment had no impact on ALPL or SP7 mRNA levels. A previous study 
identified BMP-9 as a driver of osteoblastic vSMC differentiation and medial 
calcification (Zhu et al., 2015). This study demonstrated that 9-day BMP-9 
stimulation potentiated high phosphate-induced vSMC calcification at a dose of 
50 ng/ml. Moreover, 4-day BMP-9 treatment at 5 ng/ml enhanced Sp7 and Alpl 
mRNA expression levels and induced alkaline phosphatase activity in the absence 
of high phosphate levels in murine vSMCs. Since HSVSMCs were only stimulated 
for 24-h it may be speculated that BMP-9 treatment was too short to induce a 
substantial change in osteoblastic gene expression. Longer BMP-9 exposure 
studies in absence and presence of high phosphate should be performed to 
evaluate HSVSMC calcification in the future. In line with the hypothesis that 
TGF-b1/ALK5 signalling negatively regulates osteoblastic differentiation Guerrero 
et al. found that TGF-b1 prevented high-phosphate-induced osteogenic 
differentiation of rat mesenchymal stem cells (Guerrero et al., 2014). 
In the context of macrophage-like differentiation during atherosclerotic plaque 
progression, TGF-b1-treated HSVSMCs displayed an ALK5-dependent reduction in 
CD68 mRNA expression levels. Similar trends were observed for LGALS3, 
however, changes between groups did not achieve statistical significance. In 
contrast to CD68 expression, pharmacological ALK5 inhibition triggered an 
increase in LGALS3 mRNA levels compared to vehicle-treated controls. Like 
osteoblastic markers, BMP-9 did not impact CD68 or LGALS3 mRNA expression 
levels. These data suggest that TGF-b1/ALK5 signalling may potentially act as a 
negative regulator of macrophage-like differentiation of HSVSMCs thereby 
exerting a protective role against atherosclerotic lesion formation in SVGs 
following CABG surgery. In line with these findings, it was shown that 
administration of TGF-b1 neutralising antibodies to hyperlipidaemic ApoE-
deficient mice accelerated atherosclerotic lesion formation and promoted 
plaque instability (Mallat et al., 2001). In the context of BMP-9, Kraehling et al. 
demonstrated that BMP-9 receptor ALK1 positively regulated LDL-cholesterol 
uptake into ECs and arterial wall lipid deposition (Kraehling et al., 2016). Hence, 
it is plausible that BMP-9-mediated ALK1/SMAD1 axis activation may synergise 




A future in vitro study should be performed to address this hypothesis in more 
detail. 
Data consistently demonstrated that ALK5 pathway activation promoted the 
contractile HSVSMC phenotype. In experimental and acute SVG injury in humans 
vSMCs switch to a migratory and proliferative phenotype thereby initiating NF 
and expansion (Kockx et al., 1992; Zou et al., 1998). This prompted investigation 
of BMP-9 and/or TGF-b1 stimulation on serum- and PDGF-induced HSVSMC 
proliferation as well as serum-induced scratch closure. Encouragingly, TGF-b1 
stimulation prevented a significant increase in serum-induced proliferation in 
HSVSMCs versus vehicle-treated 0.2% FCS controls. Opposed to TGF-b1, BMP-9 
had no impact on serum-induced cell proliferation. In addition, TGF-b1 
attenuated serum-induced HSVSMC-driven scratch closure potentially suggesting 
anti-migratory effects. Paralleling proliferation findings, BMP-9 had no effect on 
serum-induced scratch closure. It is important to point out that scratch assays 
were only performed for two sets of patient cells (biological n=2 CABG patients). 
Furthermore, the scratch assay cannot definitively distinguish between 
proliferation- and/or migration-driven scratch closure. Hence, more n numbers 
and Boyden chamber migration analysis should be added to this data set in the 
future. It must be noted that potential serum-derived BMP-9 impact on 
proliferation and migration in 15% FCS-cultured HSVSMCs was not accounted for 
in these experiments. Hence, a future experiment should investigate the effect 
of neutralising BMP-9 antibodies on serum-induced HSVSMC proliferation and 
migration to tease out any potential BMP-9-specific effects. Taken together, 
these data suggest that TGF-b1 may exert potent anti-proliferative and -
migratory effects in primary HSVSMCs. However, opposing studies have 
demonstrated that this pathway acts as a pathogenic driver of NF. 
A study by Tsai et al. revealed that balloon-injured rat carotid arteries displayed 
enhanced Smad3 expression compared to uninjured control (Tsai et al., 2009). 
Subsequent adenoviral-mediated Smad3 delivery to injured arteries triggered an 
increase in vSMC proliferation and worsened NF. Although TGF-b1 treatment 
alone suppressed rat aortic SMC proliferation, TGF-b1 potentiated adenoviral-
mediated Smad3 overexpression-driven proliferation. A subsequent study by the 




2012). This means that it is likely that TGF-b1-driven cell responses depend on 
intracellular signalling messenger expression levels. Although a study by 
Kobayashi et al. reported that TGF-b1/SMAD3 signalling suppressed serum-
induced SMC proliferation, Smad-3 depleted cells did not prevent TGF-b1-driven 
chemotaxis indicating that this pro-migratory effect may be driven by the lateral 
TGFBR2/ALK1/SMAD1 signalling axis (Kobayashi et al., 2005). Furthermore, 
adenoviral-mediated TGF-b1 antisense mRNA delivery to epigastric veins 
following inter-positional grafting into femoral arteries in rats significantly 
reduced NF (Wolff et al., 2006). Tranilast is a drug which inhibits up-regulation 
of Tgf-b1, Tgf-b3 and Alk5 mRNA expression levels in balloon-injured rat carotid 
arteries (Ward et al., 1998). The Tranilast Restenosis Following Angioplasty Trial 
(TREAT-2) reported a marked reduction in restenosis rates in tranilast-treated 
patients receiving percutaneous translumenal coronary angioplasty compared to 
placebo-treated control trial participants (Tamai et al., 2002). However, the 
much larger Prevention of REStenosis with tranilast and its outcomes (PRESTO) 
Trial did not find a significant improvement of restenosis in patients receiving 
PCI treatment (Holmes et al., 2002). 
In contrast and based on presented data in this chapter, it may be hypothesised 
that selective ALK5 agonism following acute SVG injury in humans may dampen 
SMC de-differentiation and NF. Indeed, previous in vitro studies found that TGF-
b1 attenuated PDGF- and/or serum-induced proliferation and migration of vSMCs 
(Martin-Garrido et al., 2013; Mii et al., 1993). In line with these findings smad3-
deficient mice displayed enhanced NF following femoral artery wire injury 
compared to wildtype controls (Kobayashi et al., 2005). The same study showed 
that TGF-b1 suppressed serum-induced murine aortic SMC proliferation in a 
Smad3-depedendent manner. Furthermore, Chen et al. found that enhanced 
ALK5/SMAD2 signalling by inhibition of antagonistic pro-proliferative FGF 
signalling induced a contractile HASMC phenotype in the presence of 10% FCS 
(Chen et al., 2016b). The same study demonstrated that SMC-specific FGF 
receptor adaptor substrate 2-α deletion in mice reduced NF following carotid 
artery ligation indicating that the ALK5 receptor protects vSMCs from de-
differentiation. These studies show that the TGF-b1/ALK5/SMAD2/3 signalling 
agonism induces a contractile SMC phenotype, attenuates SMC de-differentiation 




In conclusion, many studies reported protective and pathogenic properties of 
TGF-b1 in the context of vascular injury-driven SMC phenotype switching and NF. 
Discrepancies between opposing studies may be explained by utilisation of 
different vascular injury models in distinct rodent species, different methods 
and timing of interventional approaches and investigation of vSMCs from distinct 
species and vascular beds. Liao’s study demonstrated that intact SMC ALK5 
receptor signalling promoted NF (Liao et al., 2016). However, at the same time 
ALK5 also orchestrated physiological healing of injured vessels. On the one hand, 
TGF-b1 attenuates vSMC proliferation and promotes a contractile SMC phenotype 
and on the other hand, this ligand exerts pro-chemotactic effects and triggers 
ECM production in vSMCs (Liao et al., 2016; unpublished data by Low et al., 
2019; Martin-Garrido et al., 2013; Mii et al., 1993). Based on the 
pathophysiological ligation and wire injury response in mice several potential 
future intervention studies exploiting these effects of TGF-b1 come to mind. (1) 
Since early medial proliferation most likely precedes SMC migration to the 
media, systemic administration of recombinant TGF-b1 prior to and for the first 5 
days following carotid artery ligation may protect the contractile SMC phenotype 
thereby preventing phenotype switching (Chappell et al., 2016). (2) Intimal 
hyperplasia usually becomes visible on day 7 following carotid artery ligation 
(Kumar and Lindner, 1997). Since migrated SMCs give rise to monoclonal 
expansion/proliferation systemic administration of SB525334 (ALK5 inhibitor) or 
neutralising TGF-b1 antibodies on day 5 and 6 following carotid artery ligation 
may prevent pro-chemotactic TGF-b1 effects on medial SMCs thereby attenuating 
SMC migration to the intima (Chappell et al., 2016). (3) SMC ALK5 receptor 
signalling plays an important role in vascular repair following injury at the same 
time driving neointimal ECM deposition and remodelling following femoral artery 
wire injury (Liao et al., 2016). It is conceivable that systemic administration of 
SB525334 or neutralising TGF-b1 antibodies from day 7 until day 14 may dampen 





In conclusion, SMDS-supplemented media drove contractile marker expression in 
primary HSVSMCs which was paralleled by suppressed proliferation indicating a 
contractile phenotype. ALK1/SMAD1 target gene ID1 mRNA expression levels 
were down-regulated in SMDS-treated HSVSMCs, likely a reflection of reduced 
serum and/or serum-derived BMP-9 concentrations rather than the cell 
differentiation state. Furthermore, SMDS treatment induced TGF-b type II 
receptor ACVR2A mRNA levels suggesting a potential regulatory function for this 
receptor during contractile differentiation. Similar observations were made in 
SMDS-treated primary HCASMCs. In addition, SMDS-treated primary HCASMCs 
demonstrated a dynamic increase in TGF-b type I receptor ALK5 and ALK1 mRNA 
levels during contractile differentiation paralleling previous findings in primary 
HASMCs (Chen et al., 2016b). HAdV-5-mediated ACVR2A transgene delivery to 
primary HSVSMCs was successful. However, increased ACVR2A expression had no 
effect on aSMA mRNA levels in serum- and SMDS-treated HSVSMCs. 
Pharmacological ALK5 inhibition with SB525334 prevented SMDS-induced 
contractile differentiation of primary HSVSMCs. In line with this finding, TGF-b1 
drove contractile and suppressed osteoblastic/macrophage gene expression in an 
ALK5-dependent manner. Together, these two data sets comprehensively 
demonstrate that functional ALK5 receptor signalling plays an important role in 
contractile differentiation of primary HSVSMCs. Furthermore, TGF-b1 dampened 
serum-induced proliferation and HSVSMC-driven scratch closure thereby 
demonstrating anti-proliferative and potentially anti-migratory properties in this 
cell type. 
Finally, a crosslinking study revealed that BMP-9 bound to ALK1, ALK2, BMPR2, 
ACVR2A/B and endoglin on primary HSVSMCs. Subsequent BMP-9 stimulation of 
HSVSMCs demonstrated a time-dependent increase in SMAD1 phosphorylation, 
and potentially SMAD5, paralleled by an increase in ID1 mRNA expression levels 




Chapter 5 Evaluating TGF-β superfamily-
dependent regulation of intracellular Ca2+ 





Results presented in Chapter 4 consistently showed that the TGF-b1/ALK5 
pathway induced contractile gene and protein expression in primary HSVSMCs 
strongly suggesting that this pathway positively regulated the contractile SMC 
phenotype. Based on these findings the next aim was to evaluate the impact of 
BMP-9 and/or TGF-b1 stimulation on AngII-dependent intracellular Ca2+ 
mobilisation serving as an upstream surrogate marker of SMC contraction. 
5.1.1 Regulation of vSMC contraction and relaxation 
Vascular SMC contraction is a finely regulated process involving both Ca2+-
dependent and Ca2+-independent mechanisms (Figure 5-1) (reviewed in) (Touyz 
et al., 2018). The vasoactive peptide AngII binds to its G protein coupled 
receptor (GPCR) angiotensin II type 1 receptor (AT1R) triggering phospholipase 
(PL)C activation and subsequent breakdown of phosphatidylinositol 4,5-
bisphosphate (PIP2) into the second messengers, inositol trisphosphate (IP3) and 
diacylglycerol (DAG) (Alexander et al., 1985; Deraët et al., 2002; Miura and 
Karnik, 1999). IP3 binds to the IP3 receptor (IP3R) which serves as a Ca2+ channel 
on the membrane of the sarcoplasmic reticulum (SR). IP3R activation triggers SR 
Ca2+ release resulting in an increase in cytosolic [Ca2+] and initiating Ca2+-
dependent cell contraction (Mignery and Südhof, 1990; Mikoshiba et al., 1993). 
Ca2+ ions bind to calmodulin which then activates the myosin light chain kinase 
(MLCK) (Adelstein et al., 1982; Hong et al., 2009). Activated MLCK 
phosphorylates the MLC S20 subunit triggering MLC/actin interaction generating 
force and shortening which subsequently results in vSMC contraction (Adelstein 
and Klee, 1981; Sellers and Pato, 1984). The DAG/protein kinase C (PKC) and 
RhoA/Rho kinase (ROCK) pathways regulate Ca2+-independent SMC contraction by 
sensitising the contraction machinery (Touyz et al., 2018). DAG activates PKC 
triggering phosphorylation of PKC-potentiated protein phosphatase 1 inhibitor 
(CPI-17) which binds to myosin light chain phosphatase (MLCP) thereby inhibiting 
enzyme activity (Eto et al., 1995; Kishimoto et al., 1980; Mori et al., 1982). In 
its active state MLCP binds to MLC and de-phosphorylates the MLC S20 subunit 
(Pato and Kerc, 1985; Sellers and Pato, 1984). Hence, MLCP inhibition prevents 
de-phosphorylation of the MLC S20 subunit thereby supporting persistent SMC 




activates RhoA triggering downstream activation of ROCK which phosphorylates 
the myosin phosphatase target subunit (MYPT)1 (Bregeon et al., 2009; Feng et 
al., 1999). Furthermore, ROCK phosphorylates zipper-interacting protein kinase 
(ZIPK) which also phosphorylates MYPT1 thereby hampering binding of MLCP to 
MLC and preventing de-phosphorylation of the MLC S20 subunit (MacDonald et 
al., 2001). 
Following contraction, Ca2+ dissociates from calmodulin triggering inactivation of 
MLCK and SMC relaxation (Touyz et al., 2018). Increased 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) activity induces Ca2+ 
re-uptake into the SR resulting in a decrease in cytosolic [Ca2+] (Touyz et al., 
2018). In addition, the transmembrane Na+/Ca2+ exchanger ATP-dependently 
moves Ca2+ to the extracellular space (Touyz et al., 2018). Moreover, 
endothelium-derived NO signals via the cyclic guanosine monophosphate 
(cGMP)/protein kinase G (PKG) pathway which stimulates MLCP activity thereby 
promoting vSMC relaxation (Lee et al., 1997; Sauzeau et al., 2000; Sauzeau et 





Figure 5-1 Regulation of vascular SMC contraction and relaxation. Vasoactive peptides bind to 
transmembrane G protein-coupled receptors (GPCR) thereby recruiting phospholipase C (PLC) which breaks 
down phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). 
IP3 binds to IP3 receptor (IP3R) triggering sarcoplasmic reticulum (SR) Ca2+ release. Increased cytosolic Ca2+ 
complexes with calmodulin activating MLCK triggering myosin light chain (MLC) S20 subunit phosphorylation 
which enables MLC/actin interaction triggering force build-up and contraction. DAG activates PKC triggering 
PKC-potentiated protein phosphatase 1 inhibitor (CPI-17) phosphorylation which blunts myosin light chain 
phosphatase (MLCP) activity. Activated GPCRs signal via RhoA to activate Rho kinase (ROCK). Active ROCK 
either directly de-activates MLCP or phosphorylates zipper-interacting protein kinase (ZIPK) which attenuates 
MLCP activity. Decreased MLCP activity decreases MLC S20 de-phosphorylation which dampens relaxation. 
Sarcoplasmic/endoplasmic reticulum Ca2+ (SERCA) and transmembrane Na+/Ca2+ exchanger ATP-
dependently move cytosolic Ca2+ to the SR and extracellular space respectively. Taken and modified from 




5.1.2 TGF-b1-dependent regulation of Ca2+ handling in vSMCs 
The TGF-b1/ALK5 and AngII/AT1R systems interact in the vasculature (Rodríguez-
Vita et al., 2005). Ford et al. demonstrated that AngII drove TGFB1 (encodes 
TGF-b1) and COL1A1 (alpha-1 type I collagen) mRNA expression levels in primary 
human IMASMCs (Ford et al., 1999). Both pharmacological AT1R blockade with 
losartan and neutralising TGF-b1 antibodies attenuated this effect demonstrating 
pathway synergism in the context of vascular fibrosis. 
With regard to AngII-dependent Ca2+ handling in vSMC Zhu et al. found that 30-
min TGF-b1 stimulation reduced AngII-driven increases in cytosolic [Ca2+] in 
primary aortic SMCs from normotensive Wistar Kyoto (WKY) and spontaneously 
hypertensive rats (SHR) compared to untreated controls when external Ca2+ was 
present (Zhu et al., 1995). In contrast, TGF-b1 had no effect on AngII-dependent 
increases in cytosolic [Ca2+] when no external Ca2+ was present indicating that 
TGF-b1 negatively regulated Ca2+ influx from the extracellular space. In line with 
findings from this study, primary aortic SMCs from diabetic rats displayed 
impaired AngII-dependent cytosolic Ca2+ transients compared to normo-
glycaemic controls when extracellular Ca2+ was present (Sharma et al., 2003). 
The addition of neutralising TGF-b1 antibodies completely restored AngII-
dependent Ca2+ responses in diabetic rat aortic SMCs (RASMCs) suggesting that 
TGF-b1 suppressed AngII-mediated Ca2+ influx from the extracellular space in a 
hyperglycaemic environment. Contrasting these findings, a further study 
demonstrated that 24-h TGF-b1 treatment triggered an increase in AngII-induced 
intracellular Ca2+ mobilisation in primary aortic SMCs from SHRs compared to 
untreated controls (Bouillier et al., 2000). Opposed to these findings, TGF-b1 did 
not influence the AngII response in aortic SMCs from normotensive WKY controls 
potentially suggesting that TGF-b1 may chronically potentiate AngII-driven 
vascular contractility in hypertension. Taken together, these studies 
demonstrate that TGF-b1 has different effects on AngII-dependent Ca2+ responses 
in primary RASMCs. It appears that these TGF-b1-mediated differences may 
depend on length of TGF-b1 stimulation, AngII concentration, extracellular [Ca2+] 






• To develop and validate a protocol for assessing AngII-driven intracellular 
Ca2+ mobilisation in primary HSVSMCs and HCASMCs. 
• To determine intracellular Ca2+ release in response to BMP-9 and TGF-b1 
stimulation. 
• To characterise primary HSVSMC homogeneity versus heterogeneity in the 
context of intracellular Ca2+ mobilisation. 
• To investigate the effect of pharmacological AT1R and ROCK blockade on 
AngII-driven intracellular Ca2+ release. 





5.3.1 Development and validation of a protocol for assessing 
AngII-driven intracellular Ca2+ release in primary human 
vascular SMCs 
This protocol was partly based on a previously published study investigating 
crosstalk between vascular redox and calcium signalling in systemic hypertension 
(Alves-Lopes et al., 2020). All steps leading up to cell imaging are described in 
section 2.7. 
Primary HSVSMCs which had been fluorescently labelled with the Cal-520TM 
calcium-sensitive dye were incubated in Ca2+-free EGTA HEPES solution to ensure 
that no extracellular Ca2+ was present during measurements (Brock et al., 1985). 
The total fluorescent trace length was 6 min. At 2 min, 1 µM AngII final/Ca2+-
free EGTA HEPES solution was added to induce intracellular Ca2+ mobilisation 
and a subsequent increase in fluorescence intensity mediated by Cal520/Ca2+ ion 
interaction (Figure 5-2 A, B middle image). At 4 min, 1 µM ionomycin (IM)/Ca2+-
free EGTA HEPES solution was added to the well to induce maximum 
intracellular Ca2+ release by puncturing all cellular membranes (Figure 5-2 A, B 
right most image) (Beeler et al., 1979). Following live-cell recordings all whole 
frame fluorescent traces were background corrected using the Zeiss Zen 
software (Zeiss; Germany) and plotted using the Prism 5.0 software. Trace 
normalisation to background fluorescence enabled calculation of AngII- (AngIImax 
fluorescence – baseline fluorescenceaverage) and IM-induced fluorescence 
amplitudes (IMmax - baseline fluorescenceaverage) (Figure 5-2 D). 
AngII triggered a rapid increase in whole frame fluorescence intensity reflecting 
intracellular Ca2+ release in primary HSVSMCs quiesced for 72-h (Figure 5-2 C). 
Fluorescence intensity peaked approximately 30 s following AngII stimulation and 
normalised to baseline levels after 1 min. IM stimulation triggered a more rapid 
increase in fluorescence intensity peaking at approximately 5 s following 
stimulation and returning to baseline levels after 1 min (Figure 5-2 C). In 
contrast, 15% FCS-treated HSVSMCs displayed little to no intracellular Ca2+ 
release in response to AngII stimulation compared to quiesced HSVSMCs (mean 




0.2% FCS: 6.199 ± 0.7025, p<0.05) (Figure 5-3 A-C and E). In addition, 
preliminary findings showed that 15% FCS-treated HSVSMCs elicited enhanced IM-
induced intracellular Ca2+ release compared to the low serum-treated group (15% 
FCS: 109.8 ± 2.825, 0.2% FCS: 56.69 ± 2.649, p<0.001) (Figure 5-3 A-C and D). 
In conclusion, AngII and IM triggered an increase in Cal520/Ca2+-mediated 
fluorescence intensity reflecting intracellular Ca2+ release in primary HSVSMCs. 
HSVSMCs quiesced for 72-h displayed increased AngII Ca2+ responses compared to 
the high serum-treated group indicating a contractile phenotype. Alongside 
these observations, 15% serum cultured HSVSMCs displayed enhanced IM Ca2+ 
responses compared to quiesced controls. Together with data from section 
4.3.14 showing increased BrdU incorporation in 15% serum cultured HSVSMCs, 
these results potentially indicate that there is an unresponsive SR Ca2+ storage in 





Figure 5-2 Protocol for assessing AngII mediated intracellular Ca2+ release in primary HSVSMCs. 
Primary human SMCs were seeded into 12-well plates (1*105 cells/well, technical n=3/condition). Upon 
achieving 80% confluence, HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence 
media was replaced with 400 µL 0.5% FCS HEPES medium containing 2 µM single wave Ca2+ indicator Cal-
520. Cells were left to incubate at 37°C and 5% CO2 protected from light for 75 min. Cal-520-containing 
medium was removed and cells were gently washed once with Ca2+-free 0.1 mM EGTA HEPES solution. Cells 
were incubated in 800 µl Ca2+-free 0.1 mM EGTA HEPES solution and left to equilibrate at room temperature 
protected from light for 25 min. Following equilibration, 12-well plates were imaged (Excitation/Emission 
(Ex/Em) 490/525 nm) on a live-cell microscope (Zeiss, Germany) at 10× magnification. (A) Each well was 
imaged on a live-cell fluorescence microscope (Zeiss, Germany; Excitation (Ex) 490 nm, Emission (Em) 525 
nm) at 10´ magnification and subjected to a 6-min trace. At 2 min 100 µL AngII (1 µM in HEPES solution) was 
added to 72-h quiesced HSVSMCs triggering an increase in fluorescence intensity (AngII-dependent 
intracellular Ca2+ release). At 4 min 100 µL ionomycin (IM) (1 µM in HEPES solution) was added to the well 
triggering maximum fluorescence increase (IM-dependent intracellular Ca2+ release). (B) Representative 
images display baseline fluorescence, maximum fluorescence following AngII stimulation and maximum 
fluorescence following IM stimulation. (C) Representative background-corrected 6-min fluorescence trace 
(whole region of interest). (D) Graph represents AngII- and IM-induced amplitudes. Data are presented as 
mean ± S.E.M. (biological n=1, technical n=3).  
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Figure 5-3 15% serum suppresses AngII-mediated intracellular Ca2+ release in primary HSVSMC. Upon 
achieving 80% confluency 15% FCS-treated cells were subjected to previously described protocol (A, top 
panel). A second set of cells was starved in 0.2% FCS media for 72-h and subjected to the same protocol (B, 
bottom panel). (A) Images show representative baseline, AngIImax-induced and IMmax-induced fluorescence. 
Graphs show representative 6-min fluorescent traces from 15% FCS-treated (B) and quiesced HSVSMCs (C). 
(D) Graph shows IM-induced amplitudes. (E) Graph shows AngII-induced amplitudes. (D and E) Data are 
presented as mean ± S.E.M. (biological n=1). A Student’s t-test was performed to compare means between 
both groups. P-value <0.05 was considered statistically significant (* p-value<0.05, *** p-value<0.001).  
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5.3.2 BMP-9 attenuates TGF-β1/ALK5 pathway-driven contractile 
responses in primary HSVSMCs 
Following protocol validation, the next aim was to evaluate the impact of BMP-9 
and/or TGF-b1 treatment on AngII-induced intracellular Ca2+ mobilisation. 
Primary HSVSMCs quiesced for 72-h were treated with respective ligands in 
absence and presence of the pharmacological ALK5 inhibitor SB525334 (Thomas 
et al., 2009) and subjected to the previously described protocol. 
TGF-b1-treated HSVSMCs demonstrated enhanced AngII-induced intracellular Ca2+ 
release compared to vehicle-treated controls (mean AngII-induced fluorescence 
intensity amplitude ± S.E.M., TGF-b1: 21.04 ± 6.098, vehicle control: 12.71 ± 
1.761 [p<0.05]) (Figure 5-4 A, B and E). BMP-9 and SB525334 attenuated TGF-b1-
driven increases in AngII-dependent Ca2+ release (TGF-b1: 21.04 ± 6.098, TGF-b1 
+ BMP-9: 6.805 ± 2.593 [p<0.001], SB525334/TGF-b1: 8.676 ± 2.586 [p<0.01]) 
(Figure 5-4 A, B, C and E). BMP-9-treatment alone did not significantly affect 
AngII-triggered Ca2+ release compared to vehicle-treated controls (Figure 5-4 A, 
B and E). However, there was a slight trend towards a decrease in fluorescence 
intensity (BMP-9: 8.584 ± 2.983, vehicle control: 12.71 ± 1.761, p 0.40). Neither 
ligand, SB525334 nor DMSO vehicle treatment affected IM-induced maximum Ca2+ 
release indicating that investigated cells were viable during fluorescent imaging 
(Figure 5-4 B-D). In two sets of patient cells, the TGF-b1 treatment group 
displayed a trend towards a decrease in IM-induced Ca2+ mobilisation compared 
to vehicle-treated controls suggesting that increased cytosolic Ca2+ following 
AngII stimulation is removed to extracellular space where it is directly bound by 
EGTA and, therefore, cannot re-enter the cell. 
In summary, TGF-b1 enhanced AngII-induced intracellular Ca2+ release in an 
ALK5-dependent manner indicating that this pathway has the potential to 
positively regulate HSVSMC contractility. In contrast, BMP-9 blunted this effect 
suggesting ALK5 antagonism and/or differential regulation of Ca2+ handling in 





Figure 5-4 BMP-9 and pharmacological ALK5 inhibition prevent TGF-b1-driven enhanced intracellular 
Ca2+ release in primary HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media for 
72-h. Media was removed and cells were divided into two groups. Whereas one group of cells was incubated 
in 0.2% FCS media containing the ALK5 inhibitor SB525334 (10 µM) the other group was incubated in 0.2% 
FCS media containing vehicle control (DMSO). Following a 30-min incubation period media was removed and 
both sets of cells were subdivided into 4 groups. Both sets of 4 were stimulated with BMP-9 (10 ng/ml, B9), 
TGF-b1 (10 ng/ml, Tb1), both ligands and vehicle control in the presence of DMSO or SB525334 respectively. 
Cells were analysed at 24-h following the previously described protocol. (A, top and bottom panel) Images 
show AngII-induced maximum fluorescence for respective treatment groups. Representative 6-min fluorescent 
traces are shown in B (DMSO controls) and in C (SB525334). (D) Graph shows IM-induced amplitudes. € 
Graph shows AngII-induced amplitudes. (D and E) Data are presented as mean ± S.E.M. (biological n=4). A 
One-way repeated ANOVA with a Bonferroni correction on selected columns was performed to compare 
means between groups. P-value<0.05 was considered significant (* p-value<0.05, target group versus DMSO 
vehicle control, ## p-value<0.01, ### p-value<0.001).  
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5.3.3 Evidence for distinct Ca2+ handling in primary HCASMCs 
Primary HSVSMCs demonstrated an ALK5-dependent increase in AngII-driven 
intracellular Ca2+ mobilisation following TGF-b1 stimulation. Since SMC 
phenotype and regulation of contractility differs between distinct vascular beds, 
the next goal was to determine AngII responses in BMP-9 and/or TGF-b1-treated 
primary HCASMCs (Turner et al., 2007). HCASMCs serum-starved for 72-h were 
treated with respective ligands in absence and presence of SB525334 and 
subjected to the previously described protocol. 
Although cells were viable evidenced by enhanced IM-induced intracellular Ca2+ 
release primary HCASMCs showed negligible response to AngII stimulation (mean 
AngII-induced fluorescence intensity ± S.E.M., vehicle control: 15.32 ± 9.382) 
(Figure 5-5 A and C). Paralleling findings from HSVSMCs, BMP-9 did not 
significantly affect AngII-driven Ca2+ release compared to vehicle-treated 
controls (Figure 5-5 A and B). However, there was a visible trend towards a 
reduction in Ca2+ responses (BMP-9: 4.773 ± 1.928, DMSO/vehicle control: 15.32 
± 9.382, p=0.50). TGF-b1 and SB525334 treatment alone had no significant effect 
on AngII-mediated Ca2+ release (Figure 5-5 A and B). Nevertheless, SB525334-
treated cells tended to elicit slightly higher fluorescence intensity responses 
compared to DMSO/vehicle-treated controls (SB525334: 32.52 ± 15.86, 
DMSO/vehicle control 15.32 ± 9.382, p=0.37) (Figure 5-5 A and B). In contrast, in 
the presence of SB525334, BMP-9 and TGF-b1 co-stimulation significantly 
suppressed AngII Ca2+ responses compared to vehicle-treated controls 
(SB525334/BMP-9 + TGF-b1 9.423 ± 5.211 versus SB525334/vehicle control 32.52 
± 15.86, p<0.05) (Figure 5-5 A and B). 
Taken together, primary HCASMCs displayed higher IM-driven intracellular Ca2+ 
mobilisation than primary HSVSMCs potentially indicating increased intracellular 
Ca2+ storage which remained unresponsive to AngII treatment. In contrast to 
HSVSMCs, ALK5 inhibition in HCASMCs showed a non-significant trend towards an 
increase in AngII Ca2+ responses potentially suggesting that the ALK5 receptor 
negatively regulates arterial SMC contractility. Finally, BMP-9 alone or in 
combination with TGF-b1 suppressed AngII responses indicating that SMAD1, and 






Figure 5-5 Evidence for distinct Ca2+ handling in primary HCASMCs. 80% confluent primary HCASMCs 
were quiesced in 0.2% FCS media for 72-h. Media was removed and cells were divided into two groups. 
Whereas one group of cells was incubated in 0.2% FCS media containing the ALK5 inhibitor SB525334 (10 
µM) the other group was incubated in 0.2% FCS media containing vehicle control (DMSO). Following a 30-min 
incubation period media was removed and both sets of cells were subdivided into 4 groups. Both sets of 4 
were stimulated with BMP-9 (10 ng/ml), TGF-b1 (10 ng/ml), both ligands and vehicle control in the presence of 
DMSO or SB525334 respectively. Cells were analysed at 24-h following the previously described protocol 
(Figure 5-2). (A, top and bottom panel) Images show AngII-induced maximum fluorescence for respective 
treatment groups. (B) Graph shows IM-induced amplitudes. (C) Graph shows AngII-induced amplitudes. (D 
and E) Data are presented as mean ± S.E.M. (biological n=2, technical n=3). A One-way repeated ANOVA 
with a Bonferroni correction on selected columns was performed to compare means between groups. P-
value<0.05 was considered statistically significant (* p-value<0.05).  




















































































































5.3.4 Single cell resolution uncovers HSVSMC population 
heterogeneity 
Whole frame fluorescence intensity analysis revealed enhanced TGF-b1/ALK5-
driven AngII Ca2+ responses in primary HSVSMCs. On closer inspection, 
fluorescence intensity changed over time and appeared to be different for every 
cell captured within one frame. Furthermore, this phenomenon appeared to be 
independent of the treatment group. Taken together, these observations 
prompted development of a protocol for analysing and presenting AngII-driven 
mobilisation of intracellular Ca2+ stores on a single cell basis. 
Using live cell recordings and drawing single regions of interest around cells as 
described in section 2.7.2, Ca2+ mobilisation by AngII was analysed in individual 
cells (Figure 5-6 A). The aim was to calculate the geometric mean for all AngII-
driven responses in each individual well (1 patient, technical n=3/condition, 
Figure 5-6 C). Since some AngII-induced amplitudes displayed negative values 
the constant 4.926025 was added to each value to prevent negative values 
following log10-transformation. Values from each well were averaged and this 
average was exponentiated to the basis of 10 (10^(average)). The constant 
4.926025 was subtracted from each exponentiated value to generate the 
geometric mean. 
The histogram for the first set of patient cells displayed a bimodal distribution of 
AngII-driven Ca2+ responses for all treatment groups (Figure 5-6 B). Subsequent 
analysis of two additional sets of patient cells confirmed these preliminary 
findings (Figure 5-8 A). Although cell populations displayed heterogeneity in a 
ligand-independent manner, TGF-b1-treated SMC populations displayed a trend 
towards less non-responsive cells (bin 0, red bar versus black, blue and purple 
bars) and more cells displaying medium and higher AngII-driven responses 
compared to the other treatment groups (bin 10, 20 and 30 à red bar versus 
black, blue and purple bars). In line with this finding, TGF-b1-treated HSVSMCs 
demonstrated an increased geometric mean compared to vehicle-treated 
controls paralleling findings following whole frame fluorescence analysis 
(geometric mean AngII-induced fluorescence intensity amplitude ± S.E.M., TGF-
b1 17.55 ± 6.411, vehicle control 5.641 ± 1.699, p<0.05) (Figure 5-7 B). 




intracellular Ca2+ release in single cells (BMP-9 + TGF-b1 7.613 ± 3.065 versus 
vehicle control 5.641 ± 1.699, p>0.05). Finally, a Lowess curve fit was generated 
from 3 histograms derived from 3 individual sets of patient cells to highlight the 
ability of TGF-b1 to induce a more homogeneous cell population (Figure 5-8 B, 
red line versus black, blue and purple lines). 
In conclusion, single cell fluorescence analysis paralleled findings following 
whole frame fluorescence analysis and uncovered a heterogeneous distribution 
of AngII-driven Ca2+ responses within each treatment group. Moreover, BMP-9 






Figure 5-6 Protocol for assessing intracellular Ca2+ release in single primary HSVSMCs. 80% confluent 
primary HSVSMCs were quiesced in 0.2% FCS media for 72-h. Media was replaced with fresh 0.2% FCS 
stimulation media containing BMP-9 (10 ng/ml, B9), TGF-b1 (10 ng/ml, Tb1), both ligands and vehicle control. 
Calcium handling was determined following the previously described protocol. (A) Video files of 6-min trace 
recordings were imported into the ImageJ software to determine intracellular Ca2+ release in single primary 
HSVSMCs. (B) Graph represents distribution of AngII-induced amplitudes for each cell from each treatment 
group captured within one frame (biological n=1, technical n=3). (C) Graph shows the geometric mean of all 
AngII-induced amplitudes for each treatment group. Data are presented as mean ± S.E.M. (biological n=1, 
technical n=3).  
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Figure 5-7 Single cell resolution reveals HSVSMC population heterogeneity (A). 80% confluent primary 
HSVSMCs were quiesced in 0.2% FCS media for 72-h. Media was replaced with fresh 0.2% FCS stimulation 
media containing BMP-9 (10 ng/ml, B9), TGF-b1 (10 ng/ml, Tb1), both ligands and vehicle control. Calcium 
handling was determined following the previously described protocol. Video files of 6-min trace recordings 
were imported into the ImageJ software to determine intracellular Ca2+ release in single primary HSVSMCs. 
(A) Each dot represents one AngII-induced amplitude from each cell per treatment group (biological n=3). (B) 
Graph shows the geometric mean of all AngII-induced amplitudes for each treatment group. Data are 
presented as mean ± S.E.M. (biological n=3). A One-way repeated ANOVA with Tukey’s correction was 
performed to compare means between groups. P-value<0.05 was considered statistically significant (# p-


























































































































Figure 5-8 Single cell resolution reveals HSVSMC population heterogeneity (B). 80% confluent primary 
HSVSMCs were quiesced in 0.2% FCS media for 72-h. Media was replaced with fresh 0.2% FCS stimulation 
media containing BMP-9 (10 ng/ml, B9), TGF-b1 (10 ng/ml, Tb1), both ligands and vehicle control. Calcium 
handling was determined following the previously described protocol. Video files of 6-min trace recordings 
were imported into the ImageJ software to determine intracellular Ca2+ release in single primary HSVSMCs. 
(A) Graph demonstrates distribution of AngII-induced amplitudes for each cell from each treatment group 
captured within one frame (biological n=3). (B) A Lowess curve fit was generated from AngII-induced 
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5.3.5 AngII-induced intracellular Ca2+ mobilisation is mediated via 
AT1R in primary HSVSMCs 
The next experiment aimed to establish whether AngII signalled via the AT1R or 
the AT2R in primary HSVSMCs. To address this question, the pharmacological 
AT1R inhibitor losartan was utilised to determine AngII-dependent Ca2+ 
mobilisation in the absence and presence of TGF-b1. Losartan is a non-peptide-
based AT1R antagonist which prevents AngII-dependent AT1R activation (Chiu et 
al., 1991; Rhaleb et al., 1991). In vSMCs losartan attenuated AngII-dependent 
intracellular/extracellular Ca2+ influx and subsequent vSMC and vessel 
contraction (Chiu et al., 1991). 
Most group comparisons did not reach statistical significance in this set of 
experiments. Nevertheless, AT1R blockade with losartan appeared to blunt AngII-
induced Ca2+ release as evidenced by absence of fluorescence intensity following 
stimulation (mean AngII-induced fluorescence intensity amplitude ±S.E.M., 
losartan: -1.218 ± 1.064, vehicle control: 16.11 ± 5.813, p>0.05) (Figure 5-9 A 
and B). Opposed to previous findings, TGF-b1-treated HSVSMCs did not display a 
significant increase in Ca2+ release in response to AngII. However, TGF-b1-treated 
cells tended to display slightly higher AngII-induced fluorescence intensity 
amplitudes (TGF-b1: 31.06 ± 13.53, vehicle control: 16.11 ± 5.813, p>0.05). 
Losartan significantly attenuated AngII-induced Ca2+ mobilisation in TGF-b1- 
versus TGF-b1/vehicle-treated HSVSMCs (losartan/TGF-b1: -0.5906 ± 0.2766, 
TGF-b1: 31.06 ± 13.53, p<0.05). 
Although most differences between groups did not achieve statistical 
significance due to enhanced inter-patient variability, losartan consistently 
blunted AngII-induced Ca2+ mobilisation in primary HSVSMCs. Furthermore, it 
may be speculated that TGF-b1/ALK5 signalling may sensitise the AngII/AT1R/IP3 





Figure 5-9 AngII triggers intracellular Ca2+ release via AT1R in primary HSVSMCs. 80% confluent cells 
were quiesced in 0.2% FCS media for 72-h. Cells were analysed at 24-h following the previously described 
protocol (Figure 5-2) with the following addition. (A) Following incubation with Cal520 cells were either 
subjected to 25-min incubation in losartan (10 µM)/HEPES solution (bottom panel) or vehicle control (ddH20)/ 
HEPES solution (top panel). Images show AngII-induced maximum fluorescence for respective treatment 
groups. (B) Graph shows AngII-induced amplitudes. Data are presented as mean ± S.E.M. (biological n=5). A 
One-way repeated ANOVA with a Bonferroni correction on selected columns was performed to compare 























































5.3.6 Pharmacological ROCK blockade does not prevent AngII-
mediated intracellular Ca2+ mobilisation in primary 
HSVSMCs 
Fasudil is a drug which inhibits ROCK and PKC activity thereby promoting vSMC 
relaxation and subsequent vasorelaxation (Asano et al., 1998; Seto et al., 1991). 
This experiment was performed to evaluate whether AngII-mediated Ca2+ 
mobilisation and potential cell contraction triggered Ca2+ indicator (Cal520TM) 
quenching and a subsequent false increase in fluorescence intensity. 
Compared to untreated controls, fasudil-treated HSVSMCs displayed a similar 
amount of AngII-driven Ca2+ release (mean AngII-induced fluorescence intensity, 
fasudil ± S.E.M.:18.27 ± 8.895, vehicle control 23.17 ± 5.018, p>0.05) (Figure 
5-10 A and B). In line with previous findings, TGF-b1-stimulated cells 
demonstrated an increase in AngII-mediated Ca2+ mobilisation versus vehicle-
treated controls (TGF-b1: 55.16 ± 15.53, vehicle control: 23.17 ± 5.018, p<0.05). 
In the presence of fasudil, TGF-b1-treated cells did not elicit a significant 
increase in AngII-dependent Ca2+ responses compared to vehicle-treated controls 
although cells tended to display higher fluorescence intensities in the presence 
of TGF-b1 (fasudil/TGF-b1: 42.7 ± 14.64, fasudil/vehicle control: 18.27 ± 8.895, 
p>0.05). 
Taken together, ROCK/PKC inhibition with fasudil did not affect AngII-dependent 
Ca2+ responses in primary HSVSMCs. Hence, potential Ca2+-dependent cell 
contraction did not appear to induce Cal520 quenching-and a subsequent false 





Figure 5-10 Pharmacological Rho-kinase blockade does not prevent AngII-induced intracellular Ca2+ 
release in primary HSVSMCs. 80% confluent cells were quiesced in 0.2% FCS media for 72-h. Cells were 
analysed at 24-h following the previously described protocol (Figure 5-2) with the following addition. (A) 
Following incubation with Cal520 cells were either subjected to 25-min incubation in fasudil (10 µM)/HEPES 
solution (bottom panel) or vehicle control (ddH20)/HEPES solution (top panel). Images show AngII-induced 
maximum fluorescence for respective treatment groups. (B) Graph shows AngII-induced amplitudes. Data are 
presented as mean ± S.E.M. (biological n=3). A One-way repeated ANOVA with a Bonferroni correction on 
selected columns was performed to compare means between groups. P-value<0.05 was considered 























































5.3.7 TGF-β1 represses MAS1 mRNA expression levels in 
HSVSMCs 
Data presented in sections 4.3.7 and 4.3.12 demonstrated that TGF-b1 drove 
contractile gene expression via ALK5 in primary HSVSMCs. Moreover, TGF-b1 
ALK5-dependently increased AngII-dependent intracellular Ca2+ mobilisation in 
HSVSMCs which was prevented in the presence of BMP-9. The next aim was to 
assess AGTR1 (encodes AT1R) and MAS1 (encodes MAS proto-oncogene receptor) 
mRNA expression levels to determine whether changes in receptor expression 
levels in response to ligand treatment might explain TGF-b1/AT1R agonism and 
BMP-9/AT1R antagonism. MAS1 is the alternative receptor for angiotensin 
peptide Ang-(1-7) (Santos et al., 2003) and antagonises AngII/AT1R signalling 
(Kostenis et al., 2005). 
BMP-9-treated HSVSMCs displayed a reduction in AGTR1 mRNA expression levels 
compared to vehicle-treated controls (RQmean + error, BMP-9: 0.146 + 0.128, 
vehicle control: 1 + 0.406, p<0.05) (Figure 5-11 A). In contrast, TGF-b1 ALK5-
dependently prevented BMP-9-mediated downregulation of AGTR1 mRNA levels 
(BMP-9 + TGF-b1: 0.99 + 0.465, BMP-9: 0.146 + 0.128, p<0.05). Moreover, TGF-b1 
suppressed MAS1 mRNA levels via ALK5 (TGF-b1: 0.043 + 0.017, vehicle control: 1 
+ 0.624 [p<0.001] and SB525334/TGF-b1: 2.876 + 0.4 [p<0.001]) (Figure 5-11 B). 
BMP-9 had no effect on MAS1 mRNA levels compared to vehicle-treated controls. 
Finally, qRT-PCR did not detect AGTR2 (encodes AT2R) mRNA expression levels in 
HSVSMCs (data not shown). 
Overall, BMP-9 suppressed AGTR1 receptor mRNA expression levels. TGF-b1 
ALK5-dependently suppressed MAS1 receptor expression levels indicating 
potential AT1R agonism since the MAS1 receptor antagonises AT1R function 





Figure 5-11 TGF-b1 suppresses MAS1 gene expression via ALK5. 80% confluent primary HSVSMCs were 
quiesced in 0.2% FCS media (MEDIA1) for 72-h. To achieve pharmacological ALK5 inhibition prior to ligand 
stimulation, the first 4 groups were incubated in MEDIA1 containing 10 µM SB525334 for 30 min. In parallel, 
the second 4 groups were incubated in MEDIA1 containing DMSO vehicle (1:1,000) for 30 mins. Media was 
replaced with fresh MEDIA1 containing recombinant human BMP-9 (10 ng/mL), TGF-b1 (10 ng/mL) ± DMSO 
(1:1,000) or SB525334 (10 µM). After 24-h stimulation, primary HSVSMCs were lysed and subjected to RNA 
extraction. Reverse transcription was performed to generate cDNA. Quantitative RT-PCR was performed to 
determine relative AGTR1 (A) and MAS1 (B) mRNA expression levels. Relative target gene expression was 
normalised to UBC expression to determine dCT values, which were used to calculate relative quantification 
(RQ) values (target group versus DMSO vehicle control). Data are presented as RQ mean + RQmax mean 
(biological n=3). A One-way repeated ANOVA with a Tukey’s correction was performed to compare groups on 
the basis of dCT values. P-value<0.05 was considered statistically significant (* p-value<0.05 and *** p-






















































































The first aim of this chapter was to establish a robust protocol for assessing 
AngII-mediated intracellular Ca2+ mobilisation in primary human vSMCs. 
Following 72-h quiescence HSVSMCs labelled with Cal520TM, a fluorogenic, 
calcium-sensitive dye, demonstrated an increase in fluorescence intensity (Ca2+ 
ions binding to Cal520TM probe) following AngII stimulation indicating 
intracellular mobilisation of Ca2+ stores in the absence of extracellular Ca2+. 
Within 30 s following AngII stimulation fluorescence intensity reached its peak 
and subsequently returned to baseline levels at 60s. Trace morphology was 
similar to traces obtained from Fura-2-loaded primary RASMCs following AngII 
stimulation in the absence of extracellular Ca2+ (Bouillier et al., 2000). AngII-
induced amplitudes were subsequently calculated and served as a surrogate 
marker of SMC contractility. Ionomycin stimulation induced a rapid maximum 
increase in fluorescence intensity reflecting maximum release of intracellular 
Ca2+ stores. Firstly, IM-induced fluorescence intensity confirmed cell viability 
during fluorescence trace imaging and, secondly, IM-induced amplitudes gave a 
rough estimation of the amount of intracellular Ca2+ stores since experiments 
were performed in a Ca2+-free environment. Fluorescence intensity levels 
returned to baseline at 60 s following IM stimulation. Previous research showed 
that this drop in cytosolic [Ca2+] in primary RASMCs following IM stimulation was 
mediated by the cell membrane-based Na+/Ca2+ exchanger (Smith et al., 1989). 
Taken together, this Ca2+ handling protocol enabled robust investigation of AngII-
dependent mobilisation of intracellular Ca2+ stores in primary human vSMCs. 
Interestingly, initial findings also showed that serum treated HSVSMCs did not 
respond to AngII stimulation suggesting differential regulation of Ca2+ handling in 
proliferating SMCs. Indeed, studies investigating Ca2+ signalling remodelling 
during vSMC phenotype switching revealed a decrease in voltage-dependent 
membrane-bound L-type Ca2+ channel, SR-bound ryanodine type 3 Ca2+ release 
channel and SR-bound SERCA2A expression levels in proliferating vSMCs (Gollasch 
et al., 1998; Lipskaia et al., 2005; Vallot et al., 2000). Corriu et al. 
demonstrated that AngII triggered IP3 production and subsequent increase in 
cytosolic [Ca2+] via AT1R in quiesced primary RASMCs indicating functional 
AT1R/PLC/IP3/SR Ca2+ release coupling (Corriu et al., 1994). The authors went 




increase in cytosolic IP3 levels. However, the increase in IP3 did not induce SR 
Ca2+ release as opposed to findings in quiesced controls. This suggests that 
proliferating vSMCs are resistant to AngII-dependent SR Ca2+ release and 
subsequent contraction although AngII induces IP3 production. Hence, it may be 
speculated that SR-bound IP3R density is modulated in proliferating HSVSMCs. It 
must also be noted that serum-driven suppression of AngII-mediated Ca2+ release 
may potentially reflect an increase in serum-derived BMP-9 concentrations given 
the fact that serum displays biological BMP-9 activity (David et al., 2008). A 
future experiment should investigate the effect of neutralising BMP-9 antibodies 
on AngII-dependent Ca2+ release in 15% FCS-cultured primary HSVSMCs. In 
conclusion, it may be speculated that proliferating/de-differentiated vSMCs are 
resistant to AngII-induced Ca2+ release and contraction. Preliminary findings 
from this study warrant further experiments comparing AngII-induced Ca2+ 
transients and underlying mechanisms in proliferating versus quiesced primary 
HSVSMCs in the future. 
After establishing a reproducible and robust Ca2+ handling protocol the next step 
was to investigate the effect of long-term BMP-9 and/or TGF-b1 stimulation on 
AngII-dependent Ca2+ transients in primary HSVSMCs and HCASMCs. 24-h TGF-b1 
stimulation of primary HSVSMCs triggered an increase in AngII-dependent Ca2+ 
mobilisation compared to untreated controls, potentially indicating increased 
SMC contractility. This effect was attenuated in the presence of the ALK5 
inhibitor SB525334 and BMP-9 demonstrating that TGF-b1-driven effects were 
ALK5-dependent and that BMP-9 demonstrated TGF-b1/ALK5 antagonism. These 
findings are partially in line with previously presented data from this study 
which showed that ligand-independent and -dependent ALK5 activation 
positively regulated contractile marker expression in primary HSVSMCs. In 
contrast to findings in HSVSMCs, TGF-b1 treatment had no effect on AngII-
regulated SR Ca2+ release in primary HCASMCs. Most differences between 
HCASMC treatment groups were not statistically significant because of inter-
patient variability. However, there was a slight trend towards an increase in 
AngII-dependent Ca2+ responses in SB525334-treated cells versus vehicle-treated 
controls potentially suggesting ALK5 as a negative regulator of Ca2+ release in 
this cell type. In addition, there was a slight trend towards a suppression of Ca2+ 




paralleling trends in HSVSMCs. Moreover, IM-induced total SR Ca2+ release was 
higher in untreated HCASMCs than HSVSMCs indicating differential regulation of 
total intracellular Ca2+ storage in these two cell types. More n numbers should be 
added to these sets of experiments to overcome inter-patient variability in the 
future. Nevertheless, these findings raise several questions. Firstly, which 
mechanisms might explain why TGF-b1/ALK5 signalling positively regulates AngII-
triggered Ca2+ transients in HSVSMCs and what does this mean in the context of a 
contractile SMC phenotype and SVG disease? Secondly, how does BMP-9 
antagonise this effect? Thirdly, why do HCASMCs display differential regulation 
of Ca2+ handling compared to HSVSMCs? 
To address the first question AngII-driven Ca2+ responses were assessed in TGF-b1 
and vehicle-treated cells in the absence and presence of the AT1R blocker 
losartan to establish whether AngII transduced its signal via the AT1R or AT2R. In 
TGF-b1-treated cells, losartan significantly prevented AngII-mediated Ca2+ 
transients. In contrast to previous findings and in the absence of losartan, TGF-
b1-treated HSVSMCs did not display an increase in AngII-mediated Ca2+ release 
compared to untreated controls. The lack of significance between these two 
groups may be explained by enhanced inter-patient variability. To overcome this 
limitation more n numbers should be added to this experiment in the future. 
Although most differences between groups were not statistically significant, 
losartan-treated cells did not respond to AngII stimulation as evidenced by 
absence of increase in fluorescence intensity. These results show that AngII 
mediates intracellular Ca2+ mobilisation via AT1R in HSVSMCs. 
These findings prompted evaluation of Ang receptor mRNA expression levels 
following 24-h TGF-b1 stimulation in absence and presence of SB525334. Whereas 
AGTR1 mRNA levels were not affected, TGF-b1 ALK5-dependently suppressed 
MAS1 mRNA levels. Kostenis et al. found that the GPCR Mas1 receptor formed a 
hetero-oligomeric complex with AT1R in CHO-K1 cells and that Mas1 
overexpression dampened AngII-induced IP3 production and subsequent 
intracellular Ca2+ mobilisation (Kostenis et al., 2005). The same study 
demonstrated that genetic ablation of Mas1 in mice resulted in an increase in 
AngII-induced vasoconstriction in mesenteric microvessels compared to wild-type 




vasoconstriction. Hence, it may be speculated that TGF-b1/ALK5-dependent 
MAS1 suppression may potentiate AngII/AT1R signalling by blunting Mas-
dependent AT1R inhibition. To address this hypothesis, a future experiment 
should assess AngII-mediated Ca2+ transients in the presence of siRNA-mediated 
MAS1 suppression to determine whether cells demonstrate an increase in AngII 
Ca2+ responses in HSVSMCs. A second experiment should assess whether MAS1 
overexpression rescues TGF-b1-dependent downregulation of MAS1 and 
subsequently dampens AngII-driven Ca2+ mobilisation. A third experiment should 
investigate the antagonistic interaction between Ang (1-7) and TGF-b1/ALK5 
signalling in the context of AngII-driven Ca2+ responses in HSVSMCs. In addition, 
it may be speculated that TGF-b1/ALK5 signalling modulates downstream 
components of Ca2+ handling such as IP3R expression levels, SERCA2A expression 
levels/activity and total SR Ca2+ content in HSVSMCs. Furthermore, it is 
conceivable that TGF-b1/ALK5 signalling may also affect contraction-sensitising 
pathways such PKC or RhoA/ROCK signalling in this cell type. 
In line with presented findings from primary HSVSMCs, Bouillier et al. found that 
primary aortic SMCs from hypertensive rats treated with TGF-b1 for 24-h 
displayed enhanced intracellular Ca2+ mobilisation in response to AngII 
stimulation compared to normotensive controls (Bouillier et al., 2000). 
Interestingly, pharmacological inhibition of PKC with calphostin inhibited long-
term stimulatory effects of TGF-b1 on AngII-driven Ca2+ release indicating that 
TGF-b1 signalling may synergise with PKC. Furthermore, pharmacological 
inhibition of tyrosine kinase with genistein and global protein synthesis with 
cycloheximide also attenuated TGF-b1-driven increases in AngII-dependent Ca2+ 
transients in hypertensive RASMCs, suggesting complex interaction of regulatory 
signalling pathways. Gao et al. investigated the role of TGF-b1 in airway SMC 
hypercontractility in the context of asthma (Gao et al., 2013). Pharmacological 
SERCA inhibition with thapsigargin was utilised to determine total SR Ca2+ 
content in TGF-b1-treated and untreated primary rat airway SMCs. Results 
demonstrated that TGF-b1-treated SMCs released more Ca2+ from SR in response 
to thapsigargin than vehicle-treated controls indicating that TGF-b1 induced an 
increase in total SR Ca2+ content. Corroborating Gao’s findings, Kim et al. 
demonstrated that TGF-b1-stimulated murine airway SMCs displayed enhanced 




hypercontractility (Kim et al., 2005). Based on these findings, it may be 
speculated that TGF-b1 drives SERCA expression levels and/or activity thereby 
modulating SR Ca2+ content in SMCs. Future experiments should address the 
effect of TGF-b1 on SR Ca2+ content and SERCA expression and activity levels in 
primary HSVSMCs. 
Opposing these findings, Sharma et al. showed that TGF-b1 dose-dependently 
attenuated AngII-dependent Ca2+ mobilisation in primary RASMCs (Sharma et al., 
2003). The study also found that neutralising TGF-b1 antibodies reversed 
hyperglycaemia-induced impairment of AngII-mediated Ca2+ release indicating 
TGF-b1 as a pathological driver of vascular impairment in the context of 
diabetes. Moreover, aortas from diabetic rats displayed a reduction in IP3R 
expression levels which was reversed by systemic administration of neutralising 
TGF-b1 antibodies suggesting that TGF-b1 may impair AngII-driven Ca2+ release by 
suppressing IP3R expression in the context of diabetes. Partially in line with this 
finding, Zhu’s study showed that 30-min TGF-b1-treated primary RASMCs from 
normotensive and hypertensive rats displayed a reduction in AngII-induced 
increase in cytosolic [Ca2+] in the presence of extracellular Ca2+ (Zhu et al., 
1995). However, no difference was reported in the absence of extracellular Ca2+ 
contrasting findings by Sharma et al.. 
Both Bouillier’s and Zhu’s study showed that TGF-b1-treated primary aortic SMCs 
from normotensive rats did not display altered AngII-dependent Ca2+ responses 
compared to untreated controls (Bouillier et al., 2000; Zhu et al., 1995). These 
findings are in line with presented results from primary HCASMCs which show 
that TGF-b1 does not affect AngII-mediated Ca2+ responses contrasting results 
from HSVSMCs. Moreover, there was a trend towards an increase in AngII-driven 
Ca2+ release in the presence of pharmacological ALK5 inhibition. A study 
investigating functional aortic changes in the context of LDS found that SMC-
specific genetic ablation of Tgfbr2 in mice triggered aortic hypercontractility in 
response to noradrenaline indicating that functional vSMC TGF-b signalling may 
negatively regulate contractile responses in the systemic arterial system 
(abstract) (Zhu et al., 2017). Distinct effects of TGF-b1 on Ca2+ handling in 
HCASMCs and HSVSMCs may also be explained based on differential embryonic 




SMCs underlying venous SMC resistance to calcium channel blocker treatment 
(Thakali et al., 2010). The authors demonstrated that intracellular Ca2+ stores 
silenced L-type Ca2+ channels in venous SMCs, a mechanism absent in arterial 
SMCs. Differential mechanisms underlying Ca2+ handling in HSVSMCs and HCASMCs 
have not been studied before. However, Turner et al. established that HSVSMCs 
displayed an elevated capacity to de-differentiate compared to matched IMAG 
SMC controls (Turner et al., 2007). Hence, it appears conceivable that Ca2+ 
handling may also underlie differential regulation in venous versus arterial beds. 
Taken together these studies demonstrate that TGF-b1 regulates Ca2+ 
mobilisation in primary human vSMCs in distinct ways. TGF-b1-dependent 
modulation of agonist-driven increase in Ca2+ mobilisation appears to depend on 
many factors including SMC type (venous, arterial or airway), species (human, 
rat or mouse), the length of TGF-b1 stimulation and whether vSMCs derive from 
healthy normotensive/normo-glycaemic or diseased 
hypertensive/hyperglycaemic animals. Primary HSVSMCs utilised for Ca2+ 
handling experiments were not matched to donor patient phenotypes. Since 
many CABG patients suffer from additional co-morbidities including systemic 
hypertension and T2DM, which have been shown to influence experimental SMC 
Ca2+ handling, it is conceivable that primary HSVSMCs may also react differently 
to external stimuli depending on the patient’s co-morbidities. This may also 
partially explain enhanced inter-patient variability in performed Ca2+ handling 
experiments presented in this chapter. This potential bias may be addressed by 
phenotyping CABG patients in more detail in the future and then link these 
phenotypical characteristics such as hypertension or T2DM to AngII-dependent 
Ca2+ responses in isolated HSVSMCs. 
In addition to attenuating long-term stimulatory effects of TGF-b1 on AngII-
driven intracellular Ca2+ release, PKC inhibition with calphostin also dampened 
AngII-dependent Ca2+ mobilisation in untreated control rat vSMCs, indicating that 
PKC directly regulated AngII/AT1R-dependent SR Ca2+ release (Bouillier et al., 
2000). Nagumo et al. demonstrated that fasudil inhibited ROCK thereby 
preventing MLCP inhibition and promoting SMC relaxation (Nagumo et al., 2000). 
Moreover, the same study showed that fasudil also inhibited PKC, however to a 




ROCK/PKC blockade on acute AngII-induced intracellular Ca2+ mobilisation in 
TGF-b1-treated and untreated primary HSVSMCs. Furthermore, this experiment 
aimed to establish whether potential SMC contraction induced Cal520TM probe 
quenching which would then yield false increases in fluorescence intensity in 
response to AngII stimulation. Firstly, fasudil treatment in the absence of TGF-
b1-did not appear to affect AngII-dependent increase in fluorescence intensity 
compared to untreated vehicle controls. This indicated that (i) SMC contraction 
did not appear to trigger Cal520 probe quenching and subsequent false increase 
in fluorescence intensity and (ii) combined ROCK/PKC inhibition did not 
attenuate acute AngII-driven SR Ca2+ release. In the absence of fasudil TGF-b1 
treatment triggered an increase in AngII-dependent Ca2+ transients compared to 
untreated vehicle controls. In the presence of fasudil TGF-b1-treated cells did 
not display a significant increase in AngII-mediated Ca2+ release compared to 
vehicle controls. Although the difference between these two groups was not 
statistically significant there was a trend towards an increase in Ca2+ transients 
in the absence of fasudil. More n numbers should be added to this set of 
experiments to consolidate these findings in the future. Nevertheless, it is likely 
that short-term ROCK/PKC inhibition has little effect on TGF-b1-driven AngII-
mediated Ca2+ mobilisation. This stands in contrast to Bouillier’s study which 
demonstrated that PKC inhibition with calphostin blunted AngII-driven SR Ca2+ 
release. The difference in cell type/species (primary HSVSMC vs primary 
hypertensive RASMC) and different pharmacological inhibitors (fasudil vs 
calphostin) may explain this discrepancy. 
Ligand-dependent and -independent ALK5 activation drove contractile marker 
expression in primary HSVSMCs indicating the presence of a contractile 
phenotype. Furthermore, 24-h TGF-b1 stimulation drove MLC S20 phosphorylation 
in HSVSMCs in an ALK5-dependent manner suggesting Ca2+-independent 
modulation of SMC contractility (unpublished data) (Low et al., 2019). It may be 
speculated that TGF-b1 synergises with RhoA/ROCK signalling to (i) induce a 
contractile SMC phenotype and to (ii) promote MLC S20 phosphorylation/SMC 
hypercontractility. In line with this hypothesis, Chen et al. showed that 
pharmacological inhibition of ROCK with Y27632 inhibited TGF-b1-mediated 
differentiation of neural crest stem cells into SMCs and reversed TGF-b1-




also demonstrated that TGF-b1 directly drove RhoA activation and that dominant 
negative RhoA prevented TGF-b1-dependent pSMAD2/3 translocation to the 
nucleus highlighting the importance of functional RhoA in TGF-b1-dependent 
regulation of contractile gene expression and SMC differentiation. This may be of 
clinical relevance in the context of SVG disease. 
Another main finding within this study was that BMP-9 prevented TGF-b1-
dependent sensitisation of AngII/AT1R-dependent SR Ca2+ release in primary 
HSVSMCs. Furthermore, the presence of BMP-9 appeared to trigger a trend 
towards a decrease in AngII-dependent Ca2+ transients in primary HCASMCs. Since 
results presented in 4.3.9 showed that BMP-9 binds to ALK1 and ALK2 in HSVSMC, 
it is likely that this inhibitory downstream effect is ALK1 and/or ALK2 dependent 
(David et al., 2007). One limitation of this study is that BMP-9-dependent 
negative regulation of Ca2+ handling was not investigated in more detail. Limited 
primary cell availability coupled with an extensive experimental set-up made it 
difficult to study more mechanisms in addition to experiments investigating the 
effect of pharmacological inhibition of ALK5, AT1R and ROCK/PKC on ligand 
dependent Ca2+ handling. Future experiments are warranted to investigate BMP-
9-dependent inhibitory effects in the presence of pharmacological ALK1 
inhibition or siRNA-mediated ALK1 ablation in primary vSMCs to establish 
whether this effect is ALK1 dependent. 
One underlying BMP-9 dependent inhibitory downstream mechanism in HSVSMCs 
might have been explained by differential regulation of angiotensin receptor 
mRNA expression levels. Although single BMP-9 treatment significantly 
suppressed AT1R mRNA levels versus vehicle treated controls, this effect was 
attenuated in the presence of TGF-b1. Furthermore, BMP-9 did not affect MAS1 
mRNA levels which were suppressed by TGF-b1. Hence, it is likely that BMP-9-
driven inhibition of TGF-b1-dependent sensitisation of the AngII/AT1R system is 
not mediated via changes in angiotensin receptor levels. Furthermore, BMP-9 did 
not prevent TGF-b1/ALK5-mediated increase in contractile gene expression in 
HSVSMCs suggesting that BMP-9 was unable to counter downstream 
ALK5/SMAD2/3 signalling. Since TGF-b1 did not prevent BMP-9-dependent SMAD1 
phosphorylation it is likely that inhibitory actions of BMP-9 are mediated via 




that BMP-9/ALK1/ALK2 signalling axis modulates the PLC/IP3 system, total SR 
Ca2+ content and/or redirects Ca2+ for calcium phosphate formation. 
A future in vitro experiment should assess AngII-induced IP3 production in BMP-9 
and/or TGF-b1-treated HSVSMCs utilising a radiometric inositol phosphate 
accumulation assay. Results would then show whether ligands influenced 
AngII/AT1R-triggered and PLC-dependent catalysation of PIP2 to IP3 and DAG. As 
previously proposed, thapsigargin should be utilised to assess total SR Ca2+ 
content in ligand-treated HSVSMCs to determine potential changes which would 
then explain enhanced AngII-dependent Ca2+ release in TGF-b1-treated cells and 
decreased Ca2+ release in cells treated with TGF-b1 in the presence of BMP-9. 
Importantly, BMP-9 may redirect intracellular Ca2+ to promote calcification and 
osteoblastic differentiation of primary HSVSMCs and HCASMCs (Zhu et al., 2015). 
BMP-9 drives alkaline phosphatase (ALP) activity and subsequent bone formation 
in a SMAD1/5/8-dependent manner (Chen et al., 2010). Quantitative RT-PCR 
data from this study demonstrated that BMP-9 attenuated TGF-b1/ALK5-
dependent suppression of ALPL mRNA levels in primary HSVSMCs. Guerrero et al. 
studied TGF-b1-driven vSMC differentiation from mesenchymal stem cells in the 
presence of high phosphate a known to inducer of osteoblastic differentiation 
(Guerrero et al., 2014). The authors showed that TGF-b1 prevented phosphate-
induced osteoblastic differentiation by suppressing ALP activity and subsequent 
Ca2+ deposition. These findings suggest that TGF-b1 negatively regulates 
osteoblastic vSMC differentiation. In contrast, Zhu et al. investigated the effect 
of BMP-9 on phosphate-induced osteoblastic differentiation of primary mouse 
aortic SMCs (Zhu et al., 2015). The investigators found that BMP-9/ALK1-
dependently drove mRNA expression of osteoblastic markers, ALP activity and 
Ca2+ deposition indicating BMP-9 as a positive regulator of osteoblastic vSMC 
differentiation. In conclusion, it may be speculated that the potential TGF-b1-
dependent decrease in ALP activity in HSVSMCs may provide more Ca2+ for AngII-
operated SR Ca2+ release. In contrast, although BMP-9 did not induce ALPL mRNA 
levels in HSVSMC it is conceivable that this ligand may stimulate ALP activity 
thereby redirecting free Ca2+ to calcification and reducing SR Ca2+ availability. It 
is important to stress that these are highly speculative statements. Hence, these 




calcium deposition in ligand treated primary human vSMCs in absence and 
presence of high phosphate and (ii) assessing the impact of pharmacological ALP 
inhibition with DNB on AngII-induced intracellular Ca2+ mobilisation in ligand-
treated primary human vSMCs. 
In addition to findings based on whole region of interest fluorescence analysis, 
single cell fluorescence trace analysis revealed SMC population heterogeneity 
based on AngII-driven SR Ca2+ release. Independent of treatment, each group 
displayed a bimodal distribution of AngII-dependent Ca2+ transients. However, 
the presence of TGF-b1 triggered a trend towards a reduction in non-responding 
HSVSMCs and instead an increase in the number of cells displaying medium and 
higher AngII-mediated Ca2+ responses. The presence of BMP-9 attenuated this 
TGF-b1-driven effect. TGF-b1 appeared to promote homogeneity based on AngII-
induced release of intracellular Ca2+ stores. Subsequently one may hypothesise 
that saphenous vein media is made up of diverse SMC phenotypes reflecting local 
vessel wall heterogeneity. 
These findings are in line with previous studies reporting distinct SMC 
phenotypes residing within healthy media of pulmonary, coronary and internal 
thoracic arteries (Frid et al., 1994; Hao et al., 2002; Li et al., 2001a). It is 
important to stress that these studies investigated large arteries and, hence, 
these findings may not directly reflect on SVG media composition. Nevertheless, 
scRNAseq data shown in section 6.3.4 supports the hypothesis of local SMC 
diversity within SVG media. Li and colleagues isolated 12 distinct SMC 
phenotypes from one fragment of the human internal thoracic artery (Li et al., 
2001a). In the context of Ca2+ handling, the authors showed that spindle-shaped 
(contractile) SMCs displayed higher AngII-induced Ca2+ transients compared to 
epithelioid (synthetic) SMCs. Furthermore, the study showed that only spindle-
shaped SMCs contracted in response to AngII stimulation. Although both clone 
subtypes expressed aSMA, MYH11 and calponin, epithelioid-shaped SMCs 
displayed greater proliferative and migratory capacities in response to treatment 
with 10% serum and PDGF-BB compared to spindle-shaped SMCs. This study 
revealed two important aspects. Firstly, it showed that contractile and synthetic 
SMCs resided side by side in healthy arterial media in the absence of a 




of vascular disease/injury SMCs undergo phenotype switching to maintain 
vascular wall structure and function. Secondly, distinct SMC phenotypes reacted 
differently to pro-proliferative/-migratory stimuli. Based on this finding, it may 
be hypothesised that vSMCs react heterogeneously in certain vascular disease 
settings. 
It is important to point out some limitations in this single cell analysis. Several 
cells within one set of patient cells did not respond to AngII stimulation although 
all experiments were performed at P5. It may be possible that examined SMC 
populations were made up of different SMC phenotypes reacting differently to 
BMP-9, TGF-b1 and/or AngII stimuli (Li et al., 2001a). These phenomena may also 
contribute to inter-patient variability. Furthermore, all examined 6-min traces 
displayed a slight decline in baseline fluorescence intensity which may be 
explained by (i) photo-bleaching during fluorescence imaging or (ii) probe 
leaching into extracellular space. Although this caused negative amplitudes in 
some non-responding HSVSMCs this effect was only small. To prevent negative 
values following log10-transformation the constant 4.926025 was added to each 
amplitude from each cell to ensure that every amplitude was treated in the 
same way. Moreover, this study did not directly investigate fractional SMC 
shortening following AngII stimulation. Therefore, future experiments should be 
aimed at directly assessing SMC contraction to gain more insight into excitation-
contraction coupling in primary HSVSMCS and HCASMCs. In the context of single 
cell resolution this may be achieved by high magnification phase contrast 
microscopy of single SMCs as described by Li et al. (Li et al., 2001a). However, 
this would only allow examination of a limited number of SMCs as opposed to 
examining a whole SMC population since the authors used trypsin-EGTA to loosen 
SMCs from the culture surface. In collaboration with Dr F. Burton and Prof G. 
Smith (University of Glasgow) an attempt was made to determine fractional SMC 
shortening in fluorescence imaging videos using a software designed to detect 
cell movement. However, this attempt did not yield any valid results since (i) 
the resolution (10´ magnification for 6-min fluorescence trace imaging) was not 
sufficient to detect SMC movement and (ii) SMCs might not have displayed any 
movement in response to AngII stimulation since SMC shortening might have been 
hampered by SMC adherence to plastic substrate. This limitation may be 




compared culturing of primary RASMCs in plastic versus Matrigel-coated wells (Li 
et al., 1994). The study showed that SMCs cultured on Matrigel displayed a 
morphological phenotype which more closely resembled a contractile SMC 
phenotype compared to SMCs cultured on plastic dishes. Furthermore, the 
authors determined SMC contraction by phase-contrast microscopy. Results 
showed that the number of contracting cells (shape change > 10%) in response to 
arginine vasopressin (AVP) was greater on Matrigel compared to plastic. In 
addition, the investigators examined intracellular Ca2+ release in Fura-2-loaded 
SMCs. AVP triggered increases in cytosolic [Ca2+] in SMCs were similar between 
cells cultured on Matrigel and plastic. Based on this study, a future experiment 
should determine excitation-contraction coupling in primary HSVSMCs plated on 
Matrigel dishes. Loading SMCs with the Ca2+ indicator Cal520TM and performing 
high resolution fluorescence trace analysis in combination with phase-contrast 
imaging on a live-cell microscope may enable simultaneous visualisation of AngII-
induced intracellular Ca2+ release and downstream contraction. This experiment 
could then be complemented by determining SVG contraction intensity and 





HSVSMCs quiesced for 72-h and Cal520-loaded displayed a rapid and reproducible 
increase in fluorescence intensity in response to AngII and IM stimulation 
indicating release of intracellular Ca2+ stores. In contrast, preliminary results 
showed that serum treated HSVSMCs did not respond to AngII stimulation 
potentially suggesting that SR Ca2+ stores were unresponsive in proliferating 
HSVSMCs. 
Having established a robust Ca2+ handling protocol the next aim was to 
investigate intracellular Ca2+ release in BMP-9 and/or TGF-b1-treated primary 
HSVSMCs and HCASMCs in the absence and presence of SB525334. TGF-b1-treated 
HSVSMCs displayed an increase in AngII-driven intracellular Ca2+ mobilisation in 
an ALK5-dependent manner, potentially suggesting increased contractility. In 
contrast, BMP-9 blunted this effect indicating ALK5 antagonism and/or 
differential utilisation of intracellular Ca2+. Opposed to findings in primary 
HSVSMCs, TGF-b1 did not affect AngII-dependent Ca2+ release in primary 
HCASMCs indicating differential regulation of Ca2+ handling in this cell type. 
The next aims were to determine whether AngII signalled via the AT1R or AT2R 
and which mechanisms might explain why TGF-b1 sensitised the AngII Ca2+ 
response in primary HSVSMCs. Pharmacological AT1R inhibition with losartan 
blunted AngII-driven intracellular Ca2+ mobilisation in both untreated and TGF-
b1-treated HSVSMCs indicating AT1R-dependency. Furthermore, TGF-b1 ALK5-
dependently suppressed MAS1 receptor mRNA expression levels but did not 
affect AGTR1 expression. Since MAS1 has been shown to counter-regulate AT1R it 
may be hypothesised that reduced MAS1 levels in the presence of TGF-b1 triggers 
an increased AngII/AT1R excitation/contraction response. 
Furthermore, the ROCK/PKC/contraction inhibitor fasudil did not affect AngII-
induced Ca2+ release in untreated and TGF-b1-treated HSVSMCs indicating that 
potential Ca2+-dependent cell contraction did not trigger quenching of the Ca2+ 
indicator probe Cal520 and a subsequent false increase in fluorescence intensity. 
It may be speculated that although it is likely that fasudil dampens HSVSMC 




triggering potential downstream activation of Ca2+-sensitive signalling pathways 
such as the NFAT/calcineurin system. 
Single cell region of interest analysis revealed heterogeneous HSVSMC 
populations independent of ligand treatment. However, TGF-b1-treated HSVSMC 
populations displayed a trend towards a reduction in non-responding cells and 
instead an increase in cells responding with higher fluorescence intensities 
indicating a more homogeneous population based on intracellular Ca2+ release. 
TGF-b1-induced homogeneity was reversed in the presence of BMP-9 paralleling 
whole region of interest findings. It may be hypothesised that SMC population 
heterogeneity reflects SMC diversity within pre-implantation SVG media and that 




Chapter 6 Characterising primary HSVSMC 
transcriptome heterogeneity using single cell 





Data presented in section 5.3.4 revealed HSVSMC population heterogeneity in 
each treatment group except for TGF-b1-treated SMC populations which elicited 
a more homogeneous AngII-dependent Ca2+ response. This prompted evaluation 
of potential transcriptome heterogeneity in BMP-9 and/or TGF-b1-treated 
HSVSMCs using the 10x Chromium microfluidics-based scRNAseq platform. 
6.1.1 Single cell RNA sequencing as a technique to investigate 
vSMC heterogeneity 
It has previously been postulated that arterial vSMC heterogeneity may play a 
role in vascular disease development and progression. Single cell RNA sequencing 
enables identification of distinct vascular cells and distinct SMC phenotypes in 
whole vessel homogenates, and as such constitutes a powerful tool for the 
evaluation of cellular heterogeneity (Dobnikar et al., 2018; Wirka et al., 2019). 
Using scRNAseq analysis Dobnikar and colleagues uncovered 7 distinct SMC 
phenotypes within one region of healthy murine aortic media. Moreover, this 
study found that some SMCs within each of these 7 clusters expressed the 
mesenchymal stem cell marker Sca1 (encodes stem cells antigen 1) and that 
these Sca1+ SMCs displayed lower contractile gene expression levels. The authors 
went on to investigate Sca1 in the context of vascular injury and found that 
lineage-labelled Myh11-CreERt2/EYFP mice displayed Sca1 up-regulation in 10-
45% of EYFP+ vSMCs in dispersed ligation-injured carotid arteries (Dobnikar et 
al., 2018). This potentially indicates expansion of a rare SMC sub-population 
following vascular injury. Yao et al. used scRNAseq to investigate vSMC de-
differentiation in the context of NF following carotid balloon injury in rats (Yao 
et al., 2018). The study identified the histone variant H2az as a protective factor 
against vSMC de-differentiation and NF following vascular injury. The authors 
also demonstrated that H2az drove Smad3 recruitment thereby enabling 
activation of contractile gene expression. Wirka et al. investigated vSMC 
heterogeneity in hyperlipidaemic ApoE-/- SMC-lineage tracing mice (Wirka et al., 
2019). With the help of scRNAseq the authors showed that hyperlipidaemic ApoE-
/- SMC-lineage tracing mice displayed transformation of vSMCs into fibroblast-




identification of TCF21 (encodes transcription factor of the basic helix-loop-helix 
family) as an athero-protective gene in human CAD. 
In summary, these studies highlight that scRNAseq is a powerful technology to 
study rare SMC phenotypes/SMC heterogeneity and identify novel disease 
relevant genes in the context of vascular injury and atherosclerosis. 
Furthermore, the combination of scRNAseq and lineage tracing mice has further 
broadened the understanding of pathophysiological processes underlying NF and 
atherosclerosis development and progression. Hence, scRNAseq may help to 





• To characterise transcriptional heterogeneity versus homogeneity in 
response to BMP-9 and/or TGF-b1 treatment. 
• To identify potential SMC sub-lineages in untreated control and ligand 





6.3.1 Quality control filtering reveals high percentage of 
mitochondrial genes in primary HSVSMCs 
All steps leading up to AnnData matrix file import into the existing Python 
computational TGF-b pipeline are described in 2.10.4. In brief, the CellRanger 
v.3.1.0 and STAR aligner softwares were used to perform nucleotide sequence 
alignment against the GRCh38 reference genome. This left 1,843 untreated 
(vehicle 4 mM HCl/1% BSA, 24-h), 1,372 BMP-9-treated (10 ng/ml, 24-h), 2,038 
TGF-b1 (10 ng/ml, 24-h)and 1,938 BMP-9 (10 ng/ml)/TGF-b1 (10 ng/ml) co-
treated (24-h) HSVSMCs for analysis using an existing Python pipeline (cells 
generated from one CABG patient) (unpublished data) (Low et al., 2019). 
Preliminary quality control (QC) filtering included discarding cells expressing 
<2000 genes and genes with <100 corresponding cells. Following filtering, the 
total number of RNA molecules per cell (Figure 6-1 A), the mitochondrial gene 
percentage per cell (Figure 6-1 B) and total RNA count versus mitochondrial gene 
percentage (Figure 6-1 C) were computed. The read depth was approximately 
30,000 reads/cell. The mitochondrial gene percentage/cell average was >5%. 
Based on these findings, cut offs were defined to prevent skewing of data 
analysis. Cells containing <10,000 and >45,000 RNA molecules as well as 
displaying a mitochondrial gene percentage >12.5% were filtered out (Figure 6-2 
A). RNA molecule count versus corresponding mitochondrial gene percentage per 
cell did not demonstrate a correlation (Figure 6-2 B). Finally, the relationship 
between RNA molecule count and corresponding number of expressed genes per 
cell did not appear to behave in a linear fashion (Figure 6-2 C). 
In summary, QC filtering revealed an increase in mitochondrial gene percentage 





Figure 6-1 Preliminary quality control filtering identifies high percentage of mitochondrial genes in 
primary HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. 
Quiescence media was replaced with stimulation media containing BMP-9 (10 ng/ml), TGF-b1 (10 ng/ml), 
BMP-9 and TGF-b1 (10 ng/ml) and vehicle control (4 mM HCl/1% BSA). Following 24-h, stimulation media was 
removed. Cells were prepared as described in section 2.10.1 and subjected to scRNAseq (biological n=1 
CABG patient). Cells containing 10x barcodes which were not recognised by the CellRanger software were 
discarded. In addition, cells expressing <2000 genes and genes with <100 corresponding cells were also 
excluded from the analysis. (A) Plot displays distribution of RNA molecule counts per cell. (B) Plot displays 
distribution of mitochondrial gene fraction per cell. (C) Plot demonstrates RNA molecule counts versus 



























Figure 6-2 Final quality control filtering confirms high percentage of mitochondrial gene percentage. 
80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence media 
was replaced with stimulation media containing BMP-9 (10 ng/ml), TGF-b1 (10 ng/ml), BMP-9 and TGF-b1 (10 
ng/ml) and vehicle control (4 mM HCl/1% BSA). Following 24-h, stimulation media was removed. Cells were 
prepared as described in section 2.10.1 and subjected to scRNAseq (biological n=1 CABG patient).  To avoid 
skewing of data analysis, cells containing <10,000 and >45,000 RNA molecule counts as well as a 
mitochondrial gene percentage >12.5% were excluded from the analysis. (A) Plots demonstrate distribution of 
RNA molecule counts (left) and mitochondrial gene fraction (right) per cell. (B) Plot displays RNA molecule 
counts versus mitochondrial gene fraction per cell. (C) Plot displays RNA molecule counts versus number of 

















6.3.2 Initial principal component analysis reveals distinct 
transcriptomes for each treatment group 
Previous scRNAseq results from our group demonstrated that untreated control 
and TGF-b1-treated primary HSVSMCs displayed transcriptional differences 
following principal component analysis (PCA) (unpublished data) (Low et al., 
2019). To identify transcriptional differences between treatment groups, PCA 
was performed on all remaining cells following QC-filtering. 
Dimensionality reduction using PCA uncovered transcriptional differences 
between all treatment groups (Figure 6-3 A). Transcriptional alterations 
appeared to be larger in TGF-b1- versus BMP-9-treated HSVSMCs compared to 
untreated controls. In line with previous findings from our group, TGF-b1-treated 
HSVSMCs displayed a visible reduction in mitochondrial gene expression 
(unpublished data) (Low et al., 2019). Paralleling previously presented bulk qRT-
PCR findings from this study, BMP-9 and TGF-b1 drove relative ID1 and SERPINE1 
mRNA expression levels respectively (Figure 6-4 B and C). 
In conclusion, BMP-9 and TGF-b1 induced target gene expression demonstrating 
successful ligand stimulation. Moreover, PCA uncovered greater transcriptional 
alterations in TGF-b1- versus BMP-9-treated HSVSMCs potentially suggesting that 






Figure 6-3 Principal component analysis reveals distinct transcriptomes within each treatment group. 
80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence media 
was replaced with stimulation media containing BMP-9 (10 ng/ml), TGF-b1 (10 ng/ml), BMP-9 and TGF-b1 (10 
ng/ml) and vehicle control (4 mM HCl/1% BSA). Following 24-h, stimulation media was removed. Cells were 
prepared as described in section 2.10.1 and subjected to scRNAseq (biological n=1 CABG patient). Following 
QC filtering UMI counts were re-scaled to 10,000 in order to correct for library size (total number of UMIs). The 
constant 1 was added to each re-scaled UMI count prior to log10-transformation. Based on dispersion, highly 
variable genes were excluded from the analysis. Principal component analysis (PCA) was performed on all 
remaining cells to highlight differences between treatment groups and identify potential confounders. Finally, 
variations in cell count were regressed out. (A) Graph displays cells from each treatment group. (B) Graph 
displays distribution of RNA molecule counts per cell. The right-hand y-axis indicates RNA molecule counts. 













Figure 6-4 BMP-9 and TGF-b1 drive target gene expression in primary HSVSMCs. 80% confluent primary 
HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence media was replaced with 
stimulation media containing BMP-9 (10 ng/ml), TGF-b1 (10 ng/ml), BMP-9 and TGF-b1 (10 ng/ml) and vehicle 
control (4 mM HCl/1% BSA). Following 24-h, stimulation media was removed. Cells were prepared as 
described in section 2.10.1 and subjected to scRNAseq (biological n=1 CABG patient). (A) Graph displays 
cells from each treatment group. (B) PCA plot displays rescaled ID1 mRNA molecule counts for each 
treatment group (right-hand y-axis indicates rescaled RNA molecule counts). (C) PCA plot displays rescaled 
SERPINE1 mRNA molecule counts for each treatment group (right-hand y-axis indicates rescaled RNA 











6.3.3 Combined UMAP and Louvain clustering reveals 
transcriptome heterogeneity in primary HSVSMCs 
The previous scRNAseq study from our group revealed 11 distinct clusters within 
TGF-b1-treated HSVSMCs demonstrating transcriptome heterogeneity following 
ligand treatment (unpublished data) (Low et al., 2019). Based on this finding, 
uniform manifold approximation and projection (UMAP) non-linear 
dimensionality reduction alongside Louvain clustering were utilised to identify 
cell clusters based on transcriptome differences within untreated and 24-h 
ligand treated primary HSVSMCs. 
UMAP plots revealed 7 distinct Louvain clusters within the untreated control 
group (Figure 6-5 A), 7 clusters within the BMP-9 treatment group (Figure 6-5 B), 
8 clusters within the TGF-b1 treatment group (Figure 6-5 C) and 9 clusters within 
the combined BMP-9/TGF-b1 treatment group (Figure 6-5 D). Taken together, 






Figure 6-5  ScRNAseq uncovers transcriptional heterogeneity in each treatment group. 80% confluent 
primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence media was replaced 
with stimulation media containing BMP-9 (10 ng/ml) (B), TGF-b1 (10 ng/ml) (C), BMP-9 and TGF-b1 (10 ng/ml) 
(D) and vehicle control (4 mM HCl/1% BSA) (A). Following 24-h, stimulation media was removed. Cells were 
prepared as described in section 2.10.1 and subjected to scRNAseq (biological n=1 CABG patient). Following 
initial PCA, the 4 treatment groups were separated into 4 individual samples. PCA was performed on the Z 
scores of normalised expression values within each treatment group. Neighbourhood graphs were computed 
based on the top 40 principal components and the 10 nearest neighbours. UMAP was utilised as a non-linear 


































6.3.4 Serum-starved HSVSMC control population displays 7 
distinct clusters 
UMAP non-linear dimensionality reduction in combination with Louvain clustering 
identified 7 clusters based on transcriptome differences within untreated control 
primary HSVSMCs. Established RNA velocity and gene ontology (GO) analysis were 
performed to obtain more detailed information on transcriptome dynamics and 
underlying biological processes within each cluster (unpublished data) (Low et 
al., 2019). Figure 6-7 displays the top 30 most differentially expressed genes for 
each cluster. Relative SERPINE1 and ID1 mRNA expression was overlaid with RNA 
velocity analysis to determine dynamic ALK5 and ALK1/ALK2 pathway activation. 
RNA velocity is a high dimensional vector which predicts the future state of 
individual cells and is estimated by distinguishing between un-spliced and 
spliced mRNAs in scRNAseq protocols (La Manno et al., 2018). 
RNA velocity vectors indicated that control HSVSMCs were differentiating along 
separate lineages (Figure 6-6 A). GO analysis revealed that clusters 0 (blue), 2 
(green), 3 (red) and 5 (brown) displayed the highest fold enrichment scores, a 
measure of whether a term is over-represented in the dataset. 
RNA velocity analyses showed that most clusters appeared to be moving away 
from cluster 3 (red) which displayed enrichment terms for ascending aorta 
morphogenesis (enriched cluster genes: SOX4, encodes transcription factor SOX-
4; TGFB2), negative regulation of extracellular matrix disassembly (DPP4, 
encodes dipeptidyl peptidase 4; FAP, encodes prolyl endopeptidase FAP), atrial 
septum primum morphogenesis (SOX4; TGFB2), regulation of macrophage 
cytokine production (CD74, encodes HLA class II histocompatibility antigen 
gamma chain; TGFB2; SPON2, encodes spondin-2) and wound healing/spreading 
of cells (PDPN, encodes podoplanin; MME, encodes macrophage metalloelastase; 
CD44, encodes CD44 antigen; ARHGAP24, encodes Rho GTPase-activating protein 
24) (Table 6-1). 
Cluster 0 (blue) showed enrichment for regulation of high voltage-gated calcium 
channel activity (CACNB2, encodes voltage-dependent L-type calcium channel 
subunit beta-2; PDE4B, encodes cAMP-specific 3′,5′-cyclic phosphodiesterase 4B; 




vasculature development (ADAMTS6, encodes a disintegrin and 
metalloproteinase with thrombospondin motifs 6; LTBP1, encodes latent TGF-b-
binding protein 1; BMP4; HAND2, encodes heart- and neural crest derivatives-
expressed protein 2). In contrast, cluster 2 (green) demonstrated enrichment for 
Wnt signalling (SFRP1, encodes secreted frizzled-related protein 1; DKK1, 
encodes Dickkopf-related protein 1) and negative regulation of osteoblast 
proliferation (NRP1, encodes PKC-binding protein NELL1; GREM1, encodes 
gremlin 1; SFRP1). Cluster 5 (brown) displayed enrichment for oncogene-induced 
cell senescence (HMGA1, encodes high mobility group protein HMG-I/HMG-Y; 
HMGA2, encodes high mobility group protein HMG-C) and chronological cell 
ageing (SERPINE1; ENG). Both clusters 2 and 5 demonstrated visually higher 
relative SERPINE1 mRNA levels compared to all other clusters indicating ALK5 
pathway activation (Figure 6-6 B and C). Relative ID1 mRNA levels were low 
throughout all clusters suggesting absence of ALK1/ALK2 pathway activation. 
Lower fold enrichment scored terms for clusters 1, 4 and 6 are listed in Table 
6-1. 
Taken together, these findings demonstrate transcriptional heterogeneity within 
untreated control primary HSVSMCs which may reflect SMC diversity within pre-
implantation SVG media. Interestingly, cluster 0 (blue) displayed enrichment for 
regulation of high voltage-gated calcium channel activity which may be linked to 





Figure 6-6 UMAP/Louvain clustering and RNA velocity in untreated control primary HSVSMCs. 80% 
confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence media was 
replaced with media containing vehicle control (4 mM HCl/1% BSA). Following 24-h, media was removed. 
Cells were prepared as described in section 2.10.1 and subjected to scRNAseq (biological n=1 CABG 
patient). (A-C) Following identification of distinct clusters within untreated control HSVSMCs by UMAP 
dimensionality reduction alongside Louvain community detection, RNA velocity and partition-based graph 
abstraction were generated utilising the scvelo package. Arrows indicate directionality of RNA velocity vectors. 
(A) Louvain UMAP graph displays RNA velocity vectors within clusters. (B) Louvain UMAP graph displays 
relative SERPINE1 mRNA expression with RNA velocity overlay. (C) Louvain UMAP graph displays relative 


















Figure 6-7 Top 30 most differentially regulated genes (DEGs) per cluster in untreated control primary HSVSMCs. (A) Clusters within untreated control HSVSMCs were identified by 
UMAP dimensionality reduction alongside Louvain community detection. The top 100 most DEGs were identified by using the Mann-Whitney-Wilcoxon test in combination with Benjamini-
Hochberg correction. Graphs display the top 30 most DEGs for each cluster. 
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regulation of high voltage-gated calcium channel 
activity 
3 0.07 43.9 7.02E-05 4.67E-02 
 
negative regulation of animal organ morphogenesis 
 
4 0.16 25.08 2.89E-05 3.08E-02 
coronary vasculature development 4 0.21 19.09 7.79E-05 4.79E-02 
cartilage development 7 0.71 9.85 9.45E-06 1.51E-02 
inner ear development 7 0.93 7.53 4.97E-05 3.78E-02 
1 
regulation of cellular response to growth factor 
stimulus 




12 2.47 4.86 7.81E-06 4.16E-02 
regulation of cell migration 15 4.12 3.64 1.64E-05 5.23E-02 
anatomical structure morphogenesis 26 10.29 2.53 7.10E-06 5.67E-02 
regulation of developmental process 30 12.52 2.4 4.53E-06 7.23E-02 
2 
Wnt signaling pathway involved in somitogenesis 2 0.02 80.97 4.94E-04 2.85E-02 
 
response to cortisol 
 
2 0.02 80.97 4.94E-04 2.84E-02 
regulation of midbrain dopaminergic neuron 
differentiation 
2 0.02 80.97 4.94E-04 2.83E-02 
axon extension involved in axon guidance 3 0.04 75.91 1.85E-05 2.04E-03 
negative regulation of osteoblast proliferation 3 0.04 67.48 2.46E-05 2.58E-03 
3 
ascending aorta morphogenesis 2 0.02 > 100 3.41E-04 3.58E-02 
negative regulation of extracellular matrix 
disassembly 
2 0.02 > 100 3.41E-04 3.56E-02 
atrial septum primum morphogenesis 2 0.02 82.58 4.76E-04 4.63E-02 
regulation of macrophage cytokine production 3 0.07 41.29 8.42E-05 1.20E-02 
wound healing, spreading of cells 4 0.13 31.76 1.27E-05 2.81E-03 
4 
odontogenesis 6 0.58 10.32 3.34E-05 3.80E-02 
extracellular matrix organisation 12 1.75 6.86 2.44E-07 9.74E-04 
negative regulation of cell population 
proliferation 
13 3.4 3.83 3.88E-05 4.13E-02 
positive regulation of developmental process 19 6.79 2.8 4.30E-05 4.29E-02 
regulation of multicellular organismal process 33 15.68 2.1 2.19E-05 2.91E-02 
5 
oncogene-induced cell senescence 2 0.01 > 100 1.24E-04 2.57E-02 
chronological cell aging 2 0.01 > 100 1.24E-04 2.54E-02 
senescence-associated heterochromatin focus 
assembly 
2 0.01 > 100 2.06E-04 3.65E-02 
regulation of cytokine activity 2 0.02 > 100 3.08E-04 4.97E-02 
positive regulation of cell aging 3 0.07 43.44 7.24E-05 1.81E-02 
6 
bone development 7 0.86 8.13 3.12E-05 2.49E-02 
extracellular matrix organization 13 1.66 7.82 1.61E-08 2.58E-04 
wound healing 10 2 4.99 3.74E-05 2.85E-02 
regulation of cell migration 16 4.04 3.96 2.81E-06 3.45E-03 
circulatory system development 15 4.05 3.7 1.32E-05 1.32E-02 
Table 6-1 GO enrichment terms for top 100 most DEGs within each cluster in untreated control primary 
HSVSMCs. GO enrichment analysis was performed based on the top 100 DEGs for each cluster. The top 5 
biological processes are displayed for each cluster and are ranked by fold enrichment score with a false 





Figure 6-8 GO identifies enrichment for regulation of high voltage-gated calcium channel activity in 
cluster 0 in untreated control primary HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 0.2% 
FCS media (MEDIA1) for 72-h. Quiescence media was replaced with media containing vehicle control (4 mM 
HCl/1% BSA). Following 24-h, media was removed. Cells were prepared as described in section 2.10.1 and 
subjected to scRNAseq (biological n=1 CABG patient). Following identification of distinct clusters within 
untreated control HSVSMCs by UMAP dimensionality reduction alongside Louvain community detection, RNA 
velocity and partition-based graph abstraction were generated utilising the scvelo package. Arrows indicate 
directionality of RNA velocity vectors. Louvain UMAP graphs display relative (A) CACNB2, (B) PDE4B and (C) 










6.3.5 ScRNA-seq analysis reveals a potentially osteogenic 
HSVSMC lineage following BMP-9 treatment 
Previously presented immunoblot and qRT-PCR data in sections 4.3.10 and 4.3.11 
demonstrated that BMP-9 induced SMAD1 phosphorylation and subsequent ID1 
mRNA expression in primary HSVSMCs. Combined UMAP/Louvain clustering 
alongside RNA velocity and GO analysis was performed to identify single cell 
transcriptional differences within BMP-9-treated primary HSVSMCs. Figure 6-10 
displays the top 30 most differentially expressed genes for each cluster. 
RNA velocity vectors indicated that BMP-9 treated HSVSMCs appeared to 
differentiate along 4 separate lineages starting from cluster 0 (blue) which 
displayed enrichment for white fat cell differentiation (enriched cluster genes: 
AC092535, encodes c-terminal-binding protein 1; PPARG, encodes peroxisome 
proliferator-activated receptor gamma; SNAI2, encodes zinc finger protein 
SNAI2) (Figure 6-11) and negative regulation of oxidative stress-induced cell 
death (HSPB1, encodes heat shock protein beta-1; HGF, encodes hepatocyte 
growth factor; OXR1, oxidation resistant protein 1; FZD1, encodes frizzled-1 
(Figure 6-9 A) (Table 6-2). 
Clusters 2 (green), 5 (brown) and 6 (pink) originated from clusters 0 (blue) and 3 
(red). Whereas cluster 2 (green) showed enrichment for skeletal muscle cell 
maintenance (IGF1, encodes insulin-like growth factor-1; FZD7, encodes frizzled-
7) and determination of dorsal identity (GREM1; GREM2) (Figure 6-11), the 
smaller cluster 5 (brown) displayed enrichment for coronary vasculature 
development (ADAMTS6; LTBP1; TGFBR3; SGCD, encodes delta-sarcoglycan) and 
response to calcium ion (KCNMA1, encodes calcium-activated potassium channel 
subunit alpha-1; CALM2, encodes calmodulin 2; MEF2A, encodes myocyte-
specific enhancer factor 2A; CAV1, encodes caveolin 1; S100A16, encodes 
protein S100-A16; CCND1; NLGN1, encodes neuroligin-1). 
In contrast, the smaller cluster 6 (pink) demonstrated enrichment for response 
to laminar fluid shear stress (SREBF2, encodes sterol regulatory element-binding 
protein 2; ASS1, encodes argininosuccinate synthase; SMAD7), chondrocyte 
development (BMPR1B, encodes bone morphogenetic protein receptor type-1B; 




transcription factor 2; COL11A1, encodes collagen alpha-1 11 chain) and bone 
morphogenesis (INSIG1, encodes insulin-induced gene 1 protein; DHRS3, encodes 
short-chain dehydrogenase/reductase 3; BMPR1B; MMP16, encodes matrix 
metalloproteinase-16; SCX, encodes basic helix-loop-helix transcription factor 
scleraxis; RUNX2). 
Cluster 3 (red) also appeared to originate from cluster 0 (blue) and displayed 
enrichment for intramembranous ossification (COL1A1; CTSK, encodes cathepsin 
K; MMP2), regulation of macrophage cytokine production (CD74; TGFB2; SPON2) 
and regulation of ECM disassembly (DPP4; FAP; PDPN). Enrichment terms (and 
associated genes) in cluster 3 showed similarities to cluster 3 in untreated 
control HSVSMCs although relative ID1 mRNA levels were higher indicating BMP-
9/ALK1 or ALK2 pathway activation. Velocity vectors connected cluster 3 (red) 
to 4 (purple) and cluster 4 to 1 (orange). The 3 highest ranked biological 
processes were cellular response to prostaglandin D stimulus (TNC, encodes 
tenascin c; AKR1C2, encodes aldo-keto reductase family 1 member C2; AKR1C3), 
cellular response to hydroperoxide (PRKD1, encodes serine/threonine-protein 
kinase D1; DAPK1, encodes death-associated protein kinase 1; MGST1, 
microsomal glutathione S-transferase 1) and positive regulation of TGF-b 
production (THBS1, encodes thrombospondin-1; CD34, encodes hematopoietic 
progenitor cell antigen CD34; LUM, encodes lumican). Cluster 1 only displayed 
lowly ranked enrichment terms compared to all other examined clusters. 
Relative SERPINE1 mRNA expression levels were low throughout all clusters 
suggesting absence of ALK5 pathway activation (Figure 6-9 A). In contrast, all 
clusters except for clusters 1 (orange) and 2 (green) displayed an increase in ID1 
mRNA levels indicating BMP-9-induced downstream SMAD1 pathway activation 
(Figure 6-9 B). 
In summary BMP-9 drove 3 distinct HSVSMC lineages (clusters 2, 5 and 6) 
originating in cluster 0 (blue) which displayed an increase in PPARG and SNAI2 
mRNA expression levels. Of interest, cluster 2 displayed an increase in IGF1 
mRNA levels shown to potentiate BMP-9-induced osteogenic differentiation 
(Chen et al., 2016a). In addition, cluster 2 demonstrated an increase in GREM1 
and GREM2 mRNA levels shown to negatively regulate BMP signalling within an 




(red) showed enrichment term overlap with cluster 3 (red) in untreated control 
HSVSMCs suggesting the presence of a similar HSVSMC population. Finally, cluster 
4 (purple) displayed an increase in PRKD1, DAPK1 and MGST mRNA expression 
levels potentially reflecting transcriptional activation in response to oxidative 






Figure 6-9 UMAP/Louvain clustering and RNA velocity in BMP-9-treated primary HSVSMCs. 80% 
confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence media was 
replaced with stimulation media containing BMP-9 (10 ng/ml). Following 24-h, stimulation media was removed. 
Cells were prepared as described in section 2.10.1 and subjected to scRNAseq (biological n=1 CABG 
patient). (A-C) Following identification of distinct clusters within untreated control HSVSMCs by UMAP 
dimensionality reduction alongside Louvain community detection, RNA velocity and partition-based graph 
abstraction were generated utilising the scvelo package. Arrows indicate directionality of RNA velocity vectors. 
(A) Louvain UMAP graph displays RNA velocity vectors within clusters. (B) Louvain UMAP graph displays 
relative SERPINE1 mRNA expression with RNA velocity overlay. (C) Louvain UMAP graph displays relative 


















Figure 6-10 Top 30 most differentially regulated genes per cluster in BMP-9-treated primary HSVSMCs. (A) Clusters within BMP-9-treated HSVSMCs were identified by UMAP 
dimensionality reduction alongside Louvain community detection. The top 100 most DEGs were identified by using the Mann-Whitney-Wilcoxon test in combination with Benjamini-Hochberg 
correction. Graphs display the top 30 most DEGs for each cluster.
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cluster 0 cluster 1 cluster 2 cluster 3 















white fat cell differentiation 3 0.07 46.06 6.24E-05 2.32E-02 
negative regulation of oxidative stress-induced cell 
death 4 0.22 18.29 9.14E-05 2.98E-02 
collagen fibril organization 4 0.22 17.91 9.86E-05 2.97E-02 
positive regulation of smooth muscle cell 
proliferation 5 0.41 12.08 7.60E-05 2.76E-02 
negative regulation of extrinsic apoptotic signaling 
pathway 5 0.49 10.14 1.67E-04 3.86E-02 
1 
regulation of cellular response to growth factor 
stimulus 8 1.42 5.62 1.08E-04 4.91E-02 
extracellular matrix organization 9 1.75 5.15 7.58E-05 4.84E-02 
eye development 9 1.81 4.98 9.67E-05 5.14E-02 
regulation of binding 9 1.82 4.95 1.01E-04 4.86E-02 
heart development 12 2.54 4.72 1.07E-05 1.22E-02 
2 
skeletal muscle satellite cell maintenance involved 
in skeletal muscle regeneration 2 0.02 > 100 3.21E-04 3.01E-02 
response to L-ascorbic acid 2 0.02 85.11 4.48E-04 3.85E-02 
determination of dorsal identity 2 0.02 85.11 4.48E-04 3.82E-02 
negative regulation of vascular associated smooth 
muscle cell migration 2 0.03 70.92 5.96E-04 4.68E-02 
gastro-intestinal system smooth muscle contraction 2 0.03 70.92 5.96E-04 4.66E-02 
3 
intramembranous ossification 3 0.03 > 100 9.21E-06 4.20E-03 
regulation of macrophage cytokine production 3 0.07 40.88 8.67E-05 2.10E-02 
regulation of extracellular matrix disassembly 3 0.08 38.33 1.03E-04 2.31E-02 
response to hydroperoxide 3 0.09 32.28 1.61E-04 3.26E-02 
collagen catabolic process 4 0.21 19.02 8.04E-05 2.04E-02 
4 
cellular response to prostaglandin D stimulus 3 0.02 > 100 5.30E-06 6.04E-03 
cellular response to hydroperoxide 3 0.04 80.61 1.55E-05 9.14E-03 
positive regulation of transforming growth factor 
beta production 3 0.09 33.94 1.39E-04 4.19E-02 
negative regulation of blood coagulation 5 0.24 21.07 6.08E-06 5.71E-03 
extracellular matrix organization 13 1.68 7.74 1.83E-08 1.46E-04 
5 
membrane assembly 4 0.16 24.91 2.95E-05 3.92E-02 
coronary vasculature development 4 0.21 19.5 7.18E-05 5.21E-02 
cardiac septum development 6 0.5 12.12 1.37E-05 2.74E-02 
cardiac ventricle development 6 0.58 10.43 3.09E-05 3.79E-02 
response to calcium ion 7 0.68 10.33 6.98E-06 2.23E-02 
6 
response to laminar fluid shear stress 3 0.07 40.1 9.18E-05 3.86E-02 
chondrocyte development 4 0.12 32.08 1.24E-05 8.58E-03 
positive regulation of cartilage development 4 0.16 25.06 2.98E-05 1.70E-02 
bone morphogenesis 6 0.48 12.53 1.18E-05 8.59E-03 
cardiac ventricle development 7 0.64 10.88 5.23E-06 4.17E-03 
Table 6-2 GO enrichment terms for top 100 most DEGs within each cluster in BMP-9-treated primary 
HSVSMCs. GO enrichment analysis was performed based on the top 100 DEGs for each cluster. The top 5 
biological processes are displayed for each cluster and are ranked by fold enrichment score with a false 





Figure 6-11 GO analysis identifies a potential osteogenic sub-lineage in BMP-9-treated primary 
HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. 
Quiescence media was replaced with stimulation media containing BMP-9 (10 ng/ml). Following 24-h, 
stimulation media was removed. Cells were prepared as described in section 2.10.1 and subjected to 
scRNAseq (biological n=1 CABG patient). Following identification of distinct clusters within untreated control 
HSVSMCs by UMAP dimensionality reduction alongside Louvain community detection, RNA velocity and 
partition-based graph abstraction were generated utilising the scvelo package. Arrows indicate directionality of 
RNA velocity vectors. Louvain UMAP graphs display relative (A) PPARG, (B) SNAI2, (C) IGF1, (D) GREM1 
and (E) GREM2 mRNA expression with RNA velocity overlay.  












6.3.6 TGF-b1-treated primary HSVSMC lineages express 
contractile, fibrotic and chemotactic genes 
This study has so far comprehensively shown that TGF-b1-drives contractile gene 
expression and AngII-dependent Ca2+ transients in primary HSVSMCs implicating 
the TGF-b1/ALK5 pathway as a positive regulator of the contractile SMC 
phenotype. In addition, previous scRNAseq experiments from our group 
discovered simultaneous transcriptional activation of ALK1 and ALK5 target 
genes in HSVSMCs in response to TGF-b1 treatment demonstrating non-
overlapping ALK1- and ALK5-dominant SMC lineages within the same treatment 
group (unpublished data) (Low et al., 2019). Based on these findings, the next 
aim was to analyse scRNAseq data from TGF-b1-treated HSVSMCs to identify 
potentially contractile SMC phenotypes and ALK1/ALK5-dominant lineages. 
Single cell transcriptomics identified 8 distinct clusters within TGF-b1-treated 
cells (Figure 6-12 A) (Table 6-3). Figure 6-13 displays the top 30 most 
differentially expressed genes for each cluster. Relative SERPINE1 mRNA 
expression levels were elevated throughout all examined clusters indicating 
ALK5 pathway activation in all clusters (Figure 6-12 B). In contrast ID1 mRNA 
levels were low indicating ALK1 or ALK2 pathway inactivation (Figure 6-12 C). 
Cluster 0 (blue) did not display any and cluster 4 (purple) only displayed 2 lowly 
ranked GO enrichment terms (Table 6-3). 
RNA velocity vectors within cluster 1 (orange) indicated trans-differentiation 
towards clusters 2 (green), 3 (red) and 6 (pink) (Figure 6-12 A). The 3 highest 
ranked enrichment terms for cluster 1 (orange) were positive regulation of EMT 
(enriched cluster genes: PAX8, encodes paired box protein Pax-8; LIF, encodes 
leukaemia inhibitory factor), regulation of transepithelial transport (ACTB, 
encodes actin cytoplasmic 1; ACTG1, encodes actin cytoplasmic 2) and 
regulation of lymphangiogenesis (VEGFC, encodes vascular endothelial growth 
factor c; FOXC1, encodes forkhead box protein C1). In addition, cluster 1 showed 
enrichment for regulation of stress fibre formation (ACTG1; CTGF; ALK5; TPM1, 
encodes tropomyosin alpha-1 chain; DLC1, Rho GTPase-activating protein 7; 
expected 0.44; fold enrichment 11.47, raw p value 9.68E-05; FDR 1.61E-02; data 




Cluster 2 (green) originated from cluster 1 (orange) and showed enrichment 
terms for negative regulation of B-cell differentiation (INHBA, encodes inhibin 
beta A chain; SFRP1), response to heparin (EGR1, encodes early growth response 
protein 1; SFRP1), response to cortisol (SLIT3, encodes slit homolog 3 protein; 
IGFBP7, IGF-binding protein 7), intramembranous ossification (COL1A1; MN1, 
encodes transcriptional activator MN1) and collagen-activated tyrosine kinase 
receptor signalling pathway (COL1A1; COL4A1; COL4A2) (Figure 6-15 A-C) (Table 
6-3). Within cluster 2 (green) velocity vectors indicated a split into two potential 
SMC sub-lineages (Figure 6-12 A). 
Cluster 3 (red) also originated from cluster 1 (orange) (Figure 6-12 A). Cluster 3 
demonstrated enrichment for regulation of chemokine-mediated signalling 
pathway (HIF1A, encodes hypoxia-inducible factor 1-alpha; ROBO1, roundabout 
homolog 1; AL049569, protein-arginine deiminase type-2), induction of positive 
chemotaxis (SCG2, encodes secretogranin-2; VEGFA; CXCL12, stromal cell-
derived factor 1) (Figure 6-16 A-C), post-embryonic animal organ development 
(EFEMP1, encodes EGF-containing fibulin-like extracellular matrix protein 1; 
VEGFA; AL049569, encodes microfibrillar-associated protein 2), positive 
regulation of neuroblast proliferation (HIF1A; VEGFA; GLI3, encodes 
transcriptional activator GLI3) and collagen fibril organisation (SERPINH1, 
encodes serpin H1; COL1A1; COL1A2; COL3A1; ADAMTS2; COL5A2) (Table 6-3). 
Moreover, velocity vectors indicated that cluster 5 (brown) originated from 
cluster 3 (red) (Figure 6-12 A). The 3 highest ranked enrichment terms were 
negative regulation of neuron migration (NRG1, encodes pro-neuregulin-1 
membrane-bound isoform; ERBB4, encodes receptor tyrosine-protein kinase 
erbB-4; COL3A1), negative regulation of pathway-restricted SMAD protein 
phosphorylation (PMEPA1, encodes protein TMEPAI; ENG; LDLRAD4, encodes low-
density lipoprotein receptor class A domain-containing protein 4) (Figure 6-17 A-
C) and collagen fibril organisation (LOXL1, encodes lysyl oxidase homolog 1; DPT, 
dermatopontin; CYP1B1, encodes cytochrome P450 1B1; LOXL1; COL3A1) (Table 
6-3). 
The smaller cluster 6 (pink) originated from cluster 1 (orange) and in part from 
clusters 3 (red) and 5 (brown) as indicated by RNA velocity vectors (Figure 6-12 




(HMGA1; HMGA2) and positive regulation of cellular senescence (HMGA1; 
HMGA2; B2M, encodes beta-2-microglobulin) (Table 6-3). Finally, cluster 7 
(olive) appeared to be separated from the other clusters (Figure 6-12 A). The 
highest ranked enrichment term was negative regulation of smooth muscle 
contraction (KCNMA1; PRKG1, encodes cGMP-dependent protein kinase 1; 
AC007319, encodes calcitonin gene-related peptide type 1 receptor) (Table 6-3). 
In summary, TGF-b1 drove 3 to 4 main HSVSMC lineages. Whereas ALK5 pathway 
activity was enhanced throughout all examined clusters the ALK1/ALK2 pathway 
appeared inactive contrasting results from our previous study (unpublished data) 
(Low et al., 2019). Cluster 1 (orange) demonstrated enrichment for stress fiber 
formation. In addition, this cluster showed an increase in DLC1 mRNA levels 
shown to drive intracellular Ca2+ release in response to acetylcholine and 
coronary vasospasm (Kinjo et al., 2015; Murakami et al., 2010), potentially 
indicating a contractile SMC phenotype. In contrast, cluster 2 (green) appeared 
to be enriched for pro-fibrotic genes, such as collagen and EGR1. Cluster 3 
demonstrated enrichment for the pro-inflammatory genes VEGFA and CXCL12 
mRNA levels. Finally, cluster 5 (brown) displayed enrichment LDLRAD4 and 
PMEPA1 potentially indicating negative regulation of TGF-b signalling (Clement 





Figure 6-12 UMAP/Louvain clustering and RNA velocity in TGF-b1-treated primary HSVSMCs. 80% 
confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence media was 
replaced with stimulation media containing TGF-b1 (10 ng/ml). Following 24-h, stimulation media was 
removed. Cells were prepared as described in section 2.10.1 and subjected to scRNAseq (biological n=1 
CABG patient). (A-C) Following identification of distinct clusters within untreated control HSVSMCs by UMAP 
dimensionality reduction alongside Louvain community detection, RNA velocity and partition-based graph 
abstraction were generated utilising the scvelo package. Arrows indicate directionality of RNA velocity vectors. 
(A) Louvain UMAP graph displays RNA velocity vectors within clusters. (B) Louvain UMAP graph displays 
relative SERPINE1 mRNA expression with RNA velocity overlay. (C) Louvain UMAP graph displays relative 



















Figure 6-13 Top 30 most DEGs per cluster in TGF-b1-treated primary HSVSMCs. (A) Clusters within TGF-b1-treated HSVSMCs were identified by UMAP dimensionality reduction 
alongside Louvain community detection. The top 100 most DEGs were identified by using the Mann-Whitney-Wilcoxon test in combination with Benjamini-Hochberg correction. Graphs 
display the top 30 most DEGs for each cluster. 
A 
cluster 0 cluster 1 cluster 2 cluster 3 
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Table 6-3 GO enrichment terms for top 100 most DEGs within each cluster in TGF-b1-treated primary 
HSVSMCs. GO enrichment analysis was performed based on the top 100 DEGs for each cluster. The top 5 
biological processes are displayed for each cluster and are ranked by fold enrichment score with a false 





Figure 6-14 Cluster 1 displays enrichment for genes associated with stress fibre formation in primary 
HSVSMCs following TGF-b1 treatment. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS 
media (MEDIA1) for 72-h. Quiescence media was replaced with stimulation media containing TGF-b1 (10 
ng/ml). Following 24-h, stimulation media was removed. Cells were prepared as described in section 2.10.1 
and subjected to scRNAseq (biological n=1 CABG patient). Following identification of distinct clusters within 
untreated control HSVSMCs by UMAP dimensionality reduction alongside Louvain community detection, RNA 
velocity and partition-based graph abstraction were generated utilising the scvelo package. Arrows indicate 
directionality of RNA velocity vectors. Louvain UMAP graph displays relative (A) TPM1, (B) ACTG1, (C) 













Figure 6-15 Cluster 2 displays enrichment for pro-fibrotic genes in primary HSVSMCs following TGF-b1 
treatment. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. 
Quiescence media was replaced with stimulation media containing TGF-b1 (10 ng/ml). Following 24-h, 
stimulation media was removed. Cells were prepared as described in section 2.10.1 and subjected to 
scRNAseq (biological n=1 CABG patient). Following identification of distinct clusters within untreated control 
HSVSMCs by UMAP dimensionality reduction alongside Louvain community detection, RNA velocity and 
partition-based graph abstraction were generated utilising the scvelo package. Arrows indicate directionality of 
RNA velocity vectors. Louvain UMAP graph displays relative (A) EGR1, (B) COL1A1, (C) COL4A1 and (D) 
COL4A2 mRNA expression with RNA velocity overlay.  
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Figure 6-16 Cluster 3 demonstrates overlap of genes associated with induction of positive chemotaxis 
in primary HSVSMCs following TGF-b1 treatment. 80% confluent primary HSVSMCs were quiesced in 0.2% 
FCS media (MEDIA1) for 72-h. Quiescence media was replaced with stimulation media containing TGF-b1 (10 
ng/ml). Following 24-h, stimulation media was removed. Cells were prepared as described in section 2.10.1 
and subjected to scRNAseq (biological n=1 CABG patient). Following identification of distinct clusters within 
untreated control HSVSMCs by UMAP dimensionality reduction alongside Louvain community detection, RNA 
velocity and partition-based graph abstraction were generated utilising the scvelo package. Arrows indicate 
directionality of RNA velocity vectors. Louvain UMAP graph displays relative (A) VEGFA, (B) CXCL12 and (C) 









Figure 6-17 Cluster 5 displays overlap of genes associated with negative regulation of pathway-
restricted SMAD protein phosphorylation in primary HSVSMCs following TGF-b1 treatment. 80% 
confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. Quiescence media was 
replaced with stimulation media containing TGF-b1 (10 ng/ml). Following 24-h, stimulation media was 
removed. Cells were prepared as described in section 2.10.1 and subjected to scRNAseq (biological n=1 
CABG patient). Following identification of distinct clusters within untreated control HSVSMCs by UMAP 
dimensionality reduction alongside Louvain community detection, RNA velocity and partition-based graph 
abstraction were generated utilising the scvelo package. Arrows indicate directionality of RNA velocity vectors. 
Louvain UMAP graph displays relative (A) PMEPA1, (B) ENG and (C) LDLRAD4 mRNA expression with RNA 










6.3.7 Single cell transcriptomics uncover potential mechanisms 
for negative regulation of contractility in BMP-9/TGF-b1-co-
treated primary HSVSMCs 
Previously presented data showed that BMP-9 prevented TGF-b1-induced 
increase in AngII-driven intracellular Ca2+ mobilisation (section 5.3.2) but did not 
prevent TGF-b1-driven SERPINE1 and contractile gene expression in primary 
HSVSMCs (4.3.11). Single cell transcriptional analysis was performed to (i) 
identify a potential underlying mechanism for the inhibitory BMP-9-mediated 
effect on TGF-b1-dependent Ca2+ handling and to (ii) investigate potential BMP-
9/TGF-b1 signalling agonism and/or antagonism in primary HSVSMCs. 
Combined UMAP/Louvain clustering identified 9 clusters within BMP-9/TGF-b1-
co-treated HSVSMCs (Figure 6-18 A, Table 6-4, Table 6-5). Figure 6-19 and Figure 
6-20 display the top 30 most differentially expressed genes for each cluster. 
Cluster 3 (red) did not yield any GO enrichment terms. Relative SERPINE1 mRNA 
levels appeared visually enhanced in all clusters except cluster 4 indicating ALK5 
pathway activation (Figure 6-18 B). In contrast, only clusters 0 (blue), 4 (purple), 
6 (pink) and 7 (grey) displayed an increase in relative ID1 mRNA levels indicating 
ALK1/ALK2 pathway activation (Figure 6-18 C). In contrast to BMP-9 and TGF-b1 
stimulation alone, RNA velocity vector analysis did not show clear lineage 
differentiation paths within this treatment group. 
Cluster 0 (blue) partially originated from cluster 1 (orange). GO enrichment 
terms for cluster 0 included inorganic diphosphate transport (enriched cluster 
genes: ANKH, encodes progressive ankylosis protein homolog; ENPP1, encodes 
ectonucleotide pyrophosphatase/phosphodiesterase family member 1) (Figure 
6-21 A and B), germ cell migration (TGFB1; TGFBR1; FOXC1), positive regulation 
of hematopoietic progenitor cell differentiation (ZBTB1, encodes zinc finger and 
BTB domain-containing protein 1; FOXC1), regulation of lymphangiogenesis 
(VEGFC; FOXC1) and VEGF signalling pathway (HSPB1, encodes heat shock 
protein beta-1; VEGFC; FOXC1) (Table 6-4). Although not listed within the 5 
highest ranking enrichment terms, cluster 0 showed enrichment for negative 
regulation of Ca2+-mediated signalling (CALM2, encodes calmodulin-2; FHL2, 
encodes four and a half LIM domains protein 2; RCAN1, encodes calcipressin-1; 




not shown in table) (Figure 6-21 C). In line with an increase in ID1 mRNA levels 
this cluster also displayed enrichment for BMP signalling pathway (TGFB1; 
SMURF2, encodes E3 ubiquitin-protein ligase SMURF2; SKI, encodes Ski oncogene; 
FST, encodes follistatin; BMPR2; SCX; ID1; COMP, encodes cartilage oligomeric 
matrix protein; expected 0.45; fold enrichment 17.88, raw p value 3.01E-08; 
FDR 3.00E-05; data not shown in table). 
Cluster 1 (orange) mainly originated from cluster 4 (purple) and displayed 
similarities with cluster 2 (green) in the TGF-b1 treatment group (Figure 6-18 A). 
The top 5 enrichment terms were neural crest cell fate commitment (SOX9; 
SFRP1), negative regulation of B cell differentiation (INHBA, SFRP1), cellular 
response to heparin (SOX9; SFRP1), response to cortisol (SLIT3; IGFBP7) and 
determination of dorsal identity (GREM1; GREM2) (Table 6-4). In addition, this 
cluster enriched for collagen-activated signalling pathway (ITGA2, encodes 
integrin alpha-2; ITGA11, encodes integrin alpha-11; COL4A1; COL4A2; expected 
0.07; fold enrichment 60.18; raw p value 1.36E-06; FDR 3.30E-04; data not 
shown in table) (Figure 6-22 B and C). 
Cluster 4 (purple) demonstrated an increase in ID1 mRNA levels indicating 
ALK1/ALK2 pathway activation (Figure 6-18 A, C). RNA velocity vectors suggested 
trans-differentiation towards clusters 0 (blue) and 1 (orange). Highest ranked 
biological processes included negative regulation of cell proliferation involved in 
contact inhibition (SRPX; encodes sushi repeat-containing protein SRPX; FAP), 
response to human chorionic gonadotropin (GCLM; encodes glutamate-cysteine 
ligase regulatory subunit; MYC, encodes Myc proto-oncogene protein), positive 
regulation of CD8-positive/alpha-beta T cell differentiation (CBFB, encodes core-
binding factor subunit beta; RUNX1), negative regulation of ECM disassembly 
(DPP4; FAP) and negative regulation of endothelial cell differentiation (ZEB1, 
encodes zinc finger E-box-binding homeobox 1; VEGFA; ID1) (Table 6-4). 
Velocity vectors within cluster 2 (green) indicated that cells originated from 
within the same cluster (Figure 6-18 A). The 3 highest ranking biological 
processes were arginine metabolic process (DOK1, encodes ecto-ADP-
ribosyltransferase 4; DDAH1; encodes N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1; ASS1) (Figure 6-23 A-C), negative regulation of 




activated receptor gamma coactivator 1-alpha; IGFBP5) and glycosaminoglycan 
biosynthetic process (HAS1, encodes hyaluronan synthase 1; DCN, encodes 
decorin; UGDH, UDP-glucose 6-dehydrogenase; SDC1, encodes syndecan-1; 
ST3GAL1, encodes CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-
sialyltransferase 1; B4GALT1, encodes beta-1,4-galactosyltransferase 1) (Table 
6-4). 
Cluster 5 (brown) mainly originated from cluster 2 (green) and partially from 
cluster 0 (blue) (Figure 6-18 A). This cluster displayed biological processes 
relating to re-entry into mitotic cell cycle (CCND1; MYC), response to human 
chorionic gonadotropin (GLCM; MYC), epithelial to mesenchymal transition 
involved in endocardial cushion formation (MSX2, encodes homeobox protein 
MSX-2; ENG; TMEM100, encodes transmembrane protein 100), venous blood 
vessel development (VEGFA; BMPR2; ENG) and regulation of blood vessel 
endothelial cell proliferation involved in sprouting angiogenesis (NGFR, encodes 
tumor necrosis factor receptor superfamily member 16; VEGFA; HMOX1, encodes 
heme oxygenase 1) (Table 6-4). From cluster 5 (brown) velocity vectors 
indicated trans-differentiation towards cluster 3 (red) which did not yield any 
biological processes (Figure 6-18 A). 
Cluster 6 (pink) was small and appeared to originate from cluster 3 (red) (Figure 
6-18 A). Biological processes identified by GO comparatively yielded lower fold 
enrichment scores (Table 6-5). The top 3 identified biological processes were 
chondrocyte development (SULF2; SCX; SULF1; TGFB1; RUNX2), embryonic 
skeletal system development (SULF2; ZEB1; MMP16; SCX; SULF1; DLX2, encodes 
Homeobox protein DLX-2; RUNX2) and developmental growth involved in 
morphogenesis (TNC; PTK7, encodes inactive tyrosine-protein kinase 7; NRP2, 
encodes neuropilin-2; POSTN, encodes periostin; KIF26B, encodes kinesin-like 
protein KIF26B). Together with an increase in ID1 mRNA levels, this cluster 
showed some overlap with cluster 6 (pink) in BMP-9-treated HSVSMCs. 
Cluster 7 (olive) was also small and was situated between clusters 1 (orange) and 
4 (purple) (Figure 6-18 A). Velocity vectors did not allow to determine a clear 
origin for this cluster. The 5 highest ranking biological processes were glutamine 
catabolic process (GLS; glutaminase liver isoform, mitochondrial), regulation of 




organisation (ACTB; ACTG1; MYH10, encodes myosin-10), ventricular cardiac 
muscle cell differentiation (NRG1; MYH10; FHL2) and relaxation of muscle 
(KCNMA1; SLC8A1, encodes sodium/calcium exchanger 1; PLN, encodes cardiac 
phospholamban) (Table 6-5). 
Finally, the smallest cluster 8 (turquoise) originated from cluster 2 (green) 
(Figure 6-18 A). The top 3 biological processes were negative regulation of 
smooth muscle cell migration (IGFBP3; SERPINE1; IBFBP5), regulation of insulin-
like growth factor receptor signalling pathway (IGFBP3; IGFBP6; IGFBP7) and 
positive regulation of G1/S transition of mitotic cell cycle (EGFR, encodes 
epidermal growth factor receptor; CCND1; ADAMTS1; ANXA1, encodes annexin 
A1) (Table 6-5). 
In conclusion, UMAP/Louvain clustering identified 9 clusters within BMP-9/TGF-
b1-co-treated HSVSMCs. In contrast to single ligand-treated cells, RNA velocity 
vectors did not indicate clear lineage differentiation. Cluster 0 (blue) displayed 
an increase in ANKH and ENPP1 mRNA levels, two known negative regulators of 
vascular calcification (Chen et al., 2019; Lomashvili et al., 2014). Furthermore, 
this cluster demonstrated an increase in RCAN1 mRNA levels shown to negatively 
regulate vascular contractility (García-Redondo et al., 2018; Villahoz et al., 
2018). Cluster 1 (orange) demonstrated some overlap with cluster 2 (green) 
within the TGF-b1-treatment group potentially indicating the presence of a pro-
fibrotic SMC sub-lineage. In addition, this cluster demonstrated an increase in 
GREM1 and GREM2 mRNA levels suggesting negative regulation of BMP-9 
signalling. Moreover, cluster 2 (green) displayed enrichment for DDAH1 and ASS1 
mRNA levels indicating potential positive regulation of the citrulline/NO cycle 
(Ghose and Raushel, 1985; Leiper et al., 2007). Finally, cluster 5 demonstrated 






Figure 6-18 UMAP/Louvain clustering and RNA velocity in BMP-9/TGF-b1-co-treated primary 
HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. 
Quiescence media was replaced with stimulation media containing BMP-9 (10 ng/ml) and TGF-b1 (10 ng/ml). 
Following 24-h, stimulation media was removed. Cells were prepared as described in section 2.10.1 and 
subjected to scRNAseq (biological n=1 CABG patient). (A-C) Following identification of distinct clusters within 
untreated control HSVSMCs by UMAP dimensionality reduction alongside Louvain community detection, RNA 
velocity and partition-based graph abstraction were generated utilising the scvelo package. Arrows indicate 
directionality of RNA velocity vectors. (A) Louvain UMAP graph displays RNA velocity vectors within clusters. 
(B) Louvain UMAP graph displays relative SERPINE1 mRNA expression with RNA velocity overlay. (C) 
Louvain UMAP graph displays relative ID1 mRNA expression with RNA velocity overlay. 


















Figure 6-19 Top 30 most differentially regulated genes per cluster in BMP-9 and TGF-b1 co-treated primary HSVSMCs (part 1). (A) Clusters within BMP-9/TGF-b1-co-treated 
HSVSMCs were identified by UMAP dimensionality reduction alongside Louvain community detection. The top 100 most DEGs were identified by using the Mann-Whitney-Wilcoxon test in 
combination with Benjamini-Hochberg correction. Graphs display the top 30 most DEGs for clusters 0 to 3.  
A 
cluster 0 cluster 1 cluster 2 cluster 3 





Figure 6-20 Top 30 most differentially regulated genes per cluster in BMP-9 and TGF-b1 co-treated primary HSVSMCs (part 2). (A) Clusters within BMP-9/TGF-b1-co-treated 
HSVSMCs were identified by UMAP dimensionality reduction alongside Louvain community detection. The top 100 most DEGs were identified by using the Mann-Whitney-Wilcoxon test in 
combination with Benjamini-Hochberg correction. Graphs display the top 30 most DEGs for clusters 4 to 8
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cluster 8 














inorganic diphosphate transport 2 0.01 > 100 1.51E-04 1.75E-02 
germ cell migration 3 0.04 84.3 1.47E-05 3.17E-03 
positive regulation of hematopoietic progenitor cell 
differentiation 
2 0.03 78.68 5.23E-04 4.12E-02 
regulation of lymphangiogenesis 2 0.03 78.68 5.23E-04 4.10E-02 
vascular endothelial growth factor signaling pathway 3 0.11 26.82 2.67E-04 2.54E-02 
1 
neural crest cell fate commitment 2 0.02 > 100 3.28E-04 3.15E-02 
negative regulation of B cell differentiation 2 0.02 84.25 4.57E-04 4.17E-02 
cellular response to heparin 2 0.02 84.25 4.57E-04 4.15E-02 
response to cortisol 2 0.02 84.25 4.57E-04 4.12E-02 
determination of dorsal identity 2 0.02 84.25 4.57E-04 4.10E-02 
2 
arginine metabolic process 3 0.08 36.43 1.17E-04 3.16E-02 
negative regulation of smooth muscle cell migration 3 0.11 28.15 2.32E-04 4.68E-02 
glycosaminoglycan biosynthetic process 6 0.49 12.26 1.32E-05 5.01E-03 
epithelial cell proliferation 5 0.43 11.6 9.21E-05 2.67E-02 
tissue remodeling 5 0.48 10.43 1.48E-04 3.76E-02 
4 
negative regulation of cell proliferation involved in 
contact inhibition 
2 0.02 > 100 3.54E-04 4.25E-02 
response to human chorionic gonadotropin 2 0.02 > 100 3.54E-04 4.22E-02 
positive regulation of CD8-positive, alpha-beta T cell 
differentiation 
2 0.02 > 100 3.54E-04 4.19E-02 
negative regulation of extracellular matrix disassembly 2 0.02 > 100 3.54E-04 4.16E-02 
negative regulation of endothelial cell differentiation 3 0.04 67.48 2.46E-05 6.13E-03 
5 
re-entry into mitotic cell cycle 2 0.01 > 100 2.32E-04 3.28E-02 
response to human chorionic gonadotropin 2 0.02 > 100 3.48E-04 4.44E-02 
epithelial to mesenchymal transition involved in 
endocardial cushion formation 
3 0.06 51.11 4.88E-05 1.05E-02 
venous blood vessel development 3 0.07 40.88 8.67E-05 1.55E-02 
regulation of blood vessel endothelial cell proliferation 
involved in sprouting angiogenesis 
3 0.08 38.33 1.03E-04 1.74E-02 
Table 6-4 GO enrichment terms for top 100 most DEGs for clusters 0 to 5 in BMP-9 and TGF-b1-co-
treated primary HSVSMCs. GO enrichment analysis was performed based on the top 100 DEGs for clusters 
0 to 5. The top 5 biological processes are displayed for each cluster and are ranked by fold enrichment score 














chondrocyte differentiation 5 0.34 14.74 3.14E-05 1.93E-02 
embryonic skeletal system development 7 0.65 10.71 5.75E-06 7.07E-03 
developmental growth involved in morphogenesis 6 0.6 10.02 3.93E-05 2.16E-02 
extracellular matrix organization 10 1.8 5.55 1.60E-05 1.42E-02 
tissue morphogenesis 11 2.74 4.01 1.08E-04 4.79E-02 
7 
glutamine catabolic process 2 0.01 > 100 2.15E-04 3.06E-02 
regulation of transepithelial transport 2 0.02 > 100 3.21E-04 4.03E-02 
postsynaptic actin cytoskeleton organization 3 0.07 42.55 7.70E-05 1.45E-02 
ventricular cardiac muscle cell differentiation 3 0.08 35.46 1.24E-04 2.11E-02 
relaxation of muscle 3 0.1 30.4 1.87E-04 2.84E-02 
8 
negative regulation of smooth muscle cell migration 3 0.1 29.93 1.93E-04 3.59E-02 
regulation of insulin-like growth factor receptor 
signaling pathway 
3 0.1 28.63 2.18E-04 3.86E-02 
positive regulation of G1/S transition of mitotic cell 
cycle 
4 0.16 24.39 3.20E-05 1.00E-02 
epithelial cell morphogenesis 4 0.16 24.39 3.20E-05 9.83E-03 
animal organ regeneration 5 0.35 14.44 3.37E-05 1.01E-02 
Table 6-5 GO enrichment terms for top 100 most DEGs for clusters 6-8 in BMP-9 and TGF-b1 co-treated 
primary HSVSMCs. GO enrichment analysis was performed based on the top 100 DEGs for clusters 6 to 8. 
The top 5 biological processes are displayed for each cluster and are ranked by fold enrichment score with a 





Figure 6-21 GO analysis reveals a sub-lineage in cluster 0 enriching for genes associated with 
negative regulation of vascular calcification and contraction in BMP-9/TGF-b1-co-treated primary 
HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. 
Quiescence media was replaced with stimulation media containing BMP-9 (10 ng/ml) and TGF-b1 (10 ng/ml). 
Following 24-h, stimulation media was removed. Cells were prepared as described in section 2.10.1 and 
subjected to scRNAseq (biological n=1 CABG patient). Following identification of distinct clusters within 
untreated control HSVSMCs by UMAP dimensionality reduction alongside Louvain community detection, RNA 
velocity and partition-based graph abstraction were generated utilising the scvelo package. Arrows indicate 
directionality of RNA velocity vectors. Louvain UMAP graph displays relative (A) ANKH, (B) ENPP1 and (C) 










Figure 6-22 Cluster 1 displays overlap of pro-fibrotic genes in BMP-9/TGF-b1-co-treated primary 
HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 0.2% FCS media (MEDIA1) for 72-h. 
Quiescence media was replaced with stimulation media containing BMP-9 (10 ng/ml) and TGF-b1 (10 ng/ml). 
Following 24-h, stimulation media was removed. Cells were prepared as described in section 2.10.1 and 
subjected to scRNAseq (biological n=1 CABG patient). Following identification of distinct clusters within 
untreated control HSVSMCs by UMAP dimensionality reduction alongside Louvain community detection, RNA 
velocity and partition-based graph abstraction were generated utilising the scvelo package. Arrows indicate 
directionality of RNA velocity vectors. Louvain UMAP graph displays relative (A) ITGA2, (B) ITGA11, (C) 
COL4A1 and (D) COL4A2 mRNA expression with RNA velocity overlay.  
A ITGA2 







Figure 6-23 Cluster 2 demonstrates overlap of genes associated with regulation of the citrulline/NO 
cycle in BMP-9/TGF-b1-co-treated primary HSVSMCs. 80% confluent primary HSVSMCs were quiesced in 
0.2% FCS media (MEDIA1) for 72-h. Quiescence media was replaced with stimulation media containing BMP-
9 (10 ng/ml) and TGF-b1 (10 ng/ml). Following 24-h, stimulation media was removed. Cells were prepared as 
described in section 2.10.1 and subjected to scRNAseq (biological n=1 CABG patient). Following identification 
of distinct clusters within untreated control HSVSMCs by UMAP dimensionality reduction alongside Louvain 
community detection, RNA velocity and partition-based graph abstraction were generated utilising the scvelo 
package. Arrows indicate directionality of RNA velocity vectors. Louvain UMAP graph displays relative (A) 









The main aims of this chapter were to investigate potential transcriptional 
heterogeneity and to identify potential SMC sub-lineages within each treatment 
group. 
Untreated control HSVSMCs displayed 7 clusters indicating transcriptional 
heterogeneity. RNA velocity vectors indicated that 5 clusters originated from the 
central cluster 3 (red) and transdifferentiated along distinct trajectories. GO 
analysis based on the top 100 most DEGs within cluster 2 (blue) identified 
enrichment for the regulation of high voltage-gated calcium channel activity 
which included the genes CACNB2, PDE4B and FGF14. In line with this finding, 
Gollasch et al. demonstrated that differentiated RASMCs expressing contractile 
genes displayed higher CACNB2 protein expression levels and greater L-type Ca2+ 
currents compared to 10% serum-treated controls indicating positive Ca2+ system 
remodelling and subsequent increase in contractile function (Gollasch et al., 
1998). Partially in line with these findings, initial Ca2+ handling data 
demonstrated that AngII induced greater intracellular Ca2+ transients in serum-
starved primary HSVSMCs compared to 15% serum-treated controls potentially 
suggesting the presence of a contractile HSVSMC phenotype (section 5.3.1). 
However, it must be pointed out that no extracellular Ca2+ was present during 
these measurements and, hence, it is not clear whether serum-starved HSVSMCs 
also display higher L-type Ca2+ channel activity. Nevertheless, these findings 
warrant additional experiments investigating CACNB2 expression and activity in 
quiesced versus proliferating HSVSMCs in the future.  
Within untreated control HSVSMCs cluster 3 (red) displayed enrichment for 
cardiovascular development which included the gene TGFB2. Quiesced HSVSMCs 
demonstrated an increase in contractile protein expression indicating the 
presence of a contractile HSVSMC phenotype (Figure 4-22). Paralleling TGF-b1-
driven effects, previous work by Low et al. 2019 showed that TGF-b2 induced 
SMAD1 and SMAD2 phosphorylation and drove relative SERPINE1, CTGF, ID1 and 
ID3 mRNA expression levels in primary HSVSMCs (unpublished data) (Low et al., 
2019). Hence, it may be speculated that the TGF-b2 isoform may also induce 




In summary, combined computational UMAP/Louvain clustering identified 7 
distinct clusters in quiesced control primary HSVSMCs indicating transcriptional 
heterogeneity and potential SMC sub-lineages. Taken together with previous Ca2+ 
handling findings, these results may reflect a heterogeneous composition of 
vSMC phenotypes in pre-implantation SVG media. 
Bulk Western Blotting and qRT-PCR analysis revealed that BMP-9 drove SMAD1 
phosphorylation and subsequent downstream relative ID1 mRNA expression levels 
in primary HSVSMCs (sections 4.3.10 and 4.3.11). Paralleling these findings, 
scRNAseq analysis demonstrated that BMP-9 induced ID1 mRNA levels throughout 
most clusters within the BMP-9 treatment group confirming ALK1 or ALK2 
pathway activation. In depth analysis revealed 7 clusters reflecting 
transcriptional heterogeneity following BMP-9 stimulation. 
RNA velocity analysis within BMP-9-treated HSVSMCs indicated lineage trans-
differentiation originating from clusters 0 (blue) and 3 (red) and terminating in 
cluster 2 (green). Of interest, cluster 2 (green) displayed enrichment for relative 
IGF1, GREM1 and GREM2 mRNA expression levels. In the context of osteogenesis, 
Chen and colleagues demonstrated that adenovirus-mediated BMP-9 delivery to 
pluripotent murine C3H10T1/2 stem cells induced IGF1 protein expression (Chen 
et al., 2016a). Furthermore, exogenous IGF1 expression potentiated BMP-9-
dependent SMAD1 phosphorylation, alkaline phosphatase activity, matrix 
mineralisation and ectopic bone formation demonstrating that IGF1 synergised 
with BMP-9 signalling to drive osteogenesis. On the other hand, the BMP 
signalling antagonists GREM1 and GREM2 were shown to inhibit osteogenesis (Liu 
et al., 2020a; Wang et al., 2017). Based on these findings, it may be speculated 
that HSVSMCs identified in cluster 2 (green) were in the process of 
transdifferentiating towards an osteoblastic phenotype as evidenced by an 
increase in IGF1 mRNA levels. The increase in GREM1 and GREM2 mRNA levels 
might have reflected auto-inhibition of BMP signalling following BMP-9 
stimulation. Previous studies exploring BMP-9 in the context of osteogenesis and 
osteoblastic vSMC differentiation investigated late time-points (7-20 days) in in 
vitro experiments (Chen et al., 2016a; Zhu et al., 2015). Hence, 24-h BMP-9 
stimulation may not have been sufficient to induce more substantial osteoblastic 




combined in vitro/scRNAseq experiment investigating long-term BMP-9-driven 
effects in primary HSVSMCs in the future. 
The potential osteoblastic HSVSMC sub-lineage (cluster 2, green) partially 
originated from cluster 0 (blue) which displayed enrichment for white fat cell 
differentiation including the genes AC092535, PPARG and SNAI2. PPARG is a 
master-regulator of adipocyte and adipose tissue development (Rosen et al., 
1999). In line with this finding, Akune et al. showed that homozygous pparg-
deficient murine embryonic stem (ES) cells failed to differentiate into 
adipocytes (Akune et al., 2004). Instead, ES spontaneously underwent 
osteoblastic differentiation, while heterozygous pparg-deficient mice displayed 
an increase in bone mass and osteoblastogenesis. A study by Sun et al. confirmed 
these findings by demonstrating that targeted suppression of PPAR-g increased 
osteogenesis (Sun et al., 2013). In addition, Pérez-Mancera and colleagues 
showed that the zinc-finger transcription factor SNAI2 (SLUG) also positively 
regulated adipogenesis (Pérez-Mancera et al., 2007). Opposing anti-osteogenic 
effects of PPAR-g, however, SNAI2 also acted as a positive regulator of 
osteogenesis (Tang et al., 2016). Furthermore, it was shown that BMP-9 drove 
relative SNAI2 mRNA expression in primary human pulmonary artery ECs (Levet 
et al., 2015). Together, these studies may suggest that (i) PPAR-g acts as a 
switch between adipo- and osteogenesis, (ii) SNAI2 positively regulates adipo- 
and osteogenesis and (iii) BMP-9 induces SNAI2 expression. Hence, it may be 
speculated that an increase in BMP-9-driven SNAI2 mRNA levels in HSVSMCs 
within cluster 0 facilitated potential osteoblastic trans-differentiation towards 
cluster 2 (green). In contrast, like an increase in GREM1 and GREM2 expression, 
an increase in PPARG expression may reflect auto-inhibition of potential 
osteoblastic differentiation. However, it must be pointed out that these 
hypotheses are highly speculative and should be addressed in future in vitro 
experiments. 
Transcriptional analysis identified 8 clusters within TGF-b1-treated primary 
HSVSMCs. Relative SERPINE1 mRNA expression levels were increased throughout 
most clusters indicating ALK5 pathway activation and paralleling bulk qRT-PCR 




GO identified ALK5 as a regulator of stress fibre formation within cluster 1 
(orange). Crosas-Molist and colleagues showed that HASMCs from patients with 
Marfan syndrome (MFS), a genetic condition linked to excessive TGF-
b1/ALK5/SMAD2/3 signalling and aortic aneurysm formation, displayed an 
increase in contractile protein expression alongside more complex stress fibre 
formation (Crosas-Molist et al., 2015). The same study demonstrated that 
pharmacological ALK5 inhibition with LY364947 suppressed contractile protein 
expression and stress fibre formation. In line with these findings, data presented 
in sections 4.3.7 and 4.3.11 comprehensively demonstrated that functional ALK5 
positively regulated contractile protein expression in primary HSVSMCs. It may 
be speculated, that ALK5 also positively regulates stress fibre formation in 
primary HSVSMCs and, hence, a future experiment should determine cytoskeletal 
structures in 24-h TGF-b1-treated HSVSMCs to confirm this hypothesis. Moreover, 
cluster 1 displayed an increase in relative CTGF mRNA expression levels. CTGF is 
a key mediator of tissue fibrosis (reviewed in) (Lipson et al., 2012) and a 
validated downstream target gene of the ALK5/SMAD2/3 pathway (unpublished 
data) (Low et al., 2019). Interestingly, Chowdhury et al. showed that RhoA-
dependent CTGF expression was paralleled by an increase in actin 
polymerisation in SMCs (Chowdhury and Chaqour, 2004). The authors went on to 
show that the pharmacological actin polymerisation inhibitor latrunculin B 
inhibited stress fibre formation and CTGF expression mechanistically linking 
cytoskeletal re-arrangement with CTGF expression. Hence, the observed 
increase in relative CTGF mRNA levels within cluster 1 (orange) in TGF-b1-
treated HSVSMCs may potentially be mediated via stress fibre formation. Finally, 
cluster 1 (orange) demonstrated an increase in relative TPM1 mRNA expression 
levels. TPM1 encodes for the cytoskeletal protein tropomyosin 1-a which is a 
late marker of differentiated SMCs (Vrhovski et al., 2005). Bakin et al. showed 
that TGF-b1 induced expression of tropomyosins (TPMs) and stress fibre 
formation in epithelial cells (Bakin et al., 2004). The same study revealed that 
TGF-b1-induced stress fibre formation was attenuated following siRNA-mediated 
ablation of TPMs indicating that TPMs are crucial components of intracellular 
contractile filaments. In line with this study, Wang et al. revealed that 
overexpression of TPM1 dampened PDGF-induced primary HASMC migration and 
proliferation (Wang et al., 2011). Taken together, these findings mechanistically 




be speculated that cluster 1 displays a potentially contractile HSVSMC sub-
lineage. 
GO analysis uncovered overlap of EGR1, COL1A1, COL4A1 and COL4A2 in cluster 
2 (green) within TGF-b1-treated HSVSMCs. The transcription factor EGR-1 is a 
mediator of experimental renal fibrosis in mice and partially mediates TGF-b1-
driven Col1a1 expression (Ho et al., 2016). Moreover, adenoviral-mediated 
overexpression of EGR1 drives COL4A1 and COL4A2 expression in human skin 
fibroblasts (Bhattacharyya et al., 2011). Type 4 collagen deposition is increased 
in experimental hepatic fibrosis in rats indicating a pro-fibrotic role for type 4 
collagen (Ala-Kokko et al., 1987). In the context of vSMCs, Turner et al. showed 
that TGF-b1 drove COL4A1 and COL4A2 expression in primary HASMCs. Taken 
together, these studies outline a potential pro-fibrotic mechanism by which the 
TGF-b1/ALK5 pathway activates EGR1 which in turn drives pro-fibrotic COL1A1, 
COL4A1 and COL4A2 gene expression in primary HSVSMCs. This hypothesis may 
be confirmed by bulk qRT-PCR or immunoblot analysis. Based on these findings, 
it may be speculated that SMCs within cluster 1 (green) represent a pro-fibrotic 
HSVSMC sub-lineage. 
Within BMP-9/TGF-b1-co-treated HSVSMCs UMAP/Louvain clustering revealed 9 
clusters indicating transcriptional heterogeneity following combined ligand 
treatment. Compared to BMP-9 and TGF-b1-treated HSVSMCs, RNA velocity 
analysis did not indicate clear lineage trans-differentiation paths. 
Relative SERPINE1 expression was increased throughout most clusters hinting at 
ALK5 pathway activation. In contrast, only clusters 0 (blue) and 4 (purple) 
displayed an increase in relative ID1 expression suggesting BMP-9-driven 
ALK1/ALK2 pathway activation. Cluster 0 (blue) displayed simultaneous ALK5 and 
ALK1/ALK2 pathway activation. Within this cluster GO analysis identified 
enrichment for negative regulation of Ca2+-mediated signalling which included 
the genes CALM2, FHL2 and RCAN1. Both FHL2 and RCAN1 inhibit calcineurin 
activity, subsequent NFAT translocation to the nucleus and NFAT-dependent 
transcriptional regulation of target genes (Fuentes et al., 2000; Hojayev et al., 
2012). The calcineurin inhibitor and immunosuppressant cyclosporin a augments 




Rüegg, 1987) and triggers systemic hypertension (reviewed in) (Taler et al., 
1999). Since pharmacological calcineurin inhibition promotes intracellular Ca2+ 
release it may be speculated that an increase in RCAN1 and FHL2 expression may 
support this pro-contractile mechanism in primary HSVSMCs. Paradoxically, 
Villahoz and colleagues demonstrated that lentiviral-mediated overexpression of 
Rcan-1 in murine aortic SMCs triggered a reduction in MLC phosphorylation 
(Villahoz et al., 2018). In line with this finding, García-Redondo et al. showed 
that phenylephrine-induced aortic constriction was greater in homozygous 
Rcan1-deficient mice (García-Redondo et al., 2018). Both presented studies did 
not investigate the effect of Rcan-1 on intracellular Ca2+ release in vSMCs. 
Nevertheless, these two studies suggest that RCAN1 may also act as a negative 
regulator of vascular contractility and, hence, it may be speculated that BMP-
9/TGF-b1-co-treated HSVSMCs expressing higher levels of RCAN1 may display 
reduced intracellular Ca2+ transients following AngII stimulation. This warrants a 
future experiment investigating AngII-driven Ca2+ release in ligand-treated 
HSVSMCs following siRNA-mediated RCAN1 knockdown and plasmid-mediated 
overexpression of RCAN1. In summary, GO analysis identified a potential 
mechanism for negative regulation of AngII-driven intracellular Ca2+ release and 
HSVSMC calcification. 
PCA-dependent comparison of whole treatment groups revealed that TGF-b1 
visually suppressed mitochondrial gene expression compared to BMP-9-treated 
and/or control HSVSMCs, indicating potential mitochondrial protection (Shi et 
al., 2014) and paralleling previous results from our group (unpublished data) 
(Low et al., 2019). Furthermore, TGF-b1 induced relative SERPINE1 mRNA levels 
paralleling previous findings and demonstrating that cells responded to TGF-b1 
treatment. In contrast, there was no clear divide between ALK1 and ALK5 
HSVSMC sub-lineages following TGF-b1 treatment in the present study. This may 
partially be explained by below mentioned technical and biological differences 
between these two scRNAseq studies. Another possible explanation could be that 
this set of HSVSMCs might have expressed lower ALK1 levels and, hence, might 
not have been able to transdifferentiate into an ALK1-dominant sub-lineage. 





Since only one set of patient cells (n=1 CABG patient) was investigated, it is 
important to emphasise that conclusions/hypotheses drawn from presented 
findings in Chapter 6 require careful interpretation. Furthermore, it is important 
to address technical and biological limitations of this study. Presented results 
reflect relative mRNA expression changes which do not necessarily translate into 
biological relevance. Hence, any conclusions drawn from these results would 
have to be confirmed with at least 2 additional scRNAseq experiments and 
additional in vitro analysis to determine biological relevance in the future. 
Although UMAP/Louvain clustering enables identification of gene groups within 
one cluster, some of these identified genes are also expressed in other clusters 
of the same treatment group. Hence, in some instances this change in gene 
expression reflects a common ligand-dependent effect within all clusters within 
one entire treatment group rather than a singular effect within the investigated 
sub-cluster. 
Moreover, the sequencing depth was ~30,000 read pairs per cell in the presented 
study compared to ~50,000 read pairs per cell obtained from this group’s first 
scRNAseq experiment (unpublished data) (Low et al., 2019). However, the 
manufacturer recommends a minimum of 20,000 read pairs per cell (Chromium 
Single Cell 3ʹ Reagent Kits v3 User Guide) and, hence, the number of read pairs 
is within a recommended range. In addition, the number of investigated cells 
within this chapter’s study ranged from 1,372 (BMP-9) to 2,038 (TGF-b1) cells per 
treatment group compared to 5,245 (vehicle control) and 7,073 (TGF-b1) cells 
examined in the first scRNAseq study (unpublished data) (Low et al., 2019). The 
more sensitive v3 chemistry kit (10x Genomics) was utilised to generate the 
cDNA library for the current study whereas the less sensitive v2 chemistry kit 
was used for the previous study (unpublished data) (Low et al., 2019). 
Furthermore, the average mitochondrial gene percentage per cell was >5% in the 
present study compared to <5% in the previous study (unpublished data) (Low et 
al., 2019). A higher mitochondrial gene percentage is frequently observed in 
cells with a high metabolic turnover such as cardiomyocytes (Mercer et al., 
2011). Since primary HSVSMCs were quiesced for 72-h before 24-h ligand 
treatment, it is unlikely that a higher metabolic rate would explain this increase 
in mitochondrial gene percentage. In this case, a higher mitochondrial gene 




cytoplasm during Gel Bead loading potentially indicating mitochondrial damage. 
This may be explained by exposure to oxidative stress during culturing or the 
GEM lysis step which may have damaged the mitochondrial membrane. Cell 
viability was assessed during automated cell counting and was >95% confirming 
that viable cells were loaded onto the chip. Compared to the first scRNAseq 
study which utilised freshly isolated and passaged primary HSVSMCs, this study 
used cryo-preserved primary HSVSMCs. However, cells showed good outgrowth 
prior to study initiation at P5. Furthermore, primary HSVSMCs for this scRNAseq 
experiment derived from a 72-year-old male CABG patient with a BMI of 32. 
Although the pre-implantation SVG I/M ratio was not known for this study 
participant, it may be hypothesised that HSVSMC biology was impacted by age 
and/or obesity and, hence, might have been more susceptible to oxidative stress 
during culturing. Taken together, these differences may partially explain why 
some results from the first scRNAseq experiment could not be reproduced in the 





This study demonstrates that scRNAseq is a valid technique to determine 
transcriptional changes in single HSVSMCs following ligand treatment. Combined 
UMAP/Louvain clustering uncovered transcriptome heterogeneity in untreated 
and ligand-treated HSVSMCs potentially reflecting a heterogeneous composition 
of SMC sub-lineages within pre-implantation SVG media. 
In contrast to Low et al.’s study, QC filtering revealed a mitochondrial gene 
percentage of >5% per cell potentially indicating mitochondrial damage 
(unpublished data) (Low et al., 2019). Paralleling previous findings by Low et 
al., TGF-b1-treated HSVSMCs displayed a reduction in mitochondrial gene 
expression hinting at mitochondrial protection. Despite an increase in 
mitochondrial gene percentage, both BMP-9 and TGF-b1 drove target gene 
expression demonstrating functional ALK5 and ALK1/ALK2 pathway activation. 
Initial PCA revealed greater spatial distances between TGF-b1 and BMP-9-treated 
HSVSMCs suggesting that TGF-b1 triggered greater transcriptional activation 
compared to BMP-9. 
In untreated control HSVSMCs, GO identified overlap of genes known to regulate 
high voltage-gated calcium channel activity potentially hinting at pro-contractile 
Ca2+ system remodelling. Within BMP-9 treated HSVSMCs, combined RNA velocity 
and GO analysis uncovered a potential osteogenic HSVSMC sub-lineage. Within 
TGF-b1-treated HSVSMCs GO identified potentially contractile and pro-fibrotic 
sub-lineages as well as HSVSMCs expressing increased levels of pro-chemotactic 
genes. Finally, GO helped to uncover potential mechanisms for negative 









7.1 Overall Summary 
TGF-b1 may either signal via the ALK1 or ALK5 signalling pathways in primary 
HSVSMCs (unpublished data) (Low et al., 2019). The contribution of ALK5 
signalling to vascular injury-driven NF is controversial with some studies 
implicating this pathway as a positive regulator of NF (Cooley et al., 2014; Friedl 
et al., 2004; Jiang et al., 2009; Liao et al., 2016; Tsai et al., 2009; Wolff et al., 
2006) and other studies demonstrating protection from vSMC phenotype 
switching and NF (Chen et al., 2016b; Kobayashi et al., 2005; Martin-Garrido et 
al., 2013; Mii et al., 1993). With regards to ALK1, Garrido-Martín and colleagues 
reported an increase in neointimal ALK1 presence following vascular injury 
(Garrido-Martín et al., 2013). In line with this finding, Low et al. showed that (i) 
ALK1 co-localised with aSMA+ SMCs within SVG neointima and (ii) systemic and 
heterozygous genetic ablation of Smad1 dampened NF following experimental 
vascular injury in mice (unpublished data) (Low et al., 2019). The same study 
demonstrated that TGF-b1 induced HSVSMC migration via ALK1 implicating this 
signalling axis as a driver of NF in SVG disease. BMP-9 circulates in the blood and 
signals via ALK1 in vascular ECs and SMCs (David et al., 2008; David et al., 2007; 
Zhu et al., 2015). Next to cancer neoangiogenesis and HHT, BMP-9 is being 
investigated in the context of NF-driven PAH (Brand et al., 2016; Hodgson et al., 
2020; Wang et al., 2019; Wooderchak-Donahue et al., 2013). However, the role 
of BMP-9 is still controversial with one study implicating a protective function 
(Long et al., 2015) and an opposing study indicating BMP-9 as a driver of PAH (Tu 
et al., 2019). To date, no study has investigated the role of BMP-9 in SVG NF. 
Since BMP-9 is an ALK1 ligand and the ALK1 pathway drives HSVSMC migration 
and experimental NF it may be speculated that BMP-9 positively regulates NF via 
ALK1. Based on these findings, the first aim of this thesis was to evaluate BMP-9 
presence in pre-implantation SVGs from CABG patients and experimentally 
injured murine carotid arteries. 
IHC revealed BMP-9 presence in pre-implantation SVGs and uninjured/injured 
murine carotid arteries. Within SVGs, BMP-9 was present in all layers of the 
vessel and co-localised with aSMA+ SMCs. In uninjured murine carotid arteries 
BMP-9 mainly localised to the adventitia along with some punctate staining in 




demonstrated that total vessel BMP-9 presence was increased at day 14 
compared to day 0 uninjured controls with brighter adventitial staining and some 
punctate staining within the forming neointima. This increase was paralleled by 
a reduction in total vessel aSMA presence suggesting vSMC phenotype switching 
(Lindner et al., 1993). In 3-week-old lesions, total BMP-9 presence dropped back 
to baseline levels. 
A previous radioligand cross-linking study showed that BMP-9 bound to ALK1, 
ALK2, BMPR2, ACVR2A/B and endoglin on isolated primary HSVSMCs. Based on 
this finding and BMP-9 presence in pre-implantation SVGs and murine arterial 
vasculature, the next aim was to determine potential crosstalk between BMP-
9/ALK1/2 and TGF-b1/ALK1 signalling by assessing SMAD1 phosphorylation in 
isolated primary HSVSMCs. Recombinant BMP-9 induced sustained 
phosphorylation of SMAD1 and potentially SMAD5. TGF-b1 also induced SMAD1 
phosphorylation. However, TGF-b1-driven SMAD1 phosphorylation was delayed 
and weaker compared to BMP-9 stimulation. The presence of TGF-b1 did not 
potentiate BMP-9-driven SMAD1 phosphorylation thereby indicating absence of 
ALK1 pathway synergy. Bulk qRT-PCR analysis confirmed up-regulation of 
relative ID1 mRNA expression levels following BMP-9 stimulation. In contrast to 
SMAD1 phosphorylation, the presence of TGF-b1 attenuated BMP-9-driven ID1 
expression demonstrating lateral ALK5-mediated ALK1 pathway inhibition 
(Goumans et al., 2002). Further mechanistic studies revealed that BMP-9 did not 
affect proliferation of quiesced HSVSMCs and did not modulate serum-induced 
HSVSMC proliferation and migration. 
Further IHC analysis revealed that the contractile vSMC marker MYH11 was 
reduced in the intima compared to the media of pre-implantation SVGs from 
CABG patients. In addition, calponin staining demonstrated a trend towards a 
reduction in intimal versus medial staining suggesting in vivo HSVSMC phenotype 
switching. This is in line with findings from Low et al. which demonstrated that 
pre-implantation SVGs from 75 CABG patients displayed pre-existing intimal 
thickening evidenced by a mean I/M ratio >0.15 (unpublished data) (Low et al., 
2019). This is of clinical relevance since pre-existing intimal thickening is a 
known risk factor for early and late SVG failure (Panetta et al., 1992). Part of 




potential in vivo vSMC phenotype switching in pre-implantation SVGs in more 
detail. 
These findings prompted development and validation of an in vitro model to 
mimic phenotype switching and contractile differentiation of isolated primary 
HSVSMCs. The differentiation protocol was based on a study by Chen et al. and 
enabled investigation of dynamic changes in ALK1 and ALK5 pathway activity 
during these two opposing processes (Chen et al., 2016b). Paralleling findings in 
primary HASMCs by Chen et al. (Chen et al., 2016b), SMDS-cultured HSVSMC 
demonstrated a time-dependent increase in contractile gene and protein 
expression along with a decrease in proliferation indicating contractile 
differentiation. Accumulation of contractile gene and protein expression was 
paralleled by a decrease in ID1 expression suggesting ALK1 pathway suppression 
during contractile differentiation. Moreover, SMDS dynamically upregulated 
ACVR2A expression suggesting a role for this receptor during contractile HSVSMC 
differentiation. This finding prompted generation of an HAdV-5 expressing 
ACVR2A. Preliminary qRT-PCR data confirmed successful delivery of ACVR2A to 
primary HSVSMCs (n=1 CABG patient). However, the increase in ACVR2A did not 
affect aSMA expression in SMDS and 15% serum cultured HSVSMCs at the day 2 
time point. Although overexpression of ACVR2A had no effect during early stages 
of contractile HSVSMC differentiation, more experiments investigating changes 
in contractile gene/protein expression and proliferation at later time points are 
warranted. 
Data obtained during this PhD demonstrated that pharmacological ALK1 
inhibition did not affect SMDS-mediated accumulation of contractile gene 
expression in HSVSMCs (unpublished data) (Low et al., 2019). In contrast, 
pharmacological ALK5 inhibition prevented SMDS-induced increase in contractile 
gene and protein expression. To confirm these findings, 72-h quiesced HSVSMCs 
were stimulated with recombinant TGF-b1 and/or BMP-9 in absence and presence 
of pharmacological ALK5 inhibition. Bulk qRT-PCR analysis revealed that TGF-b1 
drove contractile gene expression in an ALK5-dependent manner. BMP-9 did not 
counter TGF-b1-driven contractile gene expression. However, BMP-9 ALK5-
dependently and mildly induced aSMA expression. In addition to bulk qRT-PCR, 




phosphorylation via ALK5, a known marker of SMC contractility (Montezano et 
al., 2018). In line with previous studies, these data indicate that both ligand-
dependent and -independent ALK5 signalling positively regulated the contractile 
HSVSMC phenotype (Chen et al., 2016b; Tang et al., 2010). Partially paralleling 
previous findings by Garrido-Martín et al. and Mii et al., further mechanistic 
studies revealed that TGF-b1 attenuated serum-induced HSVSMC proliferation 
and HSVSMC-driven scratch closure indicating protection against phenotype 
switching (Martin-Garrido et al., 2013; Mii et al., 1993). Additional qRT-PCR 
analysis demonstrated that TGF-b1 suppressed ALPL and CD68 expression via 
ALK5 suggesting negative regulation of osteoblastic and macrophage-like HSVSMC 
trans-differentiation (Guerrero et al., 2014; Mallat et al., 2001). 
Based on these results, the next aim was to assess HSVSMC contraction, using 
agonist driven intracellular Ca2+ release as a surrogate marker. 24-h TGF-b1 
stimulation of quiesced HSVSMCs triggered an increase in AngII-driven 
intracellular Ca2+ transients compared to untreated controls suggesting that TGF-
b1 drives an increase in contractile capacity. BMP-9 and pharmacological ALK5 
inhibition blocked this TGF-b1-dependent increase in intracellular Ca2+ release. 
In contrast, TGF-b1 did not affect AngII-dependent Ca2+ release in primary 
HCASMCs suggesting differential regulation of Ca2+ handling in this cell type. 
Further mechanistic studies aimed to identify via which receptor AngII mediated 
Ca2+ responses and whether AngII/Ca2+-dependent SMC contraction triggered 
Cal520TM quenching and, hence, false positive increase in fluorescence intensity. 
AngII drove Ca2+ transients via AT1R and pharmacological ROCK/PKC 
(contraction) inhibition with fasudil did not prevent AngII-driven Ca2+ release. 
Bulk qRT-PCR analysis revealed that TGF-b1 ALK5-dependently suppressed MAS1 
expression, a receptor known to negatively regulate AngII/AT1R signalling, 
suggesting synergism between TGF-b1/ALK5 and AngII/AT1R signalling in HSVSMCs 
(Ford et al., 1999; Kostenis et al., 2005; Rodríguez-Vita et al., 2005). The 
potential clinical relevance of these findings is outlined in 7.2. In addition, 
single cell resolution uncovered heterogeneous distribution of AngII-driven Ca2+ 
transients in untreated and ligand treated HSVSMC populations potentially 
reflecting vSMC heterogeneity. TGF-b1-stimulation of HSVSMC triggered a more 
homogenous Ca2+ response and this was blunted in the presence of BMP-9. 




media of large arteries (Frid et al., 1994; Hao et al., 2002; Li et al., 2001a). 
More recently, the combination of vSMC lineage tracing in transgenic mice and 
scRNAseq confirmed medial SMC heterogeneity and enabled identification of a 
potentially disease-relevant rare SMC sub-lineage in aortic media (Dobnikar et 
al., 2018). Low et al.’s study already demonstrated that TGF-b1 stimulation of 
HSVSMCs drove ALK5- and ALK1-dominant SMC sub-lineages suggesting 
simultaneous ALK5 and ALK1 pathway activation within the same SMC 
population. Taken together, these findings prompted a scRNAseq study in 
HSVSMCs following BMP-9 and/or TGF-b1 treatment to assess vSMC heterogeneity 
at a transcriptional level and identify that could explain ligand-dependent 
effects on AngII-driven Ca2+ transients. 
Computational analysis of scRNAseq data uncovered heterogeneous 
transcriptomes in all treatment groups. BMP-9 and TGF-b1 induced the 
expression of ALK1 and ALK5 target genes, respectively, and initial PCA analysis 
revealed greater transcriptional changes within the TGF-b1-treated HSVSMC 
population. Contrasting previous findings by Low and colleagues, RNA velocity 
analysis did not show a clear distinction between ALK1- and ALK5-dominant sub-
lineages within the TGF-b1 treatment group. Nevertheless, combined RNA 
velocity and GO analysis of BMP-9-treated HSVSMCs identified a potentially 
osteoblastic SMC sub-lineage as evidenced by an increase in cluster-dependent 
pro-osteogenic SNAI2 and IGF1 expression levels (Chen et al., 2016a; Tang et al., 
2016). With regards to BMP-9-driven inhibition of TGF-b1-driven Ca2+ transients, 
it may be speculated that BMP-9 redirects intracellular Ca2+ towards 
mineralisation by activating pro-osteoblastic alkaline phosphatase activity (Zhu 
et al., 2015). The clinical relevance of potential BMP-9-driven osteoblastic 
differentiation in the context of SVG occlusion is discussed in section 7.2. 
Combined RNA velocity and GO analysis of TGF-b1-treated HSVSMCs uncovered 
SMC sub-lineages with contractile and fibrotic gene expression patterns. In 
addition, a cluster of HSVSMCs expressed increased levels of pro-chemotactic 
VEGFA and CXCL12, two known positive regulators of monocyte/progenitor cell 
recruitment and subsequent NF in the context of acute vascular injury (Ohtani et 
al., 2004; Zernecke et al., 2005). Within, BMP-9/TGF-b1-co-treated HSVSMCs, 
ALK5 pathway activation was more prevalent compared to ALK1 as evidenced by 




all investigated clusters. GO analysis of co-treated HSVSMCs revealed potential 
mechanisms for negative regulation of vascular contractility (García-Redondo et 
al., 2018; Villahoz et al., 2018) and calcification (Lomashvili et al., 2004; 
Lomashvili et al., 2014; Zhao et al., 2012). As outlined in section 6.4, scRNAseq 
findings should be interpreted with caution and require validation experiments 
addressing generated hypotheses in the future. Nevertheless, taken together 
with Ca2+ handling findings uncovering heterogeneous AngII-driven Ca2+ responses 
in HSVSMCs, scRNAseq analysis revealed transcriptional heterogeneity in 
HSVSMCs that may reflect a heterogeneous composition of diverse SMC 
phenotypes within pre-implantation SVG media. Based on a study by Dobnikar et 
al., it may be speculated that diverse SMC sub-populations react differently to 
SVG injury following implantation and this may be of clinical relevance in the 
context of SVG occlusion (Dobnikar et al., 2018). 
In summary, TGF-b1 drives contractile/fibrotic gene expression, drives MLC S20 
phosphorylation and enhances AngII-driven intracellular Ca2+ transients via ALK5 
in primary HSVSMCs (Figure 7-1). This indicates that ALK5 agonism positively 
regulates the contractile HSVSMC phenotype. In contrast, BMP-9 drives SMAD1 
phosphorylation (and potentially SMAD5), ID1 expression and blunts TGF-
b1/ALK5-driven AngII-dependent Ca2+ responses via ALK1 and/or ALK2 indicating 





Figure 7-1 Proposed model of BMP-9/ALK1/2- and TGF-b1/ALK5-driven regulation of HSVSMC 
phenotypes. (A) BMP-9 drives SMAD1/5 phosphorylation via ALK1 and/or ALK2/BMPR2 complex formation. 
The SMAD1/5/SMAD4 complex translocates to the nucleus and drives ID1 and pro-osteogenic SNAI2 and 
IGF1 expression. Under disease conditions, the BMP-9/SMAD1/5 system may synergise with pro-osteogenic 
and pro-inflammatory signalling pathways. (B) TGF-b1 drives SMAD2/3 phosphorylation via TGFBR2/ALK5 
complex formation. The SMAD2/3/SMAD4 complex trans-locates to the nucleus and drives pro-contractile 
aSMA, CNN1, TAGLN, MYH11 and TPM1 and pro-fibrotic SERPINE1 and CTGF gene expression. (C) TGF-
b1 attenuates BMP-9-driven ID1 expression via ALK5. (D) TGF-b1 directly drives MLC S20 phosphorylation via 
ALK5 (unknown underlying mechanism). (E) TGF-b1 augments AngII-induced SR Ca2+ release via ALK5 
(unknown underlying mechanism). (F) The BMP-9/SMAD1/5 system attenuates TGF-b1-driven AngII-
dependent intracellular Ca2+ transients (unknown underlying mechanism). In summary, TGF-b1 promotes the 
contractile and fibrotic HSVSMC phenotypes via ALK5. BMP-9 partially antagonises TGF-b1 /ALK5-driven 




7.2 Future perspectives 
Data generated during this PhD may be of relevance to CABG patient care in the 
future. The next paragraphs aim to highlight the most clinically relevant findings 
and bring them into disease context. 
IHC analysis of pre-implantation SVGs from CABG patients revealed the presence 
of in vivo SMC phenotype switching along with BMP-9 which functionally drove 
ALK1/2 signalling and pro-osteoblastic gene expression in isolated primary 
HSVSMCs, although additional in vitro studies are required to strengthen the 
evidence supporting these investigations. The BMP-9/ALK1 axis induces 
osteoblastic vSMC differentiation and ALK1 positively regulates vascular LDL 
deposition thereby promoting vascular calcification and atherosclerosis 
respectively (Kraehling et al., 2016; Zhu et al., 2015). Pre-implantation SVGs 
display calcification (Pedigo et al., 2017), circulating BMP-9 levels are elevated 
in paediatric CKD patients (Zhu et al., 2015) and CKD is a risk factor for SVG 
occlusion (Wellenius et al., 2007). Moreover, SVGs are prone to accelerated 
atherosclerosis impeding long-term graft patency (Neitzel et al., 1986). Hence, 
it may be hypothesised that circulating BMP-9 drives SVG calcification and 
atherosclerotic plaque formation via the ALK1 pathway and serves as a 
biomarker for identifying CABG patients at risk of developing SVG failure. 
Taken together, these findings warrant a translational study investigating the 
association of circulating BMP-9 levels with SVG patency and calcification in 
CABG patients. This may be complemented with an in vivo murine vein graft 
study. Lardenoye and colleagues demonstrated accelerated atherosclerosis and 
calcification of vena cava grafts following inter-positioning into common carotid 
arteries in hyperlipidaemic APOE*3 Leiden mice (Lardenoye et al., 2002). 
Alternatively, Zhang et al. demonstrated exacerbated NF in vena cava grafts 
inter-positioned into common carotid arteries in mice with 5/6ths nephrectomy, 
a validated murine model of CKD (Zhang et al., 2017). Based on both these 
models it may be hypothesised that systemic administration of neutralising BMP-
9 antibodies attenuates vein graft NF, lipid retention and calcification. In 
addition, in vitro studies would investigate the effect of BMP-9 stimulation on (i) 




LDL-driven macrophage-like differentiation of isolated primary HSVSMCs (Beyea 
et al., 2012). 
Another main finding of this PhD was that the TGF-b1/ALK5 pathway augmented 
AngII/AT1R-driven intracellular Ca2+ mobilisation, drove contractile gene 
expression and attenuated serum-induced proliferation in HSVSMCs. Hence, it is 
conceivable that transient, selective ALK5 agonism within SVGs may induce 
AngII-driven intracellular Ca2+ release, RhoA/ROCK activation (Chen et al., 
2006), MLC S20 phosphorylation and contractile gene expression. This would be 
favourable in the context of SVG injury since this pathway would then protect 
the contractile HSVSMC phenotype thereby potentially improving graft 
contractility and preventing SMC phenotype switching and subsequent neointimal 
expansion. This warrants a pre-clinical study investigating the effect of systemic 
TGF-b1 delivery prior to and at early time points following carotid injury in mice. 
Alternatively, this hypothesis may be tested by transducing murine vein grafts ex 
vivo with a recombinant HAdV-5 expressing ALK5 prior to carotid inter-
positioning. 
In contrast, long-term TGF-b1-mediated sensitisation of AngII/AT1R-driven SR 
Ca2+ release in HSVSMCs may accelerate SVG occlusion. Jiang et al. 
demonstrated that internal jugular vein grafts inter-positioned into the common 
carotid arteries in rabbits displayed progressive neointimal expansion over a 
period of 6 months (Jiang et al., 2009). This was paralleled by an increase in 
TGF-b1 activity, ALK5/TGFBR2 ratio, SMAD2/3 phosphorylation and downstream 
CTGF expression suggesting that TGF-b1 drove fibrotic neointimal remodelling. 
Hence, it is crucial to point out that the TGF-b1/ALK5 signalling axis also drives 
ECM production thereby promoting neointimal expansion and subsequent vein 
graft occlusion. It may be hypothesised that late ALK5 antagonism may prevent 
neointimal expansion following vascular injury. This may be addressed in a pre-
clinical study investigating the effect of late systemic pharmacological blockade 
of ALK5 following carotid injury in mice. 
In summary, the work presented in this thesis shows that TGF-b1 positively 
regulates the contractile HSVSMC phenotype via ALK5 and that BMP-9 partially 




ALK2. Above-proposed studies will facilitate the understanding of how these key 
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